|
þ
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
13-4075851
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
200 Park Avenue, New York, N.Y.
|
|
10166-0188
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.01
|
|
New York Stock Exchange
|
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
|
|
New York Stock Exchange
|
5.375% Senior Notes
|
|
Irish Stock Exchange
|
5.25% Senior Notes
|
|
Irish Stock Exchange
|
Large accelerated filer
|
þ
|
Accelerated filer
|
¨
|
Non-accelerated filer
(Do not check if a smaller reporting company)
|
¨
|
Smaller reporting company
|
¨
|
|
|
Emerging growth company
|
¨
|
|
|
|
|
|
Page
|
Part I
|
||||
Item 1.
|
|
|
||
Item 1A.
|
|
|
||
Item 1B.
|
|
|
||
Item 2.
|
|
|
||
Item 3.
|
|
|
||
Item 4.
|
|
|
||
|
|
|
|
|
Part II
|
||||
Item 5.
|
|
|
||
Item 6.
|
|
|
||
Item 7.
|
|
|
||
Item 7A.
|
|
|
||
Item 8.
|
|
|
||
Item 9.
|
|
|
||
Item 9A.
|
|
|
||
Item 9B.
|
|
|
||
|
|
|
|
|
Part III
|
||||
Item 10.
|
|
|
||
Item 11.
|
|
|
||
Item 12.
|
|
|
||
Item 13.
|
|
|
||
Item 14.
|
|
|
||
|
||||
Part IV
|
||||
Item 15.
|
|
|
||
Item 16.
|
|
|
||
|
|
|
|
|
|
||||
|
|
|
||
|
||||
|
|
|
|
●
|
|
Optimize value and risk
|
|
–
|
|
Focus on in-force and new business opportunities using Accelerating Value analysis
|
|
–
|
|
Optimize cash and value
|
|
–
|
|
Balance risk across MetLife
|
|
●
|
|
Drive operational excellence
|
|
–
|
|
Become a more efficient, high performance organization
|
|
–
|
|
Focus on the customer with a disciplined approach to unit cost improvement
|
|
●
|
|
Strengthen distribution advantage
|
|
–
|
|
Transform our distribution channels to drive productivity and efficiency through digital enablement, improved customer persistency and deeper customer relationships
|
|
●
|
|
Deliver the right solutions for the right customers
|
|
–
|
|
Use customer insights to deliver differentiated value propositions - products, services and experiences to win the right customers and earn their loyalty
|
Major Products
|
|
Term Life Insurance
|
Provides a guaranteed benefit upon the death of the insured for a specified time period in return for the periodic payment of premiums. Premiums may be guaranteed at a level amount for the coverage period or may be non-level and non-guaranteed. Term contracts expire without value at the end of the coverage period when the insured party is still living.
|
Variable Life Insurance
|
Provides insurance coverage through a contract that gives the policyholder flexibility in investment choices and, depending on the product, in premium payments and coverage amounts, with certain guarantees. Premiums and account balances can be directed by the policyholder into a variety of separate account investment options or directed to the Company’s general account. In the separate account investment options, the policyholder bears the entire risk of the investment results. With some products, by maintaining certain premium level, policyholders may have the advantage of various guarantees that may protect the death benefit from adverse investment experience.
|
Universal Life Insurance
|
Provides insurance coverage on the same basis as variable life, except that premiums, and the resulting accumulated balances, are allocated only to the Company’s general account. With some products, by maintaining a certain premium level, policyholders may have the advantage of various guarantees that may protect the death benefit from adverse investment experience.
|
Dental Insurance
|
Provides insurance and ASO arrangements that assist employees, retirees and their families in maintaining oral health while reducing out-of-pocket expenses.
|
Disability
|
For groups and individuals, benefits such as income replacement, payment of business overhead expenses or mortgage protection, in the event of the disability of the insured.
|
Accident and Health Insurance
|
Provides accident, critical illness or hospital indemnity coverage to the insured.
|
Major Products
|
|
Stable Value Products
|
• General account guaranteed interest contracts
(“
GIC
s”) are designed to provide stable value investment options within tax-qualified defined contribution plans by offering a fixed maturity investment with a guarantee of liquidity at contract value for participant transactions.
• Separate account GIC
s are available to defined contribution plan sponsors by offering market value returns on separate account investments with a general account guarantee of liquidity at contract value.
• Private floating rate funding agreements
are generally privately-placed, unregistered investment contracts issued as general account obligations with interest credited based on the three-month London Interbank Offered Rate (“LIBOR”). These agreements are used for money market funds, securities lending cash collateral portfolios and short-term investment funds.
|
Pension Risk Transfers
|
General account
and
separate account annuities
are offered in connection with defined benefit pension plans which include single premium buyouts allowing for full or partial transfers of pension liabilities.
• General account annuities
include nonparticipating group contract benefits purchased for retired employees or active employees covered under terminating or ongoing pension plans.
• Separate account annuities
include both participating and non-participating group contract benefits. Participating contract benefits are purchased for retired, terminated, or active employees covered under active or terminated pension plans. The assets supporting the guaranteed benefits for each contract are held in a separate account, however, the Company fully guarantees all benefit payments. Non-participating contracts have economic features similar to our general account product, but offer the added protection of an insulated separate account. Under U.S. GAAP, these annuity contracts are treated as general account products.
|
Institutional Income Annuities
|
General account contracts that are guaranteed payout annuities purchased for employees upon retirement or termination of employment. They can be life or non-life contingent non-participating contracts which do not provide for any loan or cash surrender value and, with few exceptions, do not permit future considerations.
|
Tort Settlements
|
• Structured settlement annuities
are customized annuities designed to serve as an alternative to a lump sum payment in a lawsuit initiated because of personal injury, wrongful death, or a workers’ compensation claim or other claim for damages. Surrenders are generally not allowed, although commutations are permitted in certain circumstances. Guaranteed payments consist of life contingent annuities, term certain annuities and lump sums.
|
Capital Markets Investment Products
|
• Funding agreement-backed notes
are part of a medium term note program, under which funding agreements are issued to a special-purpose trust that issues marketable notes in U.S. dollars or foreign currencies. The proceeds of these note issuances are used to acquire a funding agreement with matching interest and maturity payment terms from Metropolitan Life Insurance Company (“MLIC”). The notes are underwritten and marketed by major investment banks’ broker-dealer operations and are sold to institutional investors.
• Funding agreement-backed commercial paper
is issued by a special purpose limited liability company which deposits the proceeds under a master funding agreement issued to it by MLIC. The commercial paper is issued in U.S. dollars or foreign currencies, receives the same short-term credit rating as MLIC and is marketed by major investment banks’ broker-dealer operations.
•
Through the Federal Home Loan Bank (“FHLB”) advance program, certain of our insurance subsidiaries are members of regional FHLBs and issue
funding agreements
to their respective FHLBs. Through the Federal Agricultural Mortgage Corporation (“Farmer Mac”) program, MLIC has issued funding agreements to a subsidiary of Farmer Mac.
|
Other Products and Services
|
Specialized life insurance products and funding agreements designed specifically to provide solutions for funding postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives.
|
Major Products
|
|
Auto Insurance
|
Provides coverage for private passenger automobiles, utility automobiles and vans, motorcycles, motor homes, antique or classic automobiles, trailers, liability, uninsured motorist, no fault or personal injury protection, as well as collision and comprehensive insurance.
|
Homeowners’ Insurance
|
Provides protection for homeowners, renters, condominium owners and residential landlords against losses arising out of damage to dwellings and contents from a wide variety of perils, as well as coverage for liability arising from ownership or occupancy.
|
Small Business Owners’ Insurance
|
Provides property, liability and business interruption insurance for small business owners arising out of damages to property and/or business interruption from a variety of perils.
|
Major Products
|
|
Life Insurance
|
Provides whole and term life, endowments, universal and variable life, as well as group products.
|
Accident & Health Insurance
|
Provides a full range of health products, including hospital indemnity, medical reimbursement, critical illness policies, as well as personal accident coverage.
|
Retirement and Savings
|
Provides both fixed and variable annuities as well as regular savings products.
|
Major Products
|
|
Life Insurance
|
Provides universal, variable and term life products. For a description of these products, see “
—
U.S.
—
Product Overview
—
Group Benefits.”
|
Retirement and Savings
|
Provides fixed annuities and pension products. Fixed annuities provide for both asset accumulation and asset distribution needs. Deposits made into deferred annuity contracts are allocated to the Company’s general account and are credited with interest at rates we determine, subject to specified minimums. Fixed income annuities provide a guaranteed monthly income for a specified period of years and/or for the life of the annuitant. Our savings oriented pension products are offered under a mandatory privatized social security system. See Note 3 of the Notes to the Consolidated Financial Statements for information about the disposition of MetLife Afore, S.A. de C.V. (“MetLife Afore”), the Company’s pension fund management business in Mexico.
|
Accident & Health Insurance
|
Provides group and individual major medical, accidental, and supplemental health products, including accidental death and disability, medical reimbursement, hospital indemnity and medical coverage for serious medical conditions, as well as dental products.
|
Credit Insurance
|
Provides policies designed to fulfill certain loan obligations in the event of the policyholder’s death.
|
Major Products
|
|
Life Insurance
|
Provides both traditional and non-traditional life insurance products, such as whole and term life, endowments and variable life products, as well as group term life programs in most markets.
|
Accident & Health Insurance
|
Provides individual and group personal accident and supplemental health products, including AD&D, hospital indemnity, scheduled medical reimbursement plans, and coverage for serious medical conditions. In addition, we provide individual and group major medical coverage in select markets.
|
Retirement and Savings
|
Provides fixed annuities and pension products, including group pension programs in select markets. In Romania, we provide through a specialized pension company a savings oriented pension product under the mandatory privatized social security system.
|
Credit Insurance
|
Provides policies designed to fulfill certain loan obligations in the event of the policyholder’s death.
|
Major Products
|
|
Variable, Universal and Term Life Insurance
|
These life products are similar to those offered by our Group Benefits business, except that these products were historically marketed to individuals through various retail distribution channels. For a description of these products, see “
—
U.S.
—
Product Overview
—
Group Benefits.”
|
Whole Life Insurance
|
Provides a benefit upon the death of the insured in return for the periodic payment of a fixed premium over a predetermined period. Whole life insurance includes policies that provide a participation feature in the form of dividends. Policyholders may receive dividends in cash, or apply them to increase death benefits, increase cash values available upon surrender or reduce the premiums required to maintain the contract in-force.
|
Variable Annuities
|
Provides for both asset accumulation and asset distribution needs. Variable annuities allow the contractholder to allocate deposits into various investment options in a separate account, as determined by the contractholder. In certain variable annuity products, contractholders may also choose to allocate all or a portion of their account to the Company’s general account and are credited with interest at rates we determine, subject to specified minimums. Contractholders may also elect certain minimum death benefit and minimum living benefit guarantees for which additional fees are charged and where asset allocation restrictions may apply.
|
Fixed and Indexed-Linked Annuities
|
Fixed annuities provide for both asset accumulation and asset distribution needs. Deposits made into deferred annuity contracts are allocated to the Company’s general account and are credited with interest at rates we determine, subject to specified minimums. Fixed income annuities provide a guaranteed monthly income for a specified period of years and/or for the life of the annuitant. Additionally, the Company has issued indexed-linked annuities which allow the contractholder to participate in returns from equity indices.
|
Long-term Care
|
Provides protection against the potentially high costs of long-term health care services. Generally pay benefits to insureds who need assistance with activities of daily living or have a cognitive impairment.
|
•
|
Employer sponsored captive programs: through these programs, employers buy a group life insurance policy with the condition that a portion of the risk is reinsured back to a captive insurer sponsored by the client.
|
•
|
Risk-sharing agreements: through these programs, clients require that we reinsure a portion of the risk back to third parties, such as minority-owned reinsurers.
|
•
|
Multinational pooling: through these agreements, employers buy many group insurance policies which are aggregated in a single insurer via reinsurance.
|
•
|
licensing companies and agents to transact business;
|
•
|
calculating the value of assets to determine compliance with statutory requirements;
|
•
|
mandating certain insurance benefits;
|
•
|
regulating certain premium rates;
|
•
|
reviewing and approving certain policy forms, including required policyholder disclosures;
|
•
|
regulating unfair trade and claims practices, including through the imposition of restrictions on marketing and sales practices, distribution arrangements and payment of inducements, and identifying and paying to the states benefits and other property that is not claimed by the owners;
|
•
|
regulating advertising;
|
•
|
protecting privacy;
|
•
|
establishing statutory capital and reserve requirements and solvency standards;
|
•
|
specifying the conditions under which a ceding company can take credit for reinsurance in its statutory financial statements (i.e., reduce its reserves by the amount of reserves ceded to a reinsurer);
|
•
|
fixing maximum interest rates on insurance policy loans and minimum rates for guaranteed crediting rates on life insurance policies and annuity contracts;
|
•
|
adopting and enforcing suitability standards with respect to the sale of annuities and other insurance products;
|
•
|
approving changes in control of insurance companies;
|
•
|
restricting the payment of dividends and other transactions between affiliates; and
|
•
|
regulating the types, amounts and valuation of investments.
|
|
A.M. Best
|
|
Fitch
|
|
Moody's
|
|
S&P
|
Ratings Structure
|
“A++ (superior)” to “S (suspended)”
|
|
“AAA (exceptionally strong)” to “C (distressed)”
|
|
“Aaa (highest quality)” to “C (lowest rated)”
|
|
“AAA (extremely strong)” to “SD (Selective Default)” or “D (Default)”
|
American Life Insurance Company
|
NR
|
|
NR
|
|
A1
|
|
AA-
|
|
|
5th of 21
|
|
4th of 22
|
|||
General American Life Insurance Company
|
A+
|
|
AA-
|
|
Aa3
|
|
AA-
|
2nd of 16
|
|
4th of 19
|
|
4th of 21
|
|
4th of 22
|
|
Metropolitan Life Insurance Company
|
A+
|
|
AA-
|
|
Aa3
|
|
AA-
|
2nd of 16
|
|
4th of 19
|
|
4th of 21
|
|
4th of 22
|
|
MetLife Insurance K.K. (MetLife Japan)
|
NR
|
|
NR
|
|
NR
|
|
AA-
|
|
|
|
4th of 22
|
||||
Metropolitan Tower Life Insurance Company
|
A+
|
|
NR
|
|
Aa3
|
|
NR
|
2nd of 16
|
|
|
4th of 21
|
|
Name
|
|
Age
|
|
Position with MetLife and Business Experience
|
||
Steven A. Kandarian
|
|
65
|
|
•
|
|
Chairman of the Board of MetLife, Inc. (January 2012-present) (Director of MetLife, Inc. since 2011)
|
|
|
|
|
•
|
|
President and Chief Executive Officer (May 2011-present) of MetLife, Inc.
|
|
|
|
|
•
|
|
Executive Vice President and Chief Investment Officer of MetLife, Inc. (April 2005-April 2011)
|
Stephen W. Gauster
|
|
47
|
|
•
|
|
Senior Vice President and Interim General Counsel of MetLife, Inc. (July 2017-present)
|
|
|
|
|
•
|
|
Senior Vice President and Chief Counsel, General Corporate Section of the Law Department (January 2016-June 2017)
|
|
|
|
|
•
|
|
Senior Vice President, Chief Corporate Counsel and Assistant Secretary, Assurant, Inc., an insurance company (September 2008-December 2015)
|
Steven J. Goulart
|
|
59
|
|
•
|
|
Executive Vice President and Chief Investment Officer of MetLife, Inc. (May 2011-present)
|
|
|
|
|
•
|
|
Head of the Portfolio Management Unit as Senior Managing Director of MLIC (January 2011-April 2011)
|
|
|
|
|
•
|
|
Senior Vice President and Treasurer, MetLife, Inc. (July 2009-April 2011)
|
John C.R. Hele
|
|
59
|
|
•
|
|
Executive Vice President and Chief Financial Officer of MetLife, Inc. (September 2012-present)
|
|
|
|
|
•
|
|
Executive Vice President, Chief Financial Officer and Treasurer, Arch Capital Group Ltd., an insurance and reinsurance company (April 2009-August 2012)
|
Michel Khalaf
|
|
54
|
|
•
|
|
President, U.S. Business of MetLife, Inc. (July 2017-present)
|
|
|
|
|
•
|
|
President, EMEA of MetLife, Inc. (November 2011-present)
|
|
|
|
|
•
|
|
Executive Vice President of MLIC (January 2011-November 2011)
|
|
|
|
|
•
|
|
Regional President, Middle East, Africa and South Asia, ALICO (November 2008-November 2011) (Mr. Khalaf joined MetLife as a result of the acquisition of ALICO)
|
Esther S. Lee
|
|
59
|
|
•
|
|
Executive Vice President and Global Chief Marketing Officer of MetLife, Inc. (January 2015-present)
|
|
|
|
|
•
|
|
Senior Vice President, Brand Marketing, Advertising and Sponsorships of AT&T, Inc., a communications company (August 2011-December 2014)
|
|
|
|
|
•
|
|
Senior Vice President, Brand Marketing and Advertising of AT&T, Inc. (June 2009-July 2011)
|
Martin J. Lippert
|
|
58
|
|
•
|
|
Executive Vice President and Head of Global Technology and Operations of MetLife, Inc. (November 2011-present)
|
|
|
|
|
•
|
|
Executive Vice President and Head of Global Technology of MetLife, Inc. (September 2011-November 2011)
|
Ramy Tadros
|
|
42
|
|
•
|
|
Executive Vice President and Chief Risk Officer of MetLife, Inc. (September 2017-present)
|
|
|
|
|
•
|
|
Management Consultant, Oliver Wyman, Inc., a consulting company (September 1997-July 2017)
|
Susan Podlogar
|
|
54
|
|
•
|
|
Executive Vice President and Chief Human Resources Officer of MetLife, Inc. (July 2017-present)
|
|
|
|
|
•
|
|
Vice President Human Resources Global Medical Devices, Human Resources Executive Committee, Johnson & Johnson, a medical devices, pharmaceutical and consumer products company
(May 2016-June 2017)
|
|
|
|
|
•
|
|
Vice President Human Resources EMEA, Global Total Rewards, Human Resources Executive Committee, Johnson & Johnson (January 2015-May 2016)
|
|
|
|
|
•
|
|
Vice President Human Resources Global Total Rewards, Human Resources Executive Committee, Johnson & Johnson (January 2012-May 2015)
|
•
|
reducing new sales of insurance products, annuities and other investment products;
|
•
|
impacting the cost and availability of financing for MetLife, Inc. and its subsidiaries;
|
•
|
adversely affecting our relationships with our sales force and independent sales intermediaries;
|
•
|
materially increasing the number or amount of policy surrenders and withdrawals by contractholders and policyholders;
|
•
|
requiring us to post additional collateral under certain of our financing and derivative transactions;
|
•
|
requiring us to reduce prices for many of our products and services to remain competitive;
|
•
|
providing termination rights for the benefit of our derivative instrument counterparties;
|
•
|
adversely affecting our ability to obtain reinsurance at reasonable prices or at all;
|
•
|
limiting our access to the capital markets;
|
•
|
increasing the cost of debt;
|
•
|
requiring us to post collateral; and
|
•
|
subjecting us to increased regulatory scrutiny.
|
•
|
Loss of key personnel or higher than expected employee attrition rates could adversely affect the performance of the acquired business and our ability to integrate it successfully.
|
•
|
Customers of the acquired business may reduce, delay or defer decisions concerning their use of its products and services as a result of the acquisition or uncertainty related to the consummation of the acquisition, including, for example, potential unfamiliarity with the MetLife brand in regions where we did not have a market presence prior to the acquisition.
|
•
|
If the acquired business relies upon independent distributors to distribute its products, these distributors may not continue to generate the same volume of business for us after the acquisition. Independent distributors may reexamine the scope of their relationship with the acquired business or us as a result of the acquisition and decide to curtail or eliminate distribution of our products.
|
•
|
If the acquired business relies on continued distribution access with another party, we are also exposed to the risk of loss of exclusivity or change in access due to regulatory changes.
|
•
|
Integrating acquired operations with our existing operations may require us to coordinate geographically separated organizations, address possible differences in corporate culture and management philosophies, merge financial processes and risk and compliance procedures, combine separate information technology platforms and integrate operations that were previously closely tied to the former parent of the acquired business or other service providers.
|
•
|
In cases where we or an acquired business operates in certain markets through joint ventures, the acquisition may affect the continued success and prospects of the joint venture.
|
•
|
We may incur significant costs in connection with any acquisition and the related integration. The costs and liabilities actually incurred in connection with an acquisition and subsequent integration process may exceed those anticipated.
|
•
|
the RBC ratio of MetLife’s largest U.S. insurance subsidiaries in the aggregate (as defined in the applicable instrument) were to be less than 175% of the company action level based on the subsidiaries’ prior year annual financial statements filed (generally around March 1) with state insurance commissioners; or
|
•
|
at the end of a quarter (“Final Quarter End Test Date”), consolidated GAAP net income for the four-quarter period ending two quarters before such quarter-end (the “Preliminary Quarter End Test Date”) is zero or a negative amount and the consolidated GAAP stockholders’ equity, minus AOCI (the “adjusted stockholders’ equity amount”), as of the Final Quarter End Test Date and the Preliminary Quarter End Test Date, declined by 10% or more from (A) its level 10 quarters before the Final Quarter End Test Date (the “Benchmark Quarter End Test Date”), for Benchmark Quarter End Test Dates after August 4, 2017 (the date of the Separation), or (B) $49,282,000,000, the consolidated GAAP stockholders’ equity, minus AOCI as of June 30, 2017 as reported on a pro forma basis reflecting the Separation in MetLife’s Form 8-K filed with the SEC on August 9, 2017, for Benchmark Quarter End Test Dates prior to August 4, 2017.
|
•
|
an election or removal of directors in which a stockholder has properly nominated one or more candidates in opposition to a nominee or nominees of MetLife, Inc.’s Board of Directors or a vote on a stockholder’s proposal to oppose a Board nominee for director, remove a director for cause or fill a vacancy caused by the removal of a director by stockholders, subject to certain conditions;
|
•
|
a merger or consolidation, a sale, lease or exchange of all or substantially all of the assets, or a recapitalization or dissolution, of MetLife, Inc., in each case requiring a vote of stockholders under applicable Delaware law;
|
•
|
any transaction that would result in an exchange or conversion of shares of common stock held by the Trust for cash, securities or other property; and
|
•
|
any proposal requiring MetLife, Inc.’s Board of Directors to amend or redeem the rights under MetLife, Inc.’s stockholder rights plan, other than a proposal with respect to which we have received advice of nationally-recognized legal counsel to the effect that the proposal is not a proper subject for stockholder action under Delaware law. MetLife, Inc. does not currently have a stockholder rights plan.
|
•
|
applicable state insurance laws and regulations may delay or impede a business combination involving us by prohibiting an entity from acquiring control (generally presumed to exist at direct or indirect ownership of 10% or more of voting stock) of an insurance company domiciled in the United States without the prior approval of the domestic insurance regulator. Many foreign jurisdictions in which we operate have similar regulatory approval requirements.
|
•
|
if the acquiring entity is a bank or non-bank SIFI, Dodd-Frank provisions that restrict or impede consolidations, mergers and acquisitions by systemically significant firms.
|
•
|
Provisions of the Investment Company Act that require approval by the contract owners of our variable contracts in order to effectuate a change of control of any affiliated investment adviser to a mutual fund underlying our variable contracts.
|
•
|
FINRA approval requirements for a change of control of any FINRA registered broker-dealer that is a direct or indirect subsidiary of MetLife, Inc.
|
•
|
Provisions of the Delaware General Corporation Law may affect the ability of an “interested stockholder” (the owner of 15% or more of the outstanding voting stock of a corporation) to engage in certain business combinations for a period of three years following the time that the stockholder becomes an “interested stockholder.”
|
|
2017
|
||||||||||||||
|
1st Quarter
|
|
2nd Quarter
|
|
3rd Quarter
|
|
4th Quarter
|
||||||||
Common Stock Price
|
|
|
|
|
|
|
|
||||||||
High
|
$
|
50.04
|
|
|
$
|
49.07
|
|
|
$
|
51.95
|
|
|
$
|
55.73
|
|
Low
|
$
|
45.80
|
|
|
$
|
44.39
|
|
|
$
|
46.68
|
|
|
$
|
50.56
|
|
|
2016
|
||||||||||||||
|
1st Quarter
|
|
2nd Quarter
|
|
3rd Quarter
|
|
4th Quarter
|
||||||||
Common Stock Price
|
|
|
|
|
|
|
|
||||||||
High
|
$
|
42.17
|
|
|
$
|
41.80
|
|
|
$
|
39.84
|
|
|
$
|
51.15
|
|
Low
|
$
|
31.38
|
|
|
$
|
32.56
|
|
|
$
|
33.73
|
|
|
$
|
39.55
|
|
|
|
|
|
|
|
Dividend
|
||||||
Declaration Date
|
|
Record Date
|
|
Payment Date
|
|
Per Share
|
|
Aggregate
|
||||
|
|
|
|
|
|
|
|
(In millions)
|
||||
October 24, 2017
|
|
November 6, 2017
|
|
December 13, 2017
|
|
$
|
0.400
|
|
|
$
|
422
|
|
July 7, 2017
|
|
August 7, 2017
|
|
September 13, 2017
|
|
$
|
0.400
|
|
|
427
|
|
|
April 25, 2017
|
|
May 8, 2017
|
|
June 13, 2017
|
|
$
|
0.400
|
|
|
431
|
|
|
January 6, 2017
|
|
February 6, 2017
|
|
March 13, 2017
|
|
$
|
0.400
|
|
|
437
|
|
|
|
|
|
|
|
|
|
|
$
|
1,717
|
|
||
|
|
|
|
|
|
|
|
|
||||
October 25, 2016
|
|
November 7, 2016
|
|
December 13, 2016
|
|
$
|
0.400
|
|
|
$
|
441
|
|
July 7, 2016
|
|
August 8, 2016
|
|
September 13, 2016
|
|
$
|
0.400
|
|
|
441
|
|
|
April 26, 2016
|
|
May 9, 2016
|
|
June 13, 2016
|
|
$
|
0.400
|
|
|
441
|
|
|
January 6, 2016
|
|
February 5, 2016
|
|
March 14, 2016
|
|
$
|
0.375
|
|
|
413
|
|
|
|
|
|
|
|
|
|
|
$
|
1,736
|
|
Period
|
|
(a) Total Number of Shares Purchased (1)
|
|
(b) Average Price Paid per Share
|
|
(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
|
(d) Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (2)
|
||
October 1 - October 31, 2017
|
|
2,466,869
|
|
|
$52.73
|
|
2,466,869
|
|
|
$253,120,134
|
November 1 - November 30, 2017
|
|
1,664,085
|
|
|
$52.16
|
|
1,664,085
|
|
|
$2,166,319,397
|
December 1 - December 31, 2017
|
|
7,730,961
|
|
|
$52.31
|
|
7,730,961
|
|
|
$1,761,926,649
|
(1)
|
Except for the foregoing, there were no shares of MetLife, Inc. common stock repurchased by MetLife, Inc.
|
(2)
|
On November 1, 2017, MetLife, Inc. announced that its Board of Directors authorized
$2.0 billion
of common stock repurchases. At December 31,
2017
, MetLife, Inc. had
$1.8 billion
of common stock repurchases remaining under the authorization. For more information on common stock repurchases, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Common Stock Repurchases,” “Risk Factors — Capital-Related Risks — Legal and Regulatory Restrictions and Uncertainty and Restrictions Under the Terms of Certain of Our Securities May Prevent Us from Repurchasing Our Stock and Paying Dividends at the Level We Wish” and Notes
15
and
22
of the Notes to the Consolidated Financial Statements.
|
|
|
As of December 31,
|
||||||||||||||||||||||
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||||
MetLife, Inc. common stock
|
|
$
|
100.00
|
|
|
$
|
167.43
|
|
|
$
|
172.20
|
|
|
$
|
157.96
|
|
|
$
|
182.79
|
|
|
$
|
198.34
|
|
S&P 500
|
|
100.00
|
|
|
132.39
|
|
|
150.51
|
|
|
152.59
|
|
|
170.84
|
|
|
208.14
|
|
||||||
S&P 500 Insurance
|
|
100.00
|
|
|
146.71
|
|
|
158.86
|
|
|
162.56
|
|
|
191.15
|
|
|
222.09
|
|
||||||
S&P 500 Financials
|
|
100.00
|
|
|
135.63
|
|
|
156.25
|
|
|
153.86
|
|
|
188.94
|
|
|
230.85
|
|
|
|
Years Ended December 31,
|
||||||||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
|
|
(In millions)
|
||||||||||||||||||
Statement of Operations Data
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Premiums
|
|
$
|
38,992
|
|
|
$
|
37,202
|
|
|
$
|
36,403
|
|
|
$
|
36,970
|
|
|
$
|
36,222
|
|
Universal life and investment-type product policy fees
|
|
5,510
|
|
|
5,483
|
|
|
5,570
|
|
|
5,824
|
|
|
5,381
|
|
|||||
Net investment income
|
|
17,363
|
|
|
16,790
|
|
|
16,205
|
|
|
18,158
|
|
|
18,956
|
|
|||||
Other revenues
|
|
1,341
|
|
|
1,685
|
|
|
1,927
|
|
|
1,962
|
|
|
1,834
|
|
|||||
Net investment gains (losses)
|
|
(308
|
)
|
|
317
|
|
|
609
|
|
|
338
|
|
|
198
|
|
|||||
Net derivative gains (losses)
|
|
(590
|
)
|
|
(690
|
)
|
|
629
|
|
|
722
|
|
|
(1,475
|
)
|
|||||
Total revenues
|
|
62,308
|
|
|
60,787
|
|
|
61,343
|
|
|
63,974
|
|
|
61,116
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Expenses
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Policyholder benefits and claims
|
|
38,313
|
|
|
36,358
|
|
|
35,144
|
|
|
35,393
|
|
|
34,239
|
|
|||||
Interest credited to policyholder account balances
|
|
5,607
|
|
|
5,176
|
|
|
4,415
|
|
|
5,726
|
|
|
6,881
|
|
|||||
Policyholder dividends
|
|
1,231
|
|
|
1,223
|
|
|
1,356
|
|
|
1,353
|
|
|
1,236
|
|
|||||
Other expenses
|
|
13,621
|
|
|
13,749
|
|
|
14,777
|
|
|
14,619
|
|
|
15,074
|
|
|||||
Total expenses
|
|
58,772
|
|
|
56,506
|
|
|
55,692
|
|
|
57,091
|
|
|
57,430
|
|
|||||
Income (loss) from continuing operations before provision for income tax
|
|
3,536
|
|
|
4,281
|
|
|
5,651
|
|
|
6,883
|
|
|
3,686
|
|
|||||
Provision for income tax expense (benefit)
|
|
(1,470
|
)
|
|
693
|
|
|
1,590
|
|
|
1,936
|
|
|
687
|
|
|||||
Income (loss) from continuing operations, net of income tax
|
|
5,006
|
|
|
3,588
|
|
|
4,061
|
|
|
4,947
|
|
|
2,999
|
|
|||||
Income (loss) from discontinued operations, net of income tax
|
|
(986
|
)
|
|
(2,734
|
)
|
|
1,324
|
|
|
1,389
|
|
|
394
|
|
|||||
Net income (loss)
|
|
4,020
|
|
|
854
|
|
|
5,385
|
|
|
6,336
|
|
|
3,393
|
|
|||||
Less: Net income (loss) attributable to noncontrolling interests
|
|
10
|
|
|
4
|
|
|
12
|
|
|
27
|
|
|
25
|
|
|||||
Net income (loss) attributable to MetLife, Inc.
|
|
4,010
|
|
|
850
|
|
|
5,373
|
|
|
6,309
|
|
|
3,368
|
|
|||||
Less: Preferred stock dividends
|
|
103
|
|
|
103
|
|
|
116
|
|
|
122
|
|
|
122
|
|
|||||
Preferred stock repurchase premium
|
|
—
|
|
|
—
|
|
|
42
|
|
|
—
|
|
|
—
|
|
|||||
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
3,907
|
|
|
$
|
747
|
|
|
$
|
5,215
|
|
|
$
|
6,187
|
|
|
$
|
3,246
|
|
|
|
Years Ended December 31,
|
||||||||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
EPS Data
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders per common share:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic
|
|
$
|
4.57
|
|
|
$
|
3.16
|
|
|
$
|
3.48
|
|
|
$
|
4.25
|
|
|
$
|
2.58
|
|
Diluted
|
|
$
|
4.53
|
|
|
$
|
3.13
|
|
|
$
|
3.44
|
|
|
$
|
4.20
|
|
|
$
|
2.55
|
|
Income (loss) from discontinued operations, net of income tax, per common share:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic
|
|
$
|
(0.92
|
)
|
|
$
|
(2.48
|
)
|
|
$
|
1.19
|
|
|
$
|
1.23
|
|
|
$
|
0.36
|
|
Diluted
|
|
$
|
(0.91
|
)
|
|
$
|
(2.46
|
)
|
|
$
|
1.18
|
|
|
$
|
1.22
|
|
|
$
|
0.36
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic
|
|
$
|
3.65
|
|
|
$
|
0.68
|
|
|
$
|
4.67
|
|
|
$
|
5.48
|
|
|
$
|
2.94
|
|
Diluted
|
|
$
|
3.62
|
|
|
$
|
0.67
|
|
|
$
|
4.62
|
|
|
$
|
5.42
|
|
|
$
|
2.91
|
|
Cash dividends declared per common share
|
|
$
|
1.600
|
|
|
$
|
1.575
|
|
|
$
|
1.475
|
|
|
$
|
1.325
|
|
|
$
|
1.010
|
|
|
|
December 31,
|
||||||||||||||||||
|
|
2017
|
|
2016
|
|
2015 (1)
|
|
2014 (1)
|
|
2013 (1)
|
||||||||||
|
|
(In millions)
|
||||||||||||||||||
Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Assets of disposed subsidiary (2)
|
|
$
|
—
|
|
|
$
|
216,983
|
|
|
$
|
216,437
|
|
|
$
|
219,937
|
|
|
$
|
225,223
|
|
Separate account assets
|
|
$
|
205,001
|
|
|
$
|
195,578
|
|
|
$
|
187,152
|
|
|
$
|
194,072
|
|
|
$
|
192,763
|
|
Total assets
|
|
$
|
719,892
|
|
|
$
|
898,764
|
|
|
$
|
877,912
|
|
|
$
|
902,322
|
|
|
$
|
886,826
|
|
Policyholder liabilities and other policy-related balances (3)
|
|
$
|
378,810
|
|
|
$
|
355,151
|
|
|
$
|
342,047
|
|
|
$
|
349,651
|
|
|
$
|
347,078
|
|
Short-term debt
|
|
$
|
477
|
|
|
$
|
242
|
|
|
$
|
100
|
|
|
$
|
100
|
|
|
$
|
175
|
|
Long-term debt
|
|
$
|
15,686
|
|
|
$
|
16,441
|
|
|
$
|
17,936
|
|
|
$
|
16,108
|
|
|
$
|
17,153
|
|
Collateral financing arrangement
|
|
$
|
1,121
|
|
|
$
|
1,274
|
|
|
$
|
1,342
|
|
|
$
|
1,399
|
|
|
$
|
1,399
|
|
Junior subordinated debt securities
|
|
$
|
3,144
|
|
|
$
|
3,169
|
|
|
$
|
3,194
|
|
|
$
|
3,193
|
|
|
$
|
3,193
|
|
Liabilities of disposed subsidiary (2)
|
|
$
|
—
|
|
|
$
|
202,707
|
|
|
$
|
204,314
|
|
|
$
|
208,341
|
|
|
$
|
215,645
|
|
Separate account liabilities
|
|
$
|
205,001
|
|
|
$
|
195,578
|
|
|
$
|
187,152
|
|
|
$
|
194,072
|
|
|
$
|
192,763
|
|
Accumulated other comprehensive income (loss)
|
|
$
|
7,427
|
|
|
$
|
5,366
|
|
|
$
|
4,767
|
|
|
$
|
10,714
|
|
|
$
|
5,158
|
|
Total MetLife, Inc.’s stockholders’ equity
|
|
$
|
58,676
|
|
|
$
|
67,531
|
|
|
$
|
68,098
|
|
|
$
|
72,208
|
|
|
$
|
61,711
|
|
Noncontrolling interests
|
|
$
|
194
|
|
|
$
|
171
|
|
|
$
|
470
|
|
|
$
|
507
|
|
|
$
|
543
|
|
|
|
Years Ended December 31,
|
|||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|||||
Other Data (4)
|
|
|
|
|
|
|
|
|
|
|
|||||
Return on MetLife, Inc.’s common stockholders’ equity
|
|
6.3
|
%
|
|
1.0
|
%
|
|
7.7
|
%
|
|
9.5
|
%
|
|
5.3
|
%
|
(1)
|
See Note 1 of the Notes to the Consolidated Financial Statements for information on prior period revisions.
|
|
|
December 31, 2015
|
|
December 31, 2014
|
|
December 31, 2013
|
|||||||||||||||||||||
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
|||||||||
|
|
(In millions)
|
|||||||||||||||||||||||||
Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Assets of disposed subsidiary
|
|
216,437
|
|
|
—
|
|
|
216,437
|
|
|
219,951
|
|
|
(14
|
)
|
|
219,937
|
|
|
225,226
|
|
|
(3
|
)
|
|
225,223
|
|
Total Assets
|
|
877,933
|
|
|
(21
|
)
|
|
877,912
|
|
|
902,337
|
|
|
(15
|
)
|
|
902,322
|
|
|
886,825
|
|
|
1
|
|
|
886,826
|
|
Policyholder liabilities and other policy-related balances
|
|
342,279
|
|
|
(232
|
)
|
|
342,047
|
|
|
349,845
|
|
|
(194
|
)
|
|
349,651
|
|
|
347,281
|
|
|
(203
|
)
|
|
347,078
|
|
Liabilities of disposed subsidiary
|
|
204,374
|
|
|
(60
|
)
|
|
204,314
|
|
|
208,406
|
|
|
(65
|
)
|
|
208,341
|
|
|
215,702
|
|
|
(57
|
)
|
|
215,645
|
|
Accumulated other comprehensive income (loss)
|
|
4,771
|
|
|
(4
|
)
|
|
4,767
|
|
|
10,649
|
|
|
65
|
|
|
10,714
|
|
|
5,104
|
|
|
54
|
|
|
5,158
|
|
Total MetLife, Inc.’s stockholders’ equity
|
|
67,949
|
|
|
149
|
|
|
68,098
|
|
|
72,053
|
|
|
155
|
|
|
72,208
|
|
|
61,553
|
|
|
158
|
|
|
61,711
|
|
|
|
Year Ended December 31, 2016
|
|
Year Ended December 31, 2015
|
|
Year Ended December 31, 2014
|
|
Year Ended December 31, 2013
|
||||||||||||||||||||||||||||
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
|
As Previously Reported
|
|
Revisions
|
|
As Revised
|
||||||||||||
Other Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Return on MetLife, Inc.’s stockholders’ equity
|
|
1.0
|
%
|
|
—
|
%
|
|
1.0
|
%
|
|
7.5
|
%
|
|
0.2
|
%
|
|
7.7
|
%
|
|
9.4
|
%
|
|
0.1
|
%
|
|
9.5
|
%
|
|
5.4
|
%
|
|
(0.1
|
%)
|
|
5.3
|
%
|
(2)
|
See
Note 3
of the Notes to the Consolidated Financial Statements.
|
(3)
|
Policyholder liabilities and other policy-related balances include future policy benefits, policyholder account balances, other policy-related balances, policyholder dividends payable and the policyholder dividend obligation.
|
(4)
|
Return on MetLife, Inc.’s common stockholders’ equity is defined as net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.’s average common stockholders’ equity.
|
|
Page
|
|
Years Ended December 31,
|
||||||||||||||
|
2017
|
|
2018
|
|
2019
|
|
2020
|
||||||||
|
Low Interest Rate Scenario
|
|
Business Plan
|
|
Low Interest Rate Scenario
|
|
Business Plan
|
|
Low Interest Rate Scenario
|
|
Business Plan
|
|
Low Interest Rate Scenario
|
|
Business Plan
|
Three-month LIBOR
|
0.65%
|
|
1.69%
|
|
0.65%
|
|
2.19%
|
|
0.65%
|
|
2.31%
|
|
0.65%
|
|
2.35%
|
10-year U.S. Treasury
|
1.50%
|
|
2.41%
|
|
1.50%
|
|
2.61%
|
|
1.50%
|
|
2.72%
|
|
1.50%
|
|
2.80%
|
(i)
|
liabilities for future policy benefits and the accounting for reinsurance;
|
(ii)
|
capitalization and amortization of DAC and the establishment and amortization of VOBA;
|
(iii)
|
estimated fair values of investments in the absence of quoted market values;
|
(iv)
|
investment impairments;
|
(v)
|
estimated fair values of freestanding derivatives and the recognition and estimated fair value of embedded derivatives requiring bifurcation;
|
(vi)
|
measurement of goodwill and related impairment;
|
(vii)
|
measurement of employee benefit plan liabilities;
|
(viii)
|
measurement of income taxes and the valuation of deferred tax assets; and
|
(ix)
|
liabilities for litigation and regulatory matters.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
General account investment return
|
$
|
(5
|
)
|
|
$
|
5
|
|
|
$
|
(3
|
)
|
Separate account investment return
|
21
|
|
|
(3
|
)
|
|
(27
|
)
|
|||
Net investment gains (losses)/Net derivative gains (losses)
|
60
|
|
|
226
|
|
|
(151
|
)
|
|||
Guaranteed minimum income benefits
|
(2
|
)
|
|
44
|
|
|
11
|
|
|||
Expense
|
12
|
|
|
2
|
|
|
(96
|
)
|
|||
In-force/Persistency
|
(10
|
)
|
|
(63
|
)
|
|
106
|
|
|||
Policyholder dividends and other
|
56
|
|
|
(189
|
)
|
|
(73
|
)
|
|||
Total
|
$
|
132
|
|
|
$
|
22
|
|
|
$
|
(233
|
)
|
•
|
Changes in net investment and net derivative gains (losses) resulted in the following changes in DAC and VOBA amortization:
|
–
|
Actual gross profits increased as a result of a decrease in liabilities associated with guarantee obligations on variable annuities, resulting in an increase of DAC and VOBA amortization of approximately $80 million, including the impact from our nonperformance risk and risk margins in the valuation. This is more than offset by the mark-to-market losses and adjustments on the freestanding derivatives hedging such guarantee obligations which resulted in a decrease in DAC and VOBA amortization of approximately $90 million.
|
–
|
The remainder of the impact decreased DAC amortization by approximately $45 million and was attributable to 2017 investment activities.
|
•
|
The change in policyholder dividends and other is primarily driven by a decrease of approximately $60 million of DAC amortization resulting from the annual actuarial assumption update of the closed block, partially offset by an increase of approximately $40 million of DAC amortization from the dividend scale update of the open block. In addition, DAC amortization decreased by approximately $55 million due to an adjustment related to certain participating whole life business assumed from Brighthouse.
|
•
|
Changes in net investment and net derivative gains (losses) resulted in the following changes in DAC and VOBA amortization:
|
–
|
Actual gross profits increased as a result of a decrease in liabilities associated with guarantee obligations on variable annuities, resulting in an increase of DAC and VOBA amortization of approximately $60 million, excluding the impact from our nonperformance risk and risk margins, which are described below. Mark-to-market losses on the freestanding derivatives hedging such guarantee obligations resulted in a decrease in DAC and VOBA amortization of approximately $180
million.
|
–
|
The Company’s nonperformance risk adjustment decreased the valuation of guaranteed liabilities, increased actual gross profits and increased DAC and VOBA amortization by approximately $40 million. This is more than offset by higher risk margins, which increased the guarantee liability valuations, decreased actual gross profits and decreased DAC and VOBA amortization by approximately $120 million.
|
–
|
The remainder of the impact decreased DAC and VOBA amortization by approximately $30 million and was attributable to 2016 investment activities and assumption updates.
|
•
|
The change in policyholder dividends and other is primarily driven by:
|
–
|
An increase of approximately $110 million of DAC and VOBA amortization resulting from the annual actuarial assumption update of the closed block.
|
–
|
An increase of approximately $70 million of DAC and VOBA amortization resulting from the dividend scale update.
|
•
|
Changes in net investment and net derivative gains (losses) resulted in the following changes in DAC and VOBA amortization:
|
–
|
Actual gross profits decreased as a result of an increase in liabilities associated with guarantee obligations on variable annuities, resulting in a decrease of DAC and VOBA amortization of approximately $90 million. Mark-to-market changes on the freestanding derivatives hedging such guarantee obligations resulted in an increase in DAC and VOBA amortization of approximately $70 million.
|
–
|
The remainder of the impact increased DAC and VOBA amortization by approximately $170 million and was attributable to 2015 investment activities.
|
•
|
Better than expected persistency and updates in persistency assumptions caused an increase in actual and expected future gross profits resulting in a decrease in DAC and VOBA amortization of approximately $110 million.
|
•
|
The change in expense resulted in an increase to DAC and VOBA amortization of approximately $100 million primarily attributable to the annual actuarial assumption update.
|
•
|
The change in policyholder dividends and other is primarily driven by an increase of approximately $70 million of DAC and VOBA amortization resulting from the actuarial assumption update, primarily related to closed block, and other model refinements.
|
|
Changes in Balance Sheet Carrying Value At December 31, 2017
|
||||||
|
Policyholder Account Balances
|
|
DAC and VOBA
|
||||
|
(In millions)
|
||||||
100% increase in our credit spread
|
$
|
230
|
|
|
$
|
19
|
|
As reported
|
$
|
323
|
|
|
$
|
27
|
|
50% decrease in our credit spread
|
$
|
386
|
|
|
$
|
35
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
38,992
|
|
|
$
|
37,202
|
|
|
$
|
36,403
|
|
Universal life and investment-type product policy fees
|
5,510
|
|
|
5,483
|
|
|
5,570
|
|
|||
Net investment income
|
17,363
|
|
|
16,790
|
|
|
16,205
|
|
|||
Other revenues
|
1,341
|
|
|
1,685
|
|
|
1,927
|
|
|||
Net investment gains (losses)
|
(308
|
)
|
|
317
|
|
|
609
|
|
|||
Net derivative gains (losses)
|
(590
|
)
|
|
(690
|
)
|
|
629
|
|
|||
Total revenues
|
62,308
|
|
|
60,787
|
|
|
61,343
|
|
|||
Expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
39,544
|
|
|
37,581
|
|
|
36,500
|
|
|||
Interest credited to policyholder account balances
|
5,607
|
|
|
5,176
|
|
|
4,415
|
|
|||
Capitalization of DAC
|
(3,002
|
)
|
|
(3,152
|
)
|
|
(3,319
|
)
|
|||
Amortization of DAC and VOBA
|
2,681
|
|
|
2,718
|
|
|
3,184
|
|
|||
Amortization of negative VOBA
|
(140
|
)
|
|
(269
|
)
|
|
(361
|
)
|
|||
Interest expense on debt
|
1,129
|
|
|
1,157
|
|
|
1,168
|
|
|||
Other expenses
|
12,953
|
|
|
13,295
|
|
|
14,105
|
|
|||
Total expenses
|
58,772
|
|
|
56,506
|
|
|
55,692
|
|
|||
Income (loss) from continuing operations before provision for income tax
|
3,536
|
|
|
4,281
|
|
|
5,651
|
|
|||
Provision for income tax expense (benefit)
|
(1,470
|
)
|
|
693
|
|
|
1,590
|
|
|||
Income (loss) from continuing operations, net of income tax
|
5,006
|
|
|
3,588
|
|
|
4,061
|
|
|||
Income (loss) from discontinued operations, net of income tax
|
(986
|
)
|
|
(2,734
|
)
|
|
1,324
|
|
|||
Net income (loss)
|
4,020
|
|
|
854
|
|
|
5,385
|
|
|||
Less: Net income (loss) attributable to noncontrolling interests
|
10
|
|
|
4
|
|
|
12
|
|
|||
Net income (loss) attributable to MetLife, Inc.
|
4,010
|
|
|
850
|
|
|
5,373
|
|
|||
Less: Preferred stock dividends
|
103
|
|
|
103
|
|
|
116
|
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
42
|
|
|||
Net income (loss) available to MetLife, Inc.’s common shareholders
|
$
|
3,907
|
|
|
$
|
747
|
|
|
$
|
5,215
|
|
|
Years Ended December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Non-VA program derivatives
|
|
|
|
||||
Interest rate
|
$
|
(39
|
)
|
|
$
|
(449
|
)
|
Foreign currency exchange rate
|
(379
|
)
|
|
352
|
|
||
Credit
|
198
|
|
|
108
|
|
||
Equity
|
6
|
|
|
12
|
|
||
Non-VA embedded derivatives
|
(131
|
)
|
|
26
|
|
||
Total non-VA program derivatives
|
(345
|
)
|
|
49
|
|
||
VA program derivatives
|
|
|
|
||||
Market risks in embedded derivatives
|
1,052
|
|
|
364
|
|
||
Nonperformance risk adjustment on embedded derivatives
|
(190
|
)
|
|
156
|
|
||
Other risks in embedded derivatives
|
68
|
|
|
(727
|
)
|
||
Total embedded derivatives
|
930
|
|
|
(207
|
)
|
||
Freestanding derivatives hedging embedded derivatives
|
(1,175
|
)
|
|
(532
|
)
|
||
Total VA program derivatives
|
(245
|
)
|
|
(739
|
)
|
||
Net derivative gains (losses)
|
$
|
(590
|
)
|
|
$
|
(690
|
)
|
•
|
Changes in foreign currency exchange rates contributed to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives related to the assumed variable annuity guarantees from our former operating joint venture in Japan. For example, the Japanese yen weakened against the euro by 10% in 2017 and strengthened by 6% in 2016.
|
•
|
Key equity index levels increased more in 2017 than in 2016, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the S&P 500 Index increased 19% in 2017 and increased 10% in 2016.
|
•
|
Long-term interest rates in Japan increased in 2017 and decreased in 2016, contributing to a favorable change in our embedded derivatives and an unfavorable change in our freestanding derivatives related to the assumed variable annuity guarantees from our former operating joint venture in Japan. This was partially offset by long-term U.S. interest rates mostly decreasing in 2017 and mostly increasing in 2016. For example, the 30-year Japan swap rate increased five basis points in 2017 and decreased 41 basis points in 2016, and the 20-year U.S. swap rate decreased three basis points in 2017 and increased three basis points in 2016.
|
•
|
Updates to actuarial policyholder behavior assumptions within the valuation model.
|
•
|
A change in the risk margin adjustment measuring policyholder behavior risks, along with market and interest rate changes, and
|
•
|
The partially offsetting impact of a combination of other factors, which include fees being deducted from accounts and changes in the benefit base, premiums, lapses, withdrawals and mortality rates.
|
•
|
Changes in operational assumptions, most notably related to updates to maintenance expense and closed block projections, resulted in a net gain of $114 million ($74 million net of income tax).
|
•
|
Changes in policyholder behavior assumptions resulted in reserve increases, partially offset by favorable DAC, resulting in a net charge of $47 million ($29 million, net of income tax).
|
•
|
Economic assumption updates resulted in reserve increases and DAC releases, resulting in a charge of $19 million ($13 million net of income tax).
|
•
|
Changes to biometric assumptions resulted in an increase in reserves, partially offset by favorable DAC, resulting in a charge of $11 million ($7 million, net of income tax).
|
|
Years Ended December 31,
|
||||||
|
2016
|
|
2015
|
||||
|
(In millions)
|
||||||
Non-VA program derivatives
|
|
|
|
||||
Interest rate
|
$
|
(449
|
)
|
|
$
|
61
|
|
Foreign currency exchange rate
|
352
|
|
|
393
|
|
||
Credit
|
108
|
|
|
7
|
|
||
Equity
|
12
|
|
|
(1
|
)
|
||
Non-VA embedded derivatives
|
26
|
|
|
66
|
|
||
Total non-VA program derivatives
|
49
|
|
|
526
|
|
||
VA program derivatives
|
|
|
|
||||
Market risks in embedded derivatives
|
364
|
|
|
246
|
|
||
Nonperformance risk adjustment on embedded derivatives
|
156
|
|
|
52
|
|
||
Other risks in embedded derivatives
|
(727
|
)
|
|
(164
|
)
|
||
Total embedded derivatives
|
(207
|
)
|
|
134
|
|
||
Freestanding derivatives hedging embedded derivatives
|
(532
|
)
|
|
(31
|
)
|
||
Total VA program derivatives
|
(739
|
)
|
|
103
|
|
||
Net derivative gains (losses)
|
$
|
(690
|
)
|
|
$
|
629
|
|
•
|
Long-term interest rates increased in 2016 and decreased in 2015, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the 10-year U.S. swap rate increased 15 basis points in 2016 and decreased 10 basis points in 2015.
|
•
|
Key equity index levels mostly increased in 2016 and decreased in 2015, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the S&P 500 Index increased 10% in 2016 and decreased 1% in 2015.
|
•
|
Updates to actuarial policyholder behavior assumptions within the valuation model; and
|
•
|
An increase in the risk margin adjustment, measuring policyholder behavior risks along with market and interest rate changes; partially offset by
|
•
|
The cross effect of capital market changes and the mismatch of fund performance between actual and modeled funds; and
|
•
|
A combination of other factors, including reserve changes influenced by benefit features and actual policyholder behavior, as well as FCTA.
|
•
|
Changes in policyholder behavior and mortality assumptions resulted in reserve increases, partially offset by favorable DAC amortization, resulting in a loss of $356 million ($231 million, net of income tax).
|
•
|
Changes in economic assumptions resulted in reserve increases and unfavorable DAC amortization resulting in a loss of $125 million ($81 million, net of income tax).
|
•
|
The remaining updates resulted in reserve increases and unfavorable DAC amortization, resulting in a loss of $167 million ($109 million, net of income tax).
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife Holdings
|
|
Corporate & Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Net income (loss)
|
$
|
2,001
|
|
|
$
|
1,298
|
|
|
$
|
613
|
|
|
$
|
301
|
|
|
$
|
914
|
|
|
$
|
(1,107
|
)
|
|
$
|
4,020
|
|
Less: Income (loss) from discontinued operations, net of income tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(986
|
)
|
|
(986
|
)
|
|||||||
Income (loss) from continuing operations, net of income tax
|
$
|
2,001
|
|
|
$
|
1,298
|
|
|
$
|
613
|
|
|
$
|
301
|
|
|
$
|
914
|
|
|
$
|
(121
|
)
|
|
$
|
5,006
|
|
Less: Net investment gains (losses)
|
180
|
|
|
128
|
|
|
(47
|
)
|
|
(10
|
)
|
|
71
|
|
|
(630
|
)
|
|
(308
|
)
|
|||||||
Less: Net derivative gains (losses)
|
(21
|
)
|
|
31
|
|
|
108
|
|
|
32
|
|
|
(339
|
)
|
|
(401
|
)
|
|
(590
|
)
|
|||||||
Less: Other adjustments to continuing operations (1)
|
(197
|
)
|
|
(43
|
)
|
|
8
|
|
|
17
|
|
|
(337
|
)
|
|
(1,070
|
)
|
|
(1,622
|
)
|
|||||||
Less: Provision for income tax (expense) benefit
|
12
|
|
|
(47
|
)
|
|
(41
|
)
|
|
(35
|
)
|
|
337
|
|
|
2,962
|
|
|
3,188
|
|
|||||||
Adjusted earnings
|
$
|
2,027
|
|
|
$
|
1,229
|
|
|
$
|
585
|
|
|
$
|
297
|
|
|
$
|
1,182
|
|
|
(982
|
)
|
|
4,338
|
|
||
Less: Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
103
|
|
|
103
|
|
||||||||||||
Adjusted earnings available to common shareholders
|
|
|
|
|
|
|
|
|
|
|
$
|
(1,085
|
)
|
|
$
|
4,235
|
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife Holdings
|
|
Corporate & Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Net income (loss)
|
$
|
1,756
|
|
|
$
|
1,420
|
|
|
$
|
629
|
|
|
$
|
311
|
|
|
$
|
300
|
|
|
$
|
(3,562
|
)
|
|
$
|
854
|
|
Less: Income (loss) from discontinued operations, net of income tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,734
|
)
|
|
(2,734
|
)
|
|||||||
Income (loss) from continuing operations, net of income tax
|
$
|
1,756
|
|
|
$
|
1,420
|
|
|
$
|
629
|
|
|
$
|
311
|
|
|
$
|
300
|
|
|
$
|
(828
|
)
|
|
$
|
3,588
|
|
Less: Net investment gains (losses)
|
(15
|
)
|
|
230
|
|
|
93
|
|
|
42
|
|
|
182
|
|
|
(215
|
)
|
|
317
|
|
|||||||
Less: Net derivative gains (losses)
|
53
|
|
|
(47
|
)
|
|
3
|
|
|
24
|
|
|
(757
|
)
|
|
34
|
|
|
(690
|
)
|
|||||||
Less: Other adjustments to continuing operations (1)
|
(263
|
)
|
|
26
|
|
|
58
|
|
|
33
|
|
|
(50
|
)
|
|
(285
|
)
|
|
(481
|
)
|
|||||||
Less: Provision for income tax (expense) benefit
|
85
|
|
|
(13
|
)
|
|
(68
|
)
|
|
(61
|
)
|
|
219
|
|
|
144
|
|
|
306
|
|
|||||||
Adjusted earnings
|
$
|
1,896
|
|
|
$
|
1,224
|
|
|
$
|
543
|
|
|
$
|
273
|
|
|
$
|
706
|
|
|
(506
|
)
|
|
4,136
|
|
||
Less: Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
103
|
|
|
103
|
|
||||||||||||
Adjusted earnings available to common shareholders
|
|
|
|
|
|
|
|
|
|
|
$
|
(609
|
)
|
|
$
|
4,033
|
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife Holdings
|
|
Corporate & Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Net income (loss)
|
$
|
2,080
|
|
|
$
|
1,813
|
|
|
$
|
503
|
|
|
$
|
288
|
|
|
$
|
1,175
|
|
|
$
|
(474
|
)
|
|
$
|
5,385
|
|
Less: Income (loss) from discontinued operations, net of income tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,324
|
|
|
1,324
|
|
|||||||
Income (loss) from continuing operations, net of income tax
|
$
|
2,080
|
|
|
$
|
1,813
|
|
|
$
|
503
|
|
|
$
|
288
|
|
|
$
|
1,175
|
|
|
$
|
(1,798
|
)
|
|
$
|
4,061
|
|
Less: Net investment gains (losses)
|
256
|
|
|
459
|
|
|
82
|
|
|
27
|
|
|
(37
|
)
|
|
(178
|
)
|
|
609
|
|
|||||||
Less: Net derivative gains (losses)
|
98
|
|
|
67
|
|
|
(135
|
)
|
|
40
|
|
|
391
|
|
|
168
|
|
|
629
|
|
|||||||
Less: Other adjustments to continuing operations (1)
|
(149
|
)
|
|
(120
|
)
|
|
(72
|
)
|
|
3
|
|
|
(455
|
)
|
|
(568
|
)
|
|
(1,361
|
)
|
|||||||
Less: Provision for income tax (expense) benefit
|
(72
|
)
|
|
19
|
|
|
3
|
|
|
(22
|
)
|
|
36
|
|
|
190
|
|
|
154
|
|
|||||||
Adjusted earnings
|
$
|
1,947
|
|
|
$
|
1,388
|
|
|
$
|
625
|
|
|
$
|
240
|
|
|
$
|
1,240
|
|
|
(1,410
|
)
|
|
4,030
|
|
||
Less: Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
116
|
|
|
116
|
|
||||||||||||
Adjusted earnings available to common shareholders
|
|
|
|
|
|
|
|
|
|
|
$
|
(1,526
|
)
|
|
$
|
3,914
|
|
(1)
|
See definitions of adjusted revenues and adjusted expenses under “— Non-GAAP and Other Financial Disclosures” for the components of such adjustments and Note 2 of the Notes to the Consolidated Financial Statements for additional details on these adjustments by financial statement line item.
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife Holdings
|
|
Corporate & Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Total revenues
|
$
|
31,810
|
|
|
$
|
11,875
|
|
|
$
|
5,118
|
|
|
$
|
3,729
|
|
|
$
|
11,005
|
|
|
$
|
(1,229
|
)
|
|
$
|
62,308
|
|
Less: Net investment gains (losses)
|
180
|
|
|
128
|
|
|
(47
|
)
|
|
(10
|
)
|
|
71
|
|
|
(630
|
)
|
|
(308
|
)
|
|||||||
Less: Net derivative gains (losses)
|
(21
|
)
|
|
31
|
|
|
108
|
|
|
32
|
|
|
(339
|
)
|
|
(401
|
)
|
|
(590
|
)
|
|||||||
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
13
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
12
|
|
|||||||
Less: Other adjustments to revenues (1)
|
(195
|
)
|
|
336
|
|
|
69
|
|
|
875
|
|
|
(83
|
)
|
|
(552
|
)
|
|
450
|
|
|||||||
Total adjusted revenues
|
$
|
31,846
|
|
|
$
|
11,367
|
|
|
$
|
4,988
|
|
|
$
|
2,833
|
|
|
$
|
11,356
|
|
|
$
|
354
|
|
|
$
|
62,744
|
|
Total expenses
|
$
|
28,797
|
|
|
$
|
9,910
|
|
|
$
|
4,308
|
|
|
$
|
3,334
|
|
|
$
|
9,881
|
|
|
$
|
2,542
|
|
|
$
|
58,772
|
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
9
|
|
|
—
|
|
|
(1
|
)
|
|
(70
|
)
|
|
2
|
|
|
(60
|
)
|
|||||||
Less: Other adjustments to expenses (1)
|
2
|
|
|
383
|
|
|
61
|
|
|
858
|
|
|
324
|
|
|
516
|
|
|
2,144
|
|
|||||||
Total adjusted expenses
|
$
|
28,795
|
|
|
$
|
9,518
|
|
|
$
|
4,247
|
|
|
$
|
2,477
|
|
|
$
|
9,627
|
|
|
$
|
2,024
|
|
|
$
|
56,688
|
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife Holdings
|
|
Corporate & Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Total revenues
|
$
|
29,254
|
|
|
$
|
11,973
|
|
|
$
|
4,816
|
|
|
$
|
3,810
|
|
|
$
|
11,710
|
|
|
$
|
(776
|
)
|
|
$
|
60,787
|
|
Less: Net investment gains (losses)
|
(15
|
)
|
|
230
|
|
|
93
|
|
|
42
|
|
|
182
|
|
|
(215
|
)
|
|
317
|
|
|||||||
Less: Net derivative gains (losses)
|
53
|
|
|
(47
|
)
|
|
3
|
|
|
24
|
|
|
(757
|
)
|
|
34
|
|
|
(690
|
)
|
|||||||
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
31
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
30
|
|
|||||||
Less: Other adjustments to revenues (1)
|
(264
|
)
|
|
601
|
|
|
48
|
|
|
936
|
|
|
(182
|
)
|
|
(925
|
)
|
|
214
|
|
|||||||
Total adjusted revenues
|
$
|
29,480
|
|
|
$
|
11,158
|
|
|
$
|
4,672
|
|
|
$
|
2,809
|
|
|
$
|
12,467
|
|
|
$
|
330
|
|
|
$
|
60,916
|
|
Total expenses
|
$
|
26,607
|
|
|
$
|
10,061
|
|
|
$
|
3,961
|
|
|
$
|
3,396
|
|
|
$
|
11,337
|
|
|
$
|
1,144
|
|
|
$
|
56,506
|
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
42
|
|
|
—
|
|
|
—
|
|
|
(268
|
)
|
|
—
|
|
|
(226
|
)
|
|||||||
Less: Other adjustments to expenses (1)
|
(1
|
)
|
|
564
|
|
|
(10
|
)
|
|
902
|
|
|
136
|
|
|
(640
|
)
|
|
951
|
|
|||||||
Total adjusted expenses
|
$
|
26,608
|
|
|
$
|
9,455
|
|
|
$
|
3,971
|
|
|
$
|
2,494
|
|
|
$
|
11,469
|
|
|
$
|
1,784
|
|
|
$
|
55,781
|
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife Holdings
|
|
Corporate & Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Total revenues
|
$
|
28,929
|
|
|
$
|
11,944
|
|
|
$
|
4,736
|
|
|
$
|
2,930
|
|
|
$
|
13,255
|
|
|
$
|
(451
|
)
|
|
$
|
61,343
|
|
Less: Net investment gains (losses)
|
256
|
|
|
459
|
|
|
82
|
|
|
27
|
|
|
(37
|
)
|
|
(178
|
)
|
|
609
|
|
|||||||
Less: Net derivative gains (losses)
|
98
|
|
|
67
|
|
|
(135
|
)
|
|
40
|
|
|
391
|
|
|
168
|
|
|
629
|
|
|||||||
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
12
|
|
|
—
|
|
|
(5
|
)
|
|
—
|
|
|
—
|
|
|
7
|
|
|||||||
Less: Other adjustments to revenues (1)
|
(163
|
)
|
|
147
|
|
|
12
|
|
|
21
|
|
|
(245
|
)
|
|
(674
|
)
|
|
(902
|
)
|
|||||||
Total adjusted revenues
|
$
|
28,738
|
|
|
$
|
11,259
|
|
|
$
|
4,777
|
|
|
$
|
2,847
|
|
|
$
|
13,146
|
|
|
$
|
233
|
|
|
$
|
61,000
|
|
Total expenses
|
$
|
25,768
|
|
|
$
|
9,689
|
|
|
$
|
4,199
|
|
|
$
|
2,599
|
|
|
$
|
11,534
|
|
|
$
|
1,903
|
|
|
$
|
55,692
|
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
9
|
|
|
—
|
|
|
(5
|
)
|
|
162
|
|
|
(9
|
)
|
|
157
|
|
|||||||
Less: Other adjustments to expenses (1)
|
(14
|
)
|
|
270
|
|
|
84
|
|
|
18
|
|
|
48
|
|
|
(97
|
)
|
|
309
|
|
|||||||
Total adjusted expenses
|
$
|
25,782
|
|
|
$
|
9,410
|
|
|
$
|
4,115
|
|
|
$
|
2,586
|
|
|
$
|
11,324
|
|
|
$
|
2,009
|
|
|
$
|
55,226
|
|
(1)
|
See definitions of adjusted revenues and adjusted expenses under “— Non-GAAP and Other Financial Disclosures” for the components of such adjustments and Note 2 of the Notes to the Consolidated Financial Statements for additional details on these adjustments by financial statement line item.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Adjusted revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
23,632
|
|
|
$
|
21,501
|
|
|
$
|
20,861
|
|
Universal life and investment-type product policy fees
|
1,012
|
|
|
989
|
|
|
943
|
|
|||
Net investment income
|
6,396
|
|
|
6,206
|
|
|
6,183
|
|
|||
Other revenues
|
806
|
|
|
784
|
|
|
751
|
|
|||
Total adjusted revenues
|
31,846
|
|
|
29,480
|
|
|
28,738
|
|
|||
Adjusted expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
23,627
|
|
|
21,591
|
|
|
20,899
|
|
|||
Interest credited to policyholder account balances
|
1,474
|
|
|
1,302
|
|
|
1,216
|
|
|||
Capitalization of DAC
|
(458
|
)
|
|
(471
|
)
|
|
(493
|
)
|
|||
Amortization of DAC and VOBA
|
459
|
|
|
471
|
|
|
471
|
|
|||
Interest expense on debt
|
11
|
|
|
9
|
|
|
4
|
|
|||
Other expenses
|
3,682
|
|
|
3,706
|
|
|
3,685
|
|
|||
Total adjusted expenses
|
28,795
|
|
|
26,608
|
|
|
25,782
|
|
|||
Provision for income tax expense (benefit)
|
1,024
|
|
|
976
|
|
|
1,009
|
|
|||
Adjusted earnings
|
$
|
2,027
|
|
|
$
|
1,896
|
|
|
$
|
1,947
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Adjusted revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
6,755
|
|
|
$
|
6,902
|
|
|
$
|
6,937
|
|
Universal life and investment-type product policy fees
|
1,584
|
|
|
1,488
|
|
|
1,542
|
|
|||
Net investment income
|
2,985
|
|
|
2,707
|
|
|
2,675
|
|
|||
Other revenues
|
43
|
|
|
61
|
|
|
105
|
|
|||
Total adjusted revenues
|
11,367
|
|
|
11,158
|
|
|
11,259
|
|
|||
Adjusted expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
5,075
|
|
|
5,211
|
|
|
5,266
|
|
|||
Interest credited to policyholder account balances
|
1,351
|
|
|
1,298
|
|
|
1,309
|
|
|||
Capitalization of DAC
|
(1,710
|
)
|
|
(1,668
|
)
|
|
(1,720
|
)
|
|||
Amortization of DAC and VOBA
|
1,300
|
|
|
1,236
|
|
|
1,253
|
|
|||
Amortization of negative VOBA
|
(111
|
)
|
|
(208
|
)
|
|
(309
|
)
|
|||
Other expenses
|
3,613
|
|
|
3,586
|
|
|
3,611
|
|
|||
Total adjusted expenses
|
9,518
|
|
|
9,455
|
|
|
9,410
|
|
|||
Provision for income tax expense (benefit)
|
620
|
|
|
479
|
|
|
461
|
|
|||
Adjusted earnings
|
$
|
1,229
|
|
|
$
|
1,224
|
|
|
$
|
1,388
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Adjusted revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
2,693
|
|
|
$
|
2,529
|
|
|
$
|
2,581
|
|
Universal life and investment-type product policy fees
|
1,044
|
|
|
1,025
|
|
|
1,117
|
|
|||
Net investment income
|
1,219
|
|
|
1,084
|
|
|
1,038
|
|
|||
Other revenues
|
32
|
|
|
34
|
|
|
41
|
|
|||
Total adjusted revenues
|
4,988
|
|
|
4,672
|
|
|
4,777
|
|
|||
Adjusted expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
2,535
|
|
|
2,443
|
|
|
2,408
|
|
|||
Interest credited to policyholder account balances
|
369
|
|
|
328
|
|
|
349
|
|
|||
Capitalization of DAC
|
(364
|
)
|
|
(321
|
)
|
|
(341
|
)
|
|||
Amortization of DAC and VOBA
|
224
|
|
|
184
|
|
|
271
|
|
|||
Amortization of negative VOBA
|
(1
|
)
|
|
(1
|
)
|
|
(1
|
)
|
|||
Interest expense on debt
|
5
|
|
|
2
|
|
|
—
|
|
|||
Other expenses
|
1,479
|
|
|
1,336
|
|
|
1,429
|
|
|||
Total adjusted expenses
|
4,247
|
|
|
3,971
|
|
|
4,115
|
|
|||
Provision for income tax expense (benefit)
|
156
|
|
|
158
|
|
|
37
|
|
|||
Adjusted earnings
|
$
|
585
|
|
|
$
|
543
|
|
|
$
|
625
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Adjusted revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
2,061
|
|
|
$
|
2,027
|
|
|
$
|
2,036
|
|
Universal life and investment-type product policy fees
|
405
|
|
|
391
|
|
|
424
|
|
|||
Net investment income
|
309
|
|
|
318
|
|
|
326
|
|
|||
Other revenues
|
58
|
|
|
73
|
|
|
61
|
|
|||
Total adjusted revenues
|
2,833
|
|
|
2,809
|
|
|
2,847
|
|
|||
Adjusted expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
1,077
|
|
|
1,067
|
|
|
988
|
|
|||
Interest credited to policyholder account balances
|
100
|
|
|
112
|
|
|
120
|
|
|||
Capitalization of DAC
|
(414
|
)
|
|
(403
|
)
|
|
(472
|
)
|
|||
Amortization of DAC and VOBA
|
357
|
|
|
408
|
|
|
497
|
|
|||
Amortization of negative VOBA
|
(19
|
)
|
|
(13
|
)
|
|
(16
|
)
|
|||
Other expenses
|
1,376
|
|
|
1,323
|
|
|
1,469
|
|
|||
Total adjusted expenses
|
2,477
|
|
|
2,494
|
|
|
2,586
|
|
|||
Provision for income tax expense (benefit)
|
59
|
|
|
42
|
|
|
21
|
|
|||
Adjusted earnings
|
$
|
297
|
|
|
$
|
273
|
|
|
$
|
240
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Adjusted revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
4,144
|
|
|
$
|
4,506
|
|
|
$
|
4,545
|
|
Universal life and investment-type product policy fees
|
1,361
|
|
|
1,436
|
|
|
1,482
|
|
|||
Net investment income
|
5,607
|
|
|
5,944
|
|
|
6,189
|
|
|||
Other revenues
|
244
|
|
|
581
|
|
|
930
|
|
|||
Total adjusted revenues
|
11,356
|
|
|
12,467
|
|
|
13,146
|
|
|||
Adjusted expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
7,000
|
|
|
7,523
|
|
|
7,346
|
|
|||
Interest credited to policyholder account balances
|
1,018
|
|
|
1,042
|
|
|
1,062
|
|
|||
Capitalization of DAC
|
(82
|
)
|
|
(281
|
)
|
|
(410
|
)
|
|||
Amortization of DAC and VOBA
|
302
|
|
|
736
|
|
|
577
|
|
|||
Interest expense on debt
|
24
|
|
|
57
|
|
|
55
|
|
|||
Other expenses
|
1,365
|
|
|
2,392
|
|
|
2,694
|
|
|||
Total adjusted expenses
|
9,627
|
|
|
11,469
|
|
|
11,324
|
|
|||
Provision for income tax expense (benefit)
|
547
|
|
|
292
|
|
|
582
|
|
|||
Adjusted earnings
|
$
|
1,182
|
|
|
$
|
706
|
|
|
$
|
1,240
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Adjusted revenues
|
|
|
|
|
|
||||||
Premiums
|
$
|
54
|
|
|
$
|
40
|
|
|
$
|
(92
|
)
|
Universal life and investment-type product policy fees
|
1
|
|
|
2
|
|
|
(4
|
)
|
|||
Net investment income
|
28
|
|
|
178
|
|
|
260
|
|
|||
Other revenues
|
271
|
|
|
110
|
|
|
69
|
|
|||
Total adjusted revenues
|
354
|
|
|
330
|
|
|
233
|
|
|||
Adjusted expenses
|
|
|
|
|
|
||||||
Policyholder benefits and claims and policyholder dividends
|
26
|
|
|
41
|
|
|
(114
|
)
|
|||
Interest credited to policyholder account balances
|
1
|
|
|
6
|
|
|
23
|
|
|||
Capitalization of DAC
|
(8
|
)
|
|
(7
|
)
|
|
(3
|
)
|
|||
Amortization of DAC and VOBA
|
6
|
|
|
8
|
|
|
(1
|
)
|
|||
Interest expense on debt
|
1,105
|
|
|
1,139
|
|
|
1,169
|
|
|||
Other expenses
|
894
|
|
|
597
|
|
|
935
|
|
|||
Total adjusted expenses
|
2,024
|
|
|
1,784
|
|
|
2,009
|
|
|||
Provision for income tax expense (benefit)
|
(688
|
)
|
|
(948
|
)
|
|
(366
|
)
|
|||
Adjusted earnings
|
(982
|
)
|
|
(506
|
)
|
|
(1,410
|
)
|
|||
Less: Preferred stock dividends
|
103
|
|
|
103
|
|
|
116
|
|
|||
Adjusted earnings available to common shareholders
|
$
|
(1,085
|
)
|
|
$
|
(609
|
)
|
|
$
|
(1,526
|
)
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Other business activities
|
$
|
18
|
|
|
$
|
(5
|
)
|
|
$
|
(41
|
)
|
Other net investment income
|
144
|
|
|
220
|
|
|
291
|
|
|||
Interest expense on debt
|
(779
|
)
|
|
(814
|
)
|
|
(843
|
)
|
|||
Preferred stock dividends
|
(103
|
)
|
|
(103
|
)
|
|
(116
|
)
|
|||
Corporate initiatives and projects
|
(179
|
)
|
|
(129
|
)
|
|
(169
|
)
|
|||
Incremental tax benefit (expense) and other tax-related items
|
61
|
|
|
438
|
|
|
(256
|
)
|
|||
Other
|
(247
|
)
|
|
(216
|
)
|
|
(392
|
)
|
|||
Adjusted earnings available to common shareholders
|
$
|
(1,085
|
)
|
|
$
|
(609
|
)
|
|
$
|
(1,526
|
)
|
•
|
credit risk, relating to the uncertainty associated with the continued ability of a given obligor to make timely payments of principal and interest;
|
•
|
interest rate risk, relating to the market price and cash flow variability associated with changes in market interest rates. Changes in market interest rates will impact the net unrealized gain or loss position of our fixed income investment portfolio and the rates of return we receive on both new funds invested and reinvestment of existing funds;
|
•
|
liquidity risk, relating to the diminished ability to sell certain investments, in times of strained market conditions;
|
•
|
market valuation risk, relating to the variability in the estimated fair value of investments associated with changes in market factors such as credit spreads and equity market levels. A widening of credit spreads will adversely impact the net unrealized gain (loss) position of the fixed income investment portfolio, will increase losses associated with credit-based non-qualifying derivatives where we assume credit exposure, and, if credit spreads widen significantly or for an extended period of time, will likely result in higher OTTI. Credit spread tightening will reduce net investment income associated with purchases of fixed maturity securities and will favorably impact the net unrealized gain (loss) position of the fixed income investment portfolio;
|
•
|
currency risk, relating to the variability in currency exchange rates for foreign denominated investments. This risk relates to potential decreases in estimated fair value and net investment income resulting from changes in currency exchange rates versus the U.S. dollar. In general, the weakening of foreign currencies versus the U.S. dollar will adversely affect the estimated fair value of our foreign denominated investments; and
|
•
|
real estate risk, relating to commercial, agricultural and residential real estate, and stemming from factors, which include, but are not limited to, market conditions, including the demand and supply of leasable commercial space, creditworthiness of borrowers and their tenants and joint venture partners, capital markets volatility and inherent interest rate movements.
|
|
Selected Country Fixed Maturity Securities at December 31, 2017
|
||||||||||||||||||
|
Sovereign
|
|
Financial
Services |
|
Non-Financial
Services |
|
Structured
|
|
Total (1)
|
||||||||||
|
(Dollars in millions)
|
||||||||||||||||||
United Kingdom
|
$
|
27
|
|
|
$
|
3,117
|
|
|
$
|
8,117
|
|
|
$
|
310
|
|
|
$
|
11,571
|
|
South Korea
|
6,458
|
|
|
14
|
|
|
375
|
|
|
103
|
|
|
6,950
|
|
|||||
Mexico
|
3,520
|
|
|
580
|
|
|
2,219
|
|
|
78
|
|
|
6,397
|
|
|||||
Total
|
$
|
10,005
|
|
|
$
|
3,711
|
|
|
$
|
10,711
|
|
|
$
|
491
|
|
|
$
|
24,918
|
|
Investment grade %
|
99
|
%
|
|
99
|
%
|
|
94
|
%
|
|
90
|
%
|
|
97
|
%
|
(1)
|
The par value and amortized cost were
$23.9 billion
and
$23.7 billion
, respectively, at December 31,
2017
.
|
|
For the Years Ended December 31,
|
|||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|||||||||||||||
|
Yield% (1)
|
|
Amount
|
|
Yield% (1)
|
|
Amount
|
|
Yield% (1)
|
|
Amount
|
|||||||||
|
(Dollars in millions)
|
|||||||||||||||||||
Fixed maturity securities (2) (3)
|
4.29
|
|
%
|
$
|
11,401
|
|
|
4.38
|
|
%
|
$
|
11,665
|
|
|
4.62
|
|
%
|
$
|
11,788
|
|
Mortgage loans (3)
|
4.58
|
|
%
|
3,081
|
|
|
4.61
|
|
%
|
2,858
|
|
|
4.89
|
|
%
|
2,772
|
|
|||
Real estate and real estate joint ventures
|
3.18
|
|
%
|
297
|
|
|
3.73
|
|
%
|
322
|
|
|
4.28
|
|
%
|
395
|
|
|||
Policy loans
|
5.39
|
|
%
|
517
|
|
|
5.29
|
|
%
|
511
|
|
|
5.30
|
|
%
|
525
|
|
|||
Equity securities
|
5.15
|
|
%
|
129
|
|
|
4.82
|
|
%
|
120
|
|
|
4.79
|
|
%
|
124
|
|
|||
Other limited partnership interests
|
14.93
|
|
%
|
797
|
|
|
9.23
|
|
%
|
478
|
|
|
9.32
|
|
%
|
535
|
|
|||
Cash and short-term investments
|
1.48
|
|
%
|
132
|
|
|
1.17
|
|
%
|
111
|
|
|
1.17
|
|
%
|
125
|
|
|||
Other invested assets
|
|
|
655
|
|
|
|
|
856
|
|
|
|
|
767
|
|
||||||
Investment income
|
4.53
|
|
%
|
17,009
|
|
|
4.58
|
|
%
|
16,921
|
|
|
4.79
|
|
%
|
17,031
|
|
|||
Investment fees and expenses
|
(0.14
|
)
|
|
(511
|
)
|
|
(0.14
|
)
|
|
(507
|
)
|
|
(0.15
|
)
|
|
(548
|
)
|
|||
Net investment income including divested businesses and lag elimination (4)
|
4.39
|
|
%
|
16,498
|
|
|
4.44
|
|
%
|
16,414
|
|
|
4.64
|
|
%
|
16,483
|
|
|||
Less: net investment income from divested businesses and lag elimination (4)
|
|
|
(46
|
)
|
|
|
|
(23
|
)
|
|
|
|
(188
|
)
|
||||||
Net investment income, as reported on an adjusted basis
|
|
|
$
|
16,544
|
|
|
|
|
$
|
16,437
|
|
|
|
|
$
|
16,671
|
|
(1)
|
Yields are calculated as investment income as a percent of average quarterly asset carrying values. Investment income excludes recognized gains and losses. Asset carrying values exclude unrealized gains (losses), collateral received in connection with our securities lending program, annuities funding structured settlement claims, freestanding derivative assets, collateral received from derivative counterparties, the effects of consolidating certain variable interest entities (“VIEs”) under GAAP that are treated as consolidated securitization entities (“CSEs”), contractholder-directed unit-linked investments and
FVO Brighthouse Common Stock
. A yield is not presented for other invested assets as it is not considered a meaningful measure of performance for this asset class.
|
(2)
|
Investment income from fixed maturity securities includes amounts from FVO securities of
$68 million
,
$37 million
and
$21 million
for the years ended December 31,
2017
,
2016
and
2015
, respectively.
|
(3)
|
Investment income from fixed maturity securities and mortgage loans includes prepayment fees.
|
(4)
|
See
Note 2
of the Notes to the Consolidated Financial Statements for further information, as well as the presentation of net investment income, as reported on an adjusted basis compared to the most directly comparable GAAP financial measure. See “
—
Non-GAAP and Other Financial Disclosures” for discussion of divested businesses and lag elimination.
|
|
December 31, 2017
|
|
December 31, 2016
|
|
||||||||
|
Estimated Fair
Value
|
|
% of
Total
|
|
Estimated Fair
Value
|
|
% of
Total
|
|
||||
|
(Dollars in millions)
|
|
||||||||||
Fixed maturity securities
|
|
|
|
|
|
|
|
|
||||
Publicly-traded
|
$
|
262,078
|
|
|
84.8
|
%
|
$
|
247,229
|
|
|
85.4
|
%
|
Privately-placed
|
46,853
|
|
|
15.2
|
|
42,334
|
|
|
14.6
|
|
||
Total fixed maturity securities
|
$
|
308,931
|
|
|
100.0
|
%
|
$
|
289,563
|
|
|
100.0
|
%
|
Percentage of cash and invested assets
|
67.6
|
%
|
|
|
|
66.8
|
%
|
|
|
|
||
Equity securities
|
|
|
|
|
|
|
|
|
||||
Publicly-traded
|
$
|
1,490
|
|
|
59.3
|
%
|
$
|
1,854
|
|
|
64.1
|
%
|
Privately-held
|
1,023
|
|
|
40.7
|
|
1,040
|
|
|
35.9
|
|
||
Total equity securities
|
$
|
2,513
|
|
|
100.0
|
%
|
$
|
2,894
|
|
|
100.0
|
%
|
Percentage of cash and invested assets
|
0.6
|
%
|
|
|
|
0.7
|
%
|
|
|
|
||
Perpetual securities included within fixed maturity and equity securities AFS
|
$
|
440
|
|
|
|
|
$
|
527
|
|
|
|
|
Redeemable preferred stock with a stated maturity included within fixed maturity securities AFS
|
$
|
884
|
|
|
|
|
$
|
758
|
|
|
|
|
•
|
The majority of the Level 3 fixed maturity and equity securities AFS were concentrated in three sectors: U.S. and foreign corporate securities and RMBS.
|
•
|
Level 3 fixed maturity securities are priced principally through market standard valuation methodologies, independent pricing services and, to a much lesser extent, independent non-binding broker quotations using inputs that are not market observable or cannot be derived principally from or corroborated by observable market data. Level 3 fixed maturity securities consist of less liquid securities with very limited trading activity or where less price transparency exists around the inputs to the valuation methodologies. Level 3 fixed maturity securities include: sub-prime RMBS; certain below investment grade private securities and less liquid investment grade corporate securities (included in U.S. and foreign corporate securities) and less liquid ABS.
|
•
|
During the year ended December 31,
2017
, Level 3 fixed maturity securities decreased by
$782 million
, or
5%
. The decrease was driven by transfers out of Level 3 in excess of transfers into Level 3, partially offset by purchases in excess of sales and an increase in estimated fair value recognized in
OCI.
|
|
|
|
|
December 31,
|
|
|||||||||||||||||||||||||||
|
|
|
|
2017
|
|
|
2016
|
|
||||||||||||||||||||||||
NAIC
Designation
|
|
NRSRO Rating
|
|
Amortized
Cost
|
|
Unrealized
Gain (Loss)
|
|
Estimated
Fair
Value
|
|
% of
Total
|
|
|
Amortized
Cost
|
|
Unrealized
Gain (Loss)
|
|
Estimated
Fair
Value
|
|
% of
Total
|
|
||||||||||||
|
|
|
|
(Dollars in millions)
|
|
|||||||||||||||||||||||||||
1
|
|
Aaa/Aa/A
|
|
$
|
201,806
|
|
|
$
|
17,024
|
|
|
$
|
218,830
|
|
|
70.8
|
%
|
|
$
|
191,867
|
|
|
$
|
14,078
|
|
|
$
|
205,945
|
|
|
71.1
|
%
|
2
|
|
Baa
|
|
67,270
|
|
|
5,126
|
|
|
72,396
|
|
|
23.4
|
|
|
62,526
|
|
|
3,294
|
|
|
65,820
|
|
|
22.7
|
|
||||||
|
|
Subtotal investment grade
|
|
269,076
|
|
|
22,150
|
|
|
291,226
|
|
|
94.2
|
|
|
254,393
|
|
|
17,372
|
|
|
271,765
|
|
|
93.8
|
|
||||||
3
|
|
Ba
|
|
11,155
|
|
|
556
|
|
|
11,711
|
|
|
3.8
|
|
|
11,729
|
|
|
427
|
|
|
12,156
|
|
|
4.2
|
|
||||||
4
|
|
B
|
|
5,004
|
|
|
151
|
|
|
5,155
|
|
|
1.7
|
|
|
4,710
|
|
|
78
|
|
|
4,788
|
|
|
1.7
|
|
||||||
5
|
|
Caa and lower
|
|
824
|
|
|
9
|
|
|
833
|
|
|
0.3
|
|
|
840
|
|
|
13
|
|
|
853
|
|
|
0.3
|
|
||||||
6
|
|
In or near default
|
|
10
|
|
|
(4
|
)
|
|
6
|
|
|
—
|
|
|
4
|
|
|
(3
|
)
|
|
1
|
|
|
—
|
|
||||||
|
|
Subtotal below investment grade
|
|
16,993
|
|
|
712
|
|
|
17,705
|
|
|
5.8
|
|
|
17,283
|
|
|
515
|
|
|
17,798
|
|
|
6.2
|
|
||||||
|
|
Total fixed maturity securities
|
|
$
|
286,069
|
|
|
$
|
22,862
|
|
|
$
|
308,931
|
|
|
100.0
|
%
|
|
$
|
271,676
|
|
|
$
|
17,887
|
|
|
$
|
289,563
|
|
|
100.0
|
%
|
|
Fixed Maturity Securities — by Sector & Credit Quality Rating
|
||||||||||||||||||||||||||
NAIC Designation:
|
1
|
|
2
|
|
3
|
|
4
|
|
5
|
|
6
|
|
Total
Estimated
Fair Value
|
||||||||||||||
NRSRO Rating:
|
Aaa/Aa/A
|
|
Baa
|
|
Ba
|
|
B
|
|
Caa and
Lower
|
|
In or Near
Default
|
|
|||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||
December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
U.S. corporate
|
$
|
37,305
|
|
|
$
|
35,096
|
|
|
$
|
6,153
|
|
|
$
|
3,387
|
|
|
$
|
717
|
|
|
$
|
3
|
|
|
$
|
82,661
|
|
Foreign government
|
53,027
|
|
|
5,135
|
|
|
2,376
|
|
|
947
|
|
|
49
|
|
|
—
|
|
|
61,534
|
|
|||||||
Foreign corporate
|
21,925
|
|
|
30,214
|
|
|
2,616
|
|
|
759
|
|
|
55
|
|
|
—
|
|
|
55,569
|
|
|||||||
U.S. government and agency
|
47,067
|
|
|
327
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
47,394
|
|
|||||||
RMBS
|
28,209
|
|
|
297
|
|
|
224
|
|
|
61
|
|
|
9
|
|
|
—
|
|
|
28,800
|
|
|||||||
State and political subdivision
|
11,921
|
|
|
454
|
|
|
78
|
|
|
—
|
|
|
—
|
|
|
2
|
|
|
12,455
|
|
|||||||
ABS
|
11,311
|
|
|
760
|
|
|
215
|
|
|
1
|
|
|
3
|
|
|
1
|
|
|
12,291
|
|
|||||||
CMBS
|
8,065
|
|
|
113
|
|
|
49
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8,227
|
|
|||||||
Total fixed maturity securities
|
$
|
218,830
|
|
|
$
|
72,396
|
|
|
$
|
11,711
|
|
|
$
|
5,155
|
|
|
$
|
833
|
|
|
$
|
6
|
|
|
$
|
308,931
|
|
Percentage of total
|
70.8
|
%
|
|
23.4
|
%
|
|
3.8
|
%
|
|
1.7
|
%
|
|
0.3
|
%
|
|
—
|
%
|
|
100.0
|
%
|
|||||||
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
U.S. corporate
|
$
|
34,753
|
|
|
$
|
32,823
|
|
|
$
|
6,949
|
|
|
$
|
3,289
|
|
|
$
|
729
|
|
|
$
|
—
|
|
|
$
|
78,543
|
|
Foreign government
|
48,371
|
|
|
4,578
|
|
|
2,144
|
|
|
830
|
|
|
53
|
|
|
—
|
|
|
55,976
|
|
|||||||
Foreign corporate
|
21,033
|
|
|
26,292
|
|
|
2,638
|
|
|
638
|
|
|
62
|
|
|
—
|
|
|
50,663
|
|
|||||||
U.S. government and agency
|
44,118
|
|
|
315
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
44,433
|
|
|||||||
RMBS
|
28,252
|
|
|
504
|
|
|
244
|
|
|
30
|
|
|
2
|
|
|
—
|
|
|
29,032
|
|
|||||||
State and political subdivision
|
11,670
|
|
|
470
|
|
|
87
|
|
|
—
|
|
|
4
|
|
|
—
|
|
|
12,231
|
|
|||||||
ABS
|
10,433
|
|
|
693
|
|
|
94
|
|
|
1
|
|
|
3
|
|
|
1
|
|
|
11,225
|
|
|||||||
CMBS
|
7,315
|
|
|
145
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7,460
|
|
|||||||
Total fixed maturity securities
|
$
|
205,945
|
|
|
$
|
65,820
|
|
|
$
|
12,156
|
|
|
$
|
4,788
|
|
|
$
|
853
|
|
|
$
|
1
|
|
|
$
|
289,563
|
|
Percentage of total
|
71.1
|
%
|
|
22.7
|
%
|
|
4.2
|
%
|
|
1.7
|
%
|
|
0.3
|
%
|
|
—
|
%
|
|
100.0
|
%
|
|
December 31,
|
||||||||||||
|
2017
|
|
2016
|
||||||||||
|
Estimated
Fair
Value
|
|
% of
Total
|
|
Estimated
Fair
Value
|
|
% of
Total
|
||||||
|
(Dollars in millions)
|
||||||||||||
Industrial
|
$
|
42,273
|
|
|
30.6
|
%
|
|
$
|
39,320
|
|
|
30.4
|
%
|
Consumer
|
31,419
|
|
|
22.7
|
|
|
29,783
|
|
|
23.1
|
|
||
Finance
|
29,884
|
|
|
21.6
|
|
|
27,787
|
|
|
21.5
|
|
||
Utility
|
21,773
|
|
|
15.8
|
|
|
19,931
|
|
|
15.4
|
|
||
Communications
|
11,072
|
|
|
8.0
|
|
|
10,635
|
|
|
8.2
|
|
||
Other
|
1,809
|
|
|
1.3
|
|
|
1,750
|
|
|
1.4
|
|
||
Total
|
$
|
138,230
|
|
|
100.0
|
%
|
|
$
|
129,206
|
|
|
100.0
|
%
|
|
December 31,
|
||||||||||||||||||||
|
2017
|
|
2016
|
||||||||||||||||||
|
Estimated
Fair
Value
|
|
% of
Total
|
|
Net
Unrealized
Gains (Losses)
|
|
Estimated
Fair
Value
|
|
% of
Total
|
|
Net
Unrealized
Gains (Losses)
|
||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||
By security type:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Collateralized mortgage obligations
|
$
|
15,388
|
|
|
53.4
|
%
|
|
$
|
913
|
|
|
$
|
16,842
|
|
|
58.0
|
%
|
|
$
|
575
|
|
Pass-through securities
|
13,412
|
|
|
46.6
|
|
|
41
|
|
|
12,190
|
|
|
42.0
|
|
|
64
|
|
||||
Total RMBS
|
$
|
28,800
|
|
|
100.0
|
%
|
|
$
|
954
|
|
|
$
|
29,032
|
|
|
100.0
|
%
|
|
$
|
639
|
|
By risk profile:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Agency
|
$
|
20,010
|
|
|
69.5
|
%
|
|
$
|
274
|
|
|
$
|
18,808
|
|
|
64.8
|
%
|
|
$
|
268
|
|
Prime
|
1,209
|
|
|
4.2
|
|
|
73
|
|
|
1,398
|
|
|
4.8
|
|
|
65
|
|
||||
Alt-A
|
4,182
|
|
|
14.5
|
|
|
372
|
|
|
4,964
|
|
|
17.1
|
|
|
160
|
|
||||
Sub-prime
|
3,399
|
|
|
11.8
|
|
|
235
|
|
|
3,862
|
|
|
13.3
|
|
|
146
|
|
||||
Total RMBS
|
$
|
28,800
|
|
|
100.0
|
%
|
|
$
|
954
|
|
|
$
|
29,032
|
|
|
100.0
|
%
|
|
$
|
639
|
|
Ratings profile:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Rated Aaa/AAA
|
$
|
20,465
|
|
|
71.1
|
%
|
|
|
|
$
|
19,207
|
|
|
66.2
|
%
|
|
|
||||
Designated NAIC 1
|
$
|
28,209
|
|
|
97.9
|
%
|
|
|
|
$
|
28,252
|
|
|
97.3
|
%
|
|
|
|
December 31,
|
||||||||||||||||||||
|
2017
|
|
2016
|
||||||||||||||||||
|
Estimated
Fair
Value
|
|
% of
Total
|
|
Net
Unrealized
Gains (Losses)
|
|
Estimated
Fair
Value
|
|
% of
Total
|
|
Net
Unrealized
Gains (Losses)
|
||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||
By collateral type:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Collateralized debt obligations
|
$
|
5,703
|
|
|
46.4
|
%
|
|
$
|
45
|
|
|
$
|
5,711
|
|
|
50.9
|
%
|
|
$
|
(42
|
)
|
Credit card loans
|
1,686
|
|
|
13.7
|
|
|
1
|
|
|
871
|
|
|
7.8
|
|
|
10
|
|
||||
Student loans
|
1,266
|
|
|
10.3
|
|
|
(1
|
)
|
|
984
|
|
|
8.7
|
|
|
(25
|
)
|
||||
Automobile loans
|
1,193
|
|
|
9.7
|
|
|
—
|
|
|
1,121
|
|
|
10.0
|
|
|
1
|
|
||||
Foreign residential loans
|
965
|
|
|
7.9
|
|
|
20
|
|
|
1,171
|
|
|
10.4
|
|
|
8
|
|
||||
Consumer loans
|
605
|
|
|
4.9
|
|
|
6
|
|
|
509
|
|
|
4.5
|
|
|
—
|
|
||||
Other loans
|
873
|
|
|
7.1
|
|
|
7
|
|
|
858
|
|
|
7.7
|
|
|
7
|
|
||||
Total
|
$
|
12,291
|
|
|
100.0
|
%
|
|
$
|
78
|
|
|
$
|
11,225
|
|
|
100.0
|
%
|
|
$
|
(41
|
)
|
Ratings profile:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Rated Aaa/AAA
|
$
|
7,108
|
|
|
57.8
|
%
|
|
|
|
$
|
5,704
|
|
|
50.8
|
%
|
|
|
||||
Designated NAIC 1
|
$
|
11,311
|
|
|
92.0
|
%
|
|
|
|
$
|
10,433
|
|
|
92.9
|
%
|
|
|
|
December 31, 2017
|
||||||||||||||||||||||||||||||||||||||||||||||
|
Aaa
|
|
Aa
|
|
A
|
|
Baa
|
|
Below
Investment
Grade
|
|
Total
|
||||||||||||||||||||||||||||||||||||
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
||||||||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||||||||||||||||||
2003 - 2010
|
$
|
116
|
|
|
$
|
124
|
|
|
$
|
4
|
|
|
$
|
5
|
|
|
$
|
22
|
|
|
$
|
23
|
|
|
$
|
15
|
|
|
$
|
15
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
157
|
|
|
$
|
167
|
|
2011
|
170
|
|
|
184
|
|
|
34
|
|
|
35
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
204
|
|
|
219
|
|
||||||||||||
2012
|
289
|
|
|
302
|
|
|
257
|
|
|
263
|
|
|
230
|
|
|
237
|
|
|
7
|
|
|
7
|
|
|
—
|
|
|
—
|
|
|
783
|
|
|
809
|
|
||||||||||||
2013
|
787
|
|
|
835
|
|
|
717
|
|
|
748
|
|
|
285
|
|
|
292
|
|
|
60
|
|
|
45
|
|
|
—
|
|
|
—
|
|
|
1,849
|
|
|
1,920
|
|
||||||||||||
2014
|
537
|
|
|
552
|
|
|
513
|
|
|
522
|
|
|
129
|
|
|
130
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,179
|
|
|
1,204
|
|
||||||||||||
2015
|
1,122
|
|
|
1,140
|
|
|
191
|
|
|
196
|
|
|
117
|
|
|
120
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,430
|
|
|
1,456
|
|
||||||||||||
2016
|
401
|
|
|
404
|
|
|
69
|
|
|
68
|
|
|
40
|
|
|
40
|
|
|
65
|
|
|
66
|
|
|
—
|
|
|
—
|
|
|
575
|
|
|
578
|
|
||||||||||||
2017
|
898
|
|
|
899
|
|
|
685
|
|
|
687
|
|
|
246
|
|
|
246
|
|
|
41
|
|
|
42
|
|
|
—
|
|
|
—
|
|
|
1,870
|
|
|
1,874
|
|
||||||||||||
Total
|
$
|
4,320
|
|
|
$
|
4,440
|
|
|
$
|
2,470
|
|
|
$
|
2,524
|
|
|
$
|
1,069
|
|
|
$
|
1,088
|
|
|
$
|
188
|
|
|
$
|
175
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8,047
|
|
|
$
|
8,227
|
|
Ratings
Distribution
|
|
|
54.0
|
%
|
|
|
|
30.7
|
%
|
|
|
|
13.2
|
%
|
|
|
|
2.1
|
%
|
|
|
|
—
|
%
|
|
|
|
100.0
|
%
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||||||||||||||||||
|
Aaa
|
|
Aa
|
|
A
|
|
Baa
|
|
Below
Investment
Grade
|
|
Total
|
||||||||||||||||||||||||||||||||||||
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
|
Amortized
Cost
|
|
Estimated
Fair
Value
|
||||||||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||||||||||||||||||
2003 - 2010
|
$
|
246
|
|
|
$
|
258
|
|
|
$
|
46
|
|
|
$
|
46
|
|
|
$
|
102
|
|
|
$
|
104
|
|
|
$
|
24
|
|
|
$
|
24
|
|
|
$
|
26
|
|
|
$
|
28
|
|
|
$
|
444
|
|
|
$
|
460
|
|
2011
|
185
|
|
|
207
|
|
|
41
|
|
|
43
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
226
|
|
|
250
|
|
||||||||||||
2012
|
292
|
|
|
308
|
|
|
262
|
|
|
271
|
|
|
228
|
|
|
236
|
|
|
6
|
|
|
6
|
|
|
—
|
|
|
—
|
|
|
788
|
|
|
821
|
|
||||||||||||
2013
|
844
|
|
|
899
|
|
|
699
|
|
|
743
|
|
|
339
|
|
|
327
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,882
|
|
|
1,969
|
|
||||||||||||
2014
|
655
|
|
|
667
|
|
|
617
|
|
|
626
|
|
|
212
|
|
|
204
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,484
|
|
|
1,497
|
|
||||||||||||
2015
|
1,322
|
|
|
1,326
|
|
|
222
|
|
|
214
|
|
|
165
|
|
|
164
|
|
|
8
|
|
|
9
|
|
|
—
|
|
|
—
|
|
|
1,717
|
|
|
1,713
|
|
||||||||||||
2016
|
516
|
|
|
514
|
|
|
77
|
|
|
75
|
|
|
30
|
|
|
31
|
|
|
130
|
|
|
130
|
|
|
—
|
|
|
—
|
|
|
753
|
|
|
750
|
|
||||||||||||
Total
|
$
|
4,060
|
|
|
$
|
4,179
|
|
|
$
|
1,964
|
|
|
$
|
2,018
|
|
|
$
|
1,076
|
|
|
$
|
1,066
|
|
|
$
|
168
|
|
|
$
|
169
|
|
|
$
|
26
|
|
|
$
|
28
|
|
|
$
|
7,294
|
|
|
$
|
7,460
|
|
Ratings
Distribution
|
|
|
56.0
|
%
|
|
|
|
27.1
|
%
|
|
|
|
14.3
|
%
|
|
|
|
2.2
|
%
|
|
|
|
0.4
|
%
|
|
|
|
100.0
|
%
|
|
December 31,
|
||||||||||||||||||||||||||
|
2017
|
|
2016
|
||||||||||||||||||||||||
|
Recorded
Investment |
|
% of
Total |
|
Valuation
Allowance |
|
% of
Recorded Investment |
|
Recorded
Investment |
|
% of
Total |
|
Valuation
Allowance |
|
% of
Recorded Investment |
||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||
Commercial
|
$
|
44,375
|
|
|
64.8
|
%
|
|
$
|
214
|
|
|
0.5
|
%
|
|
$
|
41,512
|
|
|
64.0
|
%
|
|
$
|
202
|
|
|
0.5
|
%
|
Agricultural
|
13,014
|
|
|
19.0
|
|
|
41
|
|
|
0.3
|
%
|
|
12,564
|
|
|
19.4
|
|
|
39
|
|
|
0.3
|
%
|
||||
Residential
|
11,136
|
|
|
16.2
|
|
|
59
|
|
|
0.5
|
%
|
|
10,829
|
|
|
16.6
|
|
|
63
|
|
|
0.6
|
%
|
||||
Total
|
$
|
68,525
|
|
|
100.0
|
%
|
|
$
|
314
|
|
|
0.5
|
%
|
|
$
|
64,905
|
|
|
100.0
|
%
|
|
$
|
304
|
|
|
0.5
|
%
|
|
December 31,
|
||||||||||||
|
2017
|
|
2016
|
||||||||||
|
Amount
|
|
% of
Total
|
|
Amount
|
|
% of
Total
|
||||||
|
(Dollars in millions)
|
||||||||||||
Region
|
|
|
|
|
|
|
|
||||||
Pacific
|
$
|
9,875
|
|
|
22.3
|
%
|
|
$
|
9,506
|
|
|
22.9
|
%
|
International
|
9,101
|
|
|
20.5
|
|
|
7,772
|
|
|
18.7
|
|
||
Middle Atlantic
|
7,231
|
|
|
16.3
|
|
|
7,263
|
|
|
17.5
|
|
||
South Atlantic
|
5,311
|
|
|
12.0
|
|
|
5,192
|
|
|
12.5
|
|
||
West South Central
|
3,819
|
|
|
8.6
|
|
|
3,585
|
|
|
8.6
|
|
||
East North Central
|
2,683
|
|
|
6.0
|
|
|
2,037
|
|
|
4.9
|
|
||
Mountain
|
1,188
|
|
|
2.7
|
|
|
1,202
|
|
|
2.9
|
|
||
New England
|
901
|
|
|
2.0
|
|
|
1,199
|
|
|
2.9
|
|
||
East South Central
|
840
|
|
|
1.9
|
|
|
410
|
|
|
1.0
|
|
||
West North Central
|
477
|
|
|
1.1
|
|
|
497
|
|
|
1.2
|
|
||
Multi-Region and Other
|
2,949
|
|
|
6.6
|
|
|
2,849
|
|
|
6.9
|
|
||
Total recorded investment
|
44,375
|
|
|
100.0
|
%
|
|
41,512
|
|
|
100.0
|
%
|
||
Less: valuation allowances
|
214
|
|
|
|
|
202
|
|
|
|
||||
Carrying value, net of valuation allowances
|
$
|
44,161
|
|
|
|
|
$
|
41,310
|
|
|
|
||
Property Type
|
|
|
|
|
|
|
|
||||||
Office
|
$
|
22,602
|
|
|
50.9
|
%
|
|
$
|
20,868
|
|
|
50.3
|
%
|
Retail
|
8,032
|
|
|
18.1
|
|
|
8,708
|
|
|
21.0
|
|
||
Apartment
|
6,113
|
|
|
13.8
|
|
|
5,240
|
|
|
12.6
|
|
||
Hotel
|
3,620
|
|
|
8.2
|
|
|
3,747
|
|
|
9.0
|
|
||
Industrial
|
3,125
|
|
|
7.0
|
|
|
2,659
|
|
|
6.4
|
|
||
Other
|
883
|
|
|
2.0
|
|
|
290
|
|
|
0.7
|
|
||
Total recorded investment
|
44,375
|
|
|
100.0
|
%
|
|
41,512
|
|
|
100.0
|
%
|
||
Less: valuation allowances
|
214
|
|
|
|
|
202
|
|
|
|
||||
Carrying value, net of valuation allowances
|
$
|
44,161
|
|
|
|
|
$
|
41,310
|
|
|
|
|
December 31,
|
||||||||||||
|
2017
|
|
2016
|
||||||||||
|
Carrying
Value
|
|
% of
Total
|
|
Carrying
Value
|
|
% of
Total
|
||||||
|
(Dollars in millions)
|
||||||||||||
Office
|
$
|
3,728
|
|
|
38.7
|
%
|
|
$
|
3,478
|
|
|
39.1
|
%
|
Apartment
|
1,521
|
|
|
15.8
|
|
|
1,534
|
|
|
17.3
|
|
||
Real estate funds
|
1,324
|
|
|
13.7
|
|
|
908
|
|
|
10.2
|
|
||
Retail
|
1,114
|
|
|
11.6
|
|
|
1,040
|
|
|
11.7
|
|
||
Land
|
727
|
|
|
7.5
|
|
|
558
|
|
|
6.3
|
|
||
Hotel
|
475
|
|
|
4.9
|
|
|
505
|
|
|
5.7
|
|
||
Industrial
|
361
|
|
|
3.8
|
|
|
461
|
|
|
5.2
|
|
||
Agriculture
|
29
|
|
|
0.3
|
|
|
40
|
|
|
0.4
|
|
||
Other
|
358
|
|
|
3.7
|
|
|
367
|
|
|
4.1
|
|
||
Total real estate and real estate joint ventures
|
$
|
9,637
|
|
|
100.0
|
%
|
|
$
|
8,891
|
|
|
100.0
|
%
|
|
December 31,
|
|||||||||||||
|
2017
|
|
2016
|
|||||||||||
|
Carrying
Value
|
|
% of
Total
|
|
Carrying
Value
|
|
% of
Total
|
|||||||
|
(Dollars in millions)
|
|||||||||||||
Freestanding derivatives with positive estimated fair values
|
$
|
8,551
|
|
|
49.5
|
%
|
|
$
|
12,139
|
|
|
62.8
|
%
|
|
Tax credit and renewable energy partnerships
|
3,167
|
|
|
18.3
|
|
|
3,118
|
|
|
16.1
|
|
|||
Direct financing leases
|
1,323
|
|
|
7.7
|
|
|
1,115
|
|
|
5.8
|
|
|||
Annuities funding structured settlement claims
|
1,284
|
|
|
7.4
|
|
|
—
|
|
|
—
|
|
|||
Leveraged leases, net of non-recourse debt
|
1,278
|
|
|
7.4
|
|
|
1,521
|
|
|
7.9
|
|
|||
Operating joint ventures
|
539
|
|
|
3.1
|
|
|
576
|
|
|
3.0
|
|
|||
Funds withheld
|
298
|
|
|
1.7
|
|
|
110
|
|
|
0.6
|
|
|||
Other
|
823
|
|
|
4.8
|
|
|
724
|
|
|
3.8
|
|
|||
Total
|
$
|
17,263
|
|
|
100
|
%
|
|
$
|
19,303
|
|
|
100
|
%
|
|
Percentage of cash and invested assets
|
3.8
|
%
|
|
|
|
4.5
|
%
|
|
|
•
|
A comprehensive description of the nature of our derivatives, including the strategies for which derivatives are used in managing various risks.
|
•
|
Information about the gross notional amount, estimated fair value, and primary underlying risk exposure of our derivatives by type of hedge designation, excluding embedded derivatives held at
December 31, 2017
and
2016
.
|
•
|
The statement of operations effects of derivatives in net investments in foreign operations, cash flow, fair value, or nonqualifying hedge relationships for the
years ended December 31, 2017
,
2016
and
2015
.
|
|
|
Year Ended December 31, 2017
|
Gain (loss) recognized in net income (loss)
|
|
$87 million
|
Percentage of gain (loss) attributable to observable inputs
|
|
91%
|
Primary drivers of observable gain (loss)
|
|
Decreases in interest rates on interest rate derivatives; weakening of the US dollar versus foreign currencies on receive inflation-linked foreign currency derivatives; partially offset by decreases in certain equity volatility levels and increases in certain equity index levels on equity derivatives.
|
Percentage of gain (loss) attributable to unobservable inputs
|
|
9%
|
|
|
December 31,
|
||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||
Credit Default Swaps
|
|
Gross
Notional
Amount
|
|
Estimated
Fair Value
|
|
Gross
Notional
Amount
|
|
Estimated
Fair Value
|
||||||||
|
|
(In millions)
|
||||||||||||||
Purchased
|
|
$
|
2,020
|
|
|
$
|
(36
|
)
|
|
$
|
2,001
|
|
|
$
|
(26
|
)
|
Written
|
|
11,375
|
|
|
271
|
|
|
10,732
|
|
|
152
|
|
||||
Total
|
|
$
|
13,395
|
|
|
$
|
235
|
|
|
$
|
12,733
|
|
|
$
|
126
|
|
|
|
Years Ended December 31,
|
||||||||||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||||||||||
Credit Default Swaps
|
|
Gross
Gains
(1)
|
|
Gross
Losses
(1)
|
|
Net
Gains
(Losses)
|
|
Gross
Gains
(1)
|
|
Gross
Losses
(1)
|
|
Net
Gains
(Losses)
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Purchased (2), (4)
|
|
$
|
5
|
|
|
$
|
(29
|
)
|
|
$
|
(24
|
)
|
|
$
|
7
|
|
|
$
|
(47
|
)
|
|
$
|
(40
|
)
|
Written (3), (4)
|
|
152
|
|
|
(7
|
)
|
|
145
|
|
|
95
|
|
|
(24
|
)
|
|
71
|
|
||||||
Total
|
|
$
|
157
|
|
|
$
|
(36
|
)
|
|
$
|
121
|
|
|
$
|
102
|
|
|
$
|
(71
|
)
|
|
$
|
31
|
|
(1)
|
Gains (losses) are reported in net derivative gains (losses), except for gains (losses) on the trading portfolio, which are reported in net investment income.
|
(2)
|
As of December 31, 2016, the Company no longer maintained a trading portfolio for derivatives. The gross gains and gross (losses) for purchased credit default swaps in the trading portfolio were $4 million and ($4) million, respectively, for the
year ended December 31, 2016
.
|
(3)
|
As of December 31, 2016, the Company no longer maintained a trading portfolio for derivatives. The gross gains and gross (losses) for written credit default swaps in the trading portfolio were $3 and ($3) million, respectively, for the year ended
December 31, 2016
.
|
(4)
|
Gains (losses) do not include earned income (expense) on credit default swaps.
|
|
December 31, 2017
|
||||||
Guaranteed Minimum Crediting Rate
|
Account
Value (1)
|
|
Account
Value at
Guarantee (1)
|
||||
|
(In millions)
|
||||||
Greater than 0% but less than 2%
|
$
|
4,824
|
|
|
$
|
4,705
|
|
Equal to or greater than 2% but less than 4%
|
$
|
1,832
|
|
|
$
|
1,832
|
|
Equal to or greater than 4%
|
$
|
736
|
|
|
$
|
710
|
|
(1)
|
These amounts are not adjusted for policy loans.
|
|
December 31, 2017
|
||||||
Guaranteed Minimum Crediting Rate
|
Account
Value (1)
|
|
Account
Value at
Guarantee (1)
|
||||
|
(In millions)
|
||||||
Annuities
|
|
|
|
||||
Greater than 0% but less than 2%
|
$
|
22,364
|
|
|
$
|
2,791
|
|
Equal to or greater than 2% but less than 4%
|
$
|
1,248
|
|
|
$
|
424
|
|
Equal to or greater than 4%
|
$
|
2
|
|
|
$
|
2
|
|
Life & Other
|
|
|
|
||||
Greater than 0% but less than 2%
|
$
|
9,015
|
|
|
$
|
8,723
|
|
Equal to or greater than 2% but less than 4%
|
$
|
21,992
|
|
|
$
|
8,943
|
|
Equal to or greater than 4%
|
$
|
277
|
|
|
$
|
277
|
|
|
December 31, 2017
|
||||||
Guaranteed Minimum Crediting Rate
|
Account
Value (1)
|
|
Account
Value at
Guarantee (1)
|
||||
|
(In millions)
|
||||||
Greater than 0% but less than 2%
|
$
|
1,729
|
|
|
$
|
1,627
|
|
Equal to or greater than 2% but less than 4%
|
$
|
19,688
|
|
|
$
|
16,975
|
|
Equal to or greater than 4%
|
$
|
9,136
|
|
|
$
|
6,123
|
|
(1)
|
These amounts are not adjusted for policy loans.
|
|
|||||||||||||||
|
Future Policy
Benefits
|
|
Policyholder
Account Balances
|
||||||||||||
|
December 31,
|
|
December 31,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
(In millions)
|
||||||||||||||
Asia
|
|
|
|
|
|
|
|
||||||||
GMDB
|
$
|
38
|
|
|
$
|
29
|
|
|
$
|
—
|
|
|
$
|
—
|
|
GMAB
|
—
|
|
|
—
|
|
|
19
|
|
|
36
|
|
||||
GMWB
|
92
|
|
|
98
|
|
|
182
|
|
|
189
|
|
||||
EMEA
|
|
|
|
|
|
|
|
||||||||
GMDB
|
1
|
|
|
1
|
|
|
—
|
|
|
—
|
|
||||
GMAB
|
—
|
|
|
—
|
|
|
15
|
|
|
17
|
|
||||
GMWB
|
42
|
|
|
30
|
|
|
(90
|
)
|
|
(50
|
)
|
||||
MetLife Holdings
|
|
|
|
|
|
|
|
||||||||
GMDB
|
304
|
|
|
257
|
|
|
—
|
|
|
—
|
|
||||
GMIB
|
581
|
|
|
471
|
|
|
(125
|
)
|
|
93
|
|
||||
GMAB
|
—
|
|
|
—
|
|
|
—
|
|
|
13
|
|
||||
GMWB
|
183
|
|
|
161
|
|
|
322
|
|
|
586
|
|
||||
Total
|
$
|
1,241
|
|
|
$
|
1,047
|
|
|
$
|
323
|
|
|
$
|
884
|
|
|
Total Account Value (1)
|
||||||
|
Asia & EMEA
|
|
MetLife Holdings
|
||||
|
(In millions)
|
||||||
Return of premium or five to seven year step-up
|
$
|
7,928
|
|
|
$
|
54,797
|
|
Annual step-up
|
—
|
|
|
3,719
|
|
||
Roll-up and step-up combination
|
—
|
|
|
6,605
|
|
||
Total
|
$
|
7,928
|
|
|
$
|
65,121
|
|
(1)
|
Total account value excludes $242 million for contracts with no GMDBs. Further, many of our annuity contracts offer more than one type of guarantee such that GMDB amounts listed above are not mutually exclusive to the amounts in the living benefit guarantees table below.
|
|
Total Account Value (1)
|
||||||
|
Asia & EMEA
|
|
MetLife Holdings
|
||||
|
(In millions)
|
||||||
GMIB
|
$
|
—
|
|
|
$
|
25,257
|
|
GMWB - non-life contingent (2)
|
2,364
|
|
|
3,327
|
|
||
GMWB - life-contingent
|
3,801
|
|
|
11,208
|
|
||
GMAB
|
1,214
|
|
|
571
|
|
||
|
$
|
7,379
|
|
|
$
|
40,363
|
|
(1)
|
Total account value excludes $25.0 billion for contracts with no living benefit guarantees. Further, many of our annuity contracts offer more than one type of guarantee such that living benefit guarantee amounts listed above are not mutually exclusive of the amounts in the GMDBs table above.
|
(2)
|
The Asia and EMEA segments include the non-life contingent portion of the GMWB total account value of $966 million with a guarantee at annuitization.
|
|
Total
Account Value
|
||
|
(In millions)
|
||
7-year setback, 2.5% interest rate
|
$
|
6,578
|
|
7-year setback, 1.5% interest rate
|
1,077
|
|
|
10-year setback, 1.5% interest rate
|
5,597
|
|
|
10-year mortality projection, 10-year setback, 1.0% interest rate
|
10,206
|
|
|
10-year mortality projection, 10-year setback, 0.5% interest rate
|
1,799
|
|
|
|
$
|
25,257
|
|
|
In-the-Moneyness
|
|
Total
Account Value
|
|
% of Total
|
|||
|
|
|
(In millions)
|
|
|
|||
In-the-money
|
30% +
|
|
$
|
322
|
|
|
1
|
%
|
|
20% to 30%
|
|
278
|
|
|
1
|
%
|
|
|
10% to 20%
|
|
545
|
|
|
2
|
%
|
|
|
0% to 10%
|
|
1,014
|
|
|
4
|
%
|
|
|
|
|
2,159
|
|
|
|
||
Out-of-the-money
|
-10% to 0%
|
|
2,571
|
|
|
10
|
%
|
|
|
-20% to 10%
|
|
3,145
|
|
|
13
|
%
|
|
|
-20% +
|
|
17,382
|
|
|
69
|
%
|
|
|
|
|
23,098
|
|
|
|
||
Total GMIBs
|
|
|
$
|
25,257
|
|
|
|
|
|
|
|
December 31,
|
||||||||||||||||||||||
|
|
|
|
2017
|
|
2016
|
||||||||||||||||||||
Primary Underlying Risk Exposure
|
|
|
|
Gross Notional
|
|
Estimated Fair Value
|
|
Gross Notional
|
|
Estimated Fair Value
|
||||||||||||||||
|
Instrument Type
|
|
Amount
|
|
Assets
|
|
Liabilities
|
|
Amount
|
|
Assets
|
|
Liabilities
|
|||||||||||||
|
|
|
|
(In millions)
|
||||||||||||||||||||||
Interest rate
|
|
Interest rate swaps
|
|
$
|
16,080
|
|
|
$
|
433
|
|
|
$
|
22
|
|
|
$
|
19,715
|
|
|
$
|
1,590
|
|
|
$
|
924
|
|
|
|
Interest rate futures
|
|
3,060
|
|
|
1
|
|
|
4
|
|
|
2,671
|
|
|
2
|
|
|
11
|
|
||||||
|
|
Interest rate options
|
|
10,173
|
|
|
486
|
|
|
11
|
|
|
3,423
|
|
|
449
|
|
|
1
|
|
||||||
Foreign currency exchange rate
|
|
Foreign currency forwards
|
|
2,288
|
|
|
5
|
|
|
36
|
|
|
3,086
|
|
|
10
|
|
|
222
|
|
||||||
|
|
Currency futures
|
|
—
|
|
|
—
|
|
|
—
|
|
|
85
|
|
|
—
|
|
|
—
|
|
||||||
Equity market
|
|
Equity futures
|
|
3,781
|
|
|
17
|
|
|
4
|
|
|
4,283
|
|
|
29
|
|
|
3
|
|
||||||
|
|
Equity index options
|
|
9,546
|
|
|
383
|
|
|
690
|
|
|
13,975
|
|
|
403
|
|
|
524
|
|
||||||
|
|
Equity variance swaps
|
|
4,661
|
|
|
54
|
|
|
199
|
|
|
8,263
|
|
|
83
|
|
|
239
|
|
||||||
|
|
Equity total return swaps
|
|
1,117
|
|
|
—
|
|
|
41
|
|
|
1,046
|
|
|
1
|
|
|
43
|
|
||||||
|
|
Total
|
|
$
|
50,706
|
|
|
$
|
1,379
|
|
|
$
|
1,007
|
|
|
$
|
56,547
|
|
|
$
|
2,567
|
|
|
$
|
1,967
|
|
•
|
impact our ability to generate cash flows from the sale of funding agreements and other capital market products offered by our Retirement and Income Solutions business;
|
•
|
impact the cost and availability of financing for MetLife, Inc. and its subsidiaries; and
|
•
|
result in additional collateral requirements or other required payments under certain agreements, which are eligible to be satisfied in cash or by posting investments held by the subsidiaries subject to the agreements. See “— Liquidity and Capital Uses — Pledged Collateral.”
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Sources:
|
|
|
|
|
|
||||||
Operating activities, net
|
$
|
12,283
|
|
|
$
|
14,774
|
|
|
$
|
14,052
|
|
Changes in policyholder account balances, net
|
6,131
|
|
|
4,925
|
|
|
—
|
|
|||
Changes in payables for collateral under securities loaned and other transactions, net
|
903
|
|
|
—
|
|
|
1,544
|
|
|||
Long-term debt issued
|
3,657
|
|
|
—
|
|
|
3,893
|
|
|||
Financing element on certain derivative instruments and other derivative related transactions, net
|
—
|
|
|
—
|
|
|
181
|
|
|||
Preferred stock issued, net of issuance costs
|
—
|
|
|
—
|
|
|
1,483
|
|
|||
Other, net
|
118
|
|
|
139
|
|
|
94
|
|
|||
Effect of change in foreign currency exchange rates on cash and cash equivalents
|
323
|
|
|
—
|
|
|
—
|
|
|||
Total sources
|
23,415
|
|
|
19,838
|
|
|
21,247
|
|
|||
Uses:
|
|
|
|
|
|
||||||
Investing activities, net
|
16,876
|
|
|
5,850
|
|
|
10,398
|
|
|||
Changes in policyholder account balances, net
|
—
|
|
|
—
|
|
|
1,717
|
|
|||
Changes in payables for collateral under securities loaned and other transactions, net
|
—
|
|
|
3,636
|
|
|
—
|
|
|||
Long-term debt repaid
|
1,073
|
|
|
1,279
|
|
|
1,438
|
|
|||
Collateral financing arrangements repaid
|
2,951
|
|
|
68
|
|
|
57
|
|
|||
Distribution of Brighthouse
|
2,793
|
|
|
—
|
|
|
—
|
|
|||
Financing element on certain derivative instruments and other derivative related transactions, net
|
151
|
|
|
1,367
|
|
|
—
|
|
|||
Treasury stock acquired in connection with share repurchases
|
2,927
|
|
|
372
|
|
|
1,930
|
|
|||
Repurchase of preferred stock
|
—
|
|
|
—
|
|
|
1,460
|
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
42
|
|
|||
Dividends on preferred stock
|
103
|
|
|
103
|
|
|
116
|
|
|||
Dividends on common stock
|
1,717
|
|
|
1,736
|
|
|
1,653
|
|
|||
Effect of change in foreign currency exchange rates on cash and cash equivalents
|
—
|
|
|
302
|
|
|
492
|
|
|||
Total uses
|
28,591
|
|
|
14,713
|
|
|
19,303
|
|
|||
Net increase (decrease) in cash and cash equivalents
|
$
|
(5,176
|
)
|
|
$
|
5,125
|
|
|
$
|
1,944
|
|
|
December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Short-term debt (1)
|
$
|
477
|
|
|
$
|
242
|
|
Long-term debt (2)
|
$
|
15,680
|
|
|
$
|
16,429
|
|
Collateral financing arrangement (3)
|
$
|
1,121
|
|
|
$
|
1,274
|
|
Junior subordinated debt securities (4)
|
$
|
3,144
|
|
|
$
|
3,169
|
|
(1)
|
Includes $377 million and $142 million of debt that is non-recourse to MetLife, Inc. and MLIC, subject to customary exceptions, at
December 31, 2017
and
2016
, respectively. Certain subsidiaries have pledged assets to secure this debt.
|
(2)
|
Includes $523 million and $366 million of debt that is non-recourse to MetLife, Inc. and MLIC, subject to customary exceptions, at
December 31, 2017
and
2016
, respectively. Certain investment subsidiaries have pledged assets to secure this debt.
|
(2)
|
In April 2017, in connection with the Separation, MetLife, Inc. and MetLife Reinsurance Company of South Carolina (“MRSC”) terminated the MRSC collateral financing arrangement associated with secondary guarantees. As a result, the $2.8 billion collateral financing arrangement liability outstanding was extinguished utilizing $2.8 billion of assets held in trust with the remaining $590 million of assets held in trust returned to MetLife, Inc. as a cash return of capital from a subsidiary.
For information regarding the remaining collateral financing arrangement, see
Note 13
of the Notes to the Consolidated Financial Statements.
|
(3)
|
For information regarding the junior subordinated debt securities, see
Note 14
of the Notes to the Consolidated Financial Statements and Note 5 in Schedule II of the Notes to the MetLife, Inc. (Parent Company Only) Condensed Financial Information.
|
•
|
During 2017, 2016 and 2015, following regulatory approval, MetLife Reinsurance Company of Charleston (“MRC”), a wholly-owned subsidiary of MetLife, Inc., repurchased and canceled $153 million, $68 million, and $57 million, respectively, in aggregate principal amount of its surplus notes, which were reported in collateral financing arrangement on the consolidated balance sheet;
|
•
|
In December 2017, MetLife, Inc. repaid at maturity its $500 million 1.756% senior notes;
|
•
|
In December 2017, MetLife, Inc. repaid at maturity its $500 million 1.903% senior notes;
|
•
|
In June 2016, MetLife, Inc. repaid at maturity its $1.3 billion 6.750% senior notes; and
|
•
|
In June 2015, MetLife, Inc. repaid at maturity its $1.0 billion 5.000% senior notes.
|
|
Total
|
|
One Year
or Less
|
|
More than
One Year to
Three Years
|
|
More than
Three Years
to Five Years
|
|
More than Five Years
|
||||||||||
|
(In millions)
|
||||||||||||||||||
Insurance liabilities
|
$
|
298,966
|
|
|
$
|
20,761
|
|
|
$
|
16,084
|
|
|
$
|
15,627
|
|
|
$
|
246,494
|
|
Policyholder account balances
|
224,784
|
|
|
31,285
|
|
|
23,109
|
|
|
15,684
|
|
|
154,706
|
|
|||||
Payables for collateral under securities loaned and other transactions
|
25,723
|
|
|
25,723
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Debt
|
36,153
|
|
|
2,659
|
|
|
3,569
|
|
|
3,689
|
|
|
26,236
|
|
|||||
Investment commitments
|
9,513
|
|
|
9,098
|
|
|
312
|
|
|
91
|
|
|
12
|
|
|||||
Operating leases
|
2,262
|
|
|
302
|
|
|
521
|
|
|
446
|
|
|
993
|
|
|||||
Other
|
18,258
|
|
|
17,856
|
|
|
11
|
|
|
—
|
|
|
391
|
|
|||||
Total
|
$
|
615,659
|
|
|
$
|
107,684
|
|
|
$
|
43,606
|
|
|
$
|
35,537
|
|
|
$
|
428,832
|
|
|
|
Year Ended December 31, 2017
|
|
Year Ended December 31, 2016
|
|
Year Ended December 31, 2015
|
||||||||||||||||||
|
|
Sources and Uses of Liquid Assets
|
|
Sources and Uses of Liquid Assets Included in Free Cash Flow
|
|
Sources and Uses of Liquid Assets
|
|
Sources and Uses of Liquid Assets Included in Free Cash Flow
|
|
Sources and Uses of Liquid Assets
|
|
Sources and Uses of Liquid Assets Included in Free Cash Flow
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
MetLife, Inc. (Parent Company Only)
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Sources:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Dividends and returns of capital from subsidiaries (1)
|
|
$
|
7,404
|
|
|
$
|
7,404
|
|
|
$
|
4,550
|
|
|
$
|
4,550
|
|
|
$
|
2,340
|
|
|
$
|
2,340
|
|
Long-term debt issued (2)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,739
|
|
|
1,750
|
|
||||||
Repayments on and (issuances of) loans to subsidiaries and related interest, net (3)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
383
|
|
|
383
|
|
||||||
Other, net (4)
|
|
107
|
|
|
4
|
|
|
120
|
|
|
(210
|
)
|
|
755
|
|
|
795
|
|
||||||
Total sources
|
|
7,511
|
|
|
7,408
|
|
|
4,670
|
|
|
4,340
|
|
|
6,217
|
|
|
5,268
|
|
||||||
Uses:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Capital contributions to subsidiaries (5)
|
|
339
|
|
|
124
|
|
|
1,733
|
|
|
1,733
|
|
|
667
|
|
|
667
|
|
||||||
Long-term debt repaid — unaffiliated
|
|
1,000
|
|
|
—
|
|
|
1,250
|
|
|
—
|
|
|
1,000
|
|
|
—
|
|
||||||
Interest paid on debt and financing arrangements — unaffiliated
|
|
980
|
|
|
980
|
|
|
983
|
|
|
983
|
|
|
965
|
|
|
965
|
|
||||||
Dividends on common stock
|
|
1,717
|
|
|
—
|
|
|
1,736
|
|
|
—
|
|
|
1,653
|
|
|
—
|
|
||||||
Treasury stock acquired in connection with share repurchases
|
|
2,927
|
|
|
—
|
|
|
372
|
|
|
—
|
|
|
1,930
|
|
|
—
|
|
||||||
Dividends on preferred stock
|
|
103
|
|
|
103
|
|
|
103
|
|
|
103
|
|
|
116
|
|
|
116
|
|
||||||
Issuances of and (repayments on) loans to subsidiaries and related interest, net (3)
|
|
33
|
|
|
33
|
|
|
99
|
|
|
99
|
|
|
—
|
|
|
—
|
|
||||||
Total uses
|
|
7,099
|
|
|
1,240
|
|
|
6,276
|
|
|
2,918
|
|
|
6,331
|
|
|
1,748
|
|
||||||
Net increase (decrease) in liquid assets, MetLife, Inc. (Parent Company Only)
|
|
412
|
|
|
|
|
(1,606
|
)
|
|
|
|
(114
|
)
|
|
|
|||||||||
Liquid assets, beginning of year
|
|
3,683
|
|
|
|
|
5,289
|
|
|
|
|
5,403
|
|
|
|
|||||||||
Liquid assets, end of year
|
|
$
|
4,095
|
|
|
|
|
$
|
3,683
|
|
|
|
|
$
|
5,289
|
|
|
|
||||||
Free Cash Flow, MetLife, Inc. (Parent Company Only)
|
|
|
|
6,168
|
|
|
|
|
1,422
|
|
|
|
|
3,520
|
|
|||||||||
Net cash provided by operating activities, MetLife, Inc. (Parent Company Only)
|
|
$
|
6,462
|
|
|
|
|
$
|
3,747
|
|
|
|
|
$
|
1,606
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Other MetLife Holding Companies
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Sources:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Dividends and returns of capital from subsidiaries
|
|
$
|
2,125
|
|
|
$
|
2,125
|
|
|
$
|
1,485
|
|
|
$
|
1,485
|
|
|
$
|
1,354
|
|
|
$
|
1,354
|
|
Capital contributions from MetLife, Inc.
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
150
|
|
|
150
|
|
||||||
Total sources
|
|
2,125
|
|
|
2,125
|
|
|
1,485
|
|
|
1,485
|
|
|
1,504
|
|
|
1,504
|
|
||||||
Uses:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Capital contributions to subsidiaries
|
|
12
|
|
|
12
|
|
|
53
|
|
|
53
|
|
|
27
|
|
|
27
|
|
||||||
Repayments on and (issuance of) loans to subsidiaries and affiliates and related interest, net
|
|
6
|
|
|
6
|
|
|
307
|
|
|
307
|
|
|
510
|
|
|
510
|
|
||||||
Dividends and returns of capital to MetLife, Inc.
|
|
2,200
|
|
|
2,200
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Other, net
|
|
408
|
|
|
408
|
|
|
123
|
|
|
123
|
|
|
506
|
|
|
506
|
|
||||||
Total uses
|
|
2,626
|
|
|
2,626
|
|
|
483
|
|
|
483
|
|
|
1,043
|
|
|
1,043
|
|
||||||
Net increase (decrease) in liquid assets, Other MetLife Holding Companies
|
|
(501
|
)
|
|
|
|
|
1,002
|
|
|
|
|
461
|
|
|
|
||||||||
Liquid assets, beginning of year
|
|
2,144
|
|
|
|
|
|
1,142
|
|
|
|
|
681
|
|
|
|
||||||||
Liquid assets, end of year
|
|
$
|
1,643
|
|
|
|
|
$
|
2,144
|
|
|
|
|
$
|
1,142
|
|
|
|
||||||
Free Cash Flow, Other MetLife Holding Companies
|
|
|
|
(501
|
)
|
|
|
|
1,002
|
|
|
|
|
461
|
|
|||||||||
Net increase (decrease) in liquid assets, All Holding Companies
|
|
$
|
(89
|
)
|
|
|
|
$
|
(604
|
)
|
|
|
|
$
|
347
|
|
|
|
||||||
Free Cash Flow, All Holding Companies (6) (7)
|
|
|
|
$
|
5,667
|
|
|
|
|
$
|
2,424
|
|
|
|
|
$
|
3,981
|
|
(1)
|
Dividends and returns of capital to MetLife, Inc. included $5.2 billion, $4.6 billion and $2.3 billion from operating subsidiaries and $2.2 billion, $0 and $0 from other MetLife holding companies during the years ended December 31,
2017
,
2016
and
2015
, respectively. Included in dividends and returns of capital to MetLife, Inc. above are the following which increased MetLife, Inc. liquid assets and free cash flow: dividends from Brighthouse subsidiaries, of $1.8 billion, $556 million and $500 million, and returns of capital from Brighthouse subsidiaries of $590 million, $0 and $0, during the years ended December 31,
2017
,
2016
and
2015
, respectively. Also, includes $49 million from the June 2017, issuance by Brighthouse Holdings, LLC of 50,000 units of 6.50% fixed rate cumulative preferred units to MetLife, Inc. and in turn MetLife, Inc. sold the preferred units to third-party investors.
|
(2)
|
Included in free cash flow is the portion of long-term debt issued that represents incremental debt to be at or below target leverage ratios.
|
(3)
|
See MetLife, Inc. (Parent Company Only) Condensed Statements of Cash Flows included in Schedule II of the Financial Statement Schedules for the source of liquid assets from receipts on loans to subsidiaries (excluding interest) and for the use of liquid assets for the issuances of loans to subsidiaries (excluding interest).
|
(4)
|
Other, net includes $860 million, $433 million and $171 million of net receipts by MetLife, Inc. to and from subsidiaries under a tax sharing agreement and tax payments to tax agencies during the years ended December 31,
2017
,
2016
and
2015
, respectively.
|
(5)
|
Amounts to fund business acquisitions were $215 million, $0 and $0 (included in capital contributions to subsidiaries) during the years ended December 31,
2017
,
2016
and
2015
, respectively.
|
(6)
|
In 2017, $2.1 billion of Separation-related items (comprised of certain Separation-related inflows primarily related to dividends from Brighthouse, net of outflows) were included in free cash flow, which increased our holding companies’ liquid assets, as well as our free cash flow. Excluding these Separation-related items, adjusted free cash flow would be $3.6 billion for the year ended December 31, 2017. In 2016, we incurred $2.3 billion of Separation-related items (comprised of certain Separation-related outflows, net of inflows related to dividends from Brighthouse subsidiaries) which reduced our holding companies’ liquid assets, as well as our free cash flow. Excluding these Separation-related items, adjusted free cash flow would be $4.7 billion for the year ended December 31, 2016.
|
(7)
|
See
“— Non-GAAP and Other Financial Disclosures” for the reconciliation of net cash provided by operating activities of MetLife, Inc. to free cash flow of all holding companies.
|
|
|
2018
|
|
|
2017
|
|
|
2016
|
|
2015
|
||||||||||||||||||||||||
Company
|
|
Permitted Without Approval (1)
|
|
|
Paid (2)
|
|
|
Permitted Without Approval (3)
|
|
|
Paid (2)
|
|
|
Permitted Without Approval (3)
|
|
Paid (2)
|
|
|
Permitted Without Approval (3)
|
|||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||
Metropolitan Life Insurance Company (4)
|
|
$
|
3,075
|
|
|
|
$
|
2,523
|
|
|
|
$
|
2,723
|
|
|
|
$
|
5,740
|
|
(5)
|
|
$
|
3,753
|
|
|
$
|
1,489
|
|
|
|
$
|
1,200
|
|
|
American Life Insurance Company
|
|
$
|
—
|
|
|
|
$
|
2,200
|
|
(6)
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
$
|
—
|
|
|
Brighthouse Life Insurance Company
|
|
N/A
|
|
|
|
$
|
—
|
|
|
|
$
|
473
|
|
(7
|
)
|
|
$
|
261
|
|
|
|
$
|
586
|
|
|
$
|
500
|
|
|
|
$
|
3,056
|
|
|
Metropolitan Property and Casualty Insurance Company
|
|
$
|
125
|
|
|
|
$
|
185
|
|
|
|
$
|
98
|
|
|
|
$
|
228
|
|
|
|
$
|
130
|
|
|
$
|
235
|
|
|
|
$
|
239
|
|
|
Metropolitan Tower Life Insurance Company
|
|
$
|
73
|
|
|
|
$
|
—
|
|
|
|
$
|
66
|
|
|
|
$
|
60
|
|
|
|
$
|
70
|
|
|
$
|
102
|
|
|
|
$
|
102
|
|
|
New England Life Insurance Company
|
|
N/A
|
|
|
|
$
|
—
|
|
|
|
$
|
106
|
|
(7
|
)
|
|
$
|
295
|
|
(8)
|
|
$
|
156
|
|
|
$
|
199
|
|
(9)
|
|
$
|
199
|
|
|
General American Life Insurance Company
|
|
$
|
118
|
|
|
|
$
|
1
|
|
|
|
$
|
91
|
|
|
|
$
|
—
|
|
|
|
$
|
136
|
|
|
$
|
—
|
|
|
|
$
|
88
|
|
(1)
|
Reflects dividend amounts that may be paid during
2018
without prior regulatory approval. However, because dividend tests may be based on dividends previously paid over rolling 12-month periods, if paid before a specified date during
2018
, some or all of such dividends may require regulatory approval. See also note (7) below regarding the impact of the Separation on the dividends permitted to be paid by Brighthouse Insurance and New England Life Insurance Company (“NELICO”).
|
(2)
|
Reflects all amounts paid, including those requiring regulatory approval.
|
(3)
|
Reflects dividend amounts that could have been paid during the relevant year without prior regulatory approval.
|
(4)
|
The New York Insurance Law was amended, permitting MLIC to pay dividends without prior regulatory approval under one of two alternative formulations beginning in 2016. See Note
15
of the Notes to the Consolidated Financial Statements. The dividend amounts that MLIC was permitted to pay starting in 2016 and going forward were calculated using the new formulation.
|
(5)
|
In 2016, MLIC paid an ordinary cash dividend to MetLife, Inc. in the amount of $3.6 billion. In addition, in December 2016, MLIC distributed all of the issued and outstanding shares of common stock of each of NELICO and GALIC to MetLife, Inc. in the form of a non-cash extraordinary dividend in the amount of $981 million and $1.2 billion, respectively, as calculated on a statutory basis.
|
(6)
|
Represents an extraordinary dividend.
|
(7)
|
Effective April 28, 2017 in connection with the Separation, MetLife, Inc. contributed all of the issued and outstanding shares of common stock of each of Brighthouse Insurance and NELICO to Brighthouse Holdings, LLC. As a result of the Separation, Brighthouse Insurance and NELICO ceased to be subsidiaries of MetLife, Inc. Accordingly, MetLife, Inc. will no longer receive dividends from Brighthouse Insurance or NELICO after the Separation. See Note
3
of the Notes to the Consolidated Financial Statements.
|
(8)
|
Represents an extraordinary dividend paid by NELICO in 2016 to MetLife, Inc.
|
(9)
|
Dividends paid by NELICO in 2015 were paid to its former parent, MLIC.
|
|
December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Long-term debt — unaffiliated
|
$
|
14,599
|
|
|
$
|
15,505
|
|
Long-term debt — affiliated (1)
|
$
|
2,000
|
|
|
$
|
3,100
|
|
Collateral financing arrangement (2)
|
$
|
—
|
|
|
$
|
2,797
|
|
Junior subordinated debt securities (3)
|
$
|
2,454
|
|
|
$
|
1,734
|
|
(1)
|
On April 28, 2017, in connection with the Separation, MetLife, Inc. repaid $750 million and $350 million of senior notes to MetLife Reinsurance Company of Delaware (“MRD”) due September 2032 and December 2033, respectively, in an exchange transaction. The $750 million senior note bore interest at a fixed rate of 4.21% and the $350 million senior note bore interest at a fixed rate of 5.10%. Simultaneously, MRD repaid $750 million and $350 million of surplus notes to MetLife, Inc. See “— Liquidity and Capital Uses — Affiliated Capital and Debt Transactions.”
|
(2)
|
See Note
3
of the Notes to the Consolidated Financial Statements for discussion of a $2.8 billion repayment on the MRSC collateral financing agreement liability in April 2017 in connection with the Separation, utilizing assets held in trust.
|
(3)
|
See “— Liquidity and Capital Uses — Affiliated Capital and Debt Transactions” for discussion of a $750 million junior subordinated debt securities exchange. Also see Note 5 in Schedule II of the Notes to the MetLife, Inc. (Parent Company Only) Condensed Financial Information for information regarding the Junior Subordinated Debt Securities exchange transaction in February 2017.
|
Year of Maturity
|
|
Principal
|
|
Interest Rate
|
||
|
|
(In millions)
|
|
|
||
2018
|
|
$
|
1,035
|
|
|
6.82%
|
2019
|
|
$
|
1,035
|
|
|
7.72%
|
2019
|
|
$
|
500
|
|
|
3.54%
|
2019
|
|
$
|
250
|
|
|
3.57%
|
2020
|
|
$
|
541
|
|
|
5.25%
|
2020
|
|
$
|
250
|
|
|
3.03%
|
2021
|
|
$
|
1,000
|
|
|
4.75%
|
2021
|
|
$
|
500
|
|
|
5.64%
|
2021
|
|
$
|
500
|
|
|
5.86%
|
2022
|
|
$
|
500
|
|
|
3.05%
|
2023 - 2046
|
|
$
|
10,574
|
|
|
Ranging from 3.00% - 6.50%
|
Non-GAAP financial measures:
|
Comparable GAAP financial measures:
|
||
(i)
|
adjusted revenues
|
(i)
|
revenues
|
(ii)
|
adjusted expenses
|
(ii)
|
expenses
|
(iii)
|
adjusted earnings
|
(iii)
|
income (loss) from continuing operations, net of income tax
|
(iv)
|
adjusted earnings available to common shareholders
|
(iv)
|
net income (loss) available to MetLife, Inc.’s common shareholders
|
(v)
|
free cash flow of all holding companies
|
(v)
|
MetLife, Inc.’s net cash provided by operating activities
|
•
|
adjusted earnings; and
|
•
|
adjusted earnings available to common shareholders.
|
•
|
Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity GMIB fees (“GMIB Fees”);
|
•
|
Net investment income: (i) includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) excludes post-tax adjusted earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed unit-linked investments and (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
•
|
Other revenues are adjusted for settlements of foreign currency earnings hedges.
|
•
|
Policyholder benefits and claims and policyholder dividends excludes: (i) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iii) benefits and hedging costs related to GMIBs (“GMIB Costs”), and (iv) market value adjustments associated with surrenders or terminations of contracts (“Market Value Adjustments”);
|
•
|
Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes amounts related to net investment income earned on contractholder-directed unit-linked investments;
|
•
|
Amortization of DAC and VOBA excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB Fees and GMIB Costs, and (iii) Market Value Adjustments;
|
•
|
Amortization of negative VOBA excludes amounts related to Market Value Adjustments;
|
•
|
Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
•
|
Other expenses excludes costs related to: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements, and (iii) acquisition, integration and other costs.
|
•
|
MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA, is defined as MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.
|
•
|
Adjusted ROE is defined as adjusted earnings available to common shareholders, divided by average GAAP common stockholders’ equity.
|
•
|
Adjusted ROE, excluding AOCI other than FCTA, is defined as adjusted earnings available to common shareholders divided by average GAAP common stockholders’ equity, excluding AOCI other than FCTA.
|
•
|
Allocated equity is the portion of MetLife, Inc.’s common stockholders’ equity that management allocates to each of its segments and sub-segments based on local capital requirements and economic capital. See “— Economic Capital.” Allocated equity excludes the impact of AOCI other than FCTA.
|
•
|
The impact of changes in our foreign currency exchange rates is calculated using the average foreign currency exchange rates for the current period and is applied to each of the comparable periods (“Constant Currency Basis”).
|
•
|
We sometimes refer to sales activity for various products. These sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity. Further, sales statistics for our Latin America, Asia and EMEA segments are on a Constant Currency Basis.
|
•
|
Asymmetrical and non-economic accounting refers to: (i) the portion of net derivative gains (losses) on embedded derivatives attributable to the inclusion of our credit spreads in the liability valuations, (ii) hedging activity that generates net derivative gains (losses) and creates fluctuations in net income because hedge accounting cannot be achieved and the item being hedged does not a have an offsetting gain or loss recognized in earnings, (iii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, and (iv) impact of changes in foreign currency exchange rates on the re-measurement of foreign denominated unhedged funding agreements and financing transactions to the U.S. dollar and the re-measurement of certain liabilities from non-functional currencies to functional currencies. We believe that excluding the impact of asymmetrical and non-economic accounting from total GAAP results enhances investor understanding of our performance by disclosing how these accounting practices affect reported GAAP results.
|
•
|
The Company uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. The Company defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders. A reconciliation of net cash provided by operating activities of MetLife, Inc. to free cash flow of all holding companies for the years ended December 31, 2017, 2016 and 2015 is provided below.
|
Reconciliation of Net Cash Provided by Operating Activities of MetLife, Inc. to Free Cash Flow of All Holding Companies
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
MetLife, Inc. (parent company only) net cash provided by operating activities
|
$
|
6,462
|
|
|
$
|
3,747
|
|
|
$
|
1,606
|
|
Adjustments from net cash provided by operating activities to free cash flow:
|
|
|
|
|
|
|
|
||||
Add: Incremental debt to be at or below target leverage ratios
|
—
|
|
|
—
|
|
|
1,750
|
|
|||
Add: Capital contributions to subsidiaries
|
(124
|
)
|
|
(1,733
|
)
|
|
(667
|
)
|
|||
Add: Returns of capital from subsidiaries
|
610
|
|
|
80
|
|
|
5
|
|
|||
Add: Repayments on and (issuances of) loans to subsidiaries, net
|
—
|
|
|
—
|
|
|
461
|
|
|||
Add: Investment portfolio and derivatives changes and other, net
|
(780
|
)
|
|
(672
|
)
|
|
365
|
|
|||
MetLife, Inc. (parent company only) free cash flow
|
6,168
|
|
|
1,422
|
|
|
3,520
|
|
|||
Other MetLife, Inc. holding companies:
|
|
|
|
|
|
||||||
Add: Dividends and returns of capital from subsidiaries
|
2,125
|
|
|
1,485
|
|
|
1,354
|
|
|||
Add: Capital contributions from MetLife, Inc.
|
—
|
|
|
—
|
|
|
150
|
|
|||
Add: Capital contributions to subsidiaries
|
(12
|
)
|
|
(53
|
)
|
|
(27
|
)
|
|||
Add: Repayments on and (issuances of) loans to subsidiaries, net
|
(6
|
)
|
|
(307
|
)
|
|
(510
|
)
|
|||
Add: Other expenses
|
(626
|
)
|
|
(671
|
)
|
|
(729
|
)
|
|||
Add: Dividends and returns of capital to MetLife, Inc.
|
(2,200
|
)
|
|
—
|
|
|
—
|
|
|||
Add: Investment portfolio and derivative changes and other, net
|
218
|
|
|
548
|
|
|
223
|
|
|||
Total other MetLife, Inc. holding companies free cash flow
|
(501
|
)
|
|
1,002
|
|
|
461
|
|
|||
Free cash flow of all holding companies (1)
|
$
|
5,667
|
|
|
$
|
2,424
|
|
|
$
|
3,981
|
|
|
|
|
|
|
|
||||||
Ratio of net cash provided by operating activities to consolidated net income (loss) available to MetLife, Inc.'s common shareholders:
|
|
|
|
|
|
||||||
MetLife, Inc. (parent company only) net cash provided by operating activities
|
$
|
6,462
|
|
|
$
|
3,747
|
|
|
$
|
1,606
|
|
Consolidated net income (loss) available to MetLife, Inc.’s common
shareholders (1) |
$
|
3,907
|
|
|
$
|
747
|
|
|
$
|
5,215
|
|
Ratio of net cash provided by operating activities (parent company only) to
consolidated net income (loss) available to MetLife, Inc.'s common shareholders (1) (2) |
165
|
%
|
|
502
|
%
|
|
31
|
%
|
|||
Ratio of free cash flow to adjusted earnings available to common shareholders:
|
|
|
|
|
|
||||||
Free cash flow of all holding companies (3)
|
$
|
5,667
|
|
|
$
|
2,424
|
|
|
$
|
3,981
|
|
Consolidated adjusted earnings available to common shareholders (3)
|
$
|
4,235
|
|
|
$
|
4,033
|
|
|
$
|
3,914
|
|
Ratio of free cash flow of all holding companies to consolidated adjusted
earnings available to common shareholders (3) |
134
|
%
|
|
60
|
%
|
|
102
|
%
|
(1)
|
Consolidated net income (loss) available to MetLife, Inc.’s common shareholders for 2017 includes Separation-related costs of $312 million, net of income tax. Excluding this amount from the denominator of the ratio, this ratio, as adjusted, would be 153%. Consolidated net income (loss) available to MetLife, Inc.'s common shareholders for 2016 includes Separation-related costs of $73 million, net of income tax. Excluding this amount from the denominator of the ratio, this ratio, as adjusted, would be 457%. Consolidated net income (loss) available to MetLife, Inc.'s common shareholders for 2015 includes a non-cash charge of $792 million, net of income tax, related to an uncertain tax position. Excluding this charge from the denominator of the ratio, this ratio, as adjusted, would be 27%. See “
—
Liquidity and Capital Resources
—
MetLife, Inc.
—
Liquid Assets
—
MetLife, Inc. and Other MetLife Holding Companies Sources and Uses of Liquid Assets and Sources and Uses of Liquid Assets included in Free Cash Flow.”
|
(2)
|
Including the free cash flow of other MetLife, Inc. holding companies of ($501) million,
$1.0 billion
and $461 million for the years ended December 31, 2017, 2016 and 2015, respectively, in the numerator of the ratio, this ratio, as adjusted, would be 153%, 636% and 40%, respectively. Including the free cash flow of other MetLife, Inc. holding companies in the numerator of the ratio and excluding the Separation-related costs and uncertain tax position non-cash charge from the denominator of the ratio, this ratio, as adjusted, would be 141%, 579% and 34% for the years ended December 31, 2017, 2016 and 2015, respectively.
|
(3)
|
i) In 2017, $2.1 billion of Separation-related items (comprised of certain Separation-related inflows primarily related to dividends from Brighthouse, net of outflows) were included, which increased our holding companies’ liquid assets, as well as our free cash flow. Excluding these Separation-related items, adjusted free cash flow would be $3.6 billion for the year ended December 31, 2017. Consolidated adjusted earnings available to common shareholders for 2017 was negatively impacted by notable items, primarily related to tax adjustments, of $622 million, net of income tax. Excluding the Separation-related items, which increased free cash flow, from the numerator of the ratio and excluding such notable items negatively impacting consolidated adjusted earnings available to common shareholders from the denominator of the ratio, the adjusted free cash flow ratio for 2017 would be 75%.
|
•
|
implementing a corporate risk framework, which outlines our enterprise approach for managing risk;
|
•
|
developing policies and procedures for managing, measuring, monitoring and controlling those risks identified in the corporate risk framework;
|
•
|
coordinating
Own Risk and Solvency Assessments for the Board, senior management and regulator use;
|
•
|
establishing appropriate corporate risk tolerance levels;
|
•
|
recommending risk appetite statements and investment general authorizations to the Board;
|
•
|
measuring capital on an economic basis;
|
•
|
recommending capital allocations on an economic capital basis; and
|
•
|
reporting to (i) the Finance and Risk Committee of MetLife, Inc.’s Board of Directors; (ii) the Investment Committee of MetLife, Inc.’s Board of Directors (iii) the Compensation Committee of MetLife, Inc.’s Board of Directors; and (iv) the financial and non-financial senior management committees on various aspects of risk.
|
•
|
Risks Related to Guarantee Benefits — We use a wide range of derivative contracts to mitigate the risk associated with variable annuity living guarantee benefits. These derivatives include equity and interest rate futures, interest rate swaps, currency futures/forwards, equity indexed options, total rate of return swaps, interest rate option contracts and equity variance swaps.
|
•
|
Minimum Interest Rate Guarantees — For certain liability contracts, we provide the contractholder a guaranteed minimum interest rate. These contracts include certain fixed annuities and other insurance liabilities. We purchase interest rate floors to reduce risk associated with these liability guarantees.
|
•
|
Reinvestment Risk in Long-Duration Liability Contracts — Derivatives are used to hedge interest rate risk related to certain long-duration liability contracts. Hedges include interest rate swaps and swaptions.
|
•
|
Foreign Currency Exchange Rate Risk — We use currency swaps, forwards and options to hedge foreign currency exchange rate risk. These hedges are generally used to swap foreign currency denominated bonds, investments in foreign subsidiaries or equity market exposures to U.S. dollars. Our foreign subsidiaries also use these hedges to swap non-local currency assets to local currency, to match liabilities
.
|
•
|
General ALM Hedging Strategies — In the ordinary course of managing our asset/liability risks, we use interest rate futures, interest rate swaps, interest rate caps, and inflation swaps. These hedges are designed to reduce interest rate risk or inflation risk related to the existing assets or liabilities or related to expected future cash flows.
|
•
|
the net present values of our interest rate sensitive exposures resulting from a 10% change (increase or decrease) in interest rates;
|
•
|
the U.S. dollar equivalent estimated fair values of our foreign currency exposures due to a 10% change (increase in the value of the U.S. dollar compared to all foreign currencies or decrease in the value of the U.S. dollar compared to all foreign currencies) in foreign currency exchange rates; and
|
•
|
the estimated fair value of our equity positions due to a 10% change (increase or decrease) in equity market prices.
|
•
|
interest sensitive and foreign currency exchange sensitive liabilities do not include
$193.5 billion
of insurance contracts, which are accounted for on a book value basis. Management believes that the changes in the economic value of those contracts under changing interest rates and changing foreign currency exchange rates would offset a significant portion of the fair value changes of interest sensitive and foreign currency exchange rate sensitive assets.
|
•
|
the market risk information is limited by the assumptions and parameters established in creating the related sensitivity analysis, including the impact of prepayment rates on mortgage loans;
|
•
|
sensitivities do not include the impact on asset or liability valuation of changes in market liquidity or changes in market credit spreads;
|
•
|
foreign currency risk is not isolated for certain embedded derivatives within host asset and liability contracts, as the risk on these instruments is reflected as equity;
|
•
|
for the derivatives that qualify as hedges, and for certain other assets such as mortgage loans, the impact on reported earnings may be materially different from the change in market values;
|
•
|
the analysis excludes liabilities pursuant to insurance contracts and real estate holdings; and
|
•
|
the model assumes that the composition of assets and liabilities remains unchanged throughout the period.
|
|
December 31, 2017
|
||
|
(In millions)
|
||
Interest rate risk
|
$
|
5,862
|
|
Foreign currency exchange rate risk
|
$
|
7,867
|
|
Equity market risk
|
$
|
71
|
|
|
December 31, 2017
|
||||||||||
|
Notional
Amount
|
|
Estimated
Fair
Value (1)
|
|
Assuming a
10% Increase
in the Yield
Curve
|
||||||
|
(In millions)
|
||||||||||
Assets
|
|
|
|
|
|
||||||
Fixed maturity securities
|
|
|
$
|
308,931
|
|
|
$
|
(5,130
|
)
|
||
Equity securities
|
|
|
$
|
2,513
|
|
|
—
|
|
|||
FVO general account securities
|
|
|
$
|
2,224
|
|
|
(7
|
)
|
|||
Mortgage loans
|
|
|
$
|
69,797
|
|
|
(657
|
)
|
|||
Policy loans
|
|
|
$
|
11,512
|
|
|
(103
|
)
|
|||
Short-term investments
|
|
|
$
|
4,870
|
|
|
(4
|
)
|
|||
Other invested assets
|
|
|
$
|
608
|
|
|
—
|
|
|||
Cash and cash equivalents
|
|
|
$
|
12,701
|
|
|
—
|
|
|||
Accrued investment income
|
|
|
$
|
3,524
|
|
|
—
|
|
|||
Premiums, reinsurance and other receivables
|
|
|
$
|
4,339
|
|
|
(236
|
)
|
|||
Other assets
|
|
|
$
|
328
|
|
|
(3
|
)
|
|||
Embedded derivatives within asset host contracts (2)
|
|
|
$
|
144
|
|
|
—
|
|
|||
Total assets
|
|
|
|
|
$
|
(6,140
|
)
|
||||
Liabilities (3)
|
|
|
|
|
|
||||||
Policyholder account balances
|
|
|
$
|
111,415
|
|
|
$
|
581
|
|
||
Payables for collateral under securities loaned and other transactions
|
|
|
$
|
25,723
|
|
|
—
|
|
|||
Short-term debt
|
|
|
$
|
477
|
|
|
—
|
|
|||
Long-term debt
|
|
|
$
|
17,773
|
|
|
380
|
|
|||
Collateral financing arrangement
|
|
|
$
|
894
|
|
|
—
|
|
|||
Junior subordinated debt securities
|
|
|
$
|
4,319
|
|
|
106
|
|
|||
Other liabilities
|
|
|
$
|
3,841
|
|
|
(43
|
)
|
|||
Embedded derivatives within liability host contracts (2)
|
|
|
$
|
418
|
|
|
105
|
|
|||
Total liabilities
|
|
|
|
|
$
|
1,129
|
|
||||
Derivative Instruments
|
|
|
|
|
|
||||||
Interest rate swaps
|
$
|
67,912
|
|
|
$
|
4,144
|
|
|
$
|
(629
|
)
|
Interest rate floors
|
$
|
7,201
|
|
|
$
|
92
|
|
|
(22
|
)
|
|
Interest rate caps
|
$
|
53,079
|
|
|
$
|
76
|
|
|
43
|
|
|
Interest rate futures
|
$
|
4,366
|
|
|
$
|
(2
|
)
|
|
34
|
|
|
Interest rate options
|
$
|
12,009
|
|
|
$
|
645
|
|
|
(25
|
)
|
|
Interest rate forwards
|
$
|
3,549
|
|
|
$
|
(170
|
)
|
|
(130
|
)
|
|
Interest rate total return swaps
|
$
|
1,048
|
|
|
$
|
6
|
|
|
(53
|
)
|
|
Synthetic GICs
|
$
|
11,318
|
|
|
$
|
—
|
|
|
—
|
|
|
Foreign currency swaps
|
$
|
43,170
|
|
|
$
|
(304
|
)
|
|
(62
|
)
|
|
Foreign currency forwards
|
$
|
15,823
|
|
|
$
|
(149
|
)
|
|
2
|
|
|
Currency futures
|
$
|
846
|
|
|
$
|
2
|
|
|
—
|
|
|
Currency options
|
$
|
12,531
|
|
|
$
|
(70
|
)
|
|
(4
|
)
|
|
Credit default swaps
|
$
|
13,395
|
|
|
$
|
235
|
|
|
(1
|
)
|
|
Equity futures
|
$
|
4,005
|
|
|
$
|
14
|
|
|
—
|
|
|
Equity index options
|
$
|
19,886
|
|
|
$
|
(121
|
)
|
|
(4
|
)
|
|
Equity variance swaps
|
$
|
4,661
|
|
|
$
|
(145
|
)
|
|
—
|
|
|
Equity total return swaps
|
$
|
1,117
|
|
|
$
|
(41
|
)
|
|
—
|
|
|
Total derivative instruments
|
|
|
|
|
$
|
(851
|
)
|
||||
Net Change
|
|
|
|
|
$
|
(5,862
|
)
|
(1)
|
Separate account assets and liabilities and contractholder-directed unit-linked investments and associated policyholder account balances, which are interest rate sensitive, are not included herein as any interest rate risk is borne by the contractholder. FVO general account securities and long-term debt exclude $6 million and $5 million, respectively, related to CSEs. See Note
8
of the Notes to the Consolidated Financial Statements for information regarding CSEs.
|
(2)
|
Embedded derivatives are recognized on the consolidated balance sheet in the same caption as the host contract.
|
(3)
|
Excludes $
193.5 billion
of liabilities, at carrying value, pursuant to insurance contracts reported within future policy benefits and other policy-related balances. These liabilities would economically offset a significant portion of the net change in fair value of our financial instruments resulting from a 10% increase in the yield curve.
|
|
December 31, 2017
|
||||||||||
|
Notional
Amount
|
|
Estimated
Fair
Value (1)
|
|
Assuming a
10% Increase in the Foreign Exchange Rate |
||||||
|
(In millions)
|
||||||||||
Assets
|
|
|
|
|
|
||||||
Fixed maturity securities
|
|
|
$
|
308,931
|
|
|
$
|
(9,746
|
)
|
||
Equity securities
|
|
|
$
|
2,513
|
|
|
(59
|
)
|
|||
FVO general account securities
|
|
|
$
|
2,224
|
|
|
(93
|
)
|
|||
Mortgage loans
|
|
|
$
|
69,797
|
|
|
(870
|
)
|
|||
Policy loans
|
|
|
$
|
11,512
|
|
|
(157
|
)
|
|||
Short-term investments
|
|
|
$
|
4,870
|
|
|
(312
|
)
|
|||
Other invested assets
|
|
|
$
|
608
|
|
|
(207
|
)
|
|||
Cash and cash equivalents
|
|
|
$
|
12,701
|
|
|
(478
|
)
|
|||
Accrued investment income
|
|
|
$
|
3,524
|
|
|
(103
|
)
|
|||
Premiums, reinsurance and other receivables
|
|
|
$
|
4,339
|
|
|
(43
|
)
|
|||
Other assets
|
|
|
$
|
328
|
|
|
(8
|
)
|
|||
Embedded derivatives within asset host contracts (2)
|
|
|
$
|
144
|
|
|
(14
|
)
|
|||
Total assets
|
|
|
|
|
$
|
(12,090
|
)
|
||||
Liabilities (3)
|
|
|
|
|
|
||||||
Policyholder account balances
|
|
|
$
|
111,415
|
|
|
$
|
3,722
|
|
||
Payables for collateral under securities loaned and other transactions
|
|
|
$
|
25,723
|
|
|
123
|
|
|||
Long-term debt
|
|
|
$
|
17,773
|
|
|
118
|
|
|||
Other liabilities
|
|
|
$
|
3,841
|
|
|
9
|
|
|||
Embedded derivatives within liability host contracts (2)
|
|
|
$
|
418
|
|
|
42
|
|
|||
Total liabilities
|
|
|
|
|
$
|
4,014
|
|
||||
Derivative Instruments
|
|
|
|
|
|
||||||
Interest rate swaps
|
$
|
67,912
|
|
|
$
|
4,144
|
|
|
$
|
(37
|
)
|
Interest rate floors
|
$
|
7,201
|
|
|
$
|
92
|
|
|
—
|
|
|
Interest rate caps
|
$
|
53,079
|
|
|
$
|
76
|
|
|
—
|
|
|
Interest rate futures
|
$
|
4,366
|
|
|
$
|
(2
|
)
|
|
—
|
|
|
Interest rate options
|
$
|
12,009
|
|
|
$
|
645
|
|
|
(51
|
)
|
|
Interest rate forwards
|
$
|
3,549
|
|
|
$
|
(170
|
)
|
|
4
|
|
|
Interest rate total return swaps
|
$
|
1,048
|
|
|
$
|
6
|
|
|
—
|
|
|
Synthetic GICs
|
$
|
11,318
|
|
|
$
|
—
|
|
|
—
|
|
|
Foreign currency swaps
|
$
|
43,170
|
|
|
$
|
(304
|
)
|
|
629
|
|
|
Foreign currency forwards
|
$
|
15,823
|
|
|
$
|
(149
|
)
|
|
(804
|
)
|
|
Currency futures
|
$
|
846
|
|
|
$
|
2
|
|
|
(85
|
)
|
|
Currency options
|
$
|
12,531
|
|
|
$
|
(70
|
)
|
|
542
|
|
|
Credit default swaps
|
$
|
13,395
|
|
|
$
|
235
|
|
|
(6
|
)
|
|
Equity futures
|
$
|
4,005
|
|
|
$
|
14
|
|
|
—
|
|
|
Equity index options
|
$
|
19,886
|
|
|
$
|
(121
|
)
|
|
17
|
|
|
Equity variance swaps
|
$
|
4,661
|
|
|
$
|
(145
|
)
|
|
—
|
|
|
Equity total return swaps
|
$
|
1,117
|
|
|
$
|
(41
|
)
|
|
—
|
|
|
Total derivative instruments
|
|
|
|
|
$
|
209
|
|
||||
Net Change
|
|
|
|
|
$
|
(7,867
|
)
|
(1)
|
Does not necessarily represent those financial instruments solely subject to foreign currency exchange rate risk. Separate account assets and liabilities and contractholder-directed unit-linked investments and associated policyholder account balances, which are foreign currency exchange rate sensitive, are not included herein as any foreign currency exchange rate risk is borne by the contractholder. FVO general securities and long-term debt exclude $6 million and $5 million, respectively, related to CSEs. See Note
8
of the Notes to the Consolidated Financial Statements for information regarding CSEs.
|
(2)
|
Embedded derivatives are recognized on the consolidated balance sheet in the same caption as the host contract.
|
(3)
|
Excludes $
193.5 billion
of liabilities, at carrying value, pursuant to insurance contracts reported within future policy benefits and other policy-related balances. These liabilities would economically offset a significant portion of the net change in fair value of our financial instruments resulting from a 10% increase in foreign currency exchange rates.
|
|
December 31, 2017
|
||||||||||
|
Notional
Amount
|
|
Estimated
Fair Value (1) |
|
Assuming a
10% Decrease
in Equity
Prices
|
||||||
|
(In millions)
|
||||||||||
Assets
|
|
|
|
|
|
||||||
Equity securities
|
|
|
$
|
2,513
|
|
|
$
|
(251
|
)
|
||
FVO general account securities
|
|
|
$
|
2,224
|
|
|
(157
|
)
|
|||
Embedded derivatives within asset host contracts (2)
|
|
|
$
|
144
|
|
|
—
|
|
|||
Total assets
|
|
|
|
|
$
|
(408
|
)
|
||||
Liabilities
|
|
|
|
|
|
||||||
Policyholder account balances
|
|
|
$
|
111,415
|
|
|
$
|
—
|
|
||
Embedded derivatives within liability host contracts (2)
|
|
|
$
|
418
|
|
|
(228
|
)
|
|||
Total liabilities
|
|
|
|
|
$
|
(228
|
)
|
||||
Derivative Instruments
|
|
|
|
|
|
||||||
Interest rate swaps
|
$
|
67,912
|
|
|
$
|
4,144
|
|
|
$
|
—
|
|
Interest rate floors
|
$
|
7,201
|
|
|
$
|
92
|
|
|
—
|
|
|
Interest rate caps
|
$
|
53,079
|
|
|
$
|
76
|
|
|
—
|
|
|
Interest rate futures
|
$
|
4,366
|
|
|
$
|
(2
|
)
|
|
—
|
|
|
Interest rate options
|
$
|
12,009
|
|
|
$
|
645
|
|
|
—
|
|
|
Interest rate forwards
|
$
|
3,549
|
|
|
$
|
(170
|
)
|
|
—
|
|
|
Interest rate total return swaps
|
$
|
1,048
|
|
|
$
|
6
|
|
|
—
|
|
|
Synthetic GICs
|
$
|
11,318
|
|
|
$
|
—
|
|
|
—
|
|
|
Foreign currency swaps
|
$
|
43,170
|
|
|
$
|
(304
|
)
|
|
—
|
|
|
Foreign currency forwards
|
$
|
15,823
|
|
|
$
|
(149
|
)
|
|
—
|
|
|
Currency futures
|
$
|
846
|
|
|
$
|
2
|
|
|
—
|
|
|
Currency options
|
$
|
12,531
|
|
|
$
|
(70
|
)
|
|
—
|
|
|
Credit default swaps
|
$
|
13,395
|
|
|
$
|
235
|
|
|
—
|
|
|
Equity futures
|
$
|
4,005
|
|
|
$
|
14
|
|
|
313
|
|
|
Equity index options
|
$
|
19,886
|
|
|
$
|
(121
|
)
|
|
125
|
|
|
Equity variance swaps
|
$
|
4,661
|
|
|
$
|
(145
|
)
|
|
3
|
|
|
Equity total return swaps
|
$
|
1,117
|
|
|
$
|
(41
|
)
|
|
124
|
|
|
Total derivative instruments
|
|
|
|
|
$
|
565
|
|
||||
Net Change
|
|
|
|
|
$
|
(71
|
)
|
(1)
|
Does not necessarily represent those financial instruments solely subject to equity price risk. Additionally, separate account assets and liabilities and contractholder-directed unit-linked investments and associated policyholder account balances, which are equity market sensitive, are not included herein as any equity market risk is borne by the contractholder.
|
(2)
|
Embedded derivatives are recognized on the consolidated balance sheet in the same caption as the host contract.
|
|
|
2017
|
|
2016
|
||||
Assets
|
|
|
|
|
||||
Investments:
|
|
|
|
|
||||
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $286,069 and $271,676, respectively)
|
|
$
|
308,931
|
|
|
$
|
289,563
|
|
Equity securities available-for-sale, at estimated fair value (cost: $2,140 and $2,464, respectively)
|
|
2,513
|
|
|
2,894
|
|
||
Fair value option securities, at estimated fair value ($6 and $8, respectively, relating to variable interest entities)
|
|
16,745
|
|
|
13,923
|
|
||
Mortgage loans (net of valuation allowances of $314 and $304, respectively; includes $520 and $566, respectively, under the fair value option)
|
|
68,731
|
|
|
65,167
|
|
||
Policy loans
|
|
9,669
|
|
|
9,511
|
|
||
Real estate and real estate joint ventures (includes $25 and $59, respectively, of real estate held-for-sale)
|
|
9,637
|
|
|
8,891
|
|
||
Other limited partnership interests (includes $0 and $14, respectively, relating to variable interest entities)
|
|
5,708
|
|
|
5,136
|
|
||
Short-term investments, principally at estimated fair value
|
|
4,870
|
|
|
6,523
|
|
||
Other invested assets (includes $125 and $31, respectively, relating to variable interest entities)
|
|
17,263
|
|
|
19,303
|
|
||
Total investments
|
|
444,067
|
|
|
420,911
|
|
||
Cash and cash equivalents, principally at estimated fair value (includes $12 and $1, respectively, relating to variable interest entities)
|
|
12,701
|
|
|
12,651
|
|
||
Accrued investment income
|
|
3,524
|
|
|
3,308
|
|
||
Premiums, reinsurance and other receivables (includes $3 and $2, respectively, relating to variable interest entities)
|
|
18,423
|
|
|
15,445
|
|
||
Deferred policy acquisition costs and value of business acquired
|
|
18,419
|
|
|
17,590
|
|
||
Current income tax recoverable
|
|
—
|
|
|
20
|
|
||
Goodwill
|
|
9,590
|
|
|
9,220
|
|
||
Assets of disposed subsidiary
|
|
—
|
|
|
216,983
|
|
||
Other assets (includes $2 and $3, respectively, relating to variable interest entities)
|
|
8,167
|
|
|
7,058
|
|
||
Separate account assets
|
|
205,001
|
|
|
195,578
|
|
||
Total assets
|
|
$
|
719,892
|
|
|
$
|
898,764
|
|
Liabilities and Equity
|
|
|
|
|
||||
Liabilities
|
|
|
|
|
||||
Future policy benefits
|
|
$
|
177,974
|
|
|
$
|
166,636
|
|
Policyholder account balances
|
|
182,518
|
|
|
172,486
|
|
||
Other policy-related balances
|
|
15,515
|
|
|
13,402
|
|
||
Policyholder dividends payable
|
|
682
|
|
|
696
|
|
||
Policyholder dividend obligation
|
|
2,121
|
|
|
1,931
|
|
||
Payables for collateral under securities loaned and other transactions
|
|
25,723
|
|
|
25,873
|
|
||
Short-term debt
|
|
477
|
|
|
242
|
|
||
Long-term debt (includes $6 and $12, respectively, at estimated fair value, relating to variable interest entities)
|
|
15,686
|
|
|
16,441
|
|
||
Collateral financing arrangement
|
|
1,121
|
|
|
1,274
|
|
||
Junior subordinated debt securities
|
|
3,144
|
|
|
3,169
|
|
||
Liabilities of disposed subsidiary
|
|
—
|
|
|
202,707
|
|
||
Current income tax payable
|
|
311
|
|
|
—
|
|
||
Deferred income tax liability
|
|
6,767
|
|
|
6,892
|
|
||
Other liabilities (includes $3 and $0, respectively, relating to variable interest entities)
|
|
23,982
|
|
|
23,735
|
|
||
Separate account liabilities
|
|
205,001
|
|
|
195,578
|
|
||
Total liabilities
|
|
661,022
|
|
|
831,062
|
|
||
Contingencies, Commitments and Guarantees (Note 20)
|
|
|
|
|
||||
Equity
|
|
|
|
|
||||
MetLife, Inc.’s stockholders’ equity:
|
|
|
|
|
||||
Preferred stock, par value $0.01 per share; $2,100 aggregate liquidation preference
|
|
—
|
|
|
—
|
|
||
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,168,710,101 and 1,164,029,985 shares issued, respectively; 1,043,588,396 and 1,095,519,005 shares outstanding, respectively
|
|
12
|
|
|
12
|
|
||
Additional paid-in capital
|
|
31,111
|
|
|
30,944
|
|
||
Retained earnings
|
|
26,527
|
|
|
34,683
|
|
||
Treasury stock, at cost; 125,121,705 and 68,510,980 shares, respectively
|
|
(6,401
|
)
|
|
(3,474
|
)
|
||
Accumulated other comprehensive income (loss)
|
|
7,427
|
|
|
5,366
|
|
||
Total MetLife, Inc.’s stockholders’ equity
|
|
58,676
|
|
|
67,531
|
|
||
Noncontrolling interests
|
|
194
|
|
|
171
|
|
||
Total equity
|
|
58,870
|
|
|
67,702
|
|
||
Total liabilities and equity
|
|
$
|
719,892
|
|
|
$
|
898,764
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Revenues
|
|
|
|
|
|
|
||||||
Premiums
|
|
$
|
38,992
|
|
|
$
|
37,202
|
|
|
$
|
36,403
|
|
Universal life and investment-type product policy fees
|
|
5,510
|
|
|
5,483
|
|
|
5,570
|
|
|||
Net investment income
|
|
17,363
|
|
|
16,790
|
|
|
16,205
|
|
|||
Other revenues
|
|
1,341
|
|
|
1,685
|
|
|
1,927
|
|
|||
Net investment gains (losses):
|
|
|
|
|
|
|
||||||
Other-than-temporary impairments on fixed maturity securities
|
|
(11
|
)
|
|
(96
|
)
|
|
(61
|
)
|
|||
Other-than-temporary impairments on fixed maturity securities transferred to other comprehensive income (loss)
|
|
1
|
|
|
(11
|
)
|
|
2
|
|
|||
Other net investment gains (losses)
|
|
(298
|
)
|
|
424
|
|
|
668
|
|
|||
Total net investment gains (losses)
|
|
(308
|
)
|
|
317
|
|
|
609
|
|
|||
Net derivative gains (losses)
|
|
(590
|
)
|
|
(690
|
)
|
|
629
|
|
|||
Total revenues
|
|
62,308
|
|
|
60,787
|
|
|
61,343
|
|
|||
Expenses
|
|
|
|
|
|
|
||||||
Policyholder benefits and claims
|
|
38,313
|
|
|
36,358
|
|
|
35,144
|
|
|||
Interest credited to policyholder account balances
|
|
5,607
|
|
|
5,176
|
|
|
4,415
|
|
|||
Policyholder dividends
|
|
1,231
|
|
|
1,223
|
|
|
1,356
|
|
|||
Other expenses
|
|
13,621
|
|
|
13,749
|
|
|
14,777
|
|
|||
Total expenses
|
|
58,772
|
|
|
56,506
|
|
|
55,692
|
|
|||
Income (loss) from continuing operations before provision for income tax
|
|
3,536
|
|
|
4,281
|
|
|
5,651
|
|
|||
Provision for income tax expense (benefit)
|
|
(1,470
|
)
|
|
693
|
|
|
1,590
|
|
|||
Income (loss) from continuing operations, net of income tax
|
|
5,006
|
|
|
3,588
|
|
|
4,061
|
|
|||
Income (loss) from discontinued operations, net of income tax
|
|
(986
|
)
|
|
(2,734
|
)
|
|
1,324
|
|
|||
Net income (loss)
|
|
4,020
|
|
|
854
|
|
|
5,385
|
|
|||
Less: Net income (loss) attributable to noncontrolling interests
|
|
10
|
|
|
4
|
|
|
12
|
|
|||
Net income (loss) attributable to MetLife, Inc.
|
|
4,010
|
|
|
850
|
|
|
5,373
|
|
|||
Less: Preferred stock dividends
|
|
103
|
|
|
103
|
|
|
116
|
|
|||
Preferred stock repurchase premium
|
|
—
|
|
|
—
|
|
|
42
|
|
|||
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
3,907
|
|
|
$
|
747
|
|
|
$
|
5,215
|
|
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders per common share:
|
|
|
|
|
|
|
||||||
Basic
|
|
$
|
4.57
|
|
|
$
|
3.16
|
|
|
$
|
3.48
|
|
Diluted
|
|
$
|
4.53
|
|
|
$
|
3.13
|
|
|
$
|
3.44
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
|
|
|
|
|
|
|
||||||
Basic
|
|
$
|
3.65
|
|
|
$
|
0.68
|
|
|
$
|
4.67
|
|
Diluted
|
|
$
|
3.62
|
|
|
$
|
0.67
|
|
|
$
|
4.62
|
|
Cash dividends declared per common share
|
|
$
|
1.600
|
|
|
$
|
1.575
|
|
|
$
|
1.475
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net income (loss)
|
$
|
4,020
|
|
|
$
|
854
|
|
|
$
|
5,385
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
||||||
Unrealized investment gains (losses), net of related offsets
|
4,623
|
|
|
796
|
|
|
(7,449
|
)
|
|||
Unrealized gains (losses) on derivatives
|
(1,165
|
)
|
|
573
|
|
|
589
|
|
|||
Foreign currency translation adjustments
|
767
|
|
|
(363
|
)
|
|
(1,624
|
)
|
|||
Defined benefit plans adjustment
|
144
|
|
|
131
|
|
|
354
|
|
|||
Other comprehensive income (loss), before income tax
|
4,369
|
|
|
1,137
|
|
|
(8,130
|
)
|
|||
Income tax (expense) benefit related to items of other comprehensive income (loss)
|
(984
|
)
|
|
(450
|
)
|
|
2,203
|
|
|||
Other comprehensive income (loss), net of income tax
|
3,385
|
|
|
687
|
|
|
(5,927
|
)
|
|||
Comprehensive income (loss)
|
7,405
|
|
|
1,541
|
|
|
(542
|
)
|
|||
Less: Comprehensive income (loss) attributable to noncontrolling interest, net of income tax
|
14
|
|
|
92
|
|
|
32
|
|
|||
Comprehensive income (loss) attributable to MetLife, Inc.
|
$
|
7,391
|
|
|
$
|
1,449
|
|
|
$
|
(574
|
)
|
|
|
Preferred
Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Retained
Earnings
|
|
Treasury
Stock
at Cost
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Total
MetLife, Inc.’s
Stockholders’
Equity
|
|
Noncontrolling
Interests
|
|
Total
Equity
|
||||||||||||||||||
Balance at December 31, 2014, as previously reported
|
|
$
|
1
|
|
|
$
|
12
|
|
|
$
|
30,543
|
|
|
$
|
32,020
|
|
|
$
|
(1,172
|
)
|
|
$
|
10,649
|
|
|
$
|
72,053
|
|
|
$
|
507
|
|
|
$
|
72,560
|
|
Prior-period revisions (Note 1)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
90
|
|
|
—
|
|
|
65
|
|
|
155
|
|
|
—
|
|
|
155
|
|
|||||||||
Balance at December 31, 2014
|
|
$
|
1
|
|
|
$
|
12
|
|
|
$
|
30,543
|
|
|
$
|
32,110
|
|
|
$
|
(1,172
|
)
|
|
$
|
10,714
|
|
|
$
|
72,208
|
|
|
$
|
507
|
|
|
$
|
72,715
|
|
Repurchase of preferred stock
|
|
(1
|
)
|
|
|
|
(1,459
|
)
|
|
|
|
|
|
|
|
(1,460
|
)
|
|
|
|
(1,460
|
)
|
||||||||||||||
Preferred stock repurchase premium
|
|
|
|
|
|
|
|
(42
|
)
|
|
|
|
|
|
(42
|
)
|
|
|
|
(42
|
)
|
|||||||||||||||
Preferred stock issuance
|
|
|
|
|
|
1,483
|
|
|
|
|
|
|
|
|
1,483
|
|
|
|
|
1,483
|
|
|||||||||||||||
Treasury stock acquired in connection with share repurchases
|
|
|
|
|
|
|
|
|
|
(1,930
|
)
|
|
|
|
(1,930
|
)
|
|
|
|
(1,930
|
)
|
|||||||||||||||
Stock-based compensation
|
|
|
|
|
|
182
|
|
|
|
|
|
|
|
|
182
|
|
|
|
|
182
|
|
|||||||||||||||
Dividends on preferred stock
|
|
|
|
|
|
|
|
(116
|
)
|
|
|
|
|
|
(116
|
)
|
|
|
|
(116
|
)
|
|||||||||||||||
Dividends on common stock
|
|
|
|
|
|
|
|
(1,653
|
)
|
|
|
|
|
|
(1,653
|
)
|
|
|
|
(1,653
|
)
|
|||||||||||||||
Change in equity of noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
|
(69
|
)
|
|
(69
|
)
|
|||||||||||||||
Net income (loss)
|
|
|
|
|
|
|
|
5,373
|
|
|
|
|
|
|
5,373
|
|
|
12
|
|
|
5,385
|
|
||||||||||||||
Other comprehensive income (loss), net of income tax
|
|
|
|
|
|
|
|
|
|
|
|
(5,947
|
)
|
|
(5,947
|
)
|
|
20
|
|
|
(5,927
|
)
|
||||||||||||||
Balance at December 31, 2015
|
|
—
|
|
|
12
|
|
|
30,749
|
|
|
35,672
|
|
|
(3,102
|
)
|
|
4,767
|
|
|
68,098
|
|
|
470
|
|
|
68,568
|
|
|||||||||
Treasury stock acquired in connection with share repurchases
|
|
|
|
|
|
|
|
|
|
(372
|
)
|
|
|
|
(372
|
)
|
|
|
|
(372
|
)
|
|||||||||||||||
Stock-based compensation
|
|
|
|
|
|
195
|
|
|
|
|
|
|
|
|
195
|
|
|
|
|
195
|
|
|||||||||||||||
Dividends on preferred stock
|
|
|
|
|
|
|
|
(103
|
)
|
|
|
|
|
|
(103
|
)
|
|
|
|
(103
|
)
|
|||||||||||||||
Dividends on common stock
|
|
|
|
|
|
|
|
(1,736
|
)
|
|
|
|
|
|
(1,736
|
)
|
|
|
|
(1,736
|
)
|
|||||||||||||||
Change in equity of noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
|
(391
|
)
|
|
(391
|
)
|
|||||||||||||||
Net income (loss)
|
|
|
|
|
|
|
|
850
|
|
|
|
|
|
|
850
|
|
|
4
|
|
|
854
|
|
||||||||||||||
Other comprehensive income (loss), net of income tax
|
|
|
|
|
|
|
|
|
|
|
|
599
|
|
|
599
|
|
|
88
|
|
|
687
|
|
||||||||||||||
Balance at December 31, 2016
|
|
—
|
|
|
12
|
|
|
30,944
|
|
|
34,683
|
|
|
(3,474
|
)
|
|
5,366
|
|
|
67,531
|
|
|
171
|
|
|
67,702
|
|
|||||||||
Treasury stock acquired in connection with share repurchases
|
|
|
|
|
|
|
|
|
|
(2,927
|
)
|
|
|
|
(2,927
|
)
|
|
|
|
(2,927
|
)
|
|||||||||||||||
Stock-based compensation
|
|
|
|
|
|
167
|
|
|
|
|
|
|
|
|
167
|
|
|
|
|
167
|
|
|||||||||||||||
Dividends on preferred stock
|
|
|
|
|
|
|
|
(103
|
)
|
|
|
|
|
|
(103
|
)
|
|
|
|
(103
|
)
|
|||||||||||||||
Dividends on common stock
|
|
|
|
|
|
|
|
(1,717
|
)
|
|
|
|
|
|
(1,717
|
)
|
|
|
|
(1,717
|
)
|
|||||||||||||||
Distribution of Brighthouse, net of income tax (Note 3)
|
|
|
|
|
|
|
|
(10,346
|
)
|
|
|
|
(1,320
|
)
|
|
(11,666
|
)
|
|
|
|
(11,666
|
)
|
||||||||||||||
Change in equity of noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
|
9
|
|
|
9
|
|
|||||||||||||||
Net income (loss)
|
|
|
|
|
|
|
|
4,010
|
|
|
|
|
|
|
4,010
|
|
|
10
|
|
|
4,020
|
|
||||||||||||||
Other comprehensive income (loss), net of income tax
|
|
|
|
|
|
|
|
|
|
|
|
3,381
|
|
|
3,381
|
|
|
4
|
|
|
3,385
|
|
||||||||||||||
Balance at December 31, 2017
|
|
$
|
—
|
|
|
$
|
12
|
|
|
$
|
31,111
|
|
|
$
|
26,527
|
|
|
$
|
(6,401
|
)
|
|
$
|
7,427
|
|
|
$
|
58,676
|
|
|
$
|
194
|
|
|
$
|
58,870
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from operating activities
|
|
|
|
|
|
||||||
Net income (loss)
|
$
|
4,020
|
|
|
$
|
854
|
|
|
$
|
5,385
|
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
|
|
|
|
|
|
||||||
Depreciation and amortization expenses
|
795
|
|
|
652
|
|
|
693
|
|
|||
Amortization of premiums and accretion of discounts associated with investments, net
|
(1,044
|
)
|
|
(1,110
|
)
|
|
(1,141
|
)
|
|||
(Gains) losses on investments and from sales of businesses, net
|
363
|
|
|
(183
|
)
|
|
(560
|
)
|
|||
(Gains) losses on derivatives, net
|
3,610
|
|
|
8,779
|
|
|
1,371
|
|
|||
(Income) loss from equity method investments, net of dividends or distributions
|
194
|
|
|
475
|
|
|
481
|
|
|||
Interest credited to policyholder account balances
|
6,260
|
|
|
6,282
|
|
|
5,610
|
|
|||
Universal life and investment-type product policy fees
|
(7,708
|
)
|
|
(9,207
|
)
|
|
(9,507
|
)
|
|||
Goodwill impairment
|
—
|
|
|
260
|
|
|
—
|
|
|||
Change in fair value option and trading securities
|
(436
|
)
|
|
111
|
|
|
784
|
|
|||
Change in accrued investment income
|
(280
|
)
|
|
(31
|
)
|
|
138
|
|
|||
Change in premiums, reinsurance and other receivables
|
(991
|
)
|
|
(2,158
|
)
|
|
(831
|
)
|
|||
Change in deferred policy acquisition costs and value of business acquired, net
|
(693
|
)
|
|
(937
|
)
|
|
488
|
|
|||
Change in income tax
|
(2,796
|
)
|
|
(1,522
|
)
|
|
715
|
|
|||
Change in other assets
|
691
|
|
|
3,248
|
|
|
2,752
|
|
|||
Change in insurance-related liabilities and policy-related balances
|
8,511
|
|
|
6,321
|
|
|
6,408
|
|
|||
Change in other liabilities
|
1,603
|
|
|
2,801
|
|
|
1,172
|
|
|||
Other, net
|
184
|
|
|
139
|
|
|
94
|
|
|||
Net cash provided by (used in) operating activities
|
12,283
|
|
|
14,774
|
|
|
14,052
|
|
|||
Cash flows from investing activities
|
|
|
|
|
|
||||||
Sales, maturities and repayments of:
|
|
|
|
|
|
||||||
Fixed maturity securities
|
95,945
|
|
|
150,658
|
|
|
146,732
|
|
|||
Equity securities
|
1,433
|
|
|
1,241
|
|
|
1,117
|
|
|||
Mortgage loans
|
10,353
|
|
|
12,977
|
|
|
12,647
|
|
|||
Real estate and real estate joint ventures
|
972
|
|
|
826
|
|
|
3,256
|
|
|||
Other limited partnership interests
|
1,082
|
|
|
1,542
|
|
|
1,827
|
|
|||
Purchases of:
|
|
|
|
|
|
||||||
Fixed maturity securities
|
(105,683
|
)
|
|
(146,397
|
)
|
|
(148,799
|
)
|
|||
Equity securities
|
(920
|
)
|
|
(1,006
|
)
|
|
(996
|
)
|
|||
Mortgage loans
|
(14,374
|
)
|
|
(21,017
|
)
|
|
(20,449
|
)
|
|||
Real estate and real estate joint ventures
|
(1,446
|
)
|
|
(1,515
|
)
|
|
(1,298
|
)
|
|||
Other limited partnership interests
|
(1,486
|
)
|
|
(1,313
|
)
|
|
(1,429
|
)
|
|||
Cash received in connection with freestanding derivatives
|
5,315
|
|
|
4,259
|
|
|
2,690
|
|
|||
Cash paid in connection with freestanding derivatives
|
(8,696
|
)
|
|
(6,963
|
)
|
|
(4,211
|
)
|
|||
Cash received under repurchase agreements
|
—
|
|
|
—
|
|
|
199
|
|
|||
Cash paid under repurchase agreements
|
—
|
|
|
—
|
|
|
(199
|
)
|
|||
Cash received under reverse repurchase agreements
|
—
|
|
|
—
|
|
|
199
|
|
|||
Cash paid under reverse repurchase agreements
|
—
|
|
|
—
|
|
|
(199
|
)
|
|||
Cash disposed due to distribution of Brighthouse
|
(663
|
)
|
|
—
|
|
|
—
|
|
|||
Sales of businesses, net of cash and cash equivalents disposed of $0, $135 and $0, respectively
|
—
|
|
|
156
|
|
|
—
|
|
|||
Purchases of businesses
|
(211
|
)
|
|
—
|
|
|
—
|
|
|||
Purchases of investments in operating joint ventures
|
—
|
|
|
(39
|
)
|
|
—
|
|
|||
Net change in policy loans
|
(67
|
)
|
|
195
|
|
|
287
|
|
|||
Net change in short-term investments
|
2,087
|
|
|
1,270
|
|
|
(777
|
)
|
|||
Net change in other invested assets
|
(171
|
)
|
|
(267
|
)
|
|
(936
|
)
|
|||
Other, net
|
(346
|
)
|
|
(457
|
)
|
|
(59
|
)
|
|||
Net cash provided by (used in) investing activities
|
$
|
(16,876
|
)
|
|
$
|
(5,850
|
)
|
|
$
|
(10,398
|
)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from financing activities
|
|
|
|
|
|
||||||
Policyholder account balances:
|
|
|
|
|
|
||||||
Deposits
|
$
|
88,511
|
|
|
$
|
88,188
|
|
|
$
|
92,904
|
|
Withdrawals
|
(82,380
|
)
|
|
(83,263
|
)
|
|
(94,621
|
)
|
|||
Net change in payables for collateral under securities loaned and other transactions
|
903
|
|
|
(3,636
|
)
|
|
1,544
|
|
|||
Long-term debt issued
|
3,657
|
|
|
—
|
|
|
3,893
|
|
|||
Long-term debt repaid
|
(1,073
|
)
|
|
(1,279
|
)
|
|
(1,438
|
)
|
|||
Collateral financing arrangements repaid
|
(2,951
|
)
|
|
(68
|
)
|
|
(57
|
)
|
|||
Distribution of Brighthouse
|
(2,793
|
)
|
|
—
|
|
|
—
|
|
|||
Financing element on certain derivative instruments and other derivative related transactions, net
|
(151
|
)
|
|
(1,367
|
)
|
|
181
|
|
|||
Treasury stock acquired in connection with share repurchases
|
(2,927
|
)
|
|
(372
|
)
|
|
(1,930
|
)
|
|||
Preferred stock issued, net of issuance costs
|
—
|
|
|
—
|
|
|
1,483
|
|
|||
Repurchase of preferred stock
|
—
|
|
|
—
|
|
|
(1,460
|
)
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
(42
|
)
|
|||
Dividends on preferred stock
|
(103
|
)
|
|
(103
|
)
|
|
(116
|
)
|
|||
Dividends on common stock
|
(1,717
|
)
|
|
(1,736
|
)
|
|
(1,653
|
)
|
|||
Other, net
|
118
|
|
|
139
|
|
|
94
|
|
|||
Net cash provided by (used in) financing activities
|
(906
|
)
|
|
(3,497
|
)
|
|
(1,218
|
)
|
|||
Effect of change in foreign currency exchange rates on cash and cash equivalents balances
|
323
|
|
|
(302
|
)
|
|
(492
|
)
|
|||
Change in cash and cash equivalents
|
(5,176
|
)
|
|
5,125
|
|
|
1,944
|
|
|||
Cash and cash equivalents, beginning of year
|
17,877
|
|
|
12,752
|
|
|
10,808
|
|
|||
Cash and cash equivalents, end of year
|
$
|
12,701
|
|
|
$
|
17,877
|
|
|
$
|
12,752
|
|
Cash and cash equivalents, of disposed subsidiary, beginning of year
|
$
|
5,226
|
|
|
$
|
1,570
|
|
|
$
|
1,603
|
|
Cash and cash equivalents, of disposed subsidiary, end of year
|
$
|
—
|
|
|
$
|
5,226
|
|
|
$
|
1,570
|
|
Cash and cash equivalents, from continuing operations, beginning of year
|
$
|
12,651
|
|
|
$
|
11,182
|
|
|
$
|
9,205
|
|
Cash and cash equivalents, from continuing operations, end of year
|
$
|
12,701
|
|
|
$
|
12,651
|
|
|
$
|
11,182
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
||||||
Net cash paid (received) for:
|
|
|
|
|
|
||||||
Interest
|
$
|
1,118
|
|
|
$
|
1,202
|
|
|
$
|
1,178
|
|
Income tax
|
$
|
1,530
|
|
|
$
|
672
|
|
|
$
|
1,127
|
|
Non-cash transactions
|
|
|
|
|
|
||||||
Disposal of Brighthouse (See Note 3):
|
|
|
|
|
|
||||||
Assets disposed
|
$
|
225,502
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Liabilities disposed
|
(210,999
|
)
|
|
—
|
|
|
—
|
|
|||
Net assets disposed
|
14,503
|
|
|
—
|
|
|
—
|
|
|||
Cash disposed
|
(3,456
|
)
|
|
—
|
|
|
—
|
|
|||
Net non-cash disposed
|
$
|
11,047
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Fixed maturity securities received in connection with pension risk transfer transactions
|
$
|
—
|
|
|
$
|
985
|
|
|
$
|
903
|
|
Reduction of fixed maturity securities in connection with a reinsurance transaction
|
$
|
—
|
|
|
$
|
224
|
|
|
$
|
—
|
|
Reduction of other invested assets in connection with a reinsurance transaction
|
$
|
—
|
|
|
$
|
676
|
|
|
$
|
—
|
|
Deconsolidation of operating joint venture:
|
|
|
|
|
|
||||||
Reduction of fixed maturity securities
|
$
|
—
|
|
|
$
|
917
|
|
|
$
|
—
|
|
Reduction of noncontrolling interests
|
$
|
—
|
|
|
$
|
373
|
|
|
$
|
—
|
|
Deconsolidation of real estate investment vehicles:
|
|
|
|
|
|
||||||
Reduction of long-term debt
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
571
|
|
Reduction of real estate and real estate joint ventures
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
688
|
|
•
|
such separate accounts are legally recognized;
|
•
|
assets supporting the contract liabilities are legally insulated from the Company’s general account liabilities;
|
•
|
investments are directed by the contractholder; and
|
•
|
all investment performance, net of contract fees and assessments, is passed through to the contractholder.
|
|
|
For the Years Ended December 31,
|
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In millions)
|
||||||
Assumed variable annuity guarantee reserves
|
|
$
|
184
|
|
|
$
|
80
|
|
Group annuity reserves
|
|
(33
|
)
|
|
(31
|
)
|
||
Other revisions to continuing operations, net
|
|
(10
|
)
|
|
(106
|
)
|
||
Impact to income (loss) from continuing operations before provision for income tax
|
|
141
|
|
|
(57
|
)
|
||
Provision for income tax expense (benefit) (1)
|
|
27
|
|
|
(110
|
)
|
||
Impact to income (loss) from continuing operations, net of income tax
|
|
114
|
|
|
53
|
|
||
Other revisions to discontinued operations, net of income tax (1)
|
|
(64
|
)
|
|
10
|
|
||
Impact to net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
50
|
|
|
$
|
63
|
|
(1)
|
Includes impact of certain tax-specific revisions.
|
|
|
December 31, 2016
|
||||||||||
Consolidated Balance Sheets
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised |
||||||
|
|
(In millions)
|
||||||||||
Liabilities
|
|
|
|
|
|
|
||||||
Future policy benefits
|
|
$
|
166,701
|
|
|
$
|
(65
|
)
|
|
$
|
166,636
|
|
Policyholder account balances
|
|
$
|
173,168
|
|
|
$
|
(682
|
)
|
|
$
|
172,486
|
|
Other policy-related balances
|
|
$
|
13,030
|
|
|
$
|
372
|
|
|
$
|
13,402
|
|
Deferred income tax liability
|
|
$
|
6,774
|
|
|
$
|
118
|
|
|
$
|
6,892
|
|
Other liabilities
|
|
$
|
23,700
|
|
|
$
|
35
|
|
|
$
|
23,735
|
|
Total liabilities
|
|
$
|
831,284
|
|
|
$
|
(222
|
)
|
|
$
|
831,062
|
|
Stockholders’ Equity
|
|
|
|
|
|
|
|
|||||
Retained earnings
|
|
$
|
34,480
|
|
|
$
|
203
|
|
|
$
|
34,683
|
|
Accumulated other comprehensive income
|
|
$
|
5,347
|
|
|
$
|
19
|
|
|
$
|
5,366
|
|
Total MetLife, Inc.’s stockholders’ equity
|
|
$
|
67,309
|
|
|
$
|
222
|
|
|
$
|
67,531
|
|
Total equity
|
|
$
|
67,480
|
|
|
$
|
222
|
|
|
$
|
67,702
|
|
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||
|
|
2016
|
|
2015
|
||||||||||||||||||||
Consolidated Statements of Operations
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised |
|
As
Previously Reported |
|
Revisions
|
|
As
Revised |
||||||||||||
|
|
(In millions, except per share data)
|
||||||||||||||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Universal life and investment-type product policy fees
|
|
$
|
5,482
|
|
|
$
|
1
|
|
|
$
|
5,483
|
|
|
$
|
5,570
|
|
|
$
|
—
|
|
|
$
|
5,570
|
|
Net investment income
|
|
$
|
16,790
|
|
|
$
|
—
|
|
|
$
|
16,790
|
|
|
$
|
16,243
|
|
|
$
|
(38
|
)
|
|
$
|
16,205
|
|
Other net investment gains (losses)
|
|
$
|
412
|
|
|
$
|
12
|
|
|
$
|
424
|
|
|
$
|
705
|
|
|
$
|
(37
|
)
|
|
$
|
668
|
|
Total net investment gain (losses)
|
|
$
|
305
|
|
|
$
|
12
|
|
|
$
|
317
|
|
|
$
|
646
|
|
|
$
|
(37
|
)
|
|
$
|
609
|
|
Net derivatives gain (losses)
|
|
$
|
(874
|
)
|
|
184
|
|
|
$
|
(690
|
)
|
|
$
|
545
|
|
|
$
|
84
|
|
|
$
|
629
|
|
|
Total revenues
|
|
$
|
60,590
|
|
|
$
|
197
|
|
|
$
|
60,787
|
|
|
$
|
61,334
|
|
|
$
|
9
|
|
|
$
|
61,343
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Policyholder benefits and claims
|
|
$
|
36,316
|
|
|
$
|
42
|
|
|
$
|
36,358
|
|
|
$
|
35,102
|
|
|
$
|
42
|
|
|
$
|
35,144
|
|
Other expenses
|
|
$
|
13,735
|
|
|
$
|
14
|
|
|
$
|
13,749
|
|
|
$
|
14,753
|
|
|
$
|
24
|
|
|
$
|
14,777
|
|
Total expenses
|
|
$
|
56,450
|
|
|
$
|
56
|
|
|
$
|
56,506
|
|
|
$
|
55,626
|
|
|
$
|
66
|
|
|
$
|
55,692
|
|
Income (loss) from continuing operations before provision for income tax
|
|
$
|
4,140
|
|
|
$
|
141
|
|
|
$
|
4,281
|
|
|
$
|
5,708
|
|
|
$
|
(57
|
)
|
|
$
|
5,651
|
|
Provision for income tax expense (benefit)
|
|
$
|
666
|
|
|
$
|
27
|
|
|
$
|
693
|
|
|
$
|
1,700
|
|
|
$
|
(110
|
)
|
|
$
|
1,590
|
|
Income (loss) from continuing operations, net of income tax
|
|
$
|
3,474
|
|
|
$
|
114
|
|
|
$
|
3,588
|
|
|
$
|
4,008
|
|
|
$
|
53
|
|
|
$
|
4,061
|
|
Income (loss) from discontinued operations, net of income tax
|
|
$
|
(2,670
|
)
|
|
$
|
(64
|
)
|
|
$
|
(2,734
|
)
|
|
$
|
1,314
|
|
|
$
|
10
|
|
|
$
|
1,324
|
|
Net income (loss)
|
|
$
|
804
|
|
|
$
|
50
|
|
|
$
|
854
|
|
|
$
|
5,322
|
|
|
$
|
63
|
|
|
$
|
5,385
|
|
Net income (loss)attributable to MetLife, Inc.
|
|
$
|
800
|
|
|
$
|
50
|
|
|
$
|
850
|
|
|
$
|
5,310
|
|
|
$
|
63
|
|
|
$
|
5,373
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
697
|
|
|
$
|
50
|
|
|
$
|
747
|
|
|
$
|
5,152
|
|
|
$
|
63
|
|
|
$
|
5,215
|
|
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Basic
|
|
$
|
3.06
|
|
|
$
|
0.10
|
|
|
$
|
3.16
|
|
|
$
|
3.43
|
|
|
$
|
0.05
|
|
|
$
|
3.48
|
|
Diluted
|
|
$
|
3.04
|
|
|
$
|
0.09
|
|
|
$
|
3.13
|
|
|
$
|
3.40
|
|
|
$
|
0.04
|
|
|
$
|
3.44
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Basic
|
|
$
|
0.63
|
|
|
$
|
0.05
|
|
|
$
|
0.68
|
|
|
$
|
4.61
|
|
|
$
|
0.06
|
|
|
$
|
4.67
|
|
Diluted
|
|
$
|
0.63
|
|
|
$
|
0.04
|
|
|
$
|
0.67
|
|
|
$
|
4.57
|
|
|
$
|
0.05
|
|
|
$
|
4.62
|
|
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||
|
|
2016
|
|
2015
|
||||||||||||||||||||
Consolidated Statements of Comprehensive Income (Loss)
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Net income (loss)
|
|
$
|
804
|
|
|
$
|
50
|
|
|
$
|
854
|
|
|
$
|
5,322
|
|
|
$
|
63
|
|
|
$
|
5,385
|
|
Unrealized investment gains (losses), net of related offsets
|
|
$
|
760
|
|
|
$
|
36
|
|
|
$
|
796
|
|
|
$
|
(7,443
|
)
|
|
$
|
(6
|
)
|
|
$
|
(7,449
|
)
|
Other comprehensive income (loss), before income tax
|
|
$
|
1,101
|
|
|
$
|
36
|
|
|
$
|
1,137
|
|
|
$
|
(8,124
|
)
|
|
$
|
(6
|
)
|
|
$
|
(8,130
|
)
|
Income tax (expense) benefit related to items of other comprehensive income (loss)
|
|
$
|
(437
|
)
|
|
$
|
(13
|
)
|
|
$
|
(450
|
)
|
|
$
|
2,266
|
|
|
$
|
(63
|
)
|
|
$
|
2,203
|
|
Other comprehensive income (loss), net of income tax
|
|
$
|
664
|
|
|
$
|
23
|
|
|
$
|
687
|
|
|
$
|
(5,858
|
)
|
|
$
|
(69
|
)
|
|
$
|
(5,927
|
)
|
Comprehensive income (loss)
|
|
$
|
1,468
|
|
|
$
|
73
|
|
|
$
|
1,541
|
|
|
$
|
(536
|
)
|
|
$
|
(6
|
)
|
|
$
|
(542
|
)
|
Comprehensive income (loss) attributable to MetLife, Inc.
|
|
$
|
1,376
|
|
|
$
|
73
|
|
|
$
|
1,449
|
|
|
$
|
(568
|
)
|
|
$
|
(6
|
)
|
|
$
|
(574
|
)
|
Consolidated Statements of Equity
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
||||||
|
|
(In millions)
|
||||||||||
Retained Earnings
|
|
|
|
|
|
|
||||||
Balance at December 31, 2014
|
|
$
|
32,020
|
|
|
$
|
90
|
|
|
$
|
32,110
|
|
Net income (loss)
|
|
$
|
5,310
|
|
|
$
|
63
|
|
|
$
|
5,373
|
|
Balance at December 31, 2015
|
|
$
|
35,519
|
|
|
$
|
153
|
|
|
$
|
35,672
|
|
Net income (loss)
|
|
$
|
800
|
|
|
$
|
50
|
|
|
$
|
850
|
|
Balance at December 31, 2016
|
|
$
|
34,480
|
|
|
$
|
203
|
|
|
$
|
34,683
|
|
Accumulated Other Comprehensive Income (Loss)
|
|
|
|
|
|
|
||||||
Balance at December 31, 2014
|
|
$
|
10,649
|
|
|
$
|
65
|
|
|
$
|
10,714
|
|
Other comprehensive income (loss), net of income tax
|
|
$
|
(5,878
|
)
|
|
$
|
(69
|
)
|
|
$
|
(5,947
|
)
|
Balance at December 31, 2015
|
|
$
|
4,771
|
|
|
$
|
(4
|
)
|
|
$
|
4,767
|
|
Other comprehensive income (loss), net of income tax
|
|
$
|
576
|
|
|
$
|
23
|
|
|
$
|
599
|
|
Balance at December 31, 2016
|
|
$
|
5,347
|
|
|
$
|
19
|
|
|
$
|
5,366
|
|
Total MetLife, Inc.'s Stockholders' Equity
|
|
|
|
|
|
|
||||||
Balance at December 31, 2014
|
|
$
|
72,053
|
|
|
$
|
155
|
|
|
$
|
72,208
|
|
Balance at December 31, 2015
|
|
$
|
67,949
|
|
|
$
|
149
|
|
|
$
|
68,098
|
|
Balance at December 31, 2016
|
|
$
|
67,309
|
|
|
$
|
222
|
|
|
$
|
67,531
|
|
Total Equity
|
|
|
|
|
|
|
||||||
Balance at December 31, 2014
|
|
$
|
72,560
|
|
|
$
|
155
|
|
|
$
|
72,715
|
|
Balance at December 31, 2015
|
|
$
|
68,419
|
|
|
$
|
149
|
|
|
$
|
68,568
|
|
Balance at December 31, 2016
|
|
$
|
67,480
|
|
|
$
|
222
|
|
|
$
|
67,702
|
|
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||
|
|
2016
|
|
2015
|
||||||||||||||||||||
Consolidated Statements of Cash Flows
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net income (loss)
|
|
$
|
804
|
|
|
$
|
50
|
|
|
$
|
854
|
|
|
$
|
5,322
|
|
|
$
|
63
|
|
|
$
|
5,385
|
|
(Gains) losses on investments and from sales of businesses, net
|
|
$
|
(171
|
)
|
|
$
|
(12
|
)
|
|
$
|
(183
|
)
|
|
$
|
(597
|
)
|
|
$
|
37
|
|
|
$
|
(560
|
)
|
(Gains) losses on derivatives, net
|
|
$
|
8,963
|
|
|
$
|
(184
|
)
|
|
$
|
8,779
|
|
|
$
|
1,451
|
|
|
$
|
(80
|
)
|
|
$
|
1,371
|
|
Universal life and investment-type product policy fees
|
|
$
|
(9,206
|
)
|
|
$
|
(1
|
)
|
|
$
|
(9,207
|
)
|
|
$
|
(9,507
|
)
|
|
$
|
—
|
|
|
$
|
(9,507
|
)
|
Change in premiums, reinsurance and other receivables
|
|
$
|
(2,125
|
)
|
|
$
|
(33
|
)
|
|
$
|
(2,158
|
)
|
|
$
|
(837
|
)
|
|
$
|
6
|
|
|
$
|
(831
|
)
|
Change in deferred policy acquisition costs and value of business acquired, net
|
|
$
|
(949
|
)
|
|
$
|
12
|
|
|
$
|
(937
|
)
|
|
$
|
491
|
|
|
$
|
(3
|
)
|
|
$
|
488
|
|
Change in income tax
|
|
$
|
(1,557
|
)
|
|
$
|
35
|
|
|
$
|
(1,522
|
)
|
|
$
|
825
|
|
|
$
|
(110
|
)
|
|
$
|
715
|
|
Change in insurance-related liabilities and policy-related balances
|
|
$
|
6,279
|
|
|
$
|
42
|
|
|
$
|
6,321
|
|
|
$
|
6,366
|
|
|
$
|
42
|
|
|
$
|
6,408
|
|
Change in other liabilities
|
|
$
|
2,766
|
|
|
$
|
35
|
|
|
$
|
2,801
|
|
|
$
|
1,134
|
|
|
$
|
38
|
|
|
$
|
1,172
|
|
Other, net (1)
|
|
$
|
136
|
|
|
$
|
56
|
|
|
$
|
192
|
|
|
$
|
164
|
|
|
$
|
7
|
|
|
$
|
171
|
|
(1)
|
Excludes impact related to adoption during 2017 of stock-based compensation guidance which decreased Other, net by
$53 million
and
$77 million
for the years ended December 31, 2016 and 2015, respectively. See “— Adoption of New Accounting Pronouncements.”
|
Accounting Policy
|
Note
|
Insurance
|
4
|
Deferred Policy Acquisition Costs, Value of Business Acquired and Other Intangibles
|
5
|
Reinsurance
|
6
|
Investments
|
8
|
Derivatives
|
9
|
Fair Value
|
10
|
Goodwill
|
11
|
Employee Benefit Plans
|
17
|
Income Tax
|
18
|
Litigation Contingencies
|
20
|
•
|
incremental direct costs of contract acquisition, such as commissions;
|
•
|
the portion of an employee’s total compensation and benefits related to time spent selling, underwriting or processing the issuance of new and renewal insurance business only with respect to actual policies acquired or renewed;
|
•
|
other essential direct costs that would not have been incurred had a policy not been acquired or renewed; and
|
•
|
the costs of direct-response advertising, the primary purpose of which is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits.
|
Products:
|
In proportion to the following over estimated lives of the contracts:
|
||||
•
|
Nonparticipating and non-dividend-paying traditional contracts:
|
|
Actual and expected future gross premiums.
|
||
|
•
|
Term insurance
|
|
|
|
|
•
|
Nonparticipating whole life insurance
|
|
|
|
|
•
|
Traditional group life insurance
|
|
|
|
|
•
|
Non-medical health insurance
|
|
|
|
|
•
|
Accident & health insurance
|
|
|
|
•
|
Participating, dividend-paying traditional contracts
|
|
Actual and expected future gross margins.
|
||
•
|
Fixed and variable universal life contracts
|
|
Actual and expected future gross profits.
|
||
•
|
Fixed and variable deferred annuity contracts
|
|
|
||
•
|
Credit insurance contracts
|
|
Actual and future earned premiums.
|
||
•
|
Property & casualty insurance contracts
|
|
|
||
•
|
Other short-duration contracts
|
|
|
•
|
fixed maturity and equity securities held-for-investment by the general account to support asset and liability management strategies for certain insurance products and investments in certain separate accounts (“FVO general account securities”); and
|
•
|
contractholder-directed investments supporting unit-linked variable annuity type liabilities which do not qualify for presentation and reporting as separate account summary total assets and liabilities. These investments are primarily mutual funds and, to a lesser extent, fixed maturity and equity securities, short-term investments and cash and cash equivalents. The investment returns on these investments inure to contractholders and are offset by a corresponding change in policyholder account balances through interest credited to policyholder account balances (“FVO contractholder-directed unit-linked investments”).
|
•
|
Freestanding derivatives with positive estimated fair values which are described in “— Derivatives” below.
|
•
|
Tax credit and renewable energy partnerships which derive a significant source of investment return in the form of income tax credits or other tax incentives. Where tax credits are guaranteed by a creditworthy third party, the investment is accounted for under the effective yield method. Otherwise, the investment is accounted for under the equity method. See
Note 18
.
|
•
|
Leveraged leases which are recorded net of non-recourse debt. Income is recognized by applying the leveraged lease’s estimated rate of return to the net investment in the lease. Leveraged leases derive investment returns in part from their income tax treatment. The Company regularly reviews residual values for impairment.
|
•
|
Direct financing leases gross investment is equal to the minimum lease payments plus the unguaranteed residual value. Income is recorded by applying the pre-tax internal rate of return to the investment balance. The Company regularly reviews lease receivables for impairment. Certain direct financing leases are linked to inflation.
|
•
|
Annuities funding structured settlement claims represent annuities funding claims assumed by the Company in its capacity as a structured settlements assignment company. The annuities are stated at their contract value, which represents the present value of the future periodic claim payments to be provided. The net investment income recognized reflects the amortization of discount of the annuity at its implied effective interest rate. See
Note 3
.
|
•
|
Funds withheld represent a receivable for amounts contractually withheld by ceding companies in accordance with reinsurance agreements. The Company recognizes interest on funds withheld at rates defined by the terms of the agreement which may be contractually specified or directly related to the underlying investments.
|
•
|
Investments in operating joint ventures that engage in insurance underwriting activities are accounted for under the equity method.
|
Statement of Operations Presentation:
|
Derivative:
|
|
Policyholder benefits and claims
|
•
|
Economic hedges of variable annuity guarantees included in future policy benefits
|
Net investment income
|
•
|
Economic hedges of equity method investments in joint ventures
|
|
•
|
All derivatives held in relation to trading portfolios
|
|
•
|
Derivatives held within contractholder-directed unit-linked investments
|
•
|
Fair value hedge
(a hedge of the estimated fair value of a recognized asset or liability) - in net derivative gains (losses), consistent with the change in estimated fair value of the hedged item attributable to the designated risk being hedged.
|
•
|
Cash flow hedge
(a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability) - effectiveness in OCI (deferred gains or losses on the derivative are reclassified into the statement of operations when the Company’s earnings are affected by the variability in cash flows of the hedged item); ineffectiveness in net derivative gains (losses).
|
•
|
Net investment in a foreign operation hedge
- effectiveness in OCI, consistent with the translation adjustment for the hedged net investment in the foreign operation; ineffectiveness in net derivative gains (losses).
|
•
|
the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings;
|
•
|
the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and
|
•
|
a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument.
|
•
|
the nature, frequency, and amount of cumulative financial reporting income and losses in recent years;
|
•
|
the jurisdiction in which the deferred tax asset was generated;
|
•
|
the length of time that carryforward can be utilized in the various taxing jurisdictions;
|
•
|
future taxable income exclusive of reversing temporary differences and carryforwards;
|
•
|
future reversals of existing taxable temporary differences;
|
•
|
taxable income in prior carryback years; and
|
•
|
tax planning strategies.
|
•
|
The Group Benefits business offers insurance products and services which include life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision and accident & health coverages, as well as prepaid legal plans. This business also sells administrative services-only arrangements to some employers.
|
•
|
The Retirement and Income Solutions business offers a broad range of annuity and investment products, including capital market investment products, institutional income annuities, stable value and pension risk transfer products. This business also includes products to fund tort settlements, as well as postretirement benefits and company-, bank- or trust-owned life insurance.
|
•
|
The Property & Casualty business offers personal and commercial lines of property and casualty insurance, including private passenger automobile, homeowners’ and personal excess liability insurance. In addition, Property & Casualty offers small business owners property, liability and business interruption insurance.
|
•
|
Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity GMIB fees (“GMIB Fees”);
|
•
|
Net investment income: (i) includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment, (ii) excludes post-tax adjusted earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed unit-linked investments and (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
•
|
Other revenues are adjusted for settlements of foreign currency earnings hedges.
|
•
|
Policyholder benefits and claims and policyholder dividends excludes: (i) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iii) benefits and hedging costs related to GMIBs (“GMIB Costs”) and (iv) market value adjustments associated with surrenders or terminations of contracts (“Market Value Adjustments”);
|
•
|
Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes amounts related to net investment income earned on contractholder-directed unit-linked investments;
|
•
|
Amortization of DAC and VOBA excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB Fees and GMIB Costs and (iii) Market Value Adjustments;
|
•
|
Amortization of negative VOBA excludes amounts related to Market Value Adjustments;
|
•
|
Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
•
|
Other expenses excludes costs related to: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements, and (iii) acquisition, integration and other costs.
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
Year Ended December 31, 2017
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife
Holdings
|
|
Corporate
& Other
|
|
Total
|
|
Adjustments
|
|
Total
Consolidated
|
||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Premiums
|
|
$
|
23,632
|
|
|
$
|
6,755
|
|
|
$
|
2,693
|
|
|
$
|
2,061
|
|
|
$
|
4,144
|
|
|
$
|
54
|
|
|
$
|
39,339
|
|
|
$
|
(347
|
)
|
|
$
|
38,992
|
|
Universal life and investment-type product policy fees
|
|
1,012
|
|
|
1,584
|
|
|
1,044
|
|
|
405
|
|
|
1,361
|
|
|
1
|
|
|
5,407
|
|
|
103
|
|
|
5,510
|
|
|||||||||
Net investment income
|
|
6,396
|
|
|
2,985
|
|
|
1,219
|
|
|
309
|
|
|
5,607
|
|
|
28
|
|
|
16,544
|
|
|
819
|
|
|
17,363
|
|
|||||||||
Other revenues
|
|
806
|
|
|
43
|
|
|
32
|
|
|
58
|
|
|
244
|
|
|
271
|
|
|
1,454
|
|
|
(113
|
)
|
|
1,341
|
|
|||||||||
Net investment gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(308
|
)
|
|
(308
|
)
|
|||||||||
Net derivative gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(590
|
)
|
|
(590
|
)
|
|||||||||
Total revenues
|
|
31,846
|
|
|
11,367
|
|
|
4,988
|
|
|
2,833
|
|
|
11,356
|
|
|
354
|
|
|
62,744
|
|
|
(436
|
)
|
|
62,308
|
|
|||||||||
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Policyholder benefits and claims and policyholder dividends
|
|
23,627
|
|
|
5,075
|
|
|
2,535
|
|
|
1,077
|
|
|
7,000
|
|
|
26
|
|
|
39,340
|
|
|
204
|
|
|
39,544
|
|
|||||||||
Interest credited to policyholder account balances
|
|
1,474
|
|
|
1,351
|
|
|
369
|
|
|
100
|
|
|
1,018
|
|
|
1
|
|
|
4,313
|
|
|
1,294
|
|
|
5,607
|
|
|||||||||
Capitalization of DAC
|
|
(458
|
)
|
|
(1,710
|
)
|
|
(364
|
)
|
|
(414
|
)
|
|
(82
|
)
|
|
(8
|
)
|
|
(3,036
|
)
|
|
34
|
|
|
(3,002
|
)
|
|||||||||
Amortization of DAC and VOBA
|
|
459
|
|
|
1,300
|
|
|
224
|
|
|
357
|
|
|
302
|
|
|
6
|
|
|
2,648
|
|
|
33
|
|
|
2,681
|
|
|||||||||
Amortization of negative VOBA
|
|
—
|
|
|
(111
|
)
|
|
(1
|
)
|
|
(19
|
)
|
|
—
|
|
|
—
|
|
|
(131
|
)
|
|
(9
|
)
|
|
(140
|
)
|
|||||||||
Interest expense on debt
|
|
11
|
|
|
—
|
|
|
5
|
|
|
—
|
|
|
24
|
|
|
1,105
|
|
|
1,145
|
|
|
(16
|
)
|
|
1,129
|
|
|||||||||
Other expenses
|
|
3,682
|
|
|
3,613
|
|
|
1,479
|
|
|
1,376
|
|
|
1,365
|
|
|
894
|
|
|
12,409
|
|
|
544
|
|
|
12,953
|
|
|||||||||
Total expenses
|
|
28,795
|
|
|
9,518
|
|
|
4,247
|
|
|
2,477
|
|
|
9,627
|
|
|
2,024
|
|
|
56,688
|
|
|
2,084
|
|
|
58,772
|
|
|||||||||
Provision for income tax expense (benefit)
|
|
1,024
|
|
|
620
|
|
|
156
|
|
|
59
|
|
|
547
|
|
|
(688
|
)
|
|
1,718
|
|
|
(3,188
|
)
|
|
(1,470
|
)
|
|||||||||
Adjusted earnings
|
|
$
|
2,027
|
|
|
$
|
1,229
|
|
|
$
|
585
|
|
|
$
|
297
|
|
|
$
|
1,182
|
|
|
$
|
(982
|
)
|
|
4,338
|
|
|
|
|
|
|||||
Adjustments to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Total revenues
|
|
(436
|
)
|
|
|
|
|
|||||||||||||||||||||||||||||
Total expenses
|
|
(2,084
|
)
|
|
|
|
|
|||||||||||||||||||||||||||||
Provision for income tax (expense) benefit
|
|
3,188
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax
|
|
$
|
5,006
|
|
|
|
|
$
|
5,006
|
|
At December 31, 2017
|
|
U.S.
|
|
Asia (1)
|
|
Latin
America
|
|
EMEA
|
|
MetLife
Holdings
|
|
Corporate
& Other
|
|
Total
|
||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||
Total assets
|
|
$
|
255,428
|
|
|
$
|
136,928
|
|
|
$
|
79,670
|
|
|
$
|
30,500
|
|
|
$
|
183,160
|
|
|
$
|
34,206
|
|
|
$
|
719,892
|
|
Separate account assets
|
|
$
|
81,243
|
|
|
$
|
10,032
|
|
|
$
|
56,218
|
|
|
$
|
5,975
|
|
|
$
|
51,533
|
|
|
$
|
—
|
|
|
$
|
205,001
|
|
Separate account liabilities
|
|
$
|
81,243
|
|
|
$
|
10,032
|
|
|
$
|
56,218
|
|
|
$
|
5,975
|
|
|
$
|
51,533
|
|
|
$
|
—
|
|
|
$
|
205,001
|
|
(1)
|
Total assets includes
$111.0 billion
of assets from the Japan operations which represents
15%
of total consolidated assets.
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
Year Ended December 31, 2016
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife
Holdings
|
|
Corporate
& Other
|
|
Total
|
|
Adjustments
|
|
Total
Consolidated
|
||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Premiums
|
|
$
|
21,501
|
|
|
$
|
6,902
|
|
|
$
|
2,529
|
|
|
$
|
2,027
|
|
|
$
|
4,506
|
|
|
$
|
40
|
|
|
$
|
37,505
|
|
|
$
|
(303
|
)
|
|
$
|
37,202
|
|
Universal life and investment-type product policy fees
|
|
989
|
|
|
1,488
|
|
|
1,025
|
|
|
391
|
|
|
1,436
|
|
|
2
|
|
|
5,331
|
|
|
152
|
|
|
5,483
|
|
|||||||||
Net investment income
|
|
6,206
|
|
|
2,707
|
|
|
1,084
|
|
|
318
|
|
|
5,944
|
|
|
178
|
|
|
16,437
|
|
|
353
|
|
|
16,790
|
|
|||||||||
Other revenues
|
|
784
|
|
|
61
|
|
|
34
|
|
|
73
|
|
|
581
|
|
|
110
|
|
|
1,643
|
|
|
42
|
|
|
1,685
|
|
|||||||||
Net investment gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
317
|
|
|
317
|
|
|||||||||
Net derivative gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(690
|
)
|
|
(690
|
)
|
|||||||||
Total revenues
|
|
29,480
|
|
|
11,158
|
|
|
4,672
|
|
|
2,809
|
|
|
12,467
|
|
|
330
|
|
|
60,916
|
|
|
(129
|
)
|
|
60,787
|
|
|||||||||
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Policyholder benefits and claims and policyholder dividends
|
|
21,591
|
|
|
5,211
|
|
|
2,443
|
|
|
1,067
|
|
|
7,523
|
|
|
41
|
|
|
37,876
|
|
|
(295
|
)
|
|
37,581
|
|
|||||||||
Interest credited to policyholder account balances
|
|
1,302
|
|
|
1,298
|
|
|
328
|
|
|
112
|
|
|
1,042
|
|
|
6
|
|
|
4,088
|
|
|
1,088
|
|
|
5,176
|
|
|||||||||
Capitalization of DAC
|
|
(471
|
)
|
|
(1,668
|
)
|
|
(321
|
)
|
|
(403
|
)
|
|
(281
|
)
|
|
(7
|
)
|
|
(3,151
|
)
|
|
(1
|
)
|
|
(3,152
|
)
|
|||||||||
Amortization of DAC and VOBA
|
|
471
|
|
|
1,236
|
|
|
184
|
|
|
408
|
|
|
736
|
|
|
8
|
|
|
3,043
|
|
|
(325
|
)
|
|
2,718
|
|
|||||||||
Amortization of negative VOBA
|
|
—
|
|
|
(208
|
)
|
|
(1
|
)
|
|
(13
|
)
|
|
—
|
|
|
—
|
|
|
(222
|
)
|
|
(47
|
)
|
|
(269
|
)
|
|||||||||
Interest expense on debt
|
|
9
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
57
|
|
|
1,139
|
|
|
1,207
|
|
|
(50
|
)
|
|
1,157
|
|
|||||||||
Other expenses
|
|
3,706
|
|
|
3,586
|
|
|
1,336
|
|
|
1,323
|
|
|
2,392
|
|
|
597
|
|
|
12,940
|
|
|
355
|
|
|
13,295
|
|
|||||||||
Total expenses
|
|
26,608
|
|
|
9,455
|
|
|
3,971
|
|
|
2,494
|
|
|
11,469
|
|
|
1,784
|
|
|
55,781
|
|
|
725
|
|
|
56,506
|
|
|||||||||
Provision for income tax expense (benefit)
|
|
976
|
|
|
479
|
|
|
158
|
|
|
42
|
|
|
292
|
|
|
(948
|
)
|
|
999
|
|
|
(306
|
)
|
|
693
|
|
|||||||||
Adjusted earnings
|
|
$
|
1,896
|
|
|
$
|
1,224
|
|
|
$
|
543
|
|
|
$
|
273
|
|
|
$
|
706
|
|
|
$
|
(506
|
)
|
|
4,136
|
|
|
|
|
|
|||||
Adjustments to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Total revenues
|
|
(129
|
)
|
|
|
|
|
|||||||||||||||||||||||||||||
Total expenses
|
|
(725
|
)
|
|
|
|
|
|||||||||||||||||||||||||||||
Provision for income tax (expense) benefit
|
|
306
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax
|
|
$
|
3,588
|
|
|
|
|
$
|
3,588
|
|
At December 31, 2016
|
|
U.S.
|
|
Asia (1)
|
|
Latin
America |
|
EMEA
|
|
MetLife
Holdings |
|
Corporate
& Other (2) |
|
Total
|
||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||
Total assets
|
|
$
|
253,926
|
|
|
$
|
120,656
|
|
|
$
|
67,233
|
|
|
$
|
25,596
|
|
|
$
|
183,832
|
|
|
$
|
247,521
|
|
|
$
|
898,764
|
|
Separate account assets
|
|
$
|
85,950
|
|
|
$
|
8,020
|
|
|
$
|
48,455
|
|
|
$
|
4,329
|
|
|
$
|
48,823
|
|
|
$
|
1
|
|
|
$
|
195,578
|
|
Separate account liabilities
|
|
$
|
85,950
|
|
|
$
|
8,020
|
|
|
$
|
48,455
|
|
|
$
|
4,329
|
|
|
$
|
48,823
|
|
|
$
|
1
|
|
|
$
|
195,578
|
|
(1)
|
Total assets includes
$98.0 billion
of assets from the Japan operations which represents
11%
of total consolidated assets.
|
(2)
|
Includes assets of disposed subsidiary of
$216,983
million at December 31, 2016.
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||
Year Ended December 31, 2015
|
|
U.S.
|
|
Asia
|
|
Latin
America
|
|
EMEA
|
|
MetLife
Holdings
|
|
Corporate
& Other
|
|
Total
|
|
Adjustments
|
|
Total
Consolidated
|
||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Premiums
|
|
$
|
20,861
|
|
|
$
|
6,937
|
|
|
$
|
2,581
|
|
|
$
|
2,036
|
|
|
$
|
4,545
|
|
|
$
|
(92
|
)
|
|
$
|
36,868
|
|
|
$
|
(465
|
)
|
|
$
|
36,403
|
|
Universal life and investment-type product policy fees
|
|
943
|
|
|
1,542
|
|
|
1,117
|
|
|
424
|
|
|
1,482
|
|
|
(4
|
)
|
|
5,504
|
|
|
66
|
|
|
5,570
|
|
|||||||||
Net investment income
|
|
6,183
|
|
|
2,675
|
|
|
1,038
|
|
|
326
|
|
|
6,189
|
|
|
260
|
|
|
16,671
|
|
|
(466
|
)
|
|
16,205
|
|
|||||||||
Other revenues
|
|
751
|
|
|
105
|
|
|
41
|
|
|
61
|
|
|
930
|
|
|
69
|
|
|
1,957
|
|
|
(30
|
)
|
|
1,927
|
|
|||||||||
Net investment gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
609
|
|
|
609
|
|
|||||||||
Net derivative gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
629
|
|
|
629
|
|
|||||||||
Total revenues
|
|
28,738
|
|
|
11,259
|
|
|
4,777
|
|
|
2,847
|
|
|
13,146
|
|
|
233
|
|
|
61,000
|
|
|
343
|
|
|
61,343
|
|
|||||||||
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Policyholder benefits and claims and policyholder dividends
|
|
20,899
|
|
|
5,266
|
|
|
2,408
|
|
|
988
|
|
|
7,346
|
|
|
(114
|
)
|
|
36,793
|
|
|
(293
|
)
|
|
36,500
|
|
|||||||||
Interest credited to policyholder account balances
|
|
1,216
|
|
|
1,309
|
|
|
349
|
|
|
120
|
|
|
1,062
|
|
|
23
|
|
|
4,079
|
|
|
336
|
|
|
4,415
|
|
|||||||||
Capitalization of DAC
|
|
(493
|
)
|
|
(1,720
|
)
|
|
(341
|
)
|
|
(472
|
)
|
|
(410
|
)
|
|
(3
|
)
|
|
(3,439
|
)
|
|
120
|
|
|
(3,319
|
)
|
|||||||||
Amortization of DAC and VOBA
|
|
471
|
|
|
1,253
|
|
|
271
|
|
|
497
|
|
|
577
|
|
|
(1
|
)
|
|
3,068
|
|
|
116
|
|
|
3,184
|
|
|||||||||
Amortization of negative VOBA
|
|
—
|
|
|
(309
|
)
|
|
(1
|
)
|
|
(16
|
)
|
|
—
|
|
|
—
|
|
|
(326
|
)
|
|
(35
|
)
|
|
(361
|
)
|
|||||||||
Interest expense on debt
|
|
4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
55
|
|
|
1,169
|
|
|
1,228
|
|
|
(60
|
)
|
|
1,168
|
|
|||||||||
Other expenses
|
|
3,685
|
|
|
3,611
|
|
|
1,429
|
|
|
1,469
|
|
|
2,694
|
|
|
935
|
|
|
13,823
|
|
|
282
|
|
|
14,105
|
|
|||||||||
Total expenses
|
|
25,782
|
|
|
9,410
|
|
|
4,115
|
|
|
2,586
|
|
|
11,324
|
|
|
2,009
|
|
|
55,226
|
|
|
466
|
|
|
55,692
|
|
|||||||||
Provision for income tax expense (benefit)
|
|
1,009
|
|
|
461
|
|
|
37
|
|
|
21
|
|
|
582
|
|
|
(366
|
)
|
|
1,744
|
|
|
(154
|
)
|
|
1,590
|
|
|||||||||
Adjusted earnings
|
|
$
|
1,947
|
|
|
$
|
1,388
|
|
|
$
|
625
|
|
|
$
|
240
|
|
|
$
|
1,240
|
|
|
$
|
(1,410
|
)
|
|
4,030
|
|
|
|
|
|
|||||
Adjustments to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Total revenues
|
|
343
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Total expenses
|
|
(466
|
)
|
|
|
|
|
|||||||||||||||||||||||||||||
Provision for income tax (expense) benefit
|
|
154
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax
|
|
$
|
4,061
|
|
|
|
|
$
|
4,061
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Life insurance
|
$
|
20,330
|
|
|
$
|
20,436
|
|
|
$
|
20,847
|
|
Accident & health insurance
|
14,002
|
|
|
14,128
|
|
|
13,109
|
|
|||
Annuities
|
6,999
|
|
|
5,552
|
|
|
5,730
|
|
|||
Property & casualty insurance
|
3,613
|
|
|
3,560
|
|
|
3,504
|
|
|||
Non-insurance
|
899
|
|
|
694
|
|
|
710
|
|
|||
Total
|
$
|
45,843
|
|
|
$
|
44,370
|
|
|
$
|
43,900
|
|
|
Included on Consolidated Statements of Operations
|
|
Excluded from Consolidated Statements of Operations
|
||||||||||||
|
Year
Ended
December 31,
|
|
Years
Ended December 31, |
||||||||||||
|
2017 (1)
|
|
2017 (2)
|
|
2016
|
|
2015
|
||||||||
|
(In millions)
|
||||||||||||||
Premiums
|
|
|
|
|
|
|
|
||||||||
Reinsurance assumed
|
$
|
183
|
|
|
$
|
248
|
|
|
$
|
462
|
|
|
$
|
416
|
|
Reinsurance ceded
|
(4
|
)
|
|
(7
|
)
|
|
(9
|
)
|
|
(8
|
)
|
||||
Net premiums
|
$
|
179
|
|
|
$
|
241
|
|
|
$
|
453
|
|
|
$
|
408
|
|
Universal life and investment-type product policy fees
|
|
|
|
|
|
|
|
||||||||
Reinsurance assumed
|
$
|
(4
|
)
|
|
$
|
(6
|
)
|
|
$
|
(2
|
)
|
|
$
|
2
|
|
Reinsurance ceded
|
(44
|
)
|
|
(55
|
)
|
|
(102
|
)
|
|
(114
|
)
|
||||
Net universal life and investment-type product policy fees
|
$
|
(48
|
)
|
|
$
|
(61
|
)
|
|
$
|
(104
|
)
|
|
$
|
(112
|
)
|
Policyholder benefits and claims
|
|
|
|
|
|
|
|
||||||||
Reinsurance assumed
|
$
|
150
|
|
|
$
|
196
|
|
|
$
|
385
|
|
|
$
|
330
|
|
Reinsurance ceded
|
(22
|
)
|
|
(16
|
)
|
|
(23
|
)
|
|
(28
|
)
|
||||
Net policyholder benefits and claims
|
$
|
128
|
|
|
$
|
180
|
|
|
$
|
362
|
|
|
$
|
302
|
|
Interest credited to policyholder account balances
|
|
|
|
|
|
|
|
||||||||
Reinsurance assumed
|
$
|
6
|
|
|
$
|
10
|
|
|
$
|
16
|
|
|
$
|
14
|
|
Reinsurance ceded
|
(30
|
)
|
|
(42
|
)
|
|
(75
|
)
|
|
(78
|
)
|
||||
Net interest credited to policyholder account balances
|
$
|
(24
|
)
|
|
$
|
(32
|
)
|
|
$
|
(59
|
)
|
|
$
|
(64
|
)
|
Other expenses
|
|
|
|
|
|
|
|
||||||||
Reinsurance assumed
|
$
|
39
|
|
|
$
|
10
|
|
|
$
|
88
|
|
|
$
|
76
|
|
Reinsurance ceded
|
7
|
|
|
(28
|
)
|
|
(29
|
)
|
|
(45
|
)
|
||||
Net other expenses
|
$
|
46
|
|
|
$
|
(18
|
)
|
|
$
|
59
|
|
|
$
|
31
|
|
(1)
|
Includes transactions after the Separation.
|
(2)
|
Includes transactions prior to the Separation.
|
|
December 31, 2017
|
||||||
|
Assumed
|
|
Ceded
|
||||
|
(In millions)
|
||||||
Assets
|
|
|
|
||||
Premiums, reinsurance and other receivables
|
$
|
167
|
|
|
$
|
1,793
|
|
Deferred policy acquisition costs and value of business acquired
|
384
|
|
|
(40
|
)
|
||
Total assets
|
$
|
551
|
|
|
$
|
1,753
|
|
Liabilities
|
|
|
|
||||
Future policy benefits
|
$
|
1,734
|
|
|
$
|
—
|
|
Other policy-related balances
|
119
|
|
|
28
|
|
||
Other liabilities
|
1,458
|
|
|
19
|
|
||
Total liabilities
|
$
|
3,311
|
|
|
$
|
47
|
|
|
|
For the Years Ended December 31,
|
||||||||||
|
|
2017 (1)
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Revenues
|
|
|
|
|
|
|
||||||
Premiums
|
|
$
|
820
|
|
|
$
|
1,951
|
|
|
$
|
2,142
|
|
Universal life and investment-type product policy fees
|
|
2,201
|
|
|
3,724
|
|
|
3,936
|
|
|||
Net investment income
|
|
1,783
|
|
|
3,157
|
|
|
3,038
|
|
|||
Other revenues
|
|
150
|
|
|
74
|
|
|
58
|
|
|||
Total net investment gains (losses)
|
|
(48
|
)
|
|
(140
|
)
|
|
(48
|
)
|
|||
Net derivative gains (losses)
|
|
(1,061
|
)
|
|
(5,886
|
)
|
|
(466
|
)
|
|||
Total revenues
|
|
3,845
|
|
|
2,880
|
|
|
8,660
|
|
|||
Expenses
|
|
|
|
|
|
|
||||||
Policyholder benefits and claims
|
|
2,217
|
|
|
4,487
|
|
|
3,612
|
|
|||
Interest credited to policyholder account balances
|
|
620
|
|
|
1,107
|
|
|
1,195
|
|
|||
Policyholder dividends
|
|
16
|
|
|
34
|
|
|
32
|
|
|||
Goodwill impairment
|
|
—
|
|
|
260
|
|
|
—
|
|
|||
Other expenses
|
|
853
|
|
|
1,333
|
|
|
2,043
|
|
|||
Total expenses
|
|
3,706
|
|
|
7,221
|
|
|
6,882
|
|
|||
Income (loss) from discontinued operations before provision for income tax and loss on disposal of discontinued operations
|
|
139
|
|
|
(4,341
|
)
|
|
1,778
|
|
|||
Provision for income tax expense (benefit)
|
|
(46
|
)
|
|
(1,607
|
)
|
|
454
|
|
|||
Income (loss) from discontinued operations before loss on disposal of discontinued operations, net of income tax
|
|
185
|
|
|
(2,734
|
)
|
|
1,324
|
|
|||
Transaction costs associated with the Separation, net of income tax
|
|
(216
|
)
|
|
—
|
|
|
—
|
|
|||
Tax charges associated with the Separation
|
|
(955
|
)
|
|
—
|
|
|
—
|
|
|||
Income (loss) on disposal of discontinued operations, net of income tax
|
|
(1,171
|
)
|
|
—
|
|
|
—
|
|
|||
Income (loss) from discontinued operations, net of income tax
|
|
$
|
(986
|
)
|
|
$
|
(2,734
|
)
|
|
$
|
1,324
|
|
(1)
|
Includes transactions prior to the Separation.
|
|
December 31, 2016
|
||
|
(In millions)
|
||
Assets
|
|
||
Investments:
|
|
||
Fixed maturity securities available-for-sale
|
$
|
61,326
|
|
Equity securities available-for-sale
|
300
|
|
|
Mortgage loans
|
9,378
|
|
|
Policy loans
|
1,517
|
|
|
Real estate and real estate joint ventures
|
150
|
|
|
Other limited partnership interests
|
1,642
|
|
|
Short-term investments
|
1,288
|
|
|
Other invested assets
|
3,881
|
|
|
Total investments
|
79,482
|
|
|
Cash and cash equivalents
|
5,226
|
|
|
Accrued investment income
|
680
|
|
|
Premiums, reinsurance and other receivables
|
10,636
|
|
|
Deferred policy acquisition costs and value of business acquired
|
7,207
|
|
|
Other assets
|
709
|
|
|
Separate account assets
|
113,043
|
|
|
Total assets of disposed subsidiary
|
$
|
216,983
|
|
Liabilities
|
|
||
Future policy benefits
|
$
|
33,270
|
|
Policyholder account balances
|
37,066
|
|
|
Other policy-related balances
|
1,356
|
|
|
Policyholder dividends payable
|
12
|
|
|
Payables for collateral under securities loaned and other transactions
|
7,390
|
|
|
Long-term debt
|
60
|
|
|
Collateral financing arrangements
|
2,797
|
|
|
Deferred income tax liability
|
2,594
|
|
|
Other liabilities
|
5,119
|
|
|
Separate account liabilities
|
113,043
|
|
|
Total liabilities of disposed subsidiary
|
$
|
202,707
|
|
|
For the Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Net cash provided by (used in):
|
|
|
|
|
|
||||||
Operating activities
|
$
|
1,329
|
|
|
$
|
3,697
|
|
|
$
|
4,559
|
|
Investing activities
|
$
|
(2,732
|
)
|
|
$
|
4,674
|
|
|
$
|
(7,042
|
)
|
Financing activities
|
$
|
(367
|
)
|
|
$
|
(4,715
|
)
|
|
$
|
2,452
|
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
U.S.
|
|
$
|
136,065
|
|
|
$
|
129,117
|
|
Asia
|
|
99,404
|
|
|
89,422
|
|
||
Latin America
|
|
16,758
|
|
|
14,760
|
|
||
EMEA
|
|
19,579
|
|
|
18,075
|
|
||
MetLife Holdings
|
|
103,372
|
|
|
104,271
|
|
||
Corporate & Other
|
|
829
|
|
|
(3,121
|
)
|
||
Total
|
|
$
|
376,007
|
|
|
$
|
352,524
|
|
Guarantee:
|
|
Measurement Assumptions:
|
|||
GMDBs
|
•
|
A return of purchase payment upon death even if the account value is reduced to zero.
|
|
•
|
Present value of expected death benefits in excess of the projected account balance recognizing the excess ratably over the accumulation period based on the present value of total expected assessments.
|
|
•
|
An enhanced death benefit may be available for an additional fee.
|
|
•
|
Assumptions are consistent with those used for amortizing DAC, and are thus subject to the same variability and risk.
|
|
|
|
|
•
|
Investment performance and volatility assumptions are consistent with the historical experience of the appropriate underlying equity index, such as the S&P 500 Index.
|
|
|
|
|
•
|
Benefit assumptions are based on the average benefits payable over a range of scenarios.
|
GMIBs
|
•
|
After a specified period of time determined at the time of issuance of the variable annuity contract, a minimum accumulation of purchase payments, even if the account value is reduced to zero, that can be annuitized to receive a monthly income stream that is not less than a specified amount.
|
|
•
|
Present value of expected income benefits in excess of the projected account balance at any future date of annuitization and recognizing the excess ratably over the accumulation period based on present value of total expected assessments.
|
|
•
|
Certain contracts also provide for a guaranteed lump sum return of purchase premium in lieu of the annuitization benefit.
|
|
•
|
Assumptions are consistent with those used for estimating GMDB liabilities.
|
|
|
|
|
•
|
Calculation incorporates an assumption for the percentage of the potential annuitizations that may be elected by the contractholder.
|
GMWBs
|
•
|
A return of purchase payment via partial withdrawals, even if the account value is reduced to zero, provided that cumulative withdrawals in a contract year do not exceed a certain limit.
|
|
•
|
Expected value of the life contingent payments and expected assessments using assumptions consistent with those used for estimating the GMDB liabilities.
|
|
•
|
Certain contracts include guaranteed withdrawals that are life contingent.
|
|
|
|
|
Annuity Contracts
|
|
Universal and Variable
Life Contracts |
|
|
||||||||||||||
|
GMDBs
|
|
GMIBs
|
|
Secondary
Guarantees |
|
Paid-Up
Guarantees |
|
Total
|
||||||||||
|
(In millions)
|
||||||||||||||||||
Direct and Assumed:
|
|
|
|
|
|
|
|
|
|
||||||||||
Balance at January 1, 2015
|
$
|
307
|
|
|
$
|
463
|
|
|
$
|
2,711
|
|
|
$
|
288
|
|
|
$
|
3,769
|
|
Incurred guaranteed benefits (1)
|
68
|
|
|
62
|
|
|
43
|
|
|
18
|
|
|
191
|
|
|||||
Paid guaranteed benefits
|
(11
|
)
|
|
(1
|
)
|
|
(28
|
)
|
|
—
|
|
|
(40
|
)
|
|||||
Balance at December 31, 2015
|
364
|
|
|
524
|
|
|
2,726
|
|
|
306
|
|
|
3,920
|
|
|||||
Incurred guaranteed benefits (1)
|
102
|
|
|
78
|
|
|
291
|
|
|
25
|
|
|
496
|
|
|||||
Paid guaranteed benefits
|
(15
|
)
|
|
(1
|
)
|
|
(28
|
)
|
|
—
|
|
|
(44
|
)
|
|||||
Balance at December 31, 2016
|
451
|
|
|
601
|
|
|
2,989
|
|
|
331
|
|
|
4,372
|
|
|||||
Incurred guaranteed benefits (1)
|
91
|
|
|
121
|
|
|
233
|
|
|
16
|
|
|
461
|
|
|||||
Paid guaranteed benefits
|
(14
|
)
|
|
(2
|
)
|
|
(34
|
)
|
|
—
|
|
|
(50
|
)
|
|||||
Balance at December 31, 2017
|
$
|
528
|
|
|
$
|
720
|
|
|
$
|
3,188
|
|
|
$
|
347
|
|
|
$
|
4,783
|
|
Ceded:
|
|
|
|
|
|
|
|
|
|
||||||||||
Balance at January 1, 2015
|
$
|
23
|
|
|
$
|
6
|
|
|
$
|
187
|
|
|
$
|
201
|
|
|
$
|
417
|
|
Incurred guaranteed benefits
|
(1
|
)
|
|
—
|
|
|
31
|
|
|
13
|
|
|
43
|
|
|||||
Paid guaranteed benefits
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3
|
)
|
|||||
Balance at December 31, 2015
|
19
|
|
|
6
|
|
|
218
|
|
|
214
|
|
|
457
|
|
|||||
Incurred guaranteed benefits
|
—
|
|
|
(1
|
)
|
|
(27
|
)
|
|
17
|
|
|
(11
|
)
|
|||||
Paid guaranteed benefits
|
5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5
|
|
|||||
Balance at December 31, 2016
|
24
|
|
|
5
|
|
|
191
|
|
|
231
|
|
|
451
|
|
|||||
Incurred guaranteed benefits
|
4
|
|
|
1
|
|
|
50
|
|
|
11
|
|
|
66
|
|
|||||
Paid guaranteed benefits
|
6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6
|
|
|||||
Balance at December 31, 2017
|
$
|
34
|
|
|
$
|
6
|
|
|
$
|
241
|
|
|
$
|
242
|
|
|
$
|
523
|
|
Net:
|
|
|
|
|
|
|
|
|
|
||||||||||
Balance at January 1, 2015
|
$
|
284
|
|
|
$
|
457
|
|
|
$
|
2,524
|
|
|
$
|
87
|
|
|
$
|
3,352
|
|
Incurred guaranteed benefits
|
69
|
|
|
62
|
|
|
12
|
|
|
5
|
|
|
148
|
|
|||||
Paid guaranteed benefits
|
(8
|
)
|
|
(1
|
)
|
|
(28
|
)
|
|
—
|
|
|
(37
|
)
|
|||||
Balance at December 31, 2015
|
345
|
|
|
518
|
|
|
2,508
|
|
|
92
|
|
|
3,463
|
|
|||||
Incurred guaranteed benefits
|
102
|
|
|
79
|
|
|
318
|
|
|
8
|
|
|
507
|
|
|||||
Paid guaranteed benefits
|
(20
|
)
|
|
(1
|
)
|
|
(28
|
)
|
|
—
|
|
|
(49
|
)
|
|||||
Balance at December 31, 2016
|
427
|
|
|
596
|
|
|
2,798
|
|
|
100
|
|
|
3,921
|
|
|||||
Incurred guaranteed benefits
|
87
|
|
|
120
|
|
|
183
|
|
|
5
|
|
|
395
|
|
|||||
Paid guaranteed benefits
|
(20
|
)
|
|
(2
|
)
|
|
(34
|
)
|
|
—
|
|
|
(56
|
)
|
|||||
Balance at December 31, 2017
|
$
|
494
|
|
|
$
|
714
|
|
|
$
|
2,947
|
|
|
$
|
105
|
|
|
$
|
4,260
|
|
(1)
|
Secondary guarantees include the effects of foreign currency translation of
$78 million
,
$119 million
and
($80) million
at
December 31, 2017
,
2016
and
2015
, respectively.
|
|
|
December 31,
|
|||||||||||||||||||
|
|
2017
|
|
|
2016
|
|
|||||||||||||||
|
|
In the
Event of Death |
|
|
At
Annuitization |
|
|
In the
Event of Death |
|
|
At
Annuitization |
|
|||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||
Annuity Contracts (1):
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Variable Annuity Guarantees:
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Total account value (2), (3)
|
|
$
|
66,724
|
|
|
|
$
|
26,223
|
|
|
|
$
|
66,176
|
|
|
|
$
|
25,335
|
|
|
|
Separate account value
|
|
$
|
45,431
|
|
|
|
$
|
24,336
|
|
|
|
$
|
43,359
|
|
|
|
$
|
23,330
|
|
|
|
Net amount at risk (2)
|
|
$
|
1,238
|
|
(4)
|
|
$
|
525
|
|
(5)
|
|
|
$
|
1,842
|
|
(4)
|
|
$
|
521
|
|
(5)
|
Average attained age of contractholders
|
|
65 years
|
|
|
|
65 years
|
|
|
|
64 years
|
|
|
|
65 years
|
|
|
|||||
Other Annuity Guarantees:
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Total account value (3)
|
|
N/A
|
|
|
|
$
|
1,424
|
|
|
|
N/A
|
|
|
|
$
|
1,393
|
|
|
|||
Net amount at risk
|
|
N/A
|
|
|
|
$
|
569
|
|
(6
|
)
|
|
N/A
|
|
|
|
$
|
490
|
|
(6)
|
||
Average attained age of contractholders
|
|
N/A
|
|
|
|
50 years
|
|
|
|
N/A
|
|
|
|
50 years
|
|
|
|
|
December 31,
|
||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||
|
|
Secondary
Guarantees |
|
Paid-Up
Guarantees |
|
Secondary
Guarantees |
|
Paid-Up
Guarantees |
||||||||
|
|
(Dollars in millions)
|
||||||||||||||
Universal and Variable Life Contracts (1):
|
|
|
|
|
|
|
|
|
||||||||
Total account value (3)
|
|
$
|
9,036
|
|
|
$
|
3,207
|
|
|
$
|
8,363
|
|
|
$
|
3,337
|
|
Net amount at risk (7)
|
|
$
|
66,956
|
|
|
$
|
16,615
|
|
|
$
|
70,225
|
|
|
$
|
17,785
|
|
Average attained age of policyholders
|
|
56 years
|
|
|
63 years
|
|
|
55 years
|
|
|
62 years
|
|
(1)
|
The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive.
|
(2)
|
Includes amounts, which are not reported on the consolidated balance sheets, from assumed variable annuity guarantees from the Company’s former operating joint venture in Japan.
|
(3)
|
Includes the contractholder’s investments in the general account and separate account, if applicable.
|
(4)
|
Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death.
|
(5)
|
Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved.
|
(6)
|
Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date.
|
(7)
|
Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date.
|
(1)
|
Account balances at December 31, 2016 decreased in total by
$6.7 billion
from those amounts previously reported to correct for the inclusion of contracts without guarantees.
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
FHLB of New York
|
|
$
|
733
|
|
|
$
|
748
|
|
FHLB of Des Moines
|
|
$
|
35
|
|
|
$
|
35
|
|
FHLB of Pittsburgh
|
|
$
|
11
|
|
|
$
|
11
|
|
|
|
Liability
|
|
Collateral
|
||||||||||||||
|
|
December 31,
|
||||||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||
|
|
(In millions)
|
||||||||||||||||
FHLB of New York (1)
|
|
$
|
14,445
|
|
|
$
|
14,445
|
|
|
$
|
16,605
|
|
(2)
|
|
$
|
16,828
|
|
(2)
|
Farmer Mac (3)
|
|
$
|
2,550
|
|
|
$
|
2,550
|
|
|
$
|
2,644
|
|
|
|
$
|
2,645
|
|
|
FHLB of Des Moines (1)
|
|
$
|
625
|
|
|
$
|
625
|
|
|
$
|
701
|
|
(2)
|
|
$
|
811
|
|
(2)
|
FHLB of Pittsburgh (1)
|
|
$
|
250
|
|
|
$
|
250
|
|
|
$
|
311
|
|
(2)
|
|
$
|
383
|
|
(2)
|
(1)
|
Represents funding agreements issued to the applicable FHLBank in exchange for cash and for which such FHLBank has been granted a lien on certain assets, some of which are in the custody of such FHLBank, including residential mortgage-backed securities (“RMBS”), to collateralize obligations under advances evidenced by funding agreements. The applicable subsidiary of the Company is permitted to withdraw any portion of the collateral in the custody of such FHLBank as long as there is no event of default and the remaining qualified collateral is sufficient to satisfy the collateral maintenance level. Upon any event of default by such subsidiary, the applicable FHLBank’s recovery on the collateral is limited to the amount of such subsidiary’s liability to such FHLBank.
|
(2)
|
Advances are collateralized by mortgage-backed securities. The amount of collateral presented is at estimated fair value.
|
(3)
|
Represents funding agreements issued to a subsidiary of Farmer Mac, as well as certain SPEs that have issued debt securities for which payment of interest and principal is secured by such funding agreements, and such debt securities are also guaranteed as to payment of interest and principal by Farmer Mac. The obligations under these funding agreements are secured by a pledge of certain eligible agricultural mortgage loans and may, under certain circumstances, be secured by other qualified collateral. The amount of collateral presented is at carrying value.
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Incurral Year
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
|
|||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||
2011
|
|
$
|
6,318
|
|
|
$
|
6,290
|
|
|
$
|
6,293
|
|
|
$
|
6,269
|
|
|
$
|
6,287
|
|
|
$
|
6,295
|
|
|
$
|
6,294
|
|
|
$
|
1
|
|
|
207,301
|
|
2012
|
|
|
|
6,503
|
|
|
6,579
|
|
|
6,569
|
|
|
6,546
|
|
|
6,568
|
|
|
6,569
|
|
|
3
|
|
|
208,626
|
|
|||||||||
2013
|
|
|
|
|
|
6,637
|
|
|
6,713
|
|
|
6,719
|
|
|
6,720
|
|
|
6,730
|
|
|
15
|
|
|
210,643
|
|
||||||||||
2014
|
|
|
|
|
|
|
|
6,986
|
|
|
6,919
|
|
|
6,913
|
|
|
6,910
|
|
|
5
|
|
|
210,797
|
|
|||||||||||
2015
|
|
|
|
|
|
|
|
|
|
7,040
|
|
|
7,015
|
|
|
7,014
|
|
|
12
|
|
|
211,597
|
|
||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
7,125
|
|
|
7,085
|
|
|
21
|
|
|
206,610
|
|
|||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,432
|
|
|
898
|
|
|
186,954
|
|
||||||||||||||
Total
|
|
48,034
|
|
|
|
|
|
||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(46,136
|
)
|
|
|
|
|
||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2011, net of reinsurance
|
|
5
|
|
|
|
|
|
||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
1,903
|
|
|
|
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
|||||||||||||||||||
Years
|
|
1
|
|
2
|
|
3
|
|
4
|
|
5
|
|
6
|
|
7
|
|||||||
Group Life - Term
|
|
78.3
|
%
|
|
20.0
|
%
|
|
0.7
|
%
|
|
0.2
|
%
|
|
0.4
|
%
|
|
0.1
|
%
|
|
—
|
%
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
Incurral Year
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
|
|||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||
2011
|
|
$
|
955
|
|
|
$
|
916
|
|
|
$
|
894
|
|
|
$
|
914
|
|
|
$
|
924
|
|
|
$
|
923
|
|
|
$
|
918
|
|
|
$
|
—
|
|
|
21,642
|
|
2012
|
|
|
|
966
|
|
|
979
|
|
|
980
|
|
|
1,014
|
|
|
1,034
|
|
|
1,037
|
|
|
—
|
|
|
20,085
|
|
|||||||||
2013
|
|
|
|
|
|
1,008
|
|
|
1,027
|
|
|
1,032
|
|
|
1,049
|
|
|
1,070
|
|
|
—
|
|
|
21,123
|
|
||||||||||
2014
|
|
|
|
|
|
|
|
1,076
|
|
|
1,077
|
|
|
1,079
|
|
|
1,101
|
|
|
—
|
|
|
22,838
|
|
|||||||||||
2015
|
|
|
|
|
|
|
|
|
|
1,082
|
|
|
1,105
|
|
|
1,093
|
|
|
4
|
|
|
21,136
|
|
||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
1,131
|
|
|
1,139
|
|
|
26
|
|
|
17,585
|
|
|||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,244
|
|
|
585
|
|
|
9,258
|
|
||||||||||||||
Total
|
|
7,602
|
|
|
|
|
|
||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(3,006
|
)
|
|
|
|
|
||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2011, net of reinsurance
|
|
2,539
|
|
|
|
|
|
||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
7,135
|
|
|
|
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
|||||||||||||||||||
Years
|
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
Group Long-Term Disability
|
|
4.4
|
%
|
|
18.8
|
%
|
|
13.9
|
%
|
|
8.5
|
%
|
|
7.1
|
%
|
|
6.4
|
%
|
|
5.6
|
%
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
|
|||||||||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
818
|
|
|
$
|
839
|
|
|
$
|
828
|
|
|
$
|
805
|
|
|
$
|
799
|
|
|
$
|
794
|
|
|
$
|
793
|
|
|
$
|
791
|
|
|
$
|
790
|
|
|
$
|
791
|
|
|
$
|
—
|
|
|
200,517
|
|
2009
|
|
|
|
862
|
|
|
877
|
|
|
853
|
|
|
826
|
|
|
823
|
|
|
817
|
|
|
815
|
|
|
815
|
|
|
814
|
|
|
—
|
|
|
201,579
|
|
||||||||||||
2010
|
|
|
|
|
|
863
|
|
|
873
|
|
|
853
|
|
|
847
|
|
|
833
|
|
|
826
|
|
|
825
|
|
|
822
|
|
|
1
|
|
|
202,098
|
|
|||||||||||||
2011
|
|
|
|
|
|
|
|
863
|
|
|
876
|
|
|
869
|
|
|
855
|
|
|
846
|
|
|
843
|
|
|
843
|
|
|
2
|
|
|
202,513
|
|
||||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
882
|
|
|
881
|
|
|
869
|
|
|
851
|
|
|
846
|
|
|
847
|
|
|
3
|
|
|
196,928
|
|
|||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
911
|
|
|
900
|
|
|
882
|
|
|
878
|
|
|
876
|
|
|
6
|
|
|
201,297
|
|
||||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
897
|
|
|
910
|
|
|
913
|
|
|
910
|
|
|
12
|
|
|
203,560
|
|
|||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975
|
|
|
984
|
|
|
979
|
|
|
30
|
|
|
207,485
|
|
||||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,012
|
|
|
1,002
|
|
|
77
|
|
|
204,497
|
|
|||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
957
|
|
|
161
|
|
|
173,607
|
|
||||||||||||||||||||
Total
|
|
8,841
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(7,672
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2008, net of reinsurance
|
|
27
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
1,196
|
|
|
|
|
|
|
|
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
|
||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
304
|
|
|
$
|
553
|
|
|
$
|
657
|
|
|
$
|
725
|
|
|
$
|
764
|
|
|
$
|
778
|
|
|
$
|
785
|
|
|
$
|
787
|
|
|
$
|
788
|
|
|
$
|
789
|
|
2009
|
|
|
|
321
|
|
|
563
|
|
|
681
|
|
|
755
|
|
|
789
|
|
|
803
|
|
|
810
|
|
|
813
|
|
|
813
|
|
|||||||||||
2010
|
|
|
|
|
|
319
|
|
|
572
|
|
|
695
|
|
|
762
|
|
|
796
|
|
|
810
|
|
|
816
|
|
|
818
|
|
||||||||||||
2011
|
|
|
|
|
|
|
|
324
|
|
|
590
|
|
|
711
|
|
|
777
|
|
|
810
|
|
|
825
|
|
|
831
|
|
|||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
333
|
|
|
600
|
|
|
715
|
|
|
783
|
|
|
815
|
|
|
831
|
|
||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
346
|
|
|
618
|
|
|
743
|
|
|
809
|
|
|
843
|
|
|||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
352
|
|
|
648
|
|
|
777
|
|
|
844
|
|
||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384
|
|
|
691
|
|
|
822
|
|
|||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
396
|
|
|
702
|
|
||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
379
|
|
|||||||||||||||||||
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
$
|
7,672
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
||||||||||||||||||||||||||||
Years
|
|
1
|
|
2
|
|
3
|
|
4
|
|
5
|
|
6
|
|
7
|
|
8
|
|
9
|
|
10
|
||||||||||
Auto Liability
|
|
39.3
|
%
|
|
31.3
|
%
|
|
14.0
|
%
|
|
7.9
|
%
|
|
4.0
|
%
|
|
1.8
|
%
|
|
0.9
|
%
|
|
0.5
|
%
|
|
0.1
|
%
|
|
0.2
|
%
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
|
|||||||||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
644
|
|
|
$
|
636
|
|
|
$
|
599
|
|
|
$
|
590
|
|
|
$
|
588
|
|
|
$
|
589
|
|
|
$
|
588
|
|
|
$
|
586
|
|
|
$
|
585
|
|
|
$
|
585
|
|
|
$
|
—
|
|
|
127,479
|
|
2009
|
|
|
|
506
|
|
|
523
|
|
|
510
|
|
|
507
|
|
|
503
|
|
|
501
|
|
|
498
|
|
|
497
|
|
|
497
|
|
|
—
|
|
|
106,616
|
|
||||||||||||
2010
|
|
|
|
|
|
573
|
|
|
589
|
|
|
587
|
|
|
584
|
|
|
582
|
|
|
581
|
|
|
580
|
|
|
579
|
|
|
—
|
|
|
115,510
|
|
|||||||||||||
2011
|
|
|
|
|
|
|
|
891
|
|
|
868
|
|
|
843
|
|
|
840
|
|
|
835
|
|
|
835
|
|
|
834
|
|
|
—
|
|
|
166,455
|
|
||||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
714
|
|
|
713
|
|
|
703
|
|
|
698
|
|
|
696
|
|
|
694
|
|
|
2
|
|
|
146,536
|
|
|||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
654
|
|
|
652
|
|
|
635
|
|
|
635
|
|
|
634
|
|
|
4
|
|
|
107,525
|
|
||||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
707
|
|
|
702
|
|
|
704
|
|
|
705
|
|
|
7
|
|
|
113,604
|
|
|||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
759
|
|
|
753
|
|
|
752
|
|
|
12
|
|
|
107,073
|
|
||||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
740
|
|
|
743
|
|
|
20
|
|
|
106,537
|
|
|||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
747
|
|
|
66
|
|
|
106,915
|
|
||||||||||||||||||||
Total
|
|
6,770
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(6,545
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2008, net of reinsurance
|
|
1
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
226
|
|
|
|
|
|
|
|
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
|
||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
446
|
|
|
$
|
558
|
|
|
$
|
574
|
|
|
$
|
579
|
|
|
$
|
582
|
|
|
$
|
583
|
|
|
$
|
584
|
|
|
$
|
584
|
|
|
$
|
584
|
|
|
$
|
584
|
|
2009
|
|
|
|
385
|
|
|
476
|
|
|
486
|
|
|
492
|
|
|
495
|
|
|
495
|
|
|
496
|
|
|
496
|
|
|
496
|
|
|||||||||||
2010
|
|
|
|
|
|
436
|
|
|
546
|
|
|
562
|
|
|
571
|
|
|
574
|
|
|
577
|
|
|
578
|
|
|
578
|
|
||||||||||||
2011
|
|
|
|
|
|
|
|
690
|
|
|
804
|
|
|
819
|
|
|
825
|
|
|
827
|
|
|
830
|
|
|
832
|
|
|||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
559
|
|
|
668
|
|
|
681
|
|
|
687
|
|
|
689
|
|
|
690
|
|
||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
505
|
|
|
604
|
|
|
618
|
|
|
626
|
|
|
628
|
|
|||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
574
|
|
|
670
|
|
|
685
|
|
|
692
|
|
||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
603
|
|
|
717
|
|
|
731
|
|
|||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
593
|
|
|
704
|
|
||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
610
|
|
|||||||||||||||||||
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
$
|
6,545
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
|||||||||||||||||||||||||||||
Years
|
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
|
|
$
|
6
|
|
|
7
|
|
|
8
|
|
|
9
|
|
|
10
|
|
Home
|
|
80.5
|
%
|
|
14.8
|
%
|
|
2.3
|
%
|
|
1.0
|
%
|
|
0.6
|
%
|
|
0.3
|
%
|
|
0.2
|
%
|
|
0.1
|
%
|
|
—
|
%
|
|
0.1
|
%
|
|
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||||
|
|
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||||
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Incurral Year
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
|
|||||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||||||
2010
|
|
$
|
82
|
|
|
$
|
78
|
|
|
$
|
84
|
|
|
$
|
107
|
|
|
$
|
107
|
|
|
$
|
103
|
|
|
$
|
135
|
|
|
$
|
144
|
|
|
$
|
24
|
|
|
2,490
|
|
2011
|
|
|
|
64
|
|
|
67
|
|
|
88
|
|
|
88
|
|
|
94
|
|
|
124
|
|
|
132
|
|
|
24
|
|
|
2,629
|
|
||||||||||
2012
|
|
|
|
|
|
98
|
|
|
104
|
|
|
103
|
|
|
118
|
|
|
119
|
|
|
122
|
|
|
10
|
|
|
3,962
|
|
|||||||||||
2013
|
|
|
|
|
|
|
|
148
|
|
|
150
|
|
|
174
|
|
|
168
|
|
|
167
|
|
|
19
|
|
|
4,448
|
|
||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
297
|
|
|
279
|
|
|
256
|
|
|
256
|
|
|
54
|
|
|
5,020
|
|
|||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
280
|
|
|
267
|
|
|
271
|
|
|
78
|
|
|
4,473
|
|
||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
234
|
|
|
238
|
|
|
102
|
|
|
2,314
|
|
|||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
303
|
|
|
215
|
|
|
1,456
|
|
||||||||||||||||
Total
|
|
1,633
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(1,108
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2010, net of reinsurance
|
|
27
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
552
|
|
|
|
|
|
|
|
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
|
||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
||||||||||||||||||||||||||
Incurral Year
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||
2010
|
|
$
|
20
|
|
|
$
|
40
|
|
|
$
|
53
|
|
|
$
|
65
|
|
|
$
|
79
|
|
|
$
|
89
|
|
|
$
|
114
|
|
|
$
|
121
|
|
2011
|
|
|
|
13
|
|
|
40
|
|
|
54
|
|
|
67
|
|
|
81
|
|
|
102
|
|
|
109
|
|
|||||||||
2012
|
|
|
|
|
|
30
|
|
|
65
|
|
|
85
|
|
|
99
|
|
|
106
|
|
|
112
|
|
||||||||||
2013
|
|
|
|
|
|
|
|
44
|
|
|
99
|
|
|
121
|
|
|
136
|
|
|
149
|
|
|||||||||||
2014
|
|
|
|
|
|
|
|
|
|
69
|
|
|
144
|
|
|
180
|
|
|
202
|
|
||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
81
|
|
|
154
|
|
|
192
|
|
|||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
66
|
|
|
135
|
|
||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
88
|
|
|||||||||||||||
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
$
|
1,108
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
||||||||||||||||||||||
Years
|
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
|
8
|
|
Group Disability & Group Life
|
|
23.6
|
%
|
|
25.8
|
%
|
|
13.0
|
%
|
|
9.3
|
%
|
|
8.6
|
%
|
|
8.9
|
%
|
|
11.3
|
%
|
|
5.5
|
%
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
||||||||||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
208
|
|
|
$
|
277
|
|
|
$
|
281
|
|
|
$
|
282
|
|
|
$
|
283
|
|
|
$
|
283
|
|
|
$
|
283
|
|
|
$
|
283
|
|
|
$
|
283
|
|
|
$
|
284
|
|
|
$
|
—
|
|
|
31,642
|
|
2009
|
|
|
|
236
|
|
|
319
|
|
|
324
|
|
|
325
|
|
|
325
|
|
|
325
|
|
|
326
|
|
|
326
|
|
|
327
|
|
|
—
|
|
|
31,322
|
|
||||||||||||
2010
|
|
|
|
|
|
259
|
|
|
333
|
|
|
340
|
|
|
341
|
|
|
342
|
|
|
342
|
|
|
342
|
|
|
343
|
|
|
—
|
|
|
33,386
|
|
|||||||||||||
2011
|
|
|
|
|
|
|
|
150
|
|
|
229
|
|
|
236
|
|
|
237
|
|
|
238
|
|
|
238
|
|
|
235
|
|
|
—
|
|
|
28,103
|
|
||||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
159
|
|
|
215
|
|
|
221
|
|
|
222
|
|
|
223
|
|
|
221
|
|
|
—
|
|
|
29,244
|
|
|||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
176
|
|
|
246
|
|
|
253
|
|
|
254
|
|
|
253
|
|
|
—
|
|
|
33,170
|
|
||||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
252
|
|
|
381
|
|
|
392
|
|
|
361
|
|
|
1
|
|
|
41,566
|
|
|||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330
|
|
|
470
|
|
|
440
|
|
|
2
|
|
|
47,111
|
|
||||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359
|
|
|
456
|
|
|
14
|
|
|
40,972
|
|
|||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
372
|
|
|
117
|
|
|
25,103
|
|
||||||||||||||||||||
Total
|
|
3,292
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(3,024
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2008, net of reinsurance
|
|
12
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
280
|
|
|
|
|
|
|
|
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
|
||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
205
|
|
|
$
|
271
|
|
|
$
|
276
|
|
|
$
|
277
|
|
|
$
|
277
|
|
|
$
|
277
|
|
|
$
|
277
|
|
|
$
|
278
|
|
|
$
|
278
|
|
|
$
|
281
|
|
2009
|
|
|
|
234
|
|
|
311
|
|
|
316
|
|
|
317
|
|
|
317
|
|
|
317
|
|
|
317
|
|
|
317
|
|
|
321
|
|
|||||||||||
2010
|
|
|
|
|
|
239
|
|
|
311
|
|
|
318
|
|
|
319
|
|
|
319
|
|
|
319
|
|
|
320
|
|
|
322
|
|
||||||||||||
2011
|
|
|
|
|
|
|
|
147
|
|
|
225
|
|
|
231
|
|
|
232
|
|
|
232
|
|
|
232
|
|
|
234
|
|
|||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
157
|
|
|
212
|
|
|
217
|
|
|
218
|
|
|
219
|
|
|
219
|
|
||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
172
|
|
|
238
|
|
|
243
|
|
|
244
|
|
|
244
|
|
|||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226
|
|
|
336
|
|
|
342
|
|
|
346
|
|
||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
271
|
|
|
379
|
|
|
404
|
|
|||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
245
|
|
|
437
|
|
||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
216
|
|
|||||||||||||||||||
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
$
|
3,024
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
|
|
||||||||||||||||||||||||||
Years
|
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
|
8
|
|
|
9
|
|
|
10
|
|
Protection Life
|
|
65.1
|
%
|
|
27.8
|
%
|
|
2.3
|
%
|
|
0.5
|
%
|
|
0.1
|
%
|
|
—
|
%
|
|
0.2
|
%
|
|
0.2
|
%
|
|
0.6
|
%
|
|
1.3
|
%
|
|
|
Incurred Claims and Allocated Claim Adjustment Expense, Net of Reinsurance
|
|
At December 31, 2017
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
|
Total IBNR
Liabilities Plus
Expected
Development on
Reported Claims
|
|
Cumulative
Number of
Reported
Claims
|
|||||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
||||||||||||||||||||||||||
|
|
(Dollars in millions)
|
|||||||||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
133
|
|
|
$
|
149
|
|
|
$
|
151
|
|
|
$
|
151
|
|
|
$
|
151
|
|
|
$
|
152
|
|
|
$
|
152
|
|
|
$
|
152
|
|
|
$
|
152
|
|
|
$
|
154
|
|
|
$
|
—
|
|
|
89,217
|
|
2009
|
|
|
|
153
|
|
|
171
|
|
|
173
|
|
|
173
|
|
|
174
|
|
|
174
|
|
|
174
|
|
|
174
|
|
|
177
|
|
|
—
|
|
|
92,530
|
|
||||||||||||
2010
|
|
|
|
|
|
180
|
|
|
201
|
|
|
202
|
|
|
203
|
|
|
204
|
|
|
204
|
|
|
204
|
|
|
207
|
|
|
—
|
|
|
96,276
|
|
|||||||||||||
2011
|
|
|
|
|
|
|
|
216
|
|
|
240
|
|
|
242
|
|
|
243
|
|
|
243
|
|
|
243
|
|
|
240
|
|
|
—
|
|
|
105,965
|
|
||||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
209
|
|
|
235
|
|
|
237
|
|
|
237
|
|
|
238
|
|
|
236
|
|
|
—
|
|
|
99,498
|
|
|||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
226
|
|
|
255
|
|
|
257
|
|
|
258
|
|
|
255
|
|
|
1
|
|
|
103,110
|
|
||||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
235
|
|
|
261
|
|
|
263
|
|
|
261
|
|
|
2
|
|
|
96,260
|
|
|||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
202
|
|
|
229
|
|
|
231
|
|
|
3
|
|
|
84,678
|
|
||||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
265
|
|
|
305
|
|
|
7
|
|
|
101,478
|
|
|||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
383
|
|
|
48
|
|
|
101,116
|
|
||||||||||||||||||||
Total
|
|
2,449
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
(2,365
|
)
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
All outstanding liabilities for incurral years prior to 2008, net of reinsurance
|
|
3
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||
Total unpaid claims and claim adjustment expenses, net of reinsurance
|
|
$
|
87
|
|
|
|
|
|
|
|
Cumulative Paid Claims and Paid Allocated Claim Adjustment Expenses, Net of Reinsurance
|
||||||||||||||||||||||||||||||||||||||
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||||||||||||||||||
|
|
(Unaudited)
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Incurral Year
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
||||||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||
2008
|
|
$
|
133
|
|
|
$
|
149
|
|
|
$
|
151
|
|
|
$
|
151
|
|
|
$
|
151
|
|
|
$
|
152
|
|
|
$
|
152
|
|
|
$
|
152
|
|
|
$
|
152
|
|
|
$
|
154
|
|
2009
|
|
|
|
153
|
|
|
171
|
|
|
173
|
|
|
173
|
|
|
174
|
|
|
174
|
|
|
174
|
|
|
174
|
|
|
177
|
|
|||||||||||
2010
|
|
|
|
|
|
180
|
|
|
201
|
|
|
202
|
|
|
203
|
|
|
203
|
|
|
204
|
|
|
204
|
|
|
207
|
|
||||||||||||
2011
|
|
|
|
|
|
|
|
216
|
|
|
240
|
|
|
242
|
|
|
243
|
|
|
243
|
|
|
243
|
|
|
240
|
|
|||||||||||||
2012
|
|
|
|
|
|
|
|
|
|
209
|
|
|
235
|
|
|
237
|
|
|
237
|
|
|
238
|
|
|
236
|
|
||||||||||||||
2013
|
|
|
|
|
|
|
|
|
|
|
|
226
|
|
|
255
|
|
|
257
|
|
|
258
|
|
|
255
|
|
|||||||||||||||
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
233
|
|
|
259
|
|
|
262
|
|
|
258
|
|
||||||||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
202
|
|
|
229
|
|
|
228
|
|
|||||||||||||||||
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
249
|
|
|
298
|
|
||||||||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
312
|
|
|||||||||||||||||||
Total cumulative paid claims and paid allocated claim adjustment expenses, net of reinsurance
|
|
$
|
2,365
|
|
|
|
Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance
|
|
|
||||||||||||||||||||||||||
Years
|
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
|
8
|
|
|
9
|
|
|
10
|
|
Protection Health
|
|
86.7
|
%
|
|
11.2
|
%
|
|
0.6
|
%
|
|
0.1
|
%
|
|
—
|
%
|
|
—
|
%
|
|
(0.3)%
|
|
0.5
|
%
|
|
0.8
|
%
|
|
1.4
|
%
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016 (1)
|
|
2015 (2)
|
||||||
|
|
(In millions)
|
||||||||||
Balance at December 31 of prior period
|
|
$
|
16,157
|
|
|
$
|
9,669
|
|
|
$
|
9,525
|
|
Less: Reinsurance recoverables
|
|
1,968
|
|
|
476
|
|
|
454
|
|
|||
Net balance at December 31 of prior period
|
|
14,189
|
|
|
9,193
|
|
|
9,071
|
|
|||
Cumulative adjustment (3)
|
|
—
|
|
|
4,819
|
|
|
—
|
|
|||
Net balance at January 1,
|
|
14,189
|
|
|
14,012
|
|
|
9,071
|
|
|||
Incurred related to:
|
|
|
|
|
|
|
||||||
Current year
|
|
24,370
|
|
|
24,011
|
|
|
9,533
|
|
|||
Prior years (4)
|
|
133
|
|
|
382
|
|
|
(78
|
)
|
|||
Total incurred
|
|
24,503
|
|
|
24,393
|
|
|
9,455
|
|
|||
Paid related to:
|
|
|
|
|
|
|
||||||
Current year
|
|
(18,525
|
)
|
|
(18,696
|
)
|
|
(6,759
|
)
|
|||
Prior years
|
|
(5,271
|
)
|
|
(5,520
|
)
|
|
(2,574
|
)
|
|||
Total paid
|
|
(23,796
|
)
|
|
(24,216
|
)
|
|
(9,333
|
)
|
|||
Net balance at December 31,
|
|
14,896
|
|
|
14,189
|
|
|
9,193
|
|
|||
Add: Reinsurance recoverables
|
|
2,198
|
|
|
1,968
|
|
|
476
|
|
|||
Balance at December 31,
|
|
$
|
17,094
|
|
|
$
|
16,157
|
|
|
$
|
9,669
|
|
(1)
|
In addition to the revisions discussed in
Note 1
, at December 31, 2016, the Net balance decreased by
$736 million
and the Reinsurance recoverables increased by
$742 million
from those amounts previously reported primarily to correct for the improper classification of reinsurance recoverables.
|
(2)
|
Limited to property & casualty, group accident and non-medical health policies and contracts.
|
(3)
|
Reflects the accumulated adjustment, net of reinsurance, upon implementation of the new short-duration contracts guidance which clarified the requirement to include claim information for long-duration contracts. The accumulated adjustment primarily reflects unpaid claim liabilities, net of reinsurance, for long-duration contracts as of the beginning of the period presented. Prior periods have not been restated. See
Note 1
.
|
(4)
|
During
2017
,
as a result of changes in estimates of insured events in the respective prior year, claims and claim adjustment expenses associated with prior years
increased due to events incurred in prior years but reported during current year
.
During
2016
,
as a result of changes in estimates of insured events in the respective prior year, claims and claim adjustment expenses associated with prior years
increased due to the implementation of new guidance related to short-
duration contracts. During
2015
, as a result of changes in estimates of insured events in the respective prior year, claims and claim adjustment expenses associated with prior years decreased due to a reduction in prior year automobile bodily injury and homeowners’ severity.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
DAC:
|
|
|
|
|
|
||||||
Balance at January 1,
|
$
|
13,830
|
|
|
$
|
13,464
|
|
|
$
|
13,024
|
|
Capitalizations
|
3,002
|
|
|
3,152
|
|
|
3,319
|
|
|||
Amortization related to:
|
|
|
|
|
|
||||||
Net investment gains (losses) and net derivative gains (losses)
|
60
|
|
|
229
|
|
|
(150
|
)
|
|||
Other expenses
|
(2,426
|
)
|
|
(2,555
|
)
|
|
(2,590
|
)
|
|||
Total amortization
|
(2,366
|
)
|
|
(2,326
|
)
|
|
(2,740
|
)
|
|||
Unrealized investment gains (losses)
|
(525
|
)
|
|
(171
|
)
|
|
443
|
|
|||
Effect of foreign currency translation and other
|
848
|
|
|
(289
|
)
|
|
(582
|
)
|
|||
Balance at December 31,
|
14,789
|
|
|
13,830
|
|
|
13,464
|
|
|||
VOBA:
|
|
|
|
|
|
||||||
Balance at January 1,
|
3,760
|
|
|
3,966
|
|
|
4,705
|
|
|||
Amortization related to:
|
|
|
|
|
|
||||||
Net investment gains (losses) and net derivative gains (losses)
|
—
|
|
|
(3
|
)
|
|
(1
|
)
|
|||
Other expenses
|
(315
|
)
|
|
(389
|
)
|
|
(443
|
)
|
|||
Total amortization
|
(315
|
)
|
|
(392
|
)
|
|
(444
|
)
|
|||
Unrealized investment gains (losses)
|
(4
|
)
|
|
8
|
|
|
5
|
|
|||
Effect of foreign currency translation and other
|
189
|
|
|
178
|
|
|
(300
|
)
|
|||
Balance at December 31,
|
3,630
|
|
|
3,760
|
|
|
3,966
|
|
|||
Total DAC and VOBA:
|
|
|
|
|
|
||||||
Balance at December 31,
|
$
|
18,419
|
|
|
$
|
17,590
|
|
|
$
|
17,430
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
DSI:
|
|
|
|
|
|
|
||||||
Balance at January 1,
|
|
$
|
241
|
|
|
$
|
242
|
|
|
$
|
224
|
|
Capitalization
|
|
16
|
|
|
22
|
|
|
28
|
|
|||
Amortization
|
|
(29
|
)
|
|
(23
|
)
|
|
(30
|
)
|
|||
Unrealized investment gains (losses)
|
|
(6
|
)
|
|
—
|
|
|
20
|
|
|||
Effect of foreign currency translation
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
|||
Balance at December 31,
|
|
$
|
220
|
|
|
$
|
241
|
|
|
$
|
242
|
|
VODA and VOCRA:
|
|
|
|
|
|
|
||||||
Balance at January 1,
|
|
$
|
509
|
|
|
$
|
583
|
|
|
$
|
692
|
|
Amortization
|
|
(51
|
)
|
|
(57
|
)
|
|
(56
|
)
|
|||
Effect of foreign currency translation
|
|
1
|
|
|
(17
|
)
|
|
(53
|
)
|
|||
Balance at December 31,
|
|
$
|
459
|
|
|
$
|
509
|
|
|
$
|
583
|
|
Accumulated amortization
|
|
$
|
345
|
|
|
$
|
294
|
|
|
$
|
237
|
|
Negative VOBA:
|
|
|
|
|
|
|
||||||
Balance at January 1,
|
|
$
|
935
|
|
|
$
|
1,193
|
|
|
$
|
1,596
|
|
Amortization
|
|
(140
|
)
|
|
(269
|
)
|
|
(361
|
)
|
|||
Effect of foreign currency translation and other
|
|
32
|
|
|
11
|
|
|
(42
|
)
|
|||
Balance at December 31,
|
|
$
|
827
|
|
|
$
|
935
|
|
|
$
|
1,193
|
|
Accumulated amortization
|
|
$
|
3,174
|
|
|
$
|
3,034
|
|
|
$
|
2,765
|
|
|
|
VOBA
|
|
VODA and VOCRA
|
|
Negative VOBA
|
||||||
|
|
(In millions)
|
||||||||||
2018
|
|
$
|
293
|
|
|
$
|
47
|
|
|
$
|
(60
|
)
|
2019
|
|
$
|
272
|
|
|
$
|
43
|
|
|
$
|
(40
|
)
|
2020
|
|
$
|
248
|
|
|
$
|
40
|
|
|
$
|
(41
|
)
|
2021
|
|
$
|
222
|
|
|
$
|
36
|
|
|
$
|
(40
|
)
|
2022
|
|
$
|
208
|
|
|
$
|
33
|
|
|
$
|
(38
|
)
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Premiums
|
|
|
|
|
|
|
||||||
Direct premiums
|
|
$
|
39,595
|
|
|
$
|
37,975
|
|
|
$
|
37,044
|
|
Reinsurance assumed
|
|
1,773
|
|
|
1,363
|
|
|
1,382
|
|
|||
Reinsurance ceded
|
|
(2,376
|
)
|
|
(2,136
|
)
|
|
(2,023
|
)
|
|||
Net premiums
|
|
$
|
38,992
|
|
|
$
|
37,202
|
|
|
$
|
36,403
|
|
Universal life and investment-type product policy fees
|
|
|
|
|
|
|
||||||
Direct universal life and investment-type product policy fees
|
|
$
|
5,978
|
|
|
$
|
5,884
|
|
|
$
|
5,952
|
|
Reinsurance assumed
|
|
83
|
|
|
96
|
|
|
105
|
|
|||
Reinsurance ceded
|
|
(551
|
)
|
|
(497
|
)
|
|
(487
|
)
|
|||
Net universal life and investment-type product policy fees
|
|
$
|
5,510
|
|
|
$
|
5,483
|
|
|
$
|
5,570
|
|
Policyholder benefits and claims
|
|
|
|
|
|
|
||||||
Direct policyholder benefits and claims
|
|
$
|
39,354
|
|
|
$
|
37,186
|
|
|
$
|
36,143
|
|
Reinsurance assumed
|
|
1,388
|
|
|
1,085
|
|
|
984
|
|
|||
Reinsurance ceded
|
|
(2,429
|
)
|
|
(1,913
|
)
|
|
(1,983
|
)
|
|||
Net policyholder benefits and claims
|
|
$
|
38,313
|
|
|
$
|
36,358
|
|
|
$
|
35,144
|
|
Other expenses
|
|
|
|
|
|
|
||||||
Direct other expenses
|
|
$
|
13,610
|
|
|
$
|
13,958
|
|
|
$
|
14,934
|
|
Reinsurance assumed
|
|
246
|
|
|
169
|
|
|
146
|
|
|||
Reinsurance ceded
|
|
(235
|
)
|
|
(378
|
)
|
|
(303
|
)
|
|||
Net other expenses
|
|
$
|
13,621
|
|
|
$
|
13,749
|
|
|
$
|
14,777
|
|
|
|
December 31,
|
||||||||||||||||||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||||||||||||||||||
|
|
Direct
|
|
Assumed
|
|
Ceded
|
|
Total
Balance Sheet |
|
Direct
|
|
Assumed
|
|
Ceded
|
|
Total
Balance Sheet |
||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Premiums, reinsurance and other receivables
|
|
$
|
6,300
|
|
|
$
|
866
|
|
|
$
|
11,257
|
|
|
$
|
18,423
|
|
|
$
|
5,927
|
|
|
$
|
543
|
|
|
$
|
8,975
|
|
|
$
|
15,445
|
|
Deferred policy acquisition costs and value of business acquired
|
|
18,350
|
|
|
398
|
|
|
(329
|
)
|
|
18,419
|
|
|
17,878
|
|
|
16
|
|
|
(304
|
)
|
|
17,590
|
|
||||||||
Total assets
|
|
$
|
24,650
|
|
|
$
|
1,264
|
|
|
$
|
10,928
|
|
|
$
|
36,842
|
|
|
$
|
23,805
|
|
|
$
|
559
|
|
|
$
|
8,671
|
|
|
$
|
33,035
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Future policy benefits
|
|
$
|
174,694
|
|
|
$
|
3,280
|
|
|
$
|
—
|
|
|
$
|
177,974
|
|
|
$
|
165,121
|
|
|
$
|
1,515
|
|
|
$
|
—
|
|
|
$
|
166,636
|
|
Policyholder account balances
|
|
182,226
|
|
|
293
|
|
|
(1
|
)
|
|
182,518
|
|
|
171,961
|
|
|
527
|
|
|
(2
|
)
|
|
172,486
|
|
||||||||
Other policy-related balances
|
|
14,962
|
|
|
520
|
|
|
33
|
|
|
15,515
|
|
|
13,071
|
|
|
324
|
|
|
7
|
|
|
13,402
|
|
||||||||
Other liabilities
|
|
17,077
|
|
|
1,896
|
|
|
5,009
|
|
|
23,982
|
|
|
18,815
|
|
|
405
|
|
|
4,515
|
|
|
23,735
|
|
||||||||
Total liabilities
|
|
$
|
388,959
|
|
|
$
|
5,989
|
|
|
$
|
5,041
|
|
|
$
|
399,989
|
|
|
$
|
368,968
|
|
|
$
|
2,771
|
|
|
$
|
4,520
|
|
|
$
|
376,259
|
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
Closed Block Liabilities
|
|
|
|
|
||||
Future policy benefits
|
|
$
|
40,463
|
|
|
$
|
40,834
|
|
Other policy-related balances
|
|
222
|
|
|
257
|
|
||
Policyholder dividends payable
|
|
437
|
|
|
443
|
|
||
Policyholder dividend obligation
|
|
2,121
|
|
|
1,931
|
|
||
Current income tax payable
|
|
—
|
|
|
4
|
|
||
Other liabilities
|
|
212
|
|
|
196
|
|
||
Total closed block liabilities
|
|
43,455
|
|
|
43,665
|
|
||
Assets Designated to the Closed Block
|
|
|
|
|
||||
Investments:
|
|
|
|
|
||||
Fixed maturity securities available-for-sale, at estimated fair value
|
|
27,904
|
|
|
27,220
|
|
||
Equity securities available-for-sale, at estimated fair value
|
|
70
|
|
|
100
|
|
||
Mortgage loans
|
|
5,878
|
|
|
5,935
|
|
||
Policy loans
|
|
4,548
|
|
|
4,553
|
|
||
Real estate and real estate joint ventures
|
|
613
|
|
|
655
|
|
||
Other invested assets
|
|
731
|
|
|
1,246
|
|
||
Total investments
|
|
39,744
|
|
|
39,709
|
|
||
Accrued investment income
|
|
477
|
|
|
467
|
|
||
Premiums, reinsurance and other receivables; cash and cash equivalents
|
|
14
|
|
|
86
|
|
||
Current income tax recoverable
|
|
35
|
|
|
—
|
|
||
Deferred income tax assets
|
|
36
|
|
|
177
|
|
||
Total assets designated to the closed block
|
|
40,306
|
|
|
40,439
|
|
||
Excess of closed block liabilities over assets designated to the closed block
|
|
3,149
|
|
|
3,226
|
|
||
Amounts included in AOCI:
|
|
|
|
|
||||
Unrealized investment gains (losses), net of income tax
|
|
1,863
|
|
|
1,517
|
|
||
Unrealized gains (losses) on derivatives, net of income tax
|
|
(7
|
)
|
|
95
|
|
||
Allocated to policyholder dividend obligation, net of income tax
|
|
(1,379
|
)
|
|
(1,255
|
)
|
||
Total amounts included in AOCI
|
|
477
|
|
|
357
|
|
||
Maximum future earnings to be recognized from closed block assets and liabilities
|
|
$
|
3,626
|
|
|
$
|
3,583
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Balance at January 1,
|
|
$
|
1,931
|
|
|
$
|
1,783
|
|
|
$
|
3,155
|
|
Change in unrealized investment and derivative gains (losses)
|
|
190
|
|
|
148
|
|
|
(1,372
|
)
|
|||
Balance at December 31,
|
|
$
|
2,121
|
|
|
$
|
1,931
|
|
|
$
|
1,783
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Revenues
|
|
|
|
|
|
|
||||||
Premiums
|
|
$
|
1,736
|
|
|
$
|
1,804
|
|
|
$
|
1,850
|
|
Net investment income
|
|
1,818
|
|
|
1,902
|
|
|
1,982
|
|
|||
Net investment gains (losses)
|
|
1
|
|
|
(10
|
)
|
|
(23
|
)
|
|||
Net derivative gains (losses)
|
|
(32
|
)
|
|
25
|
|
|
27
|
|
|||
Total revenues
|
|
3,523
|
|
|
3,721
|
|
|
3,836
|
|
|||
Expenses
|
|
|
|
|
|
|
||||||
Policyholder benefits and claims
|
|
2,453
|
|
|
2,563
|
|
|
2,564
|
|
|||
Policyholder dividends
|
|
976
|
|
|
953
|
|
|
1,015
|
|
|||
Other expenses
|
|
125
|
|
|
133
|
|
|
143
|
|
|||
Total expenses
|
|
3,554
|
|
|
3,649
|
|
|
3,722
|
|
|||
Revenues, net of expenses before provision for income tax expense (benefit)
|
|
(31
|
)
|
|
72
|
|
|
114
|
|
|||
Provision for income tax expense (benefit)
|
|
12
|
|
|
24
|
|
|
41
|
|
|||
Revenues, net of expenses and provision for income tax expense (benefit)
|
|
$
|
(43
|
)
|
|
$
|
48
|
|
|
$
|
73
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||||||||
|
Cost or
Amortized
Cost
|
|
Gross Unrealized
|
|
Estimated
Fair
Value
|
|
Cost or
Amortized
Cost
|
|
Gross Unrealized
|
|
Estimated
Fair
Value
|
||||||||||||||||||||||||||||
|
|
Gains
|
|
Temporary
Losses |
|
OTTI
Losses (1) |
|
Gains
|
|
Temporary
Losses |
|
OTTI
Losses (1) |
|
||||||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
U.S. corporate
|
$
|
76,005
|
|
|
$
|
7,007
|
|
|
$
|
351
|
|
|
$
|
—
|
|
|
$
|
82,661
|
|
|
$
|
73,280
|
|
|
$
|
6,027
|
|
|
$
|
764
|
|
|
$
|
—
|
|
|
$
|
78,543
|
|
Foreign government
|
55,351
|
|
|
6,495
|
|
|
312
|
|
|
—
|
|
|
61,534
|
|
|
49,864
|
|
|
6,485
|
|
|
373
|
|
|
—
|
|
|
55,976
|
|
||||||||||
Foreign corporate
|
52,409
|
|
|
3,836
|
|
|
676
|
|
|
—
|
|
|
55,569
|
|
|
49,308
|
|
|
2,926
|
|
|
1,572
|
|
|
(1
|
)
|
|
50,663
|
|
||||||||||
U.S. government and agency
|
43,446
|
|
|
4,227
|
|
|
279
|
|
|
—
|
|
|
47,394
|
|
|
41,294
|
|
|
3,682
|
|
|
543
|
|
|
—
|
|
|
44,433
|
|
||||||||||
RMBS
|
27,846
|
|
|
1,145
|
|
|
233
|
|
|
(42
|
)
|
|
28,800
|
|
|
28,393
|
|
|
1,039
|
|
|
410
|
|
|
(10
|
)
|
|
29,032
|
|
||||||||||
State and political subdivision
|
10,752
|
|
|
1,717
|
|
|
13
|
|
|
1
|
|
|
12,455
|
|
|
10,977
|
|
|
1,340
|
|
|
85
|
|
|
1
|
|
|
12,231
|
|
||||||||||
ABS
|
12,213
|
|
|
116
|
|
|
39
|
|
|
(1
|
)
|
|
12,291
|
|
|
11,266
|
|
|
90
|
|
|
128
|
|
|
3
|
|
|
11,225
|
|
||||||||||
CMBS
|
8,047
|
|
|
222
|
|
|
42
|
|
|
—
|
|
|
8,227
|
|
|
7,294
|
|
|
237
|
|
|
71
|
|
|
—
|
|
|
7,460
|
|
||||||||||
Total fixed maturity securities
|
$
|
286,069
|
|
|
$
|
24,765
|
|
|
$
|
1,945
|
|
|
$
|
(42
|
)
|
|
$
|
308,931
|
|
|
$
|
271,676
|
|
|
$
|
21,826
|
|
|
$
|
3,946
|
|
|
$
|
(7
|
)
|
|
$
|
289,563
|
|
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Common stock
|
$
|
1,687
|
|
|
$
|
364
|
|
|
$
|
16
|
|
|
$
|
—
|
|
|
$
|
2,035
|
|
|
$
|
1,827
|
|
|
$
|
464
|
|
|
$
|
13
|
|
|
$
|
—
|
|
|
$
|
2,278
|
|
Non-redeemable preferred stock
|
453
|
|
|
29
|
|
|
4
|
|
|
—
|
|
|
478
|
|
|
637
|
|
|
19
|
|
|
40
|
|
|
—
|
|
|
616
|
|
||||||||||
Total equity securities
|
$
|
2,140
|
|
|
$
|
393
|
|
|
$
|
20
|
|
|
$
|
—
|
|
|
$
|
2,513
|
|
|
$
|
2,464
|
|
|
$
|
483
|
|
|
$
|
53
|
|
|
$
|
—
|
|
|
$
|
2,894
|
|
(1)
|
Noncredit OTTI losses included in AOCI in an unrealized gain position are due to increases in estimated fair value subsequent to initial recognition of noncredit losses on such securities. See also “— Net Unrealized Investment Gains (Losses).”
|
|
Due in One Year or Less
|
|
Due After One Year Through Five Years
|
|
Due After Five Years Through Ten Years
|
|
Due After Ten Years
|
|
Structured Securities
|
|
Total Fixed Maturity Securities
|
||||||||||||
|
(In millions)
|
||||||||||||||||||||||
Amortized cost
|
$
|
11,378
|
|
|
$
|
62,647
|
|
|
$
|
61,043
|
|
|
$
|
102,895
|
|
|
$
|
48,106
|
|
|
$
|
286,069
|
|
Estimated fair value
|
$
|
11,437
|
|
|
$
|
65,423
|
|
|
$
|
64,499
|
|
|
$
|
118,254
|
|
|
$
|
49,318
|
|
|
$
|
308,931
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||||||||||
|
Less than 12 Months
|
|
Equal to or Greater than 12 Months
|
|
Less than 12 Months
|
|
Equal to or Greater than 12 Months
|
||||||||||||||||||||||||
|
Estimated Fair Value
|
|
Gross Unrealized Losses
|
|
Estimated Fair Value
|
|
Gross Unrealized Losses
|
|
Estimated Fair Value
|
|
Gross Unrealized Losses
|
|
Estimated Fair Value
|
|
Gross Unrealized Losses
|
||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
U.S. corporate
|
$
|
5,604
|
|
|
$
|
92
|
|
|
$
|
4,115
|
|
|
$
|
259
|
|
|
$
|
11,471
|
|
|
$
|
466
|
|
|
$
|
2,938
|
|
|
$
|
298
|
|
Foreign government
|
4,234
|
|
|
83
|
|
|
3,251
|
|
|
229
|
|
|
5,955
|
|
|
260
|
|
|
918
|
|
|
113
|
|
||||||||
Foreign corporate
|
4,422
|
|
|
99
|
|
|
6,802
|
|
|
577
|
|
|
10,147
|
|
|
573
|
|
|
5,493
|
|
|
998
|
|
||||||||
U.S. government and agency
|
18,273
|
|
|
93
|
|
|
3,560
|
|
|
186
|
|
|
9,104
|
|
|
523
|
|
|
141
|
|
|
20
|
|
||||||||
RMBS
|
6,359
|
|
|
50
|
|
|
4,159
|
|
|
141
|
|
|
9,449
|
|
|
291
|
|
|
1,800
|
|
|
109
|
|
||||||||
State and political subdivision
|
182
|
|
|
2
|
|
|
346
|
|
|
12
|
|
|
1,747
|
|
|
80
|
|
|
56
|
|
|
6
|
|
||||||||
ABS
|
1,695
|
|
|
7
|
|
|
729
|
|
|
31
|
|
|
2,224
|
|
|
28
|
|
|
2,328
|
|
|
103
|
|
||||||||
CMBS
|
1,174
|
|
|
9
|
|
|
413
|
|
|
33
|
|
|
998
|
|
|
22
|
|
|
564
|
|
|
49
|
|
||||||||
Total fixed maturity securities
|
$
|
41,943
|
|
|
$
|
435
|
|
|
$
|
23,375
|
|
|
$
|
1,468
|
|
|
$
|
51,095
|
|
|
$
|
2,243
|
|
|
$
|
14,238
|
|
|
$
|
1,696
|
|
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Common stock
|
$
|
126
|
|
|
$
|
16
|
|
|
$
|
4
|
|
|
$
|
—
|
|
|
$
|
105
|
|
|
$
|
13
|
|
|
$
|
11
|
|
|
$
|
—
|
|
Non-redeemable preferred stock
|
42
|
|
|
1
|
|
|
41
|
|
|
3
|
|
|
139
|
|
|
7
|
|
|
125
|
|
|
33
|
|
||||||||
Total equity securities
|
$
|
168
|
|
|
$
|
17
|
|
|
$
|
45
|
|
|
$
|
3
|
|
|
$
|
244
|
|
|
$
|
20
|
|
|
$
|
136
|
|
|
$
|
33
|
|
Total number of securities in an unrealized loss position
|
2,651
|
|
|
|
|
1,965
|
|
|
|
|
3,580
|
|
|
|
|
1,307
|
|
|
|
•
|
The Company calculates the recovery value by performing a discounted cash flow analysis based on the present value of future cash flows. The discount rate is generally the effective interest rate of the security prior to impairment.
|
•
|
When determining collectability and the period over which value is expected to recover, the Company applies considerations utilized in its overall impairment evaluation process which incorporates information regarding the specific security, fundamentals of the industry and geographic area in which the security issuer operates, and overall macroeconomic conditions. Projected future cash flows are estimated using assumptions derived from management’s best estimates of likely scenario-based outcomes after giving consideration to a variety of variables that include, but are not limited to: payment terms of the security; the likelihood that the issuer can service the interest and principal payments; the quality and amount of any credit enhancements; the security’s position within the capital structure of the issuer; possible corporate restructurings or asset sales by the issuer; and changes to the rating of the security or the issuer by rating agencies.
|
•
|
Additional considerations are made when assessing the unique features that apply to certain Structured Securities including, but not limited to: the quality of underlying collateral, expected prepayment speeds, current and forecasted loss severity, consideration of the payment terms of the underlying loans or assets backing a particular security, and the payment priority within the tranche structure of the security.
|
•
|
When determining the amount of the credit loss for U.S. and foreign corporate securities, foreign government securities and state and political subdivision securities, the estimated fair value is considered the recovery value when available information does not indicate that another value is more appropriate. When information is identified that indicates a recovery value other than estimated fair value, management considers in the determination of recovery value the same considerations utilized in its overall impairment evaluation process as described above, as well as any private and public sector programs to restructure such securities.
|
|
|
December 31,
|
||||||||||||
|
|
2017
|
|
2016
|
||||||||||
|
|
Carrying
Value |
|
% of
Total |
|
Carrying
Value |
|
% of
Total |
||||||
|
|
(Dollars in millions)
|
||||||||||||
Mortgage loans:
|
|
|
|
|
|
|
|
|
||||||
Commercial
|
|
$
|
44,375
|
|
|
64.6
|
%
|
|
$
|
41,512
|
|
|
63.7
|
%
|
Agricultural
|
|
13,014
|
|
|
18.9
|
|
|
12,564
|
|
|
19.3
|
|
||
Residential
|
|
11,136
|
|
|
16.2
|
|
|
10,829
|
|
|
16.6
|
|
||
Subtotal (1)
|
|
68,525
|
|
|
99.7
|
|
|
64,905
|
|
|
99.6
|
|
||
Valuation allowances
|
|
(314
|
)
|
|
(0.5
|
)
|
|
(304
|
)
|
|
(0.5
|
)
|
||
Subtotal mortgage loans, net
|
|
68,211
|
|
|
99.2
|
|
|
64,601
|
|
|
99.1
|
|
||
Residential — FVO
|
|
520
|
|
|
0.8
|
|
|
566
|
|
|
0.9
|
|
||
Total mortgage loans, net
|
|
$
|
68,731
|
|
|
100.0
|
%
|
|
$
|
65,167
|
|
|
100.0
|
%
|
(1)
|
Purchases of mortgage loans, primarily residential, were
$3.1 billion
and
$2.9 billion
for the years ended December 31,
2017
and
2016
, respectively.
|
|
Evaluated Individually for Credit Losses
|
|
Evaluated Collectively for Credit Losses
|
|
Impaired Loans
|
||||||||||||||||||||||||||||||
|
Impaired Loans with a Valuation Allowance
|
|
Impaired Loans without a Valuation Allowance
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
Unpaid
Principal
Balance
|
|
Recorded
Investment
|
|
Valuation
Allowances |
|
Unpaid
Principal
Balance
|
|
Recorded
Investment |
|
Recorded
Investment |
|
Valuation
Allowances |
|
Carrying
Value |
|
Average
Recorded Investment |
||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||||
December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Commercial
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
44,375
|
|
|
$
|
214
|
|
|
$
|
—
|
|
|
$
|
5
|
|
Agricultural
|
22
|
|
|
21
|
|
|
2
|
|
|
27
|
|
|
27
|
|
|
12,966
|
|
|
39
|
|
|
46
|
|
|
32
|
|
|||||||||
Residential
|
—
|
|
|
—
|
|
|
—
|
|
|
358
|
|
|
324
|
|
|
10,812
|
|
|
59
|
|
|
324
|
|
|
285
|
|
|||||||||
Total
|
$
|
22
|
|
|
$
|
21
|
|
|
$
|
2
|
|
|
$
|
385
|
|
|
$
|
351
|
|
|
$
|
68,153
|
|
|
$
|
312
|
|
|
$
|
370
|
|
|
$
|
322
|
|
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
Commercial
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
12
|
|
|
$
|
12
|
|
|
$
|
41,500
|
|
|
$
|
202
|
|
|
$
|
12
|
|
|
$
|
90
|
|
Agricultural
|
11
|
|
|
10
|
|
|
1
|
|
|
27
|
|
|
27
|
|
|
12,527
|
|
|
38
|
|
|
36
|
|
|
49
|
|
|||||||||
Residential
|
—
|
|
|
—
|
|
|
—
|
|
|
265
|
|
|
241
|
|
|
10,588
|
|
|
63
|
|
|
241
|
|
|
188
|
|
|||||||||
Total
|
$
|
11
|
|
|
$
|
10
|
|
|
$
|
1
|
|
|
$
|
304
|
|
|
$
|
280
|
|
|
$
|
64,615
|
|
|
$
|
303
|
|
|
$
|
289
|
|
|
$
|
327
|
|
|
Commercial
|
|
Agricultural
|
|
Residential
|
|
Total
|
||||||||
|
(In millions)
|
||||||||||||||
Balance at January 1, 2015
|
$
|
202
|
|
|
$
|
35
|
|
|
$
|
42
|
|
|
$
|
279
|
|
Provision (release)
|
5
|
|
|
2
|
|
|
30
|
|
|
37
|
|
||||
Charge-offs, net of recoveries
|
(19
|
)
|
|
—
|
|
|
(16
|
)
|
|
(35
|
)
|
||||
Balance at December 31, 2015
|
188
|
|
|
37
|
|
|
56
|
|
|
281
|
|
||||
Provision (release) (1)
|
157
|
|
|
3
|
|
|
23
|
|
|
183
|
|
||||
Charge-offs, net of recoveries (1)
|
(143
|
)
|
|
(1
|
)
|
|
(16
|
)
|
|
(160
|
)
|
||||
Balance at December 31, 2016
|
202
|
|
|
39
|
|
|
63
|
|
|
304
|
|
||||
Provision (release)
|
12
|
|
|
4
|
|
|
8
|
|
|
24
|
|
||||
Charge-offs, net of recoveries
|
—
|
|
|
(2
|
)
|
|
(12
|
)
|
|
(14
|
)
|
||||
Balance at December 31, 2017
|
$
|
214
|
|
|
$
|
41
|
|
|
$
|
59
|
|
|
$
|
314
|
|
(1)
|
In connection with an acquisition in 2010, certain impaired commercial mortgage loans were acquired and accordingly, were not originated by the Company. Such commercial mortgage loans have been accounted for as purchased credit impaired (“PCI”) commercial mortgage loans. Decreases in cash flows expected to be collected on PCI commercial mortgage loans can result in provisions for losses on mortgage loans. For the year ended December 31,
2016
, in connection with the maturity of an acquired PCI commercial mortgage loan, an increase to the commercial mortgage loan valuation allowance of
$143 million
was recorded and charged-off upon maturity. The Company has recovered a substantial portion of the loss on the loan incurred through an indemnification agreement entered into in connection with the acquisition in 2010
.
|
|
Recorded Investment
|
|
Estimated
Fair Value |
|
% of
Total |
||||||||||||||||||||
|
Debt Service Coverage Ratios
|
|
Total
|
|
% of
Total
|
|
|||||||||||||||||||
|
> 1.20x
|
|
1.00x - 1.20x
|
|
< 1.00x
|
|
|||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||
December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Loan-to-value ratios:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Less than 65%
|
$
|
37,073
|
|
|
$
|
1,483
|
|
|
$
|
201
|
|
|
$
|
38,757
|
|
|
87.4
|
%
|
|
$
|
39,528
|
|
|
87.7
|
%
|
65% to 75%
|
4,183
|
|
|
98
|
|
|
119
|
|
|
4,400
|
|
|
9.9
|
|
|
4,408
|
|
|
9.8
|
|
|||||
76% to 80%
|
235
|
|
|
210
|
|
|
57
|
|
|
502
|
|
|
1.1
|
|
|
476
|
|
|
1.0
|
|
|||||
Greater than 80%
|
401
|
|
|
168
|
|
|
147
|
|
|
716
|
|
|
1.6
|
|
|
672
|
|
|
1.5
|
|
|||||
Total
|
$
|
41,892
|
|
|
$
|
1,959
|
|
|
$
|
524
|
|
|
$
|
44,375
|
|
|
100.0
|
%
|
|
$
|
45,084
|
|
|
100.0
|
%
|
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Loan-to-value ratios:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Less than 65%
|
$
|
36,067
|
|
|
$
|
1,077
|
|
|
$
|
707
|
|
|
$
|
37,851
|
|
|
91.2
|
%
|
|
$
|
38,237
|
|
|
91.5
|
%
|
65% to 75%
|
3,044
|
|
|
—
|
|
|
202
|
|
|
3,246
|
|
|
7.8
|
|
|
3,185
|
|
|
7.6
|
|
|||||
76% to 80%
|
195
|
|
|
—
|
|
|
—
|
|
|
195
|
|
|
0.5
|
|
|
182
|
|
|
0.4
|
|
|||||
Greater than 80%
|
118
|
|
|
27
|
|
|
75
|
|
|
220
|
|
|
0.5
|
|
|
213
|
|
|
0.5
|
|
|||||
Total
|
$
|
39,424
|
|
|
$
|
1,104
|
|
|
$
|
984
|
|
|
$
|
41,512
|
|
|
100.0
|
%
|
|
$
|
41,817
|
|
|
100.0
|
%
|
|
December 31,
|
||||||||||||
|
2017
|
|
2016
|
||||||||||
|
Recorded
Investment
|
|
% of
Total
|
|
Recorded
Investment
|
|
% of
Total
|
||||||
|
(Dollars in millions)
|
||||||||||||
Loan-to-value ratios:
|
|
|
|
|
|
|
|
||||||
Less than 65%
|
$
|
12,347
|
|
|
94.9
|
%
|
|
$
|
12,023
|
|
|
95.7
|
%
|
65% to 75%
|
618
|
|
|
4.7
|
|
|
436
|
|
|
3.5
|
|
||
76% to 80%
|
40
|
|
|
0.3
|
|
|
17
|
|
|
0.1
|
|
||
Greater than 80%
|
9
|
|
|
0.1
|
|
|
88
|
|
|
0.7
|
|
||
Total
|
$
|
13,014
|
|
|
100.0
|
%
|
|
$
|
12,564
|
|
|
100.0
|
%
|
|
December 31,
|
||||||||||||
|
2017
|
|
2016
|
||||||||||
|
Recorded
Investment |
|
% of
Total |
|
Recorded
Investment |
|
% of
Total |
||||||
|
(Dollars in millions)
|
||||||||||||
Performance indicators:
|
|
|
|
|
|
|
|
||||||
Performing
|
$
|
10,622
|
|
|
95.4
|
%
|
|
$
|
10,448
|
|
|
96.5
|
%
|
Nonperforming
|
514
|
|
|
4.6
|
|
|
381
|
|
|
3.5
|
|
||
Total
|
$
|
11,136
|
|
|
100.0
|
%
|
|
$
|
10,829
|
|
|
100.0
|
%
|
|
Past Due
|
|
Greater than 90 Days Past Due and Still
Accruing Interest
|
|
Nonaccrual
|
||||||||||||||||||
|
December 31, 2017
|
|
December 31, 2016
|
|
December 31, 2017
|
|
December 31, 2016
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||
|
(In millions)
|
||||||||||||||||||||||
Commercial
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Agricultural
|
134
|
|
|
127
|
|
|
125
|
|
|
104
|
|
|
36
|
|
|
23
|
|
||||||
Residential
|
514
|
|
|
381
|
|
|
33
|
|
|
37
|
|
|
481
|
|
|
344
|
|
||||||
Total
|
$
|
648
|
|
|
$
|
511
|
|
|
$
|
158
|
|
|
$
|
144
|
|
|
$
|
517
|
|
|
$
|
367
|
|
|
December 31,
|
||||||||||||||
|
2017
|
|
2016
|
||||||||||||
|
Leveraged
Leases
|
|
Direct
Financing
Leases
|
|
Leveraged
Leases
|
|
Direct
Financing
Leases
|
||||||||
|
(In millions)
|
||||||||||||||
Rental receivables, net
|
$
|
912
|
|
|
$
|
2,303
|
|
|
$
|
1,172
|
|
|
$
|
1,683
|
|
Estimated residual values
|
838
|
|
|
42
|
|
|
952
|
|
|
71
|
|
||||
Subtotal
|
1,750
|
|
|
2,345
|
|
|
2,124
|
|
|
1,754
|
|
||||
Unearned income
|
(472
|
)
|
|
(1,022
|
)
|
|
(603
|
)
|
|
(639
|
)
|
||||
Investment in leases, net of non-recourse debt
|
$
|
1,278
|
|
|
$
|
1,323
|
|
|
$
|
1,521
|
|
|
$
|
1,115
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Fixed maturity securities
|
|
$
|
22,645
|
|
|
$
|
20,330
|
|
|
$
|
18,158
|
|
Fixed maturity securities with noncredit OTTI losses included in AOCI
|
|
41
|
|
|
8
|
|
|
(76
|
)
|
|||
Total fixed maturity securities
|
|
22,686
|
|
|
20,338
|
|
|
18,082
|
|
|||
Equity securities
|
|
421
|
|
|
485
|
|
|
422
|
|
|||
Derivatives
|
|
1,453
|
|
|
2,923
|
|
|
2,350
|
|
|||
Other
|
|
46
|
|
|
23
|
|
|
287
|
|
|||
Subtotal
|
|
24,606
|
|
|
23,769
|
|
|
21,141
|
|
|||
Amounts allocated from:
|
|
|
|
|
|
|
||||||
Future policy benefits
|
|
(77
|
)
|
|
(1,114
|
)
|
|
(163
|
)
|
|||
DAC and VOBA related to noncredit OTTI losses recognized in AOCI
|
|
—
|
|
|
(3
|
)
|
|
—
|
|
|||
DAC, VOBA and DSI
|
|
(1,768
|
)
|
|
(1,430
|
)
|
|
(1,273
|
)
|
|||
Policyholder dividend obligation
|
|
(2,121
|
)
|
|
(1,931
|
)
|
|
(1,783
|
)
|
|||
Subtotal
|
|
(3,966
|
)
|
|
(4,478
|
)
|
|
(3,219
|
)
|
|||
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI
|
|
(12
|
)
|
|
(1
|
)
|
|
27
|
|
|||
Deferred income tax benefit (expense)
|
|
(6,958
|
)
|
|
(6,634
|
)
|
|
(6,149
|
)
|
|||
Net unrealized investment gains (losses)
|
|
13,670
|
|
|
12,656
|
|
|
11,800
|
|
|||
Net unrealized investment gains (losses) attributable to noncontrolling interests
|
|
(8
|
)
|
|
(6
|
)
|
|
(31
|
)
|
|||
Net unrealized investment gains (losses) attributable to MetLife, Inc.
|
|
$
|
13,662
|
|
|
$
|
12,650
|
|
|
$
|
11,769
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Balance at January 1,
|
|
$
|
12,650
|
|
|
$
|
11,769
|
|
|
$
|
16,300
|
|
Fixed maturity securities on which noncredit OTTI losses have been recognized
|
|
33
|
|
|
84
|
|
|
36
|
|
|||
Unrealized investment gains (losses) during the year
|
|
804
|
|
|
2,544
|
|
|
(11,668
|
)
|
|||
Unrealized investment gains (losses) relating to:
|
|
|
|
|
|
|
||||||
Future policy benefits
|
|
1,037
|
|
|
(951
|
)
|
|
2,723
|
|
|||
DAC and VOBA related to noncredit OTTI losses recognized in AOCI
|
|
3
|
|
|
(3
|
)
|
|
4
|
|
|||
DAC, VOBA and DSI
|
|
(338
|
)
|
|
(157
|
)
|
|
673
|
|
|||
Policyholder dividend obligation
|
|
(190
|
)
|
|
(148
|
)
|
|
1,372
|
|
|||
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI
|
|
(11
|
)
|
|
(28
|
)
|
|
(15
|
)
|
|||
Deferred income tax benefit (expense)
|
|
(324
|
)
|
|
(485
|
)
|
|
2,342
|
|
|||
Net unrealized investment gains (losses)
|
|
13,664
|
|
|
12,625
|
|
|
11,767
|
|
|||
Net unrealized investment gains (losses) attributable to noncontrolling interests
|
|
(2
|
)
|
|
25
|
|
|
2
|
|
|||
Balance at December 31,
|
|
$
|
13,662
|
|
|
$
|
12,650
|
|
|
$
|
11,769
|
|
Change in net unrealized investment gains (losses)
|
|
$
|
1,014
|
|
|
$
|
856
|
|
|
$
|
(4,533
|
)
|
Change in net unrealized investment gains (losses) attributable to noncontrolling interests
|
|
(2
|
)
|
|
25
|
|
|
2
|
|
|||
Change in net unrealized investment gains (losses) attributable to MetLife, Inc.
|
|
$
|
1,012
|
|
|
$
|
881
|
|
|
$
|
(4,531
|
)
|
|
December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Securities on loan: (1)
|
|
|
|
||||
Amortized cost
|
$
|
17,801
|
|
|
$
|
18,798
|
|
Estimated fair value
|
$
|
19,028
|
|
|
$
|
19,753
|
|
Cash collateral received from counterparties (2)
|
$
|
19,417
|
|
|
$
|
20,114
|
|
Security collateral received from counterparties (3)
|
$
|
19
|
|
|
$
|
20
|
|
Reinvestment portfolio — estimated fair value
|
$
|
19,508
|
|
|
$
|
20,133
|
|
(1)
|
Included within fixed maturity securities.
|
(2)
|
Included within payables for collateral under securities loaned and other transactions.
|
(3)
|
Security collateral received from counterparties may not be sold or re-pledged, unless the counterparty is in default, and is not reflected on the consolidated financial statements.
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||||||||||
|
Remaining Tenor of Securities Lending Agreements
|
|
|
|
Remaining Tenor of Securities Lending Agreements
|
|
|
||||||||||||||||||||||||
|
Open (1)
|
|
1 Month
or Less
|
|
Over
1 to 6
Months
|
|
Total
|
|
Open (1)
|
|
1 Month
or Less
|
|
Over
1 to 6
Months
|
|
Total
|
||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||
Cash collateral liability by loaned security type:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
U.S. government and agency
|
$
|
3,753
|
|
|
$
|
6,031
|
|
|
$
|
8,607
|
|
|
$
|
18,391
|
|
|
$
|
4,480
|
|
|
$
|
6,496
|
|
|
$
|
8,383
|
|
|
$
|
19,359
|
|
Foreign government
|
—
|
|
|
192
|
|
|
834
|
|
|
1,026
|
|
|
—
|
|
|
569
|
|
|
143
|
|
|
712
|
|
||||||||
U.S. corporate
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
43
|
|
|
—
|
|
|
43
|
|
||||||||
Total
|
$
|
3,753
|
|
|
$
|
6,223
|
|
|
$
|
9,441
|
|
|
$
|
19,417
|
|
|
$
|
4,480
|
|
|
$
|
7,108
|
|
|
$
|
8,526
|
|
|
$
|
20,114
|
|
(1)
|
The related loaned security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||
|
|
(In millions)
|
||||||
Securities on loan: (1)
|
|
|
|
|
||||
Amortized cost
|
|
$
|
994
|
|
|
$
|
98
|
|
Estimated fair value
|
|
$
|
1,141
|
|
|
$
|
113
|
|
Cash collateral received from counterparties (2)
|
|
$
|
1,102
|
|
|
$
|
102
|
|
Reinvestment portfolio — estimated fair value
|
|
$
|
1,102
|
|
|
$
|
100
|
|
(1)
|
Included within fixed maturity securities, short-term investments and cash equivalents.
|
(2)
|
Included within payables for collateral under securities loaned and other transactions and other liabilities.
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||
|
|
Remaining Tenor of
Repurchase Agreements
|
|
|
|
Remaining Tenor of
Repurchase Agreements
|
|
|
||||||||||||||||
|
|
1 Month
or Less
|
|
Over
1 to 6
Months
|
|
Total
|
|
1 Month
or Less
|
|
Over
1 to 6
Months
|
|
Total
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Cash collateral liability by loaned security type:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
U.S. government and agency
|
|
$
|
1,005
|
|
|
$
|
—
|
|
|
$
|
1,005
|
|
|
$
|
5
|
|
|
$
|
—
|
|
|
$
|
5
|
|
All other corporate and government
|
|
44
|
|
|
53
|
|
|
97
|
|
|
46
|
|
|
51
|
|
|
97
|
|
||||||
Total
|
|
$
|
1,049
|
|
|
$
|
53
|
|
|
$
|
1,102
|
|
|
$
|
51
|
|
|
$
|
51
|
|
|
$
|
102
|
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
Invested assets on deposit (regulatory deposits)
|
|
$
|
1,879
|
|
|
$
|
1,925
|
|
Invested assets held in trust (collateral financing arrangement and reinsurance agreements)
|
|
2,490
|
|
|
2,057
|
|
||
Invested assets pledged as collateral (1)
|
|
24,174
|
|
|
23,882
|
|
||
Total invested assets on deposit, held in trust and pledged as collateral
|
|
$
|
28,543
|
|
|
$
|
27,864
|
|
(1)
|
The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Note
4
), derivative transactions (see Note
9
), secured debt (see Note 12), and a collateral financing arrangement (see Note
13
).
|
|
December 31,
|
|
||||||
|
2017
|
|
2016
|
|
||||
|
Fixed Maturity Securities
|
|
||||||
|
(In millions)
|
|
||||||
Outstanding principal and interest balance (1)
|
$
|
4,763
|
|
|
$
|
5,624
|
|
|
Carrying value (2)
|
$
|
3,954
|
|
|
$
|
4,427
|
|
|
(1)
|
Represents the contractually required payments, which include contractual principal, whether or not currently due, and accrued interest.
|
(2)
|
Estimated fair value plus accrued interest.
|
|
Years Ended December 31,
|
|
||||||
|
2017
|
|
2016
|
|
||||
|
Fixed Maturity Securities
|
|
||||||
|
(In millions)
|
|||||||
Contractually required payments (including interest)
|
$
|
95
|
|
|
$
|
1,464
|
|
|
Cash flows expected to be collected (1)
|
$
|
73
|
|
|
$
|
1,338
|
|
|
Fair value of investments acquired
|
$
|
67
|
|
|
$
|
984
|
|
|
(1)
|
Represents undiscounted principal and interest cash flow expectations, at the date of acquisition.
|
|
Years Ended December 31,
|
|
||||||
|
2017
|
|
2016
|
|
||||
|
Fixed Maturity Securities
|
|
||||||
|
(In millions)
|
|||||||
Accretable yield, January 1,
|
$
|
1,733
|
|
|
$
|
1,780
|
|
|
Investments purchased
|
6
|
|
|
354
|
|
|
||
Accretion recognized in earnings
|
(281
|
)
|
|
(269
|
)
|
|
||
Disposals
|
(42
|
)
|
|
(2
|
)
|
|
||
Reclassification (to) from nonaccretable difference
|
104
|
|
|
(130
|
)
|
|
||
Accretable yield, December 31,
|
$
|
1,520
|
|
|
$
|
1,733
|
|
|
|
December 31,
|
||||||||||||||
|
2017
|
|
2016
|
||||||||||||
|
Total
Assets |
|
Total
Liabilities |
|
Total
Assets |
|
Total
Liabilities |
||||||||
|
(In millions)
|
||||||||||||||
Renewable energy partnership (1)
|
$
|
116
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Securitization entities (assets (primarily FVO securities) and liabilities (primarily debt)) (2)
|
7
|
|
|
6
|
|
|
9
|
|
|
12
|
|
||||
Other investments (3)
|
25
|
|
|
—
|
|
|
50
|
|
|
—
|
|
||||
Total
|
$
|
148
|
|
|
$
|
9
|
|
|
$
|
59
|
|
|
$
|
12
|
|
(1)
|
Assets of the renewable energy partnership, primarily consisting of other invested assets, were consolidated in earlier periods as the two investors are subsidiaries of MLIC and Brighthouse, respectively. As a result of the Separation and a reassessment in 2017, the renewable energy partnership was determined to be a consolidated VIE.
|
(2)
|
The Company consolidates entities that are structured as collateralized debt obligations. The assets of these entities can only be used to settle their respective liabilities, and under no circumstances is the Company liable for any principal or interest shortfalls should any arise.
|
(3)
|
Other investments is primarily comprised of other invested assets.
|
|
December 31,
|
||||||||||||||
|
2017
|
|
2016
|
||||||||||||
|
Carrying
Amount |
|
Maximum
Exposure to Loss (1) |
|
Carrying
Amount |
|
Maximum
Exposure to Loss (1) |
||||||||
|
(In millions)
|
||||||||||||||
Fixed maturity securities AFS:
|
|
|
|
|
|
|
|
||||||||
Structured Securities (2)
|
$
|
47,614
|
|
|
$
|
47,614
|
|
|
$
|
46,773
|
|
|
$
|
46,773
|
|
U.S. and foreign corporate
|
1,560
|
|
|
1,560
|
|
|
1,940
|
|
|
1,940
|
|
||||
Other limited partnership interests
|
4,834
|
|
|
8,543
|
|
|
4,714
|
|
|
8,990
|
|
||||
Other invested assets
|
2,291
|
|
|
2,625
|
|
|
2,206
|
|
|
2,777
|
|
||||
Other (3)
|
82
|
|
|
87
|
|
|
199
|
|
|
215
|
|
||||
Total
|
$
|
56,381
|
|
|
$
|
60,429
|
|
|
$
|
55,832
|
|
|
$
|
60,695
|
|
(1)
|
The maximum exposure to loss relating to fixed maturity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests and real estate joint ventures is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties of
$117 million
and
$150 million
at December 31,
2017
and
2016
, respectively. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee.
|
(2)
|
For these variable interests, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.
|
(3)
|
Other is primarily comprised of real estate joint ventures and a joint venture related loan.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Investment income:
|
|
|
|
|
|
||||||
Fixed maturity securities
|
$
|
11,497
|
|
|
$
|
11,721
|
|
|
$
|
11,809
|
|
Equity securities
|
129
|
|
|
121
|
|
|
124
|
|
|||
FVO securities — FVO general account securities (1)
|
68
|
|
|
37
|
|
|
21
|
|
|||
Mortgage loans
|
3,082
|
|
|
2,858
|
|
|
2,772
|
|
|||
Policy loans
|
517
|
|
|
511
|
|
|
525
|
|
|||
Real estate and real estate joint ventures
|
646
|
|
|
652
|
|
|
872
|
|
|||
Other limited partnership interests
|
798
|
|
|
478
|
|
|
535
|
|
|||
Cash, cash equivalents and short-term investments
|
228
|
|
|
153
|
|
|
140
|
|
|||
Operating joint ventures
|
28
|
|
|
33
|
|
|
25
|
|
|||
Other
|
192
|
|
|
248
|
|
|
200
|
|
|||
Subtotal
|
17,185
|
|
|
16,812
|
|
|
17,023
|
|
|||
Less: Investment expenses
|
1,122
|
|
|
972
|
|
|
1,082
|
|
|||
Subtotal, net
|
16,063
|
|
|
15,840
|
|
|
15,941
|
|
|||
FVO securities — FVO contractholder-directed unit-linked investments (1)
|
1,300
|
|
|
950
|
|
|
264
|
|
|||
Net investment income
|
$
|
17,363
|
|
|
$
|
16,790
|
|
|
$
|
16,205
|
|
(1)
|
Changes in estimated fair value subsequent to purchase for securities still held as of the end of the respective periods included in net investment income were principally from FVO contractholder-directed unit-linked investments, and were
$662 million
,
$427 million
and
($456) million
for the years ended
December 31, 2017
,
2016
, and
2015
, respectively.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Total gains (losses) on fixed maturity securities:
|
|
|
|
|
|
||||||
Total OTTI losses recognized — by sector and industry:
|
|
|
|
|
|
||||||
U.S. and foreign corporate securities — by industry:
|
|
|
|
|
|
||||||
Consumer
|
$
|
(4
|
)
|
|
$
|
—
|
|
|
$
|
(20
|
)
|
Industrial
|
—
|
|
|
(63
|
)
|
|
(2
|
)
|
|||
Utility
|
—
|
|
|
(21
|
)
|
|
(15
|
)
|
|||
Communications
|
—
|
|
|
(3
|
)
|
|
—
|
|
|||
Total U.S. and foreign corporate securities
|
(4
|
)
|
|
(87
|
)
|
|
(37
|
)
|
|||
ABS
|
(3
|
)
|
|
(2
|
)
|
|
—
|
|
|||
RMBS
|
—
|
|
|
(18
|
)
|
|
(16
|
)
|
|||
State and political subdivision
|
(3
|
)
|
|
—
|
|
|
(6
|
)
|
|||
OTTI losses on fixed maturity securities recognized in earnings
|
(10
|
)
|
|
(107
|
)
|
|
(59
|
)
|
|||
Fixed maturity securities — net gains (losses) on sales and disposals (1)
|
328
|
|
|
251
|
|
|
318
|
|
|||
Total gains (losses) on fixed maturity securities
|
318
|
|
|
144
|
|
|
259
|
|
|||
Total gains (losses) on equity securities:
|
|
|
|
|
|
||||||
Total OTTI losses recognized — by sector:
|
|
|
|
|
|
||||||
Common stock
|
(24
|
)
|
|
(75
|
)
|
|
(36
|
)
|
|||
Non-redeemable preferred stock
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
|||
OTTI losses on equity securities recognized in earnings
|
(25
|
)
|
|
(75
|
)
|
|
(37
|
)
|
|||
Equity securities — net gains (losses) on sales and disposals
|
117
|
|
|
19
|
|
|
43
|
|
|||
Total gains (losses) on equity securities
|
92
|
|
|
(56
|
)
|
|
6
|
|
|||
FVO securities — FVO general account securities
|
—
|
|
|
—
|
|
|
—
|
|
|||
Mortgage loans (2)
|
14
|
|
|
(231
|
)
|
|
(93
|
)
|
|||
Real estate and real estate joint ventures
|
603
|
|
|
182
|
|
|
433
|
|
|||
Other limited partnership interests
|
(59
|
)
|
|
(64
|
)
|
|
(66
|
)
|
|||
Other
|
(113
|
)
|
|
(130
|
)
|
|
1
|
|
|||
Subtotal
|
855
|
|
|
(155
|
)
|
|
540
|
|
|||
FVO CSEs:
|
|
|
|
|
|
||||||
Securities
|
—
|
|
|
1
|
|
|
—
|
|
|||
Long-term debt — related to securities
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||
Non-investment portfolio gains (losses) (3) (4) (5) (6)
|
(1,162
|
)
|
|
471
|
|
|
69
|
|
|||
Subtotal
|
(1,163
|
)
|
|
472
|
|
|
69
|
|
|||
Total net investment gains (losses)
|
$
|
(308
|
)
|
|
$
|
317
|
|
|
$
|
609
|
|
(1)
|
Fixed
maturity securities net gains (losses) on sales and disposals for the year ended
December 31, 2017
includes
$276 million
in previously deferred gains on prior period transfers of securities to Brighthouse, as such gains are no longer eliminated in consolidation after the Separation. See
Note 3
.
|
(2)
|
Mortgage loans gains (losses) for the year ended
December 31, 2017
include
$47 million
of previously deferred gains on prior period transfers of mortgage loans to Brighthouse as such gains are no longer eliminated in consolidation after the Separation. See
Note 3
.
|
(3)
|
Non-investment portfolio gains (losses) for the year ended
December 31, 2017
includes a loss of
$1,016 million
which represents a mark-to-market loss attributable to the FVO Brighthouse Common Stock held by the Company at Separation. See
Note 3
.
|
(4)
|
Non-investment portfolio gains (losses) for the year ended
December 31, 2017
includes a loss of
$95 million
which represents the change in estimated fair value of FVO Brighthouse Common Stock held by the Company from the date of Separation to
December 31, 2017
. See
Note 3
.
|
(5)
|
Non-investment portfolio gains (losses) for the year ended
December 31, 2017
includes a
$98 million
loss due to the disposition of MetLife Afore. See
Note 3
.
|
(6)
|
Non-investment portfolio gains (losses) for the year ended
December 31, 2016
includes a gain of
$102 million
in connection with the U.S. Retail Advisor Force Divestiture. See
Note 3
.
|
|
Years Ended December 31,
|
||||||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
Fixed Maturity Securities
|
|
Equity Securities
|
||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||
Proceeds
|
$
|
56,509
|
|
|
$
|
86,179
|
|
|
$
|
82,871
|
|
|
$
|
1,255
|
|
|
$
|
278
|
|
|
$
|
278
|
|
Gross investment gains
|
$
|
753
|
|
|
$
|
1,048
|
|
|
$
|
1,144
|
|
|
$
|
131
|
|
|
$
|
36
|
|
|
$
|
73
|
|
Gross investment losses
|
(425
|
)
|
|
(797
|
)
|
|
(826
|
)
|
|
(14
|
)
|
|
(17
|
)
|
|
(30
|
)
|
||||||
OTTI losses
|
(10
|
)
|
|
(107
|
)
|
|
(59
|
)
|
|
(25
|
)
|
|
(75
|
)
|
|
(37
|
)
|
||||||
Net investment gains (losses)
|
$
|
318
|
|
|
$
|
144
|
|
|
$
|
259
|
|
|
$
|
92
|
|
|
$
|
(56
|
)
|
|
$
|
6
|
|
|
Years Ended December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Balance at January 1,
|
$
|
187
|
|
|
$
|
211
|
|
Additions:
|
|
|
|
||||
Initial impairments — credit loss OTTI on securities not previously impaired
|
—
|
|
|
1
|
|
||
Additional impairments — credit loss OTTI on securities previously impaired
|
—
|
|
|
18
|
|
||
Reductions:
|
|
|
|
||||
Sales (maturities, pay downs or prepayments) of securities previously impaired as credit loss OTTI
|
(48
|
)
|
|
(43
|
)
|
||
Securities impaired to net present value of expected future cash flows
|
—
|
|
|
(1
|
)
|
||
Increase in cash flows — accretion of previous credit loss OTTI
|
(1
|
)
|
|
1
|
|
||
Balance at December 31,
|
$
|
138
|
|
|
$
|
187
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Freestanding derivatives and hedging gains (losses) (1)
|
$
|
(1,389
|
)
|
|
$
|
(509
|
)
|
|
$
|
429
|
|
Embedded derivatives gains (losses)
|
799
|
|
|
(181
|
)
|
|
200
|
|
|||
Total net derivative gains (losses)
|
$
|
(590
|
)
|
|
$
|
(690
|
)
|
|
$
|
629
|
|
(1)
|
Includes foreign currency transaction gains (losses) on hedged items in cash flow and nonqualifying hedging relationships, which are not presented elsewhere in this note.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Qualifying hedges:
|
|
|
|
|
|
||||||
Net investment income
|
$
|
299
|
|
|
$
|
267
|
|
|
$
|
206
|
|
Interest credited to policyholder account balances
|
(64
|
)
|
|
(1
|
)
|
|
27
|
|
|||
Other expenses
|
(10
|
)
|
|
(12
|
)
|
|
(6
|
)
|
|||
Nonqualifying hedges:
|
|
|
|
|
|
||||||
Net investment income
|
—
|
|
|
(1
|
)
|
|
(6
|
)
|
|||
Net derivative gains (losses)
|
551
|
|
|
705
|
|
|
663
|
|
|||
Policyholder benefits and claims
|
9
|
|
|
7
|
|
|
2
|
|
|||
Total
|
$
|
785
|
|
|
$
|
965
|
|
|
$
|
886
|
|
|
Net
Derivative Gains (Losses) |
|
Net
Investment Income (1) |
|
Policyholder
Benefits and Claims (2) |
||||||
|
(In millions)
|
||||||||||
Year Ended December 31, 2017
|
|
|
|
|
|
||||||
Interest rate derivatives
|
$
|
(549
|
)
|
|
$
|
1
|
|
|
$
|
(1
|
)
|
Foreign currency exchange rate derivatives
|
(742
|
)
|
|
—
|
|
|
5
|
|
|||
Credit derivatives — purchased
|
(24
|
)
|
|
—
|
|
|
—
|
|
|||
Credit derivatives — written
|
145
|
|
|
—
|
|
|
—
|
|
|||
Equity derivatives
|
(1,046
|
)
|
|
(9
|
)
|
|
(252
|
)
|
|||
Total
|
$
|
(2,216
|
)
|
|
$
|
(8
|
)
|
|
$
|
(248
|
)
|
Year Ended December 31, 2016
|
|
|
|
|
|
||||||
Interest rate derivatives
|
$
|
(990
|
)
|
|
$
|
—
|
|
|
$
|
46
|
|
Foreign currency exchange rate derivatives
|
882
|
|
|
—
|
|
|
(18
|
)
|
|||
Credit derivatives — purchased
|
(40
|
)
|
|
—
|
|
|
—
|
|
|||
Credit derivatives — written
|
71
|
|
|
—
|
|
|
—
|
|
|||
Equity derivatives
|
(681
|
)
|
|
(16
|
)
|
|
(138
|
)
|
|||
Total
|
$
|
(758
|
)
|
|
$
|
(16
|
)
|
|
$
|
(110
|
)
|
Year Ended December 31, 2015
|
|
|
|
|
|
||||||
Interest rate derivatives
|
$
|
(354
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
Foreign currency exchange rate derivatives
|
502
|
|
|
—
|
|
|
—
|
|
|||
Credit derivatives — purchased
|
7
|
|
|
(3
|
)
|
|
—
|
|
|||
Credit derivatives — written
|
(69
|
)
|
|
—
|
|
|
—
|
|
|||
Equity derivatives
|
(340
|
)
|
|
(10
|
)
|
|
—
|
|
|||
Total
|
$
|
(254
|
)
|
|
$
|
(13
|
)
|
|
$
|
—
|
|
(1)
|
Changes in estimated fair value related to economic hedges of equity method investments in joint ventures, derivatives held in relation to trading portfolios and derivatives held within contractholder-directed unit-linked investments.
As of D
ecember 31
, 2016, the Company no longer maintained a trading portfolio for derivatives.
|
(2)
|
Changes in estimated fair value related to economic hedges of variable annuity guarantees included in future policy benefits.
|
Derivatives in Fair Value
Hedging Relationships
|
|
Hedged Items in Fair Value
Hedging Relationships
|
|
Net Derivative
Gains (Losses)
Recognized
for Derivatives
|
|
Net Derivative
Gains (Losses)
Recognized for
Hedged Items
|
|
Ineffectiveness
Recognized in
Net Derivative
Gains (Losses)
|
||||||
|
|
|
|
(In millions)
|
||||||||||
Year Ended December 31, 2017
|
|
|
|
|
|
|
||||||||
Interest rate swaps:
|
|
Fixed maturity securities
|
|
$
|
4
|
|
|
$
|
(4
|
)
|
|
$
|
—
|
|
|
|
Policyholder liabilities (1)
|
|
(69
|
)
|
|
134
|
|
|
65
|
|
|||
Foreign currency swaps:
|
|
Foreign-denominated fixed maturity securities
|
|
(27
|
)
|
|
29
|
|
|
2
|
|
|||
|
|
Foreign-denominated policyholder account balances (2)
|
|
65
|
|
|
(44
|
)
|
|
21
|
|
|||
Foreign currency forwards:
|
|
Foreign-denominated fixed maturity securities
|
|
13
|
|
|
(11
|
)
|
|
2
|
|
|||
Total
|
|
$
|
(14
|
)
|
|
$
|
104
|
|
|
$
|
90
|
|
||
Year Ended December 31, 2016
|
|
|
|
|
|
|
||||||||
Interest rate swaps:
|
|
Fixed maturity securities
|
|
$
|
7
|
|
|
$
|
(9
|
)
|
|
$
|
(2
|
)
|
|
|
Policyholder liabilities (1)
|
|
(108
|
)
|
|
90
|
|
|
(18
|
)
|
|||
Foreign currency swaps:
|
|
Foreign-denominated fixed maturity securities
|
|
13
|
|
|
(12
|
)
|
|
1
|
|
|||
|
|
Foreign-denominated policyholder account balances (2)
|
|
(95
|
)
|
|
92
|
|
|
(3
|
)
|
|||
Foreign currency forwards:
|
|
Foreign-denominated fixed maturity securities
|
|
127
|
|
|
(119
|
)
|
|
8
|
|
|||
Total
|
|
$
|
(56
|
)
|
|
$
|
42
|
|
|
$
|
(14
|
)
|
||
Year Ended December 31, 2015
|
|
|
|
|
|
|
||||||||
Interest rate swaps:
|
|
Fixed maturity securities
|
|
$
|
4
|
|
|
$
|
(1
|
)
|
|
$
|
3
|
|
|
|
Policyholder liabilities (1)
|
|
(4
|
)
|
|
(6
|
)
|
|
(10
|
)
|
|||
Foreign currency swaps:
|
|
Foreign-denominated fixed maturity securities
|
|
15
|
|
|
(7
|
)
|
|
8
|
|
|||
|
|
Foreign-denominated policyholder account balances (2)
|
|
(240
|
)
|
|
232
|
|
|
(8
|
)
|
|||
Foreign currency forwards:
|
|
Foreign-denominated fixed maturity securities
|
|
(75
|
)
|
|
68
|
|
|
(7
|
)
|
|||
Total
|
|
$
|
(300
|
)
|
|
$
|
286
|
|
|
$
|
(14
|
)
|
(1)
|
Fixed rate liabilities reported in policyholder account balances or future policy benefits.
|
(2)
|
Fixed rate or floating rate liabilities.
|
Derivatives in Cash Flow
Hedging Relationships |
|
Amount of Gains
(Losses)Deferred in AOCI on Derivatives |
|
Amount and Location
of Gains (Losses) Reclassified from AOCI into Income (Loss) |
|
Amount and Location
of Gains (Losses) Recognized in Income (Loss) on Derivatives |
||||||||||||||
|
|
(Effective Portion)
|
|
(Effective Portion)
|
|
(Ineffective Portion)
|
||||||||||||||
|
|
|
|
Net Derivative
Gains (Losses) |
|
Net Investment
Income |
|
Other
Expenses |
|
Net Derivative
Gains (Losses) |
||||||||||
|
|
(In millions)
|
||||||||||||||||||
Year Ended December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest rate swaps
|
|
$
|
78
|
|
|
$
|
24
|
|
|
$
|
16
|
|
|
$
|
—
|
|
|
$
|
18
|
|
Interest rate forwards
|
|
210
|
|
|
(11
|
)
|
|
2
|
|
|
1
|
|
|
(2
|
)
|
|||||
Foreign currency swaps
|
|
(335
|
)
|
|
974
|
|
|
—
|
|
|
2
|
|
|
(4
|
)
|
|||||
Credit forwards
|
|
—
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Total
|
|
$
|
(47
|
)
|
|
$
|
988
|
|
|
$
|
18
|
|
|
$
|
3
|
|
|
$
|
12
|
|
Year Ended December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest rate swaps
|
|
$
|
50
|
|
|
$
|
56
|
|
|
$
|
12
|
|
|
$
|
—
|
|
|
$
|
(1
|
)
|
Interest rate forwards
|
|
(366
|
)
|
|
(1
|
)
|
|
4
|
|
|
1
|
|
|
—
|
|
|||||
Foreign currency swaps
|
|
589
|
|
|
(350
|
)
|
|
(2
|
)
|
|
2
|
|
|
1
|
|
|||||
Credit forwards
|
|
—
|
|
|
3
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|||||
Total
|
|
$
|
273
|
|
|
$
|
(292
|
)
|
|
$
|
15
|
|
|
$
|
3
|
|
|
$
|
—
|
|
Year Ended December 31, 2015
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest rate swaps
|
|
$
|
76
|
|
|
$
|
84
|
|
|
$
|
11
|
|
|
$
|
—
|
|
|
$
|
2
|
|
Interest rate forwards
|
|
(3
|
)
|
|
4
|
|
|
3
|
|
|
2
|
|
|
—
|
|
|||||
Foreign currency swaps
|
|
(194
|
)
|
|
(720
|
)
|
|
(1
|
)
|
|
1
|
|
|
9
|
|
|||||
Credit forwards
|
|
—
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Total
|
|
$
|
(121
|
)
|
|
$
|
(631
|
)
|
|
$
|
13
|
|
|
$
|
3
|
|
|
$
|
11
|
|
Derivatives in Net Investment Hedging Relationships (1), (2)
|
|
Amount of Gains (Losses) Deferred in AOCI
|
||||||||||
|
Years Ended December 31,
|
|||||||||||
|
2017
|
|
2016
|
|
2015
|
|||||||
|
|
(In millions)
|
||||||||||
Foreign currency forwards
|
|
$
|
(155
|
)
|
|
$
|
(267
|
)
|
|
$
|
255
|
|
Currency options
|
|
(290
|
)
|
|
(35
|
)
|
|
(138
|
)
|
|||
Total
|
|
$
|
(445
|
)
|
|
$
|
(302
|
)
|
|
$
|
117
|
|
(1)
|
During the
years ended December 31, 2017
,
2016
and 2015, there were
no
sales or substantial liquidations of net investments in foreign operations that would have required the reclassification of gains or losses from AOCI into earnings.
|
(2)
|
There was
no
ineffectiveness recognized for the Company’s hedges of net investments in foreign operations. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.
|
|
|
December 31,
|
||||||||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||||||||
Rating Agency Designation of Referenced
Credit Obligations (1)
|
|
Estimated
Fair Value
of Credit
Default
Swaps
|
|
Maximum
Amount of Future Payments under Credit Default Swaps |
|
Weighted
Average Years to Maturity (2) |
|
Estimated
Fair Value
of Credit
Default
Swaps
|
|
Maximum
Amount of Future Payments under Credit Default Swaps |
|
Weighted
Average Years to Maturity (2) |
||||||||||
|
|
(Dollars in millions)
|
||||||||||||||||||||
Aaa/Aa/A
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Single name credit default swaps (3)
|
|
$
|
7
|
|
|
$
|
375
|
|
|
2.6
|
|
|
$
|
6
|
|
|
$
|
449
|
|
|
3.1
|
|
Credit default swaps referencing indices
|
|
44
|
|
|
2,268
|
|
|
2.7
|
|
|
34
|
|
|
2,335
|
|
|
3.6
|
|
||||
Subtotal
|
|
51
|
|
|
2,643
|
|
|
2.7
|
|
|
40
|
|
|
2,784
|
|
|
3.5
|
|
||||
Baa
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Single name credit default swaps (3)
|
|
7
|
|
|
605
|
|
|
1.8
|
|
|
5
|
|
|
751
|
|
|
2.5
|
|
||||
Credit default swaps referencing indices
|
|
183
|
|
|
7,662
|
|
|
5.0
|
|
|
88
|
|
|
6,711
|
|
|
5.0
|
|
||||
Subtotal
|
|
190
|
|
|
8,267
|
|
|
4.8
|
|
|
93
|
|
|
7,462
|
|
|
4.8
|
|
||||
Ba
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Single name credit default swaps (3)
|
|
1
|
|
|
115
|
|
|
3.4
|
|
|
(2
|
)
|
|
135
|
|
|
4.1
|
|
||||
Credit default swaps referencing indices
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Subtotal
|
|
1
|
|
|
115
|
|
|
3.4
|
|
|
(2
|
)
|
|
135
|
|
|
4.1
|
|
||||
B
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Single name credit default swaps (3)
|
|
2
|
|
|
20
|
|
|
3.5
|
|
|
1
|
|
|
70
|
|
|
1.8
|
|
||||
Credit default swaps referencing indices
|
|
27
|
|
|
330
|
|
|
5.0
|
|
|
20
|
|
|
281
|
|
|
5.0
|
|
||||
Subtotal
|
|
29
|
|
|
350
|
|
|
4.9
|
|
|
21
|
|
|
351
|
|
|
4.3
|
|
||||
Total
|
|
$
|
271
|
|
|
$
|
11,375
|
|
|
4.3
|
|
|
$
|
152
|
|
|
$
|
10,732
|
|
|
4.4
|
|
(1)
|
The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used.
|
(2)
|
The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.
|
(3)
|
Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or state and political subdivisions.
|
|
|
December 31,
|
||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||
Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement (1)
|
|
Assets
|
|
Liabilities
|
|
Assets
|
|
Liabilities
|
||||||||
|
|
(In millions)
|
||||||||||||||
Gross estimated fair value of derivatives:
|
|
|
|
|
|
|
|
|
||||||||
OTC-bilateral (1)
|
|
$
|
7,955
|
|
|
$
|
4,059
|
|
|
$
|
9,976
|
|
|
$
|
5,721
|
|
OTC-cleared (1), (6)
|
|
649
|
|
|
223
|
|
|
2,275
|
|
|
1,142
|
|
||||
Exchange-traded
|
|
22
|
|
|
8
|
|
|
33
|
|
|
15
|
|
||||
Total gross estimated fair value of derivatives (1)
|
|
8,626
|
|
|
4,290
|
|
|
12,284
|
|
|
6,878
|
|
||||
Amounts offset on the consolidated balance sheets
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Estimated fair value of derivatives presented on the consolidated balance sheets (1), (6)
|
|
8,626
|
|
|
4,290
|
|
|
12,284
|
|
|
6,878
|
|
||||
Gross amounts not offset on the consolidated balance sheets:
|
|
|
|
|
|
|
|
|
||||||||
Gross estimated fair value of derivatives: (2)
|
|
|
|
|
|
|
|
|
||||||||
OTC-bilateral
|
|
(2,528
|
)
|
|
(2,528
|
)
|
|
(3,787
|
)
|
|
(3,787
|
)
|
||||
OTC-cleared
|
|
(35
|
)
|
|
(35
|
)
|
|
(903
|
)
|
|
(903
|
)
|
||||
Exchange-traded
|
|
(1
|
)
|
|
(1
|
)
|
|
(5
|
)
|
|
(5
|
)
|
||||
Cash collateral: (3), (4)
|
|
|
|
|
|
|
|
|
||||||||
OTC-bilateral
|
|
(4,169
|
)
|
|
—
|
|
|
(4,244
|
)
|
|
(84
|
)
|
||||
OTC-cleared
|
|
(584
|
)
|
|
(179
|
)
|
|
(1,335
|
)
|
|
(234
|
)
|
||||
Exchange-traded
|
|
—
|
|
|
(5
|
)
|
|
—
|
|
|
(9
|
)
|
||||
Securities collateral: (5)
|
|
|
|
|
|
|
|
|
||||||||
OTC-bilateral
|
|
(1,004
|
)
|
|
(1,474
|
)
|
|
(1,640
|
)
|
|
(1,818
|
)
|
||||
OTC-cleared
|
|
—
|
|
|
(9
|
)
|
|
—
|
|
|
—
|
|
||||
Exchange-traded
|
|
—
|
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
||||
Net amount after application of master netting agreements and collateral
|
|
$
|
305
|
|
|
$
|
57
|
|
|
$
|
370
|
|
|
$
|
38
|
|
(1)
|
At
December 31, 2017
and
2016
, derivative assets included income or (expense) accruals reported in accrued investment income or in other liabilities of
$75 million
and
$145 million
, respectively, and derivative liabilities included (income) or expense accruals reported in accrued investment income or in other liabilities of
($49) million
and
($43) million
, respectively.
|
(2)
|
Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.
|
(3)
|
Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives is included in cash and cash equivalents, short-term investments or in fixed maturity securities, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet.
|
(4)
|
The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At
December 31, 2017
and
2016
, the Company received excess cash collateral of
$253 million
and
$164 million
, respectively, and provided excess cash collateral of
$272 million
and
$461 million
, respectively, which is not included in the table above due to the foregoing limitation.
|
(5)
|
Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at
December 31, 2017
,
none
of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At
December 31, 2017
and
2016
, the Company received excess securities collateral with an estimated fair value of
$108 million
and
$82 million
, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At
December 31, 2017
and
2016
, the Company provided excess securities collateral with an estimated fair value of
$305 million
and
$189 million
, respectively, for its OTC-bilateral derivatives,
$522 million
and
$544 million
, respectively, for its OTC-cleared derivatives, and
$89 million
and
$116 million
, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.
|
(6)
|
Effective January 3, 2017, the CME amended its rulebook, resulting in the characterization of variation margin transfers as settlement payments, as opposed to adjustments to collateral. See
Note 1
for further information on the CME amendments.
|
|
|
December 31,
|
||||||||||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||||||||||
|
|
Derivatives Subject to Credit-Contingent Provisions
|
|
Derivatives Not Subject to Credit-Contingent Provisions
|
|
Total
|
|
Derivatives Subject to Credit-Contingent Provisions
|
|
Derivatives Not Subject to Credit-Contingent Provisions
|
|
Total
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Estimated Fair Value of Derivatives in a Net Liability Position (1)
|
|
$
|
1,508
|
|
|
$
|
24
|
|
|
$
|
1,532
|
|
|
$
|
1,909
|
|
|
$
|
25
|
|
|
$
|
1,934
|
|
Estimated Fair Value of Collateral Provided:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Fixed maturity securities
|
|
$
|
1,675
|
|
|
$
|
26
|
|
|
$
|
1,701
|
|
|
$
|
1,965
|
|
|
$
|
31
|
|
|
$
|
1,996
|
|
Cash
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
91
|
|
|
$
|
—
|
|
|
$
|
91
|
|
Estimated Fair Value of Incremental Collateral Provided Upon:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
One-notch downgrade in the Company’s credit or financial strength rating, as applicable
|
|
$
|
15
|
|
|
$
|
—
|
|
|
$
|
15
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
6
|
|
Downgrade in the Company’s credit or financial strength rating, as applicable, to a level that triggers full overnight collateralization or termination of the derivative position
|
|
$
|
20
|
|
|
$
|
—
|
|
|
$
|
20
|
|
|
$
|
9
|
|
|
$
|
—
|
|
|
$
|
9
|
|
(1)
|
After taking into consideration the existence of netting agreements.
|
|
|
|
|
December 31,
|
||||||
|
|
Balance Sheet Location
|
|
2017
|
|
2016
|
||||
|
|
|
|
(In millions)
|
||||||
Embedded derivatives within asset host contracts:
|
|
|
|
|
|
|
||||
Ceded guaranteed minimum benefits
|
|
Premiums, reinsurance and other receivables
|
|
$
|
144
|
|
|
$
|
143
|
|
Options embedded in debt or equity securities
|
|
Investments
|
|
(132
|
)
|
|
(88
|
)
|
||
Embedded derivatives within asset host contracts
|
|
$
|
12
|
|
|
$
|
55
|
|
||
Embedded derivatives within liability host contracts:
|
|
|
|
|
||||||
Direct guaranteed minimum benefits
|
|
Policyholder account balances
|
|
$
|
32
|
|
|
$
|
361
|
|
Assumed guaranteed minimum benefits
|
|
Policyholder account balances
|
|
291
|
|
|
523
|
|
||
Funds withheld on ceded reinsurance
|
|
Other liabilities
|
|
25
|
|
|
(30
|
)
|
||
Fixed annuities with equity indexed returns
|
|
Policyholder account balances
|
|
70
|
|
|
18
|
|
||
Embedded derivatives within liability host contracts
|
|
$
|
418
|
|
|
$
|
872
|
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Net derivative gains (losses) (1)
|
|
$
|
799
|
|
|
$
|
(181
|
)
|
|
$
|
200
|
|
(1)
|
The valuation of guaranteed minimum benefits includes a nonperformance risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment were
($190) million
,
$156 million
and
$52 million
for the years ended December 31,
2017
,
2016
and
2015
, respectively.
|
Level 1
|
Unadjusted quoted prices in active markets for identical assets or liabilities. The Company defines active markets based on average trading volume for equity securities. The size of the bid/ask spread is used as an indicator of market activity for fixed maturity securities.
|
Level 2
|
Quoted prices in markets that are not active or inputs that are observable either directly or indirectly. These inputs can include quoted prices for similar assets or liabilities other than quoted prices in Level 1, quoted prices in markets that are not active, or other significant inputs that are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
|
Level 3
|
Unobservable inputs that are supported by little or no market activity and are significant to the determination of estimated fair value of the assets or liabilities. Unobservable inputs reflect the reporting entity’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.
|
|
|
December 31, 2017
|
||||||||||||||
|
|
Fair Value Hierarchy
|
|
|
||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated Fair Value |
||||||||
|
|
(In millions)
|
||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
||||||||
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
||||||||
U.S. corporate
|
|
$
|
—
|
|
|
$
|
78,171
|
|
|
$
|
4,490
|
|
|
$
|
82,661
|
|
Foreign government
|
|
—
|
|
|
61,325
|
|
|
209
|
|
|
61,534
|
|
||||
Foreign corporate
|
|
—
|
|
|
48,840
|
|
|
6,729
|
|
|
55,569
|
|
||||
U.S. government and agency
|
|
26,052
|
|
|
21,342
|
|
|
—
|
|
|
47,394
|
|
||||
RMBS
|
|
—
|
|
|
25,339
|
|
|
3,461
|
|
|
28,800
|
|
||||
State and political subdivision
|
|
—
|
|
|
12,455
|
|
|
—
|
|
|
12,455
|
|
||||
ABS
|
|
—
|
|
|
11,204
|
|
|
1,087
|
|
|
12,291
|
|
||||
CMBS
|
|
—
|
|
|
7,934
|
|
|
293
|
|
|
8,227
|
|
||||
Total fixed maturity securities
|
|
26,052
|
|
|
266,610
|
|
|
16,269
|
|
|
308,931
|
|
||||
Equity securities
|
|
1,104
|
|
|
981
|
|
|
428
|
|
|
2,513
|
|
||||
FVO securities (1)
|
|
14,028
|
|
|
2,355
|
|
|
362
|
|
|
16,745
|
|
||||
Short-term investments (2)
|
|
3,001
|
|
|
1,252
|
|
|
33
|
|
|
4,286
|
|
||||
Residential mortgage loans — FVO
|
|
—
|
|
|
—
|
|
|
520
|
|
|
520
|
|
||||
Other investments
|
|
81
|
|
|
84
|
|
|
—
|
|
|
165
|
|
||||
Derivative assets: (3)
|
|
|
|
|
|
|
|
|
||||||||
Interest rate
|
|
2
|
|
|
5,553
|
|
|
8
|
|
|
5,563
|
|
||||
Foreign currency exchange rate
|
|
2
|
|
|
1,954
|
|
|
113
|
|
|
2,069
|
|
||||
Credit
|
|
—
|
|
|
240
|
|
|
38
|
|
|
278
|
|
||||
Equity market
|
|
18
|
|
|
548
|
|
|
75
|
|
|
641
|
|
||||
Total derivative assets
|
|
22
|
|
|
8,295
|
|
|
234
|
|
|
8,551
|
|
||||
Embedded derivatives within asset host contracts (4)
|
|
—
|
|
|
—
|
|
|
144
|
|
|
144
|
|
||||
Separate account assets (5)
|
|
89,916
|
|
|
114,124
|
|
|
961
|
|
|
205,001
|
|
||||
Total assets
|
|
$
|
134,204
|
|
|
$
|
393,701
|
|
|
$
|
18,951
|
|
|
$
|
546,856
|
|
Liabilities
|
|
|
|
|
|
|
|
|
||||||||
Derivative liabilities: (3)
|
|
|
|
|
|
|
|
|
||||||||
Interest rate
|
|
$
|
4
|
|
|
$
|
638
|
|
|
$
|
130
|
|
|
$
|
772
|
|
Foreign currency exchange rate
|
|
—
|
|
|
2,553
|
|
|
37
|
|
|
2,590
|
|
||||
Credit
|
|
—
|
|
|
43
|
|
|
—
|
|
|
43
|
|
||||
Equity market
|
|
4
|
|
|
731
|
|
|
199
|
|
|
934
|
|
||||
Total derivative liabilities
|
|
8
|
|
|
3,965
|
|
|
366
|
|
|
4,339
|
|
||||
Embedded derivatives within liability host contracts (4)
|
|
—
|
|
|
—
|
|
|
418
|
|
|
418
|
|
||||
Separate account liabilities (5)
|
|
—
|
|
|
7
|
|
|
2
|
|
|
9
|
|
||||
Total liabilities
|
|
$
|
8
|
|
|
$
|
3,972
|
|
|
$
|
786
|
|
|
$
|
4,766
|
|
|
|
December 31, 2016
|
||||||||||||||
|
|
Fair Value Hierarchy
|
|
|
||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated
Fair Value
|
||||||||
|
|
(In millions)
|
||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
||||||||
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
||||||||
U.S. corporate
|
|
$
|
—
|
|
|
$
|
72,811
|
|
|
$
|
5,732
|
|
|
$
|
78,543
|
|
Foreign government
|
|
—
|
|
|
55,687
|
|
|
289
|
|
|
55,976
|
|
||||
Foreign corporate
|
|
—
|
|
|
44,858
|
|
|
5,805
|
|
|
50,663
|
|
||||
U.S. government and agency
|
|
24,943
|
|
|
19,490
|
|
|
—
|
|
|
44,433
|
|
||||
RMBS
|
|
—
|
|
|
25,194
|
|
|
3,838
|
|
|
29,032
|
|
||||
State and political subdivision
|
|
—
|
|
|
12,221
|
|
|
10
|
|
|
12,231
|
|
||||
ABS
|
|
—
|
|
|
10,196
|
|
|
1,029
|
|
|
11,225
|
|
||||
CMBS
|
|
—
|
|
|
7,112
|
|
|
348
|
|
|
7,460
|
|
||||
Total fixed maturity securities
|
|
24,943
|
|
|
247,569
|
|
|
17,051
|
|
|
289,563
|
|
||||
Equity securities
|
|
1,334
|
|
|
1,092
|
|
|
468
|
|
|
2,894
|
|
||||
FVO securities (1)
|
|
11,123
|
|
|
2,513
|
|
|
287
|
|
|
13,923
|
|
||||
Short-term investments (2)
|
|
4,091
|
|
|
1,868
|
|
|
46
|
|
|
6,005
|
|
||||
Residential mortgage loans — FVO
|
|
—
|
|
|
—
|
|
|
566
|
|
|
566
|
|
||||
Other investments
|
|
86
|
|
|
71
|
|
|
—
|
|
|
157
|
|
||||
Derivative assets: (3)
|
|
|
|
|
|
|
|
|
||||||||
Interest rate
|
|
3
|
|
|
7,556
|
|
|
2
|
|
|
7,561
|
|
||||
Foreign currency exchange rate
|
|
—
|
|
|
3,783
|
|
|
80
|
|
|
3,863
|
|
||||
Credit
|
|
—
|
|
|
145
|
|
|
30
|
|
|
175
|
|
||||
Equity market
|
|
30
|
|
|
390
|
|
|
120
|
|
|
540
|
|
||||
Total derivative assets
|
|
33
|
|
|
11,874
|
|
|
232
|
|
|
12,139
|
|
||||
Embedded derivatives within asset host contracts (4)
|
|
—
|
|
|
—
|
|
|
143
|
|
|
143
|
|
||||
Separate account assets (5)
|
|
82,818
|
|
|
111,612
|
|
|
1,148
|
|
|
195,578
|
|
||||
Total assets
|
|
$
|
124,428
|
|
|
$
|
376,599
|
|
|
$
|
19,941
|
|
|
$
|
520,968
|
|
Liabilities
|
|
|
|
|
|
|
|
|
||||||||
Derivative liabilities: (3)
|
|
|
|
|
|
|
|
|
||||||||
Interest rate
|
|
$
|
12
|
|
|
$
|
1,713
|
|
|
$
|
500
|
|
|
$
|
2,225
|
|
Foreign currency exchange rate
|
|
—
|
|
|
3,784
|
|
|
54
|
|
|
3,838
|
|
||||
Credit
|
|
—
|
|
|
49
|
|
|
—
|
|
|
49
|
|
||||
Equity market
|
|
3
|
|
|
566
|
|
|
240
|
|
|
809
|
|
||||
Total derivative liabilities
|
|
15
|
|
|
6,112
|
|
|
794
|
|
|
6,921
|
|
||||
Embedded derivatives within liability host contracts (4)
|
|
—
|
|
|
—
|
|
|
872
|
|
|
872
|
|
||||
Separate account liabilities (5)
|
|
—
|
|
|
16
|
|
|
7
|
|
|
23
|
|
||||
Total liabilities
|
|
$
|
15
|
|
|
$
|
6,128
|
|
|
$
|
1,673
|
|
|
$
|
7,816
|
|
(1)
|
FVO securities were comprised of over 85% FVO contractholder-directed unit-linked investments at both
December 31, 2017
and
2016
.
|
(2)
|
Short-term investments as presented in the tables above differ from the amounts presented on the consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis.
|
(3)
|
Derivative assets are presented within other invested assets on the consolidated balance sheets and derivative liabilities are presented within other liabilities on the consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.
|
(4)
|
Embedded derivatives within asset host contracts are presented within premiums, reinsurance and other receivables and other invested assets on the consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances and other liabilities on the consolidated balance sheets. At
December 31, 2017
and
2016
, debt and equity securities also included embedded derivatives of
($132) million
and
($88) million
, respectively.
|
(5)
|
Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities.
|
Instrument
|
|
Level 2
Observable Inputs
|
Level 3
Unobservable Inputs
|
||
Fixed maturity securities
|
|||||
U.S. corporate and Foreign corporate securities
|
|||||
|
Valuation Approaches: Principally the market and income approaches.
|
Valuation Approaches: Principally the market approach.
|
|||
|
Key Inputs:
|
Key Inputs:
|
|||
|
•
|
quoted prices in markets that are not active
|
•
|
illiquidity premium
|
|
|
•
|
benchmark yields; spreads off benchmark yields; new issuances; issuer rating
|
•
|
delta spread adjustments to reflect specific credit-related issues
|
|
|
•
|
trades of identical or comparable securities; duration
|
•
|
credit spreads
|
|
|
•
|
Privately-placed securities are valued using the additional key inputs:
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
|
|
|
•
|
market yield curve; call provisions
|
|
|
|
|
•
|
observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer
|
•
|
independent non-binding broker quotations
|
|
|
•
|
delta spread adjustments to reflect specific credit-related issues
|
|
|
Foreign government, U.S. government and agency and State and political subdivision securities
|
|||||
|
Valuation Approaches: Principally the market approach.
|
Valuation Approaches: Principally the market approach.
|
|||
|
Key Inputs:
|
Key Inputs:
|
|||
|
•
|
quoted prices in markets that are not active
|
•
|
independent non-binding broker quotations
|
|
|
•
|
benchmark U.S. Treasury yield or other yields
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
|
|
•
|
the spread off the U.S. Treasury yield curve for the identical security
|
|
||
|
•
|
issuer ratings and issuer spreads; broker-dealer quotes
|
•
|
credit spreads
|
|
|
•
|
comparable securities that are actively traded
|
|
|
|
Structured Securities
|
|||||
|
Valuation Approaches: Principally the market and income approaches.
|
Valuation Approaches: Principally the market and income approaches.
|
|||
|
Key Inputs:
|
Key Inputs:
|
|||
|
•
|
quoted prices in markets that are not active
|
•
|
credit spreads
|
|
|
•
|
spreads for actively traded securities; spreads off benchmark yields
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
|
|
•
|
expected prepayment speeds and volumes
|
|
||
|
•
|
current and forecasted loss severity; ratings; geographic region
|
•
|
independent non-binding broker quotations
|
|
|
•
|
weighted average coupon and weighted average maturity
|
|
|
|
|
•
|
average delinquency rates; debt-service coverage ratios
|
|
|
|
|
•
|
issuance-specific information, including, but not limited to:
|
|
|
|
|
|
•
|
collateral type; structure of the security; vintage of the loans
|
|
|
|
|
•
|
payment terms of the underlying assets
|
|
|
|
|
•
|
payment priority within the tranche; deal performance
|
|
|
(1)
|
Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, other limited partnership interests, short-term investments and cash and cash equivalents. Fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents are similar in nature to the instruments described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”
|
Instrument
|
|
Interest Rate
|
|
Foreign Currency
Exchange Rate
|
|
Credit
|
|
Equity Market
|
Inputs common to Level 2 and Level 3 by instrument type
|
•
|
swap yield curves
|
•
|
swap yield curves
|
•
|
swap yield curves
|
•
|
swap yield curves
|
•
|
basis curves
|
•
|
basis curves
|
•
|
credit curves
|
•
|
spot equity index levels
|
|
•
|
interest rate volatility (1)
|
•
|
currency spot rates
|
•
|
recovery rates
|
•
|
dividend yield curves
|
|
|
|
|
•
|
cross currency basis curves
|
|
|
•
|
equity volatility (1)
|
|
|
|
•
|
currency volatility (1)
|
|
|
|
|
Level 3
|
•
|
swap yield curves (2)
|
•
|
swap yield curves (2)
|
•
|
swap yield curves (2)
|
•
|
dividend yield curves (2)
|
|
•
|
basis curves (2)
|
•
|
basis curves (2)
|
•
|
credit curves (2)
|
•
|
equity volatility (1), (2)
|
|
•
|
repurchase rates
|
•
|
cross currency basis curves (2)
|
•
|
credit spreads
|
•
|
correlation between model inputs (1)
|
|
|
|
•
|
currency correlation
|
•
|
repurchase rates
|
|
|
|
|
|
•
|
currency volatility (1)
|
•
|
independent non-binding broker quotations
|
|
|
(1)
|
Option-based only.
|
(2)
|
Extrapolation beyond the observable limits of the curve(s).
|
|
|
|
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
|
Impact of
Increase in Input on Estimated Fair Value (2) |
||||||||
|
Valuation Techniques
|
|
Significant
Unobservable Inputs
|
|
Range
|
|
Weighted
Average (1) |
|
Range
|
|
Weighted
Average (1) |
|
|||||||
Fixed maturity securities (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
U.S. corporate and foreign corporate
|
•
|
Matrix pricing
|
|
•
|
Offered quotes (4)
|
|
83
|
-
|
142
|
|
110
|
|
18
|
-
|
138
|
|
106
|
|
Increase
|
|
•
|
Market pricing
|
|
•
|
Quoted prices (4)
|
|
10
|
-
|
443
|
|
121
|
|
6
|
-
|
700
|
|
116
|
|
Increase
|
|
•
|
Consensus pricing
|
|
•
|
Offered quotes (4)
|
|
97
|
-
|
104
|
|
101
|
|
37
|
-
|
120
|
|
102
|
|
Increase
|
RMBS
|
•
|
Market pricing
|
|
•
|
Quoted prices (4)
|
|
—
|
-
|
126
|
|
94
|
|
19
|
-
|
137
|
|
91
|
|
Increase (5)
|
ABS
|
•
|
Market pricing
|
|
•
|
Quoted prices (4)
|
|
5
|
-
|
117
|
|
100
|
|
5
|
-
|
106
|
|
99
|
|
Increase (5)
|
|
•
|
Consensus pricing
|
|
•
|
Offered quotes (4)
|
|
100
|
-
|
103
|
|
100
|
|
96
|
-
|
102
|
|
100
|
|
Increase (5)
|
Derivatives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate
|
•
|
Present value techniques
|
|
•
|
Swap yield (6)
|
|
200
|
-
|
300
|
|
|
|
200
|
-
|
300
|
|
|
|
Increase (7)
|
|
|
|
|
•
|
Repurchase rates (8)
|
|
(5)
|
-
|
5
|
|
|
|
(44)
|
-
|
18
|
|
|
|
Decrease (7)
|
Foreign currency exchange rate
|
•
|
Present value techniques
|
|
•
|
Swap yield (6)
|
|
(14)
|
-
|
309
|
|
|
|
50
|
-
|
328
|
|
|
|
Increase (7)
|
Credit
|
•
|
Present value techniques
|
|
•
|
Credit spreads (9)
|
|
—
|
-
|
—
|
|
|
|
97
|
-
|
98
|
|
|
|
Decrease (7)
|
|
•
|
Consensus pricing
|
|
•
|
Offered quotes (10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity market
|
•
|
Present value techniques or option pricing models
|
|
•
|
Volatility (11)
|
|
11%
|
-
|
31%
|
|
|
|
12%
|
-
|
32%
|
|
|
|
Increase (7)
|
|
|
|
|
•
|
Correlation (12)
|
|
10%
|
-
|
30%
|
|
|
|
40%
|
-
|
40%
|
|
|
|
|
Embedded derivatives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Direct, assumed and ceded guaranteed minimum benefits
|
•
|
Option pricing techniques
|
|
•
|
Mortality rates:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ages 0 - 40
|
|
0%
|
-
|
0.21%
|
|
|
|
0%
|
-
|
0.21%
|
|
|
|
Decrease (13)
|
|
|
|
|
|
Ages 41 - 60
|
|
0.03%
|
-
|
0.75%
|
|
|
|
0.01%
|
-
|
0.78%
|
|
|
|
Decrease (13)
|
|
|
|
|
|
Ages 61 - 115
|
|
0.15%
|
-
|
100%
|
|
|
|
0.04%
|
-
|
100%
|
|
|
|
Decrease (13)
|
|
|
|
|
•
|
Lapse rates:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Durations 1 - 10
|
|
0.25%
|
-
|
100%
|
|
|
|
0.25%
|
-
|
100%
|
|
|
|
Decrease (14)
|
|
|
|
|
|
Durations 11 - 20
|
|
2%
|
-
|
100%
|
|
|
|
2%
|
-
|
100%
|
|
|
|
Decrease (14)
|
|
|
|
|
|
Durations 21 - 116
|
|
1.25%
|
-
|
100%
|
|
|
|
1.25%
|
-
|
100%
|
|
|
|
Decrease (14)
|
|
|
|
|
•
|
Utilization rates
|
|
0%
|
-
|
25%
|
|
|
|
0%
|
-
|
25%
|
|
|
|
Increase (15)
|
|
|
|
|
•
|
Withdrawal rates
|
|
0%
|
-
|
20%
|
|
|
|
0%
|
-
|
20%
|
|
|
|
(16)
|
|
|
|
|
•
|
Long-term equity volatilities
|
|
8.25%
|
-
|
33%
|
|
|
|
9.95%
|
-
|
33%
|
|
|
|
Increase (17)
|
|
|
|
|
•
|
Nonperformance risk spread
|
|
0.02%
|
-
|
1.32%
|
|
|
|
0.04%
|
-
|
1.70%
|
|
|
|
Decrease (18)
|
(1)
|
The weighted average for fixed maturity securities is determined based on the estimated fair value of the securities.
|
(2)
|
The impact of a decrease in input would have the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions.
|
(3)
|
Significant increases (decreases) in expected default rates in isolation would result in substantially lower (higher) valuations.
|
(4)
|
Range and weighted average are presented in accordance with the market convention for fixed maturity securities of dollars per hundred dollars of par.
|
(5)
|
Changes in the assumptions used for the probability of default are accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.
|
(6)
|
Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.
|
(7)
|
Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions.
|
(8)
|
Ranges represent different repurchase rates utilized as components within the valuation methodology and are presented in basis points.
|
(9)
|
Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps.
|
(10)
|
At both
December 31, 2017
and
2016
, independent non-binding broker quotations were used in the determination of less than
1%
of the total net derivative estimated fair value.
|
(11)
|
Ranges represent the underlying equity volatility quoted in percentage points. Since this valuation methodology uses a range of inputs across multiple volatility surfaces to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.
|
(12)
|
Ranges represent the different correlation factors utilized as components within the valuation methodology. Presenting a range of correlation factors is more representative of the unobservable input used in the valuation. Increases (decreases) in correlation in isolation will increase (decrease) the significance of the change in valuations.
|
(13)
|
Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
(14)
|
Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
(15)
|
The utilization rate assumption estimates the percentage of contractholders with a GMIB or lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
(16)
|
The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.
|
(17)
|
Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
(18)
|
Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the embedded derivative.
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||||||||||||||||||||
|
|
Fixed Maturity Securities
|
|
|
|
|
||||||||||||||||||
|
|
Corporate (1)
|
|
Foreign
Government |
|
Structured
Securities
|
|
State and
Political Subdivision |
|
Equity
Securities |
|
FVO
Securities |
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Balance, January 1, 2016
|
|
$
|
10,311
|
|
|
$
|
829
|
|
|
$
|
5,121
|
|
|
$
|
34
|
|
|
$
|
334
|
|
|
$
|
270
|
|
Total realized/unrealized gains (losses) included in net income (loss) (2) (3)
|
|
5
|
|
|
12
|
|
|
103
|
|
|
1
|
|
|
(24
|
)
|
|
2
|
|
||||||
Total realized/unrealized gains (losses) included in AOCI
|
|
59
|
|
|
(42
|
)
|
|
56
|
|
|
2
|
|
|
19
|
|
|
—
|
|
||||||
Purchases (4)
|
|
2,754
|
|
|
44
|
|
|
2,221
|
|
|
—
|
|
|
23
|
|
|
99
|
|
||||||
Sales (4)
|
|
(996
|
)
|
|
(45
|
)
|
|
(1,483
|
)
|
|
—
|
|
|
(15
|
)
|
|
(35
|
)
|
||||||
Issuances (4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Settlements (4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Transfers into Level 3 (5)
|
|
969
|
|
|
3
|
|
|
25
|
|
|
7
|
|
|
327
|
|
|
18
|
|
||||||
Transfers out of Level 3 (5)
|
|
(1,565
|
)
|
|
(512
|
)
|
|
(828
|
)
|
|
(34
|
)
|
|
(196
|
)
|
|
(67
|
)
|
||||||
Balance, December 31, 2016
|
|
11,537
|
|
|
289
|
|
|
5,215
|
|
|
10
|
|
|
468
|
|
|
287
|
|
||||||
Total realized/unrealized gains (losses) included in net income (loss) (2) (3)
|
|
3
|
|
|
4
|
|
|
94
|
|
|
—
|
|
|
—
|
|
|
22
|
|
||||||
Total realized/unrealized gains (losses) included in AOCI
|
|
708
|
|
|
—
|
|
|
133
|
|
|
—
|
|
|
19
|
|
|
—
|
|
||||||
Purchases (4)
|
|
3,830
|
|
|
30
|
|
|
1,376
|
|
|
—
|
|
|
25
|
|
|
292
|
|
||||||
Sales (4)
|
|
(1,763
|
)
|
|
(53
|
)
|
|
(1,598
|
)
|
|
—
|
|
|
(51
|
)
|
|
(141
|
)
|
||||||
Issuances (4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Settlements (4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Transfers into Level 3 (5)
|
|
72
|
|
|
5
|
|
|
70
|
|
|
—
|
|
|
1
|
|
|
8
|
|
||||||
Transfers out of Level 3 (5)
|
|
(3,168
|
)
|
|
(66
|
)
|
|
(449
|
)
|
|
(10
|
)
|
|
(34
|
)
|
|
(106
|
)
|
||||||
Balance, December 31, 2017
|
|
$
|
11,219
|
|
|
$
|
209
|
|
|
$
|
4,841
|
|
|
$
|
—
|
|
|
$
|
428
|
|
|
$
|
362
|
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2015: (6)
|
|
$
|
13
|
|
|
$
|
12
|
|
|
$
|
103
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(27
|
)
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2016: (6)
|
|
$
|
6
|
|
|
$
|
12
|
|
|
$
|
103
|
|
|
$
|
1
|
|
|
$
|
(29
|
)
|
|
$
|
3
|
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2017: (6)
|
|
$
|
1
|
|
|
$
|
4
|
|
|
$
|
84
|
|
|
$
|
—
|
|
|
$
|
(17
|
)
|
|
$
|
19
|
|
Gains (Losses) Data for the year ended December 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Total realized/unrealized gains (losses) included in net income (loss) (2) (3)
|
|
$
|
53
|
|
|
$
|
13
|
|
|
$
|
103
|
|
|
$
|
—
|
|
|
$
|
11
|
|
|
$
|
(30
|
)
|
Total realized/unrealized gains (losses) included in AOCI
|
|
$
|
(637
|
)
|
|
$
|
(23
|
)
|
|
$
|
(77
|
)
|
|
$
|
1
|
|
|
$
|
(54
|
)
|
|
$
|
—
|
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||||||||||||||||
|
|
Short-term
Investments
|
|
Residential Mortgage
Loans - FVO
|
|
Net
Derivatives (7)
|
|
Net Embedded
Derivatives (8)
|
|
Separate
Accounts (9)
|
||||||||||
|
|
(In millions)
|
||||||||||||||||||
Balance, January 1, 2016
|
|
$
|
244
|
|
|
$
|
314
|
|
|
$
|
(179
|
)
|
|
$
|
(178
|
)
|
|
$
|
1,558
|
|
Total realized/unrealized gains (losses) included in net income (loss) (2) (3)
|
|
1
|
|
|
8
|
|
|
(31
|
)
|
|
(214
|
)
|
|
(2
|
)
|
|||||
Total realized/unrealized gains (losses) included in AOCI
|
|
4
|
|
|
—
|
|
|
(367
|
)
|
|
(20
|
)
|
|
—
|
|
|||||
Purchases (4)
|
|
50
|
|
|
297
|
|
|
28
|
|
|
—
|
|
|
375
|
|
|||||
Sales (4)
|
|
(50
|
)
|
|
(11
|
)
|
|
—
|
|
|
—
|
|
|
(512
|
)
|
|||||
Issuances (4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
62
|
|
|||||
Settlements (4)
|
|
—
|
|
|
(42
|
)
|
|
(13
|
)
|
|
(317
|
)
|
|
(51
|
)
|
|||||
Transfers into Level 3 (5)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
19
|
|
|||||
Transfers out of Level 3 (5)
|
|
(203
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(308
|
)
|
|||||
Balance, December 31, 2016
|
|
46
|
|
|
566
|
|
|
(562
|
)
|
|
(729
|
)
|
|
1,141
|
|
|||||
Total realized/unrealized gains (losses) included in net income (loss) (2) (3)
|
|
—
|
|
|
40
|
|
|
87
|
|
|
823
|
|
|
(8
|
)
|
|||||
Total realized/unrealized gains (losses) included in AOCI
|
|
—
|
|
|
—
|
|
|
216
|
|
|
(46
|
)
|
|
—
|
|
|||||
Purchases (4)
|
|
32
|
|
|
175
|
|
|
—
|
|
|
—
|
|
|
187
|
|
|||||
Sales (4)
|
|
(1
|
)
|
|
(179
|
)
|
|
—
|
|
|
—
|
|
|
(80
|
)
|
|||||
Issuances (4)
|
|
—
|
|
|
—
|
|
|
(7
|
)
|
|
—
|
|
|
1
|
|
|||||
Settlements (4)
|
|
—
|
|
|
(82
|
)
|
|
134
|
|
|
(322
|
)
|
|
(93
|
)
|
|||||
Transfers into Level 3 (5)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
35
|
|
|||||
Transfers out of Level 3 (5)
|
|
(44
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(224
|
)
|
|||||
Balance, December 31, 2017
|
|
$
|
33
|
|
|
$
|
520
|
|
|
$
|
(132
|
)
|
|
$
|
(274
|
)
|
|
$
|
959
|
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2015: (6)
|
|
$
|
—
|
|
|
$
|
20
|
|
|
$
|
(170
|
)
|
|
$
|
216
|
|
|
$
|
—
|
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2016: (6)
|
|
$
|
1
|
|
|
$
|
8
|
|
|
$
|
(56
|
)
|
|
$
|
(242
|
)
|
|
$
|
—
|
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at December 31, 2017: (6)
|
|
$
|
—
|
|
|
$
|
27
|
|
|
$
|
53
|
|
|
$
|
793
|
|
|
$
|
—
|
|
Gains (Losses) Data for the year ended December 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total realized/unrealized gains (losses) included in net income (loss) (2) (3)
|
|
$
|
1
|
|
|
$
|
20
|
|
|
$
|
(149
|
)
|
|
$
|
155
|
|
|
$
|
14
|
|
Total realized/unrealized gains (losses) included in AOCI
|
|
$
|
(1
|
)
|
|
$
|
—
|
|
|
$
|
(2
|
)
|
|
$
|
1
|
|
|
$
|
—
|
|
(1)
|
Comprised of U.S. and foreign corporate securities.
|
(2)
|
Amortization of premium/accretion of discount is included within net investment income. Impairments charged to net income (loss) on securities are included in net investment gains (losses), while changes in estimated fair value of residential mortgage loans — FVO are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivatives gains (losses).
|
(3)
|
Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.
|
(4)
|
Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements.
|
(5)
|
Gains and losses in net income (loss) and OCI are calculated assuming transfers into and/or out of Level 3 occurred at the beginning of the period. Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.
|
(6)
|
Changes in unrealized gains (losses) included in net income (loss) relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).
|
(7)
|
Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.
|
(8)
|
Embedded derivative assets and liabilities are presented net for purposes of the rollforward.
|
(9)
|
Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net investment gains (losses).
Separate account assets and liabilities are presented net for the purposes of the rollforward.
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
Unpaid principal balance
|
|
$
|
650
|
|
|
$
|
794
|
|
Difference between estimated fair value and unpaid principal balance
|
|
(130
|
)
|
|
(228
|
)
|
||
Carrying value at estimated fair value
|
|
$
|
520
|
|
|
$
|
566
|
|
Loans in nonaccrual status
|
|
$
|
198
|
|
|
$
|
214
|
|
Loans more than 90 days past due
|
|
$
|
94
|
|
|
$
|
137
|
|
Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance
|
|
$
|
(102
|
)
|
|
$
|
(150
|
)
|
|
At December 31,
|
|
Years Ended December 31,
|
||||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
Carrying Value After Measurement
|
|
Gains (Losses)
|
||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||
Other limited partnership interests (1)
|
$
|
58
|
|
|
$
|
96
|
|
|
$
|
57
|
|
|
$
|
(65
|
)
|
|
$
|
(64
|
)
|
|
$
|
(31
|
)
|
Other assets (2)
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
10
|
|
|
$
|
(30
|
)
|
|
$
|
—
|
|
(1)
|
For these cost method investments, estimated fair value is determined from information provided on the financial statements of the underlying entities including NAV data. These investments include private equity and debt funds that typically invest primarily in various strategies including domestic and international leveraged buyout funds; power, energy, timber and infrastructure development funds; venture capital funds; and below investment grade debt and mezzanine debt funds. Distributions will be generated from investment gains, from operating income from the underlying investments of the funds and from liquidation of the underlying assets of the funds. The Company estimates that the underlying assets of the funds will be liquidated over the next
two
to
10 years
. Unfunded commitments for these investments at both
December 31, 2017
and
2016
were not significant.
|
(2)
|
As discussed in
Note 3
, during the year ended December 31, 2016, the Company recognized an impairment of computer software in connection with the U.S. Retail Advisor Force Divestiture.
|
|
|
December 31, 2017
|
||||||||||||||||||
|
|
|
|
Fair Value Hierarchy
|
|
|
||||||||||||||
|
|
Carrying
Value
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated
Fair Value
|
||||||||||
|
|
(In millions)
|
||||||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Mortgage loans
|
|
$
|
68,211
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
69,797
|
|
|
$
|
69,797
|
|
Policy loans
|
|
$
|
9,669
|
|
|
$
|
—
|
|
|
$
|
336
|
|
|
$
|
11,176
|
|
|
$
|
11,512
|
|
Other limited partnership interests
|
|
$
|
219
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
216
|
|
|
$
|
216
|
|
Other invested assets
|
|
$
|
443
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
443
|
|
|
$
|
443
|
|
Premiums, reinsurance and other receivables
|
|
$
|
4,155
|
|
|
$
|
—
|
|
|
$
|
1,283
|
|
|
$
|
3,056
|
|
|
$
|
4,339
|
|
Other assets
|
|
$
|
285
|
|
|
$
|
—
|
|
|
$
|
189
|
|
|
$
|
139
|
|
|
$
|
328
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Policyholder account balances
|
|
$
|
114,355
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
116,534
|
|
|
$
|
116,534
|
|
Long-term debt
|
|
$
|
15,675
|
|
|
$
|
—
|
|
|
$
|
17,773
|
|
|
$
|
—
|
|
|
$
|
17,773
|
|
Collateral financing arrangement
|
|
$
|
1,121
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
894
|
|
|
$
|
894
|
|
Junior subordinated debt securities
|
|
$
|
3,144
|
|
|
$
|
—
|
|
|
$
|
4,319
|
|
|
$
|
—
|
|
|
$
|
4,319
|
|
Other liabilities
|
|
$
|
3,208
|
|
|
$
|
—
|
|
|
$
|
1,496
|
|
|
$
|
2,345
|
|
|
$
|
3,841
|
|
Separate account liabilities
|
|
$
|
124,011
|
|
|
$
|
—
|
|
|
$
|
124,011
|
|
|
$
|
—
|
|
|
$
|
124,011
|
|
|
|
December 31, 2016
|
||||||||||||||||||
|
|
|
|
Fair Value Hierarchy
|
|
|
||||||||||||||
|
|
Carrying
Value
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated
Fair Value
|
||||||||||
|
|
(In millions)
|
||||||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Mortgage loans
|
|
$
|
64,601
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
65,742
|
|
|
$
|
65,742
|
|
Policy loans
|
|
$
|
9,511
|
|
|
$
|
—
|
|
|
$
|
335
|
|
|
$
|
10,921
|
|
|
$
|
11,256
|
|
Other limited partnership interests
|
|
$
|
340
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
371
|
|
|
$
|
371
|
|
Other invested assets
|
|
$
|
497
|
|
|
$
|
145
|
|
|
$
|
—
|
|
|
$
|
352
|
|
|
$
|
497
|
|
Premiums, reinsurance and other receivables
|
|
$
|
4,088
|
|
|
$
|
—
|
|
|
$
|
1,152
|
|
|
$
|
3,127
|
|
|
$
|
4,279
|
|
Other assets
|
|
$
|
237
|
|
|
$
|
—
|
|
|
$
|
198
|
|
|
$
|
71
|
|
|
$
|
269
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Policyholder account balances
|
|
$
|
108,255
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
110,359
|
|
|
$
|
110,359
|
|
Long-term debt
|
|
$
|
16,422
|
|
|
$
|
—
|
|
|
$
|
17,972
|
|
|
$
|
—
|
|
|
$
|
17,972
|
|
Collateral financing arrangement
|
|
$
|
1,274
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
978
|
|
|
$
|
978
|
|
Junior subordinated debt securities
|
|
$
|
3,169
|
|
|
$
|
—
|
|
|
$
|
3,982
|
|
|
$
|
—
|
|
|
$
|
3,982
|
|
Other liabilities
|
|
$
|
1,767
|
|
|
$
|
—
|
|
|
$
|
1,493
|
|
|
$
|
275
|
|
|
$
|
1,768
|
|
Separate account liabilities
|
|
$
|
118,385
|
|
|
$
|
—
|
|
|
$
|
118,385
|
|
|
$
|
—
|
|
|
$
|
118,385
|
|
|
U.S.
|
|
Asia (1)
|
|
Latin
America
|
|
EMEA
|
|
MetLife
Holdings
|
|
Corporate
& Other
|
|
Total
|
||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
Balance at January 1, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Goodwill
|
$
|
1,451
|
|
|
$
|
4,615
|
|
|
$
|
1,385
|
|
|
$
|
1,232
|
|
|
$
|
1,567
|
|
|
$
|
42
|
|
|
$
|
10,292
|
|
Accumulated impairment (2)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(680
|
)
|
|
—
|
|
|
(680
|
)
|
|||||||
Total goodwill, net
|
1,451
|
|
|
4,615
|
|
|
1,385
|
|
|
1,232
|
|
|
887
|
|
|
42
|
|
|
9,612
|
|
|||||||
Effect of foreign currency translation and other
|
—
|
|
|
(107
|
)
|
|
(199
|
)
|
|
(89
|
)
|
|
—
|
|
|
—
|
|
|
(395
|
)
|
|||||||
Balance at December 31, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Goodwill
|
1,451
|
|
|
4,508
|
|
|
1,186
|
|
|
1,143
|
|
|
1,567
|
|
|
42
|
|
|
9,897
|
|
|||||||
Accumulated impairment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(680
|
)
|
|
—
|
|
|
(680
|
)
|
|||||||
Total goodwill, net
|
1,451
|
|
|
4,508
|
|
|
1,186
|
|
|
1,143
|
|
|
887
|
|
|
42
|
|
|
9,217
|
|
|||||||
Dispositions (3)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(42
|
)
|
|
(42
|
)
|
|||||||
Effect of foreign currency translation and other
|
—
|
|
|
88
|
|
|
40
|
|
|
(83
|
)
|
|
—
|
|
|
—
|
|
|
45
|
|
|||||||
Balance at December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Goodwill
|
1,451
|
|
|
4,596
|
|
|
1,226
|
|
|
1,060
|
|
|
1,567
|
|
|
—
|
|
|
9,900
|
|
|||||||
Accumulated impairment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(680
|
)
|
|
—
|
|
|
(680
|
)
|
|||||||
Total goodwill, net
|
1,451
|
|
|
4,596
|
|
|
1,226
|
|
|
1,060
|
|
|
887
|
|
|
—
|
|
|
9,220
|
|
|||||||
Acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
103
|
|
|
103
|
|
|||||||
Dispositions (4)
|
—
|
|
|
—
|
|
|
(16
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(16
|
)
|
|||||||
Effect of foreign currency translation and other
|
—
|
|
|
77
|
|
|
96
|
|
|
110
|
|
|
—
|
|
|
—
|
|
|
283
|
|
|||||||
Balance at December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Goodwill
|
1,451
|
|
|
4,673
|
|
|
1,306
|
|
|
1,170
|
|
|
1,567
|
|
|
103
|
|
|
10,270
|
|
|||||||
Accumulated impairment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(680
|
)
|
|
—
|
|
|
(680
|
)
|
|||||||
Total goodwill, net
|
$
|
1,451
|
|
|
$
|
4,673
|
|
|
$
|
1,306
|
|
|
$
|
1,170
|
|
|
$
|
887
|
|
|
$
|
103
|
|
|
$
|
9,590
|
|
(1)
|
Includes goodwill of
$4.5 billion
,
$4.4 billion
and
$4.3 billion
from the Japan operations at December 31, 2017, 2016 and 2015, respectively.
|
(2)
|
The
$680 million
accumulated impairment in the MetLife Holdings segment relates to the retail annuities business impaired in 2012 that was not part of the separation of Brighthouse. See
Note 3
.
|
(3)
|
In connection with the U.S. Retail Advisor Force Divestiture, goodwill in Corporate & Other was reduced by
$42 million
for the year ended December 31, 2016. See
Note 3
.
|
(4)
|
In connection with the disposition of Mexico Afore, goodwill was reduced by
$16 million
for the year ended December 31, 2017. See
Note 3
.
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|||||||||||||||||||||||
|
Interest Rates (1)
|
|
|
|
2017
|
|
2016
|
|||||||||||||||||||||||||||
|
Range
|
|
Weighted
Average |
Maturity
|
Face
Value
|
|
Unamortized
Discount and Issuance Costs
|
|
Carrying
Value
|
|
Face
Value
|
|
Unamortized
Discount and Issuance Costs
|
|
Carrying
Value
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
(In millions)
|
|||||||||||||||||||||||
Senior notes
|
3.00
|
%
|
-
|
7.72%
|
|
4.84%
|
|
2018
|
-
|
2046
|
|
$
|
14,685
|
|
|
$
|
(86
|
)
|
|
$
|
14,599
|
|
|
$
|
15,597
|
|
|
$
|
(92
|
)
|
|
$
|
15,505
|
|
Surplus notes
|
7.63
|
%
|
-
|
7.88%
|
|
7.79%
|
|
2024
|
-
|
2025
|
|
507
|
|
|
(5
|
)
|
|
502
|
|
|
507
|
|
|
(6
|
)
|
|
501
|
|
||||||
Other notes (2)
|
2.20
|
%
|
-
|
7.29%
|
|
4.56%
|
|
2018
|
-
|
2058
|
|
578
|
|
|
$
|
(4
|
)
|
|
574
|
|
|
420
|
|
|
(5
|
)
|
|
415
|
|
|||||
Capital lease obligations
|
|
|
|
|
|
|
|
|
|
|
5
|
|
|
—
|
|
|
5
|
|
|
8
|
|
|
—
|
|
|
8
|
|
|||||||
Total long-term debt
|
|
|
|
|
|
|
|
|
|
|
15,775
|
|
|
(95
|
)
|
|
15,680
|
|
|
16,532
|
|
|
(103
|
)
|
|
16,429
|
|
|||||||
Total short-term debt
|
|
|
|
|
|
|
|
|
|
|
477
|
|
|
—
|
|
|
477
|
|
|
242
|
|
|
—
|
|
|
242
|
|
|||||||
Total
|
|
|
|
|
|
|
|
|
|
|
$
|
16,252
|
|
|
$
|
(95
|
)
|
|
$
|
16,157
|
|
|
$
|
16,774
|
|
|
$
|
(103
|
)
|
|
$
|
16,671
|
|
(1)
|
Range of interest rates and weighted average interest rates are for the year ended December 31,
2017
.
|
(2)
|
During 2017, an affiliate issued
$139 million
of long-term debt to a third party.
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(Dollars in millions)
|
||||||
Commercial paper
|
|
$
|
100
|
|
|
$
|
100
|
|
Short-term borrowings (1)
|
|
377
|
|
|
142
|
|
||
Total short-term debt
|
|
$
|
477
|
|
|
$
|
242
|
|
Average daily balance
|
|
$
|
280
|
|
|
$
|
135
|
|
Average days outstanding
|
|
27 days
|
|
|
21 days
|
|
(1)
|
Includes
$374 million
and
$133 million
at December 31, 2017 and 2016, respectively, of short-term debt related to repurchase agreements, secured by assets of subsidiaries.
|
Borrower(s)
|
|
Expiration
|
|
Maximum
Capacity |
|
Letters of
Credit Issued |
|
Drawdowns
|
|
Unused
Commitments |
|||||||||
|
|
|
|
(In millions)
|
|||||||||||||||
MetLife, Inc. and MetLife Funding, Inc.
|
|
December 2021 (1)
|
|
$
|
3,000
|
|
(1)
|
|
$
|
130
|
|
|
$
|
—
|
|
|
$
|
2,870
|
|
(1)
|
All borrowings under the Credit Facility must be repaid by
December 20, 2021
, except that letters of credit outstanding upon termination may remain outstanding until December 20, 2022.
|
Account Party/Borrower(s)
|
|
Expiration
|
|
Maximum Capacity
|
|
Letters of
Credit Issued |
|
Drawdowns
|
|
Unused
Commitments |
||||||||
|
|
|
|
(In millions)
|
||||||||||||||
MetLife, Inc.
|
|
June 2018 (1)
|
|
$
|
395
|
|
|
$
|
395
|
|
|
$
|
—
|
|
|
$
|
—
|
|
MetLife Reinsurance Company of Vermont and MetLife, Inc.
|
|
December 2024 (2), (3)
|
|
400
|
|
|
380
|
|
|
—
|
|
|
20
|
|
||||
MetLife Reinsurance Company of Vermont and MetLife, Inc.
|
|
December 2037 (2), (4)
|
|
2,896
|
|
|
2,354
|
|
|
—
|
|
|
542
|
|
||||
Total
|
|
|
|
$
|
3,691
|
|
|
$
|
3,129
|
|
|
$
|
—
|
|
|
$
|
562
|
|
(1)
|
Capacity decreases in March 2018 and June 2018 to
$200 million
and
$0
, respectively.
|
(2)
|
MetLife, Inc. is a guarantor under the applicable facility.
|
(3)
|
Capacity decreases in June 2022, December 2022, June 2023, December 2023 and December 2024 to
$380 million
,
$360 million
,
$310 million
,
$260 million
and
$0
, respectively.
|
(4)
|
Capacity at December 31, 2017 of
$2.6 billion
increases periodically to a maximum of
$2.9 billion
in 2024, decreases periodically commencing in 2025 to
$2.0 billion
in 2037, and decreases to
$0
at expiration in December 2037. Unused commitment of
$542 million
is based on maximum capacity. As of December 31, 2017, Brighthouse is a beneficiary of
$2.4 billion
of letters of credit issued under this committed facility. See
Note 3
.
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
Surplus notes outstanding (1)
|
|
$
|
1,121
|
|
|
$
|
1,274
|
|
Receivable from unaffiliated financial institution (1)
|
|
$
|
146
|
|
|
$
|
166
|
|
Pledged collateral (2)
|
|
$
|
97
|
|
|
$
|
160
|
|
Assets held in trust (2)
|
|
$
|
1,248
|
|
|
$
|
1,211
|
|
(1)
|
Carrying value.
|
(2)
|
Estimated fair value.
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
||||||||||||||||||||
Issuer
|
|
Issue
Date
|
|
Interest
Rate (1)
|
|
Scheduled
Redemption
Date
|
|
Interest Rate
Subsequent to
Scheduled
Redemption
Date (2)
|
|
Final
Maturity
|
|
Face
Value
|
|
Unamortized
Discount
and Issuance Costs
|
|
Carrying
Value
|
|
Face
Value |
|
Unamortized
Discount and Issuance Costs |
|
Carrying
Value
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(In millions)
|
||||||||||||||||||||||
MetLife, Inc.
|
|
December 2006
|
|
6.400%
|
|
December 2036
|
|
LIBOR + 2.205%
|
|
December 2066
|
|
$
|
1,250
|
|
|
$
|
(21
|
)
|
|
$
|
1,229
|
|
|
$
|
1,250
|
|
|
$
|
(11
|
)
|
|
$
|
1,239
|
|
MetLife Capital Trust IV (3)
|
|
December 2007
|
|
7.875%
|
|
December 2037
|
|
LIBOR + 3.960%
|
|
December 2067
|
|
700
|
|
|
(17
|
)
|
|
683
|
|
|
700
|
|
|
(10
|
)
|
|
690
|
|
||||||
MetLife, Inc. (4)
|
|
April 2008
|
|
9.250%
|
|
April 2038
|
|
LIBOR + 5.540%
|
|
April 2068
|
|
750
|
|
|
(11
|
)
|
|
739
|
|
|
750
|
|
|
(6
|
)
|
|
744
|
|
||||||
MetLife, Inc.
|
|
July 2009
|
|
10.750%
|
|
August 2039
|
|
LIBOR + 7.548%
|
|
August 2069
|
|
500
|
|
|
(7
|
)
|
|
493
|
|
|
500
|
|
|
(4
|
)
|
|
496
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,200
|
|
|
$
|
(56
|
)
|
|
$
|
3,144
|
|
|
$
|
3,200
|
|
|
$
|
(31
|
)
|
|
$
|
3,169
|
|
(1)
|
Prior to the scheduled redemption date, interest is payable semiannually in arrears.
|
(2)
|
In the event the securities are not redeemed on or before the scheduled redemption date, interest will accrue after such date at an annual rate of three-month LIBOR plus the indicated margin, payable quarterly in arrears.
|
(3)
|
MetLife Capital Trust IV is a VIE which is consolidated on the financial statements of the Company. The securities issued by this entity are exchangeable surplus trust securities, which are exchangeable for a like amount of MetLife, Inc.’s junior subordinated debt securities on the scheduled redemption date, mandatorily under certain circumstances, and at any time upon MetLife, Inc. exercising its option to redeem the securities.
|
(4)
|
On February 10, 2017, in connection with the Separation, MetLife, Inc. exchanged
$750 million
aggregate principal amount of its
9.250%
Fixed-to-Floating Rate Junior Subordinated Debentures due 2068 for
$750 million
aggregate liquidation preference of the
9.250%
Fixed-to-Floating Rate Exchangeable Surplus Trust Securities of MetLife Capital Trust X (the “Trust”). As a result of the exchange, MetLife, Inc. became the sole beneficial owner of the Trust, a special purpose entity which issued the exchangeable surplus trust securities to third-party investors. On March 23, 2017, MetLife, Inc. dissolved the Trust.
|
Series
|
|
Shares
Authorized |
|
Shares
Issued |
|
Shares
Outstanding |
|||
Floating Rate Non-Cumulative Preferred Stock, Series A
|
|
27,600,000
|
|
|
24,000,000
|
|
|
24,000,000
|
|
5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C
|
|
1,500,000
|
|
|
1,500,000
|
|
|
1,500,000
|
|
Series A Junior Participating Preferred Stock
|
|
10,000,000
|
|
|
—
|
|
|
—
|
|
Not designated
|
|
160,900,000
|
|
|
—
|
|
|
—
|
|
Total
|
|
200,000,000
|
|
|
25,500,000
|
|
|
25,500,000
|
|
|
|
|
|
|
|
Dividend
|
||||||||||||||||||||||
Declaration Date
|
|
Record Date
|
|
Payment Date
|
|
Series A
Per Share
|
|
Series A
Aggregate
|
|
Series B
Per Share
|
|
Series B
Aggregate
|
|
Series C
Per Share
|
|
Series C
Aggregate
|
||||||||||||
|
|
|
|
|
|
(In millions, except per share data)
|
||||||||||||||||||||||
November 15, 2017
|
|
November 30, 2017
|
|
December 15, 2017
|
|
$
|
0.253
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
26.250
|
|
|
$
|
39
|
|
August 15, 2017
|
|
August 31, 2017
|
|
September 15, 2017
|
|
$
|
0.256
|
|
|
6
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|||
May 15, 2017
|
|
May 31, 2017
|
|
June 15, 2017
|
|
$
|
0.256
|
|
|
7
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
26.250
|
|
|
39
|
|
|||
March 6, 2017
|
|
February 28, 2017
|
|
March 15, 2017
|
|
$
|
0.250
|
|
|
6
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
$
|
25
|
|
|
|
|
$
|
—
|
|
|
|
|
$
|
78
|
|
||||||
November 15, 2016
|
|
November 30, 2016
|
|
December 15, 2016
|
|
$
|
0.253
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
26.250
|
|
|
$
|
39
|
|
August 15, 2016
|
|
August 31, 2016
|
|
September 15, 2016
|
|
$
|
0.256
|
|
|
6
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|||
May 16, 2016
|
|
May 31, 2016
|
|
June 15, 2016
|
|
$
|
0.256
|
|
|
7
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
26.250
|
|
|
39
|
|
|||
March 7, 2016
|
|
February 29, 2016
|
|
March 15, 2016
|
|
$
|
0.253
|
|
|
6
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
$
|
25
|
|
|
|
|
$
|
—
|
|
|
|
|
$
|
78
|
|
||||||
November 16, 2015
|
|
November 30, 2015
|
|
December 15, 2015
|
|
$
|
0.253
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
28.292
|
|
|
$
|
43
|
|
August 17, 2015
|
|
August 31, 2015
|
|
September 15, 2015
|
|
$
|
0.256
|
|
|
6
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|||
May 15, 2015
|
|
May 31, 2015
|
|
June 15, 2015
|
|
$
|
0.256
|
|
|
7
|
|
|
$
|
0.406
|
|
|
24
|
|
|
$
|
—
|
|
|
—
|
|
|||
March 5, 2015
|
|
February 28, 2015
|
|
March 16, 2015
|
|
$
|
0.250
|
|
|
6
|
|
|
$
|
0.406
|
|
|
24
|
|
|
$
|
—
|
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
$
|
25
|
|
|
|
|
$
|
48
|
|
|
|
|
$
|
43
|
|
|
|
|
|
|
|
Dividend
|
||||||
Declaration Date
|
|
Record Date
|
|
Payment Date
|
|
Per Share
|
|
Aggregate
|
||||
|
|
|
|
|
|
(In millions, except per share data)
|
||||||
October 24, 2017
|
|
November 6, 2017
|
|
December 13, 2017
|
|
$
|
0.400
|
|
|
$
|
422
|
|
July 7, 2017
|
|
August 7, 2017
|
|
September 13, 2017
|
|
$
|
0.400
|
|
|
427
|
|
|
April 25, 2017
|
|
May 8, 2017
|
|
June 13, 2017
|
|
$
|
0.400
|
|
|
431
|
|
|
January 6, 2017
|
|
February 6, 2017
|
|
March 13, 2017
|
|
$
|
0.400
|
|
|
437
|
|
|
|
|
|
|
|
|
|
|
$
|
1,717
|
|
||
October 25, 2016
|
|
November 7, 2016
|
|
December 13, 2016
|
|
$
|
0.400
|
|
|
$
|
441
|
|
July 7, 2016
|
|
August 8, 2016
|
|
September 13, 2016
|
|
$
|
0.400
|
|
|
441
|
|
|
April 26, 2016
|
|
May 9, 2016
|
|
June 13, 2016
|
|
$
|
0.400
|
|
|
441
|
|
|
January 6, 2016
|
|
February 5, 2016
|
|
March 14, 2016
|
|
$
|
0.375
|
|
|
413
|
|
|
|
|
|
|
|
|
|
|
$
|
1,736
|
|
||
October 27, 2015
|
|
November 6, 2015
|
|
December 11, 2015
|
|
$
|
0.375
|
|
|
$
|
419
|
|
July 7, 2015
|
|
August 7, 2015
|
|
September 11, 2015
|
|
$
|
0.375
|
|
|
420
|
|
|
April 28, 2015
|
|
May 11, 2015
|
|
June 12, 2015
|
|
$
|
0.375
|
|
|
420
|
|
|
January 6, 2015
|
|
February 6, 2015
|
|
March 13, 2015
|
|
$
|
0.350
|
|
|
394
|
|
|
|
|
|
|
|
|
|
|
$
|
1,653
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Stock Options and Unit Options
|
$
|
8
|
|
|
$
|
9
|
|
|
$
|
12
|
|
Performance Shares and Performance Units (1)
|
62
|
|
|
75
|
|
|
59
|
|
|||
Restricted Stock Units and Restricted Units
|
58
|
|
|
63
|
|
|
66
|
|
|||
Total compensation expense
|
$
|
128
|
|
|
$
|
147
|
|
|
$
|
137
|
|
Income tax benefit
|
$
|
45
|
|
|
$
|
51
|
|
|
$
|
48
|
|
(1)
|
Performance Shares expected to vest and the related compensation expenses may be further adjusted by the performance factor most likely to be achieved, as estimated by management, at the end of the performance period.
|
|
December 31, 2017
|
||||
|
Expense
|
|
Weighted Average
Period
|
||
|
(In millions)
|
|
(Years)
|
||
Stock Options
|
$
|
4
|
|
|
1.77
|
Performance Shares
|
$
|
30
|
|
|
1.59
|
Restricted Stock Units
|
$
|
40
|
|
|
1.84
|
|
Shares
Under
Option
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic
Value (1)
|
|||||
|
|
|
|
|
(Years)
|
|
(In millions)
|
|||||
Outstanding at January 1, 2017
|
19,482,388
|
|
|
$
|
44.73
|
|
|
3.68
|
|
$
|
218
|
|
Granted (2)
|
709,085
|
|
|
$
|
46.85
|
|
|
|
|
|
||
Exercised (2)
|
(3,475,198
|
)
|
|
$
|
33.36
|
|
|
|
|
|
||
Expired (2)
|
(2,913,457
|
)
|
|
$
|
56.06
|
|
|
|
|
|
||
Forfeited (2)
|
(115,670
|
)
|
|
$
|
40.06
|
|
|
|
|
|
||
Other Separation adjustment (2)
|
2,322,606
|
|
|
$
|
38.40
|
|
|
|
|
|
||
Outstanding at December 31, 2017
|
16,009,754
|
|
|
$
|
38.77
|
|
|
3.54
|
|
$
|
198
|
|
Vested and expected to vest at December 31, 2017
|
15,991,119
|
|
|
$
|
38.76
|
|
|
3.13
|
|
$
|
238
|
|
Exercisable at December 31, 2017
|
14,487,455
|
|
|
$
|
38.46
|
|
|
3.02
|
|
$
|
185
|
|
(1)
|
The intrinsic value of each Stock Option is the closing price on a particular date less the exercise price of the Stock Option, so long as the difference is greater than zero. The aggregate intrinsic value of all outstanding Stock Options is computed using the closing Share price on December 31,
2017
of
$50.56
and December 31,
2016
of
$48.02
, as applicable.
|
(2)
|
For Stock Options outstanding as of August 4, 2017, MetLife, Inc. increased the number of Stock Options by an adjustment ratio, and lowered their exercise price by dividing it by the same adjustment ratio, to maintain the intrinsic value of the award pursuant to the anti-dilution provisions of the 2015 Stock Plan and the 2005 Stock Plan as a result of the Separation. MetLife, Inc. determined the adjustment ratio by dividing the
$53.92
closing price of MetLife, Inc. common stock on August 4, 2017 by the
$48.17
opening price of MetLife, Inc. common stock on August 7, 2017, the next trading day. Each of “Granted,” “Exercised,” “Expired,” and “Forfeited” reflects the impact of this adjustment, as applicable, regardless of the date of the transaction during 2017. “Other Separation adjustment” reflects the remaining adjustment to produce the Stock Options outstanding at December 31, 2017.
|
|
|
Years Ended December 31,
|
||||
|
|
2017
|
|
2016
|
|
2015
|
Dividend yield
|
|
3.05%
|
|
3.90%
|
|
2.72%
|
Risk-free rate of return
|
|
0.94% - 3.22%
|
|
0.62% - 2.85%
|
|
0.20% - 3.04%
|
Expected volatility
|
|
34.19%
|
|
33.58%
|
|
32.56%
|
Exercise multiple
|
|
1.43
|
|
1.43
|
|
1.44
|
Post-vesting termination rate
|
|
2.94%
|
|
2.58%
|
|
2.73%
|
Contractual term (years)
|
|
10
|
|
10
|
|
10
|
Expected life (years)
|
|
6
|
|
7
|
|
7
|
Weighted average exercise price of stock options granted
|
|
$46.85
|
|
$34.33
|
|
$45.91
|
Weighted average fair value of stock options granted
|
|
$12.36
|
|
$8.27
|
|
$11.87
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Total intrinsic value of stock options exercised
|
|
$
|
59
|
|
|
$
|
42
|
|
|
$
|
44
|
|
Cash received from exercise of stock options
|
|
$
|
116
|
|
|
$
|
84
|
|
|
$
|
121
|
|
Income tax benefit realized from stock options exercised
|
|
$
|
20
|
|
|
$
|
15
|
|
|
$
|
15
|
|
|
Performance Shares
|
|
Restricted Stock Units
|
||||||||||
|
Shares
|
|
Weighted
Average Fair Value (1) |
|
Units
|
|
Weighted
Average Fair Value (1) |
||||||
Outstanding at January 1, 2017
|
3,817,100
|
|
|
$
|
49.88
|
|
|
3,422,013
|
|
|
$
|
39.08
|
|
Granted (2)
|
1,225,333
|
|
|
$
|
45.60
|
|
|
1,445,238
|
|
|
$
|
42.45
|
|
Forfeited (2)
|
(270,292
|
)
|
|
$
|
42.94
|
|
|
(251,216
|
)
|
|
$
|
35.64
|
|
Payable (2) (3)
|
(1,192,734
|
)
|
|
$
|
44.84
|
|
|
(1,720,168
|
)
|
|
$
|
36.81
|
|
Other Separation adjustment (2)
|
454,353
|
|
|
$
|
42.34
|
|
|
408,510
|
|
|
$
|
37.07
|
|
Outstanding at December 31, 2017
|
4,033,760
|
|
|
$
|
46.02
|
|
|
3,304,377
|
|
|
$
|
37.17
|
|
Vested and expected to vest at December 31, 2017
|
3,971,002
|
|
|
$
|
46.02
|
|
|
3,246,476
|
|
|
$
|
37.14
|
|
(1)
|
Values for shares outstanding at January 1, 2017, represent weighted average number of shares multiplied by the fair value per share at December 31, 2016. Otherwise, all values represent weighted average of number of shares multiplied by the fair value per share at
December 31, 2017
. Fair value per share of Restricted Stock Units on
December 31, 2017
was equal to Grant Date fair value per share.
|
(2)
|
For Performance Shares, Restricted Stock Units, and Deferred Shares outstanding as of August 4, 2017, MetLife, Inc. increased the number of units by an adjustment ratio to maintain the intrinsic value of the award or Deferred Shares pursuant to the anti-dilution provisions of the 2015 Stock Plan and the 2005 Stock Plan as a result of the Separation. MetLife, Inc. determined the adjustment ratio by dividing the
$53.92
closing price of MetLife, Inc. common stock on August 4, 2017 by the
$48.17
opening price of MetLife, Inc. common stock on August 7, 2017, the next trading day. Each of “Granted,” “Forfeited,” and “Payable” reflects the impact of this adjustment, as applicable, regardless of the date of the transaction during 2017. “Other Separation adjustment” reflects the remaining adjustment to produce the Performance Shares and Restricted Stock Units outstanding at December 31, 2017.
|
(3)
|
Includes both Shares paid and Deferred Shares for later payment.
|
|
Unit
Options
|
|
Performance
Units |
|
Restricted
Units |
|||
Outstanding at January 1, 2017
|
855,897
|
|
|
615,356
|
|
|
763,723
|
|
Granted (1)
|
24,175
|
|
|
238,487
|
|
|
375,414
|
|
Exercised (1)
|
(200,687
|
)
|
|
—
|
|
|
—
|
|
Forfeited (1)
|
(100,439
|
)
|
|
(53,499
|
)
|
|
(82,940
|
)
|
Paid (1)
|
—
|
|
|
(185,178
|
)
|
|
(368,049
|
)
|
Other Separation adjustment (1)
|
102,066
|
|
|
73,063
|
|
|
90,928
|
|
Outstanding at December 31, 2017
|
681,012
|
|
|
688,229
|
|
|
779,076
|
|
Vested and expected to vest at December 31, 2017
|
612,911
|
|
|
619,406
|
|
|
701,168
|
|
(1)
|
For Unit Options, Performance Units, and Restricted Units outstanding as of August 4, 2017, MetLife, Inc. increased the number of units, and for Units Options lowered the exercise price by an adjustment ratio to maintain the intrinsic value of the award pursuant to the anti-dilution provisions of the 2015 Stock Plan and the 2005 Stock Plan as a result of the Separation. MetLife, Inc. determined the adjustment ratio by dividing the
$53.92
closing price of MetLife, Inc. common stock on August 4, 2017 by the
$48.17
opening price of MetLife, Inc. common stock on August 7, 2017, the next trading day. Each of “Granted,” “Exercised,” “Forfeited,” and “Paid” reflects the impact of this adjustment, as applicable, regardless of the date of the transaction during 2017. “Other Separation adjustment” reflects the remaining adjustment to produce the Unit Options, Performance Units, and Restricted Units outstanding at December 31, 2017.
|
|
|
|
|
Years Ended December 31,
|
||||||||||
Company
|
|
State of Domicile
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
|
|
(In millions)
|
||||||||||
Metropolitan Life Insurance Company (1)
|
|
New York
|
|
$
|
1,982
|
|
|
$
|
3,444
|
|
|
$
|
3,703
|
|
American Life Insurance Company
|
|
Delaware
|
|
$
|
3,077
|
|
|
$
|
341
|
|
|
$
|
335
|
|
Brighthouse Life Insurance Company (2)
|
|
Delaware
|
|
N/A
|
|
|
$
|
1,186
|
|
|
$
|
(1,022
|
)
|
|
Metropolitan Property and Casualty Insurance Company
|
|
Rhode Island
|
|
$
|
197
|
|
|
$
|
171
|
|
|
$
|
204
|
|
Metropolitan Tower Life Insurance Company
|
|
Delaware
|
|
$
|
74
|
|
|
$
|
8
|
|
|
$
|
(42
|
)
|
New England Life Insurance Company (2)
|
|
Massachusetts
|
|
N/A
|
|
|
$
|
109
|
|
|
$
|
157
|
|
|
General American Life Insurance Company
|
|
Missouri
|
|
$
|
90
|
|
|
$
|
(2
|
)
|
|
$
|
204
|
|
Other (3)
|
|
Various
|
|
$
|
11
|
|
|
$
|
(70
|
)
|
|
$
|
20
|
|
(1)
|
In December 2016, MLIC transferred all of the issued and outstanding shares of the common stock of each of
New England Life Insurance Company
(“NELICO”) and General American Life Insurance Company (“GALIC”) to MetLife, Inc., in the form of a non-cash extraordinary
dividend.
|
(2)
|
Effective April 28, 2017 in connection with the Separation, MetLife, Inc. contributed all of the issued and outstanding shares of common stock of each of Brighthouse Insurance and NELICO to Brighthouse Holdings, LLC. As a result of the Separation, Brighthouse Insurance and NELICO ceased to be subsidiaries of MetLife, Inc.
|
(3)
|
Effective April 28, 2017 in connection with the Separation, MetLife, Inc. contributed all of the issued and outstanding shares of Brighthouse Life Insurance Company of NY (“Brighthouse NY”) to Brighthouse Holdings, LLC. As a result of the Separation, Brighthouse NY ceased to be a subsidiary of MetLife, Inc. For the years ended December 31, 2016 and 2015, statutory net income (loss) of Brighthouse NY was
($87) million
and
$17 million
, respectively.
|
|
|
December 31,
|
||||||
Company
|
|
2017
|
|
2016
|
||||
|
|
(In millions)
|
||||||
Metropolitan Life Insurance Company (1)
|
|
$
|
10,384
|
|
|
$
|
11,195
|
|
American Life Insurance Company
|
|
$
|
6,548
|
|
|
$
|
5,895
|
|
Brighthouse Life Insurance Company (2)
|
|
N/A
|
|
|
$
|
4,374
|
|
|
Metropolitan Property and Casualty Insurance Company
|
|
$
|
2,266
|
|
|
$
|
2,271
|
|
Metropolitan Tower Life Insurance Company
|
|
$
|
733
|
|
|
$
|
669
|
|
New England Life Insurance Company (2)
|
|
N/A
|
|
|
$
|
455
|
|
|
General American Life Insurance Company
|
|
$
|
988
|
|
|
$
|
923
|
|
Other (3)
|
|
$
|
100
|
|
|
$
|
303
|
|
(1)
|
In December 2016, MLIC transferred all of the issued and outstanding shares of the common stock of each of NELICO and GALIC to MetLife, Inc. in the form of a non-cash extraordinary dividend.
|
(2)
|
Effective April 28, 2017 in connection with the Separation, MetLife, Inc. contributed all of the issued and outstanding shares of common stock of each of Brighthouse Insurance and NELICO to Brighthouse Holdings, LLC. As a result of the Separation, Brighthouse Insurance and NELICO ceased to be subsidiaries of MetLife, Inc.
|
(3)
|
Effective April 28, 2017 in connection with the Separation, MetLife, Inc. contributed all of the issued and outstanding shares of Brighthouse NY to Brighthouse Holdings, LLC. As a result of the Separation, Brighthouse NY ceased to be a subsidiary of MetLife, Inc. At December 31, 2016, Brighthouse NY statutory capital and surplus was
$196 million
.
|
|
|
2018
|
|
2017
|
|
|
2016
|
||||||||
Company
|
|
Permitted Without
Approval (1) |
|
Paid (2)
|
|
|
Paid (2)
|
||||||||
|
|
(In millions)
|
|
||||||||||||
Metropolitan Life Insurance Company
|
|
$
|
3,075
|
|
|
$
|
2,523
|
|
|
|
$
|
5,740
|
|
(3
|
)
|
American Life Insurance Company
|
|
$
|
—
|
|
|
$
|
2,200
|
|
(4)
|
|
$
|
—
|
|
|
|
Brighthouse Life Insurance Company (5)
|
|
N/A
|
|
|
$
|
—
|
|
|
|
$
|
261
|
|
|
||
Metropolitan Property and Casualty Insurance Company
|
|
$
|
125
|
|
|
$
|
185
|
|
|
|
$
|
228
|
|
|
|
Metropolitan Tower Life Insurance Company
|
|
$
|
73
|
|
|
$
|
—
|
|
|
|
$
|
60
|
|
|
|
New England Life Insurance Company (5)
|
|
N/A
|
|
|
$
|
—
|
|
|
|
$
|
295
|
|
(6
|
)
|
|
General American Life Insurance Company
|
|
$
|
118
|
|
|
$
|
1
|
|
|
|
$
|
—
|
|
|
(1)
|
Reflects dividend amounts that may be paid during 2018 without prior regulatory approval. However, because dividend tests may be based on dividends previously paid over rolling 12-month periods, if paid before a specified date during 2018, some or all of such dividends may require regulatory approval.
|
(2)
|
Reflects all amounts paid, including those requiring regulatory approval.
|
(3)
|
In 2016, MLIC paid an ordinary cash dividend to MetLife, Inc. in the amount of
$3.6 billion
. In addition, in December 2016, MLIC distributed all of the issued and outstanding shares of common stock of each of NELICO and GALIC to MetLife, Inc. in the form of a non-cash extraordinary dividend in the amount of
$981 million
and
$1.2 billion
, respectively, as calculated on a statutory basis.
|
(4)
|
Represents an extraordinary dividend.
|
(5)
|
Effective April 28, 2017 in connection with the Separation, MetLife, Inc. contributed all of the issued and outstanding shares of common stock of each of
Brighthouse Insurance
and NELICO to Brighthouse Holdings, LLC. As a result of the Separation, Brighthouse Insurance and NELICO ceased to be subsidiaries of MetLife, Inc. See Note
3
for other Brighthouse dividend transactions prior to the Separation.
|
(6)
|
Represents
an extraordinary dividend paid by NELICO in 2016 to MetLife, Inc.
|
|
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
|
|
Unrealized Gains
(Losses) on
Derivatives
|
|
Foreign
Currency
Translation
Adjustments
|
|
Defined
Benefit
Plans
Adjustment
|
|
Total
|
||||||||||
|
(In millions)
|
||||||||||||||||||
Balance at December 31, 2014
|
$
|
15,224
|
|
|
$
|
1,076
|
|
|
$
|
(3,303
|
)
|
|
$
|
(2,283
|
)
|
|
$
|
10,714
|
|
OCI before reclassifications
|
(7,224
|
)
|
|
(19
|
)
|
|
(1,646
|
)
|
|
125
|
|
|
(8,764
|
)
|
|||||
Deferred income tax benefit (expense)
|
2,456
|
|
|
6
|
|
|
(1
|
)
|
|
(43
|
)
|
|
2,418
|
|
|||||
AOCI before reclassifications, net of income tax
|
10,456
|
|
|
1,063
|
|
|
(4,950
|
)
|
|
(2,201
|
)
|
|
4,368
|
|
|||||
Amounts reclassified from AOCI
|
(223
|
)
|
|
608
|
|
|
—
|
|
|
229
|
|
|
614
|
|
|||||
Deferred income tax benefit (expense)
|
78
|
|
|
(213
|
)
|
|
—
|
|
|
(80
|
)
|
|
(215
|
)
|
|||||
Amounts reclassified from AOCI, net of income tax
|
(145
|
)
|
|
395
|
|
|
—
|
|
|
149
|
|
|
399
|
|
|||||
Balance at December 31, 2015
|
10,311
|
|
|
1,458
|
|
|
(4,950
|
)
|
|
(2,052
|
)
|
|
4,767
|
|
|||||
OCI before reclassifications
|
800
|
|
|
344
|
|
|
(476
|
)
|
|
(62
|
)
|
|
606
|
|
|||||
Deferred income tax benefit (expense)
|
(338
|
)
|
|
(100
|
)
|
|
114
|
|
|
24
|
|
|
(300
|
)
|
|||||
AOCI before reclassifications, net of income tax
|
10,773
|
|
|
1,702
|
|
|
(5,312
|
)
|
|
(2,090
|
)
|
|
5,073
|
|
|||||
Amounts reclassified from AOCI
|
21
|
|
|
229
|
|
|
—
|
|
|
193
|
|
|
443
|
|
|||||
Deferred income tax benefit (expense)
|
(9
|
)
|
|
(66
|
)
|
|
—
|
|
|
(75
|
)
|
|
(150
|
)
|
|||||
Amounts reclassified from AOCI, net of income tax
|
12
|
|
|
163
|
|
|
—
|
|
|
118
|
|
|
293
|
|
|||||
Balance at December 31, 2016
|
10,785
|
|
|
1,865
|
|
|
(5,312
|
)
|
|
(1,972
|
)
|
|
5,366
|
|
|||||
OCI before reclassifications
|
5,392
|
|
|
(140
|
)
|
|
765
|
|
|
(23
|
)
|
|
5,994
|
|
|||||
Deferred income tax benefit (expense)
|
(1,732
|
)
|
|
47
|
|
|
125
|
|
|
8
|
|
|
(1,552
|
)
|
|||||
AOCI before reclassifications, net of income tax
|
14,445
|
|
|
1,772
|
|
|
(4,422
|
)
|
|
(1,987
|
)
|
|
9,808
|
|
|||||
Amounts reclassified from AOCI
|
(289
|
)
|
|
(1,025
|
)
|
|
—
|
|
|
167
|
|
|
(1,147
|
)
|
|||||
Deferred income tax benefit (expense)
|
87
|
|
|
356
|
|
|
—
|
|
|
(43
|
)
|
|
400
|
|
|||||
Amounts reclassified from AOCI, net of income tax
|
(202
|
)
|
|
(669
|
)
|
|
—
|
|
|
124
|
|
|
(747
|
)
|
|||||
Disposal of subsidiary (2)
|
(2,286
|
)
|
|
(305
|
)
|
|
51
|
|
|
28
|
|
|
(2,512
|
)
|
|||||
Deferred income tax benefit (expense)
|
800
|
|
|
107
|
|
|
(19
|
)
|
|
(10
|
)
|
|
878
|
|
|||||
Disposal of subsidiary, net of income tax
|
(1,486
|
)
|
|
(198
|
)
|
|
32
|
|
|
18
|
|
|
(1,634
|
)
|
|||||
Balance at December 31, 2017
|
$
|
12,757
|
|
|
$
|
905
|
|
|
$
|
(4,390
|
)
|
|
$
|
(1,845
|
)
|
|
$
|
7,427
|
|
(1)
|
See
Note 8
for information on offsets to investments related to future policy benefits, DAC, VOBA and DSI, and the policyholder dividend obligation.
|
(2)
|
See Note 3.
|
AOCI Components
|
|
Amounts Reclassified from AOCI
|
|
Consolidated Statements of
Operations Locations
|
||||||||||
|
|
Years Ended December 31,
|
|
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
|
|
||||||
|
|
(In millions)
|
|
|
||||||||||
Net unrealized investment gains (losses):
|
|
|
|
|
|
|
|
|
||||||
Net unrealized investment gains (losses)
|
|
$
|
404
|
|
|
$
|
78
|
|
|
$
|
263
|
|
|
Net investment gains (losses)
|
Net unrealized investment gains (losses)
|
|
20
|
|
|
39
|
|
|
35
|
|
|
Net investment income
|
|||
Net unrealized investment gains (losses)
|
|
(49
|
)
|
|
(37
|
)
|
|
56
|
|
|
Net derivative gains (losses)
|
|||
Net unrealized investment gains (losses)
|
|
(86
|
)
|
|
(101
|
)
|
|
(131
|
)
|
|
Discontinued operations
|
|||
Net unrealized investment gains (losses), before income tax
|
|
289
|
|
|
(21
|
)
|
|
223
|
|
|
|
|||
Income tax (expense) benefit
|
|
(87
|
)
|
|
9
|
|
|
(78
|
)
|
|
|
|||
Net unrealized investment gains (losses), net of income tax
|
|
202
|
|
|
(12
|
)
|
|
145
|
|
|
|
|||
Unrealized gains (losses) on derivatives - cash flow hedges:
|
|
|
|
|
|
|
|
|
||||||
Interest rate swaps
|
|
24
|
|
|
56
|
|
|
84
|
|
|
Net derivative gains (losses)
|
|||
Interest rate swaps
|
|
16
|
|
|
12
|
|
|
11
|
|
|
Net investment income
|
|||
Interest rate swaps
|
|
2
|
|
|
36
|
|
|
2
|
|
|
Discontinued operations
|
|||
Interest rate forwards
|
|
(11
|
)
|
|
(1
|
)
|
|
4
|
|
|
Net derivative gains (losses)
|
|||
Interest rate forwards
|
|
2
|
|
|
4
|
|
|
3
|
|
|
Net investment income
|
|||
Interest rate forwards
|
|
1
|
|
|
1
|
|
|
2
|
|
|
Other expenses
|
|||
Interest rate forwards
|
|
3
|
|
|
4
|
|
|
4
|
|
|
Discontinued operations
|
|||
Foreign currency swaps
|
|
974
|
|
|
(350
|
)
|
|
(720
|
)
|
|
Net derivative gains (losses)
|
|||
Foreign currency swaps
|
|
—
|
|
|
(2
|
)
|
|
(1
|
)
|
|
Net investment income
|
|||
Foreign currency swaps
|
|
2
|
|
|
2
|
|
|
1
|
|
|
Other expenses
|
|||
Foreign currency swaps
|
|
11
|
|
|
5
|
|
|
—
|
|
|
Discontinued operations
|
|||
Credit forwards
|
|
1
|
|
|
3
|
|
|
1
|
|
|
Net derivative gains (losses)
|
|||
Credit forwards
|
|
—
|
|
|
1
|
|
|
—
|
|
|
Net investment income
|
|||
Credit forwards
|
|
—
|
|
|
—
|
|
|
1
|
|
|
Discontinued operations
|
|||
Gains (losses) on cash flow hedges, before income tax
|
|
1,025
|
|
|
(229
|
)
|
|
(608
|
)
|
|
|
|||
Income tax (expense) benefit
|
|
(356
|
)
|
|
66
|
|
|
213
|
|
|
|
|||
Gains (losses) on cash flow hedges, net of income tax
|
|
669
|
|
|
(163
|
)
|
|
(395
|
)
|
|
|
|||
Defined benefit plans adjustment: (1)
|
|
|
|
|
|
|
|
|
||||||
Amortization of net actuarial gains (losses)
|
|
(190
|
)
|
|
(199
|
)
|
|
(231
|
)
|
|
|
|||
Amortization of prior service (costs) credit
|
|
23
|
|
|
6
|
|
|
6
|
|
|
|
|||
Discontinued operations
|
|
—
|
|
|
—
|
|
|
(4
|
)
|
|
|
|||
Amortization of defined benefit plan items, before income tax
|
|
(167
|
)
|
|
(193
|
)
|
|
(229
|
)
|
|
|
|||
Income tax (expense) benefit
|
|
43
|
|
|
75
|
|
|
80
|
|
|
|
|||
Amortization of defined benefit plan items, net of income tax
|
|
(124
|
)
|
|
(118
|
)
|
|
(149
|
)
|
|
|
|||
Total reclassifications, net of income tax
|
|
$
|
747
|
|
|
$
|
(293
|
)
|
|
$
|
(399
|
)
|
|
|
(1)
|
These AOCI components are included in the computation of net periodic benefit costs. See
Note 17
.
|
|
|
Years Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
|
(In millions)
|
||||||||||
Employee and related costs
|
|
$
|
3,595
|
|
|
$
|
3,840
|
|
|
$
|
3,950
|
|
Professional services
|
|
1,693
|
|
|
1,619
|
|
|
1,568
|
|
|||
General and administrative expenses
|
|
1,129
|
|
|
1,007
|
|
|
1,417
|
|
|||
Pension, postretirement and postemployment benefit costs
|
|
307
|
|
|
400
|
|
|
367
|
|
|||
Premium taxes, other taxes, and licenses & fees
|
|
842
|
|
|
688
|
|
|
691
|
|
|||
Commissions and other variable expenses
|
|
5,387
|
|
|
5,741
|
|
|
6,112
|
|
|||
Capitalization of DAC
|
|
(3,002
|
)
|
|
(3,152
|
)
|
|
(3,319
|
)
|
|||
Amortization of DAC and VOBA
|
|
2,681
|
|
|
2,718
|
|
|
3,184
|
|
|||
Amortization of negative VOBA
|
|
(140
|
)
|
|
(269
|
)
|
|
(361
|
)
|
|||
Interest expense on debt
|
|
1,129
|
|
|
1,157
|
|
|
1,168
|
|
|||
Total other expenses
|
|
$
|
13,621
|
|
|
$
|
13,749
|
|
|
$
|
14,777
|
|
|
Years Ended December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
Severance
|
||||||
|
(In millions)
|
||||||
Balance at January 1,
|
$
|
35
|
|
|
$
|
—
|
|
Restructuring charges
|
38
|
|
|
35
|
|
||
Cash payments
|
(51
|
)
|
|
—
|
|
||
Balance at December 31,
|
$
|
22
|
|
|
$
|
35
|
|
Total restructuring charges incurred since inception of initiative
|
$
|
73
|
|
|
$
|
35
|
|
|
|
Years Ended December 31,
|
||||||||||||||||||||||
|
|
2016
|
|
2015
|
||||||||||||||||||||
|
|
Severance
|
|
Lease and
Asset
Impairment
|
|
Total
|
|
Severance
|
|
Lease and
Asset
Impairment
|
|
Total
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Balance at January 1,
|
|
$
|
18
|
|
|
$
|
4
|
|
|
$
|
22
|
|
|
$
|
31
|
|
|
$
|
6
|
|
|
$
|
37
|
|
Restructuring charges
|
|
—
|
|
|
1
|
|
|
1
|
|
|
60
|
|
|
4
|
|
|
64
|
|
||||||
Cash payments
|
|
(17
|
)
|
|
(4
|
)
|
|
(21
|
)
|
|
(73
|
)
|
|
(6
|
)
|
|
(79
|
)
|
||||||
Balance at December 31,
|
|
$
|
1
|
|
|
$
|
1
|
|
|
$
|
2
|
|
|
$
|
18
|
|
|
$
|
4
|
|
|
$
|
22
|
|
Total restructuring charges incurred since inception of initiative
|
|
$
|
383
|
|
|
$
|
47
|
|
|
$
|
430
|
|
|
$
|
383
|
|
|
$
|
46
|
|
|
$
|
429
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||||||||||||||||
|
Pension Benefits
|
|
Other Postretirement
Benefits
|
|
Pension Benefits
|
|
Other Postretirement
Benefits
|
||||||||||||||||||||||||||||||||||||||||
|
U.S.
Plans
|
|
Non-
U.S.
Plans
|
|
Total
|
|
U.S.
Plans
|
|
Non-
U.S.
Plans
|
|
Total
|
|
U.S.
Plans
|
|
Non-
U.S.
Plans
|
|
Total
|
|
U.S.
Plans
|
|
Non-
U.S.
Plans
|
|
Total
|
||||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||||||||||
Benefit obligations
|
$
|
10,500
|
|
|
$
|
909
|
|
|
$
|
11,409
|
|
|
$
|
1,648
|
|
|
$
|
26
|
|
|
$
|
1,674
|
|
|
$
|
9,859
|
|
|
$
|
882
|
|
|
$
|
10,741
|
|
|
$
|
1,734
|
|
|
$
|
25
|
|
|
$
|
1,759
|
|
Estimated fair value of plan assets
|
9,371
|
|
|
317
|
|
|
9,688
|
|
|
1,426
|
|
|
8
|
|
|
1,434
|
|
|
8,721
|
|
|
288
|
|
|
9,009
|
|
|
1,379
|
|
|
7
|
|
|
1,386
|
|
||||||||||||
Over (under) funded status
|
$
|
(1,129
|
)
|
|
$
|
(592
|
)
|
|
$
|
(1,721
|
)
|
|
$
|
(222
|
)
|
|
$
|
(18
|
)
|
|
$
|
(240
|
)
|
|
$
|
(1,138
|
)
|
|
$
|
(594
|
)
|
|
$
|
(1,732
|
)
|
|
$
|
(355
|
)
|
|
$
|
(18
|
)
|
|
$
|
(373
|
)
|
Net periodic benefit costs
|
$
|
267
|
|
|
$
|
82
|
|
|
$
|
349
|
|
|
$
|
(12
|
)
|
|
$
|
2
|
|
|
$
|
(10
|
)
|
|
$
|
278
|
|
|
$
|
81
|
|
|
$
|
359
|
|
|
$
|
37
|
|
|
$
|
2
|
|
|
$
|
39
|
|
|
|
December 31,
|
||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||
|
|
Pension
Benefits (1) |
|
Other
Postretirement
Benefits
|
|
Pension
Benefits (1) |
|
Other
Postretirement
Benefits
|
||||||||
|
|
(In millions)
|
||||||||||||||
Change in benefit obligations:
|
|
|
|
|
|
|
|
|
||||||||
Benefit obligations at January 1,
|
|
$
|
10,741
|
|
|
$
|
1,759
|
|
|
$
|
10,293
|
|
|
$
|
1,892
|
|
Service costs
|
|
238
|
|
|
6
|
|
|
272
|
|
|
9
|
|
||||
Interest costs
|
|
429
|
|
|
76
|
|
|
423
|
|
|
82
|
|
||||
Plan participants’ contributions
|
|
—
|
|
|
33
|
|
|
—
|
|
|
30
|
|
||||
Net actuarial (gains) losses
|
|
595
|
|
|
(95
|
)
|
|
362
|
|
|
(115
|
)
|
||||
Acquisition, divestitures, settlements and curtailments
|
|
(27
|
)
|
|
—
|
|
|
(37
|
)
|
|
18
|
|
||||
Change in benefits
|
|
—
|
|
|
—
|
|
|
(11
|
)
|
|
(43
|
)
|
||||
Benefits paid
|
|
(600
|
)
|
|
(107
|
)
|
|
(582
|
)
|
|
(111
|
)
|
||||
Effect of foreign currency translation
|
|
33
|
|
|
2
|
|
|
21
|
|
|
(3
|
)
|
||||
Benefit obligations at December 31,
|
|
11,409
|
|
|
1,674
|
|
|
10,741
|
|
|
1,759
|
|
||||
Change in plan assets:
|
|
|
|
|
|
|
|
|
||||||||
Estimated fair value of plan assets at January 1,
|
|
9,009
|
|
|
1,386
|
|
|
8,603
|
|
|
1,382
|
|
||||
Actual return on plan assets
|
|
968
|
|
|
125
|
|
|
618
|
|
|
75
|
|
||||
Acquisition, divestitures and settlements
|
|
(30
|
)
|
|
(1
|
)
|
|
(7
|
)
|
|
(1
|
)
|
||||
Plan participants’ contributions
|
|
—
|
|
|
33
|
|
|
—
|
|
|
30
|
|
||||
Employer contributions
|
|
329
|
|
|
(2
|
)
|
|
374
|
|
|
13
|
|
||||
Benefits paid
|
|
(600
|
)
|
|
(107
|
)
|
|
(582
|
)
|
|
(111
|
)
|
||||
Effect of foreign currency translation
|
|
12
|
|
|
—
|
|
|
3
|
|
|
(2
|
)
|
||||
Estimated fair value of plan assets at December 31,
|
|
9,688
|
|
|
1,434
|
|
|
9,009
|
|
|
1,386
|
|
||||
Over (under) funded status at December 31,
|
|
$
|
(1,721
|
)
|
|
$
|
(240
|
)
|
|
$
|
(1,732
|
)
|
|
$
|
(373
|
)
|
Amounts recognized on the consolidated balance sheets:
|
|
|
|
|
|
|
|
|
||||||||
Other assets
|
|
$
|
59
|
|
|
$
|
160
|
|
|
$
|
3
|
|
|
$
|
1
|
|
Other liabilities
|
|
(1,780
|
)
|
|
(400
|
)
|
|
(1,735
|
)
|
|
(374
|
)
|
||||
Net amount recognized
|
|
$
|
(1,721
|
)
|
|
$
|
(240
|
)
|
|
$
|
(1,732
|
)
|
|
$
|
(373
|
)
|
AOCI:
|
|
|
|
|
|
|
|
|
||||||||
Net actuarial (gains) losses
|
|
$
|
2,917
|
|
|
$
|
(55
|
)
|
|
$
|
2,993
|
|
|
$
|
89
|
|
Prior service costs (credit)
|
|
(11
|
)
|
|
(27
|
)
|
|
(11
|
)
|
|
(49
|
)
|
||||
AOCI, before income tax
|
|
$
|
2,906
|
|
|
$
|
(82
|
)
|
|
$
|
2,982
|
|
|
$
|
40
|
|
Accumulated benefit obligation
|
|
$
|
10,996
|
|
|
N/A
|
|
|
$
|
10,340
|
|
|
N/A
|
|
(1)
|
Includes nonqualified unfunded plans, for which the aggregate PBO was
$1.2 billion
and
$1.1 billion
at
December 31, 2017
and
2016
, respectively.
|
|
December 31,
|
||||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
PBO Exceeds Estimated Fair Value
of Plan Assets
|
|
ABO Exceeds Estimated Fair Value
of Plan Assets
|
||||||||||||
|
(In millions)
|
||||||||||||||
Projected benefit obligations
|
$
|
2,016
|
|
|
$
|
10,670
|
|
|
$
|
1,996
|
|
|
$
|
1,894
|
|
Accumulated benefit obligations
|
$
|
1,904
|
|
|
$
|
10,318
|
|
|
$
|
1,890
|
|
|
$
|
1,785
|
|
Estimated fair value of plan assets
|
$
|
285
|
|
|
$
|
8,979
|
|
|
$
|
266
|
|
|
$
|
228
|
|
|
Years Ended December 31,
|
||||||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||||||||||||||
|
Pension Benefits
|
|
Other Postretirement Benefits
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
||||||||||||
|
(In millions)
|
||||||||||||||||||||||
Net periodic benefit costs:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Service costs
|
$
|
238
|
|
|
$
|
6
|
|
|
$
|
272
|
|
|
$
|
9
|
|
|
$
|
275
|
|
|
$
|
17
|
|
Interest costs
|
429
|
|
|
76
|
|
|
423
|
|
|
82
|
|
|
414
|
|
|
89
|
|
||||||
Settlement and curtailment costs (1)
|
4
|
|
|
2
|
|
|
2
|
|
|
19
|
|
|
(1
|
)
|
|
3
|
|
||||||
Expected return on plan assets
|
(516
|
)
|
|
(72
|
)
|
|
(527
|
)
|
|
(75
|
)
|
|
(534
|
)
|
|
(80
|
)
|
||||||
Amortization of net actuarial (gains) losses
|
195
|
|
|
—
|
|
|
189
|
|
|
10
|
|
|
189
|
|
|
42
|
|
||||||
Amortization of prior service costs (credit)
|
(1
|
)
|
|
(22
|
)
|
|
—
|
|
|
(6
|
)
|
|
(1
|
)
|
|
(5
|
)
|
||||||
Total net periodic benefit costs (credit)
|
349
|
|
|
(10
|
)
|
|
359
|
|
|
39
|
|
|
342
|
|
|
66
|
|
||||||
Other changes in plan assets and benefit obligations recognized in OCI:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net actuarial (gains) losses
|
149
|
|
|
(146
|
)
|
|
238
|
|
|
(124
|
)
|
|
43
|
|
|
(161
|
)
|
||||||
Prior service costs (credit)
|
(1
|
)
|
|
—
|
|
|
(11
|
)
|
|
(41
|
)
|
|
—
|
|
|
(7
|
)
|
||||||
Amortization of net actuarial (gains) losses
|
(195
|
)
|
|
—
|
|
|
(189
|
)
|
|
(10
|
)
|
|
(189
|
)
|
|
(42
|
)
|
||||||
Amortization of prior service (costs) credit
|
1
|
|
|
22
|
|
|
—
|
|
|
6
|
|
|
1
|
|
|
5
|
|
||||||
Discontinued operations
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
1
|
|
|
(2
|
)
|
|
(2
|
)
|
||||||
Disposal of subsidiary
|
(30
|
)
|
|
2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Total recognized in OCI
|
(76
|
)
|
|
(122
|
)
|
|
37
|
|
|
(168
|
)
|
|
(147
|
)
|
|
(207
|
)
|
||||||
Total recognized in net periodic benefit costs and OCI
|
$
|
273
|
|
|
$
|
(132
|
)
|
|
$
|
396
|
|
|
$
|
(129
|
)
|
|
$
|
195
|
|
|
$
|
(141
|
)
|
(1)
|
The Company recognized curtailment charges in 2016 on certain postretirement benefit plans in connection with the U.S. Retail Advisor Force Divestiture. See Note
3
.
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
|||
December 31, 2017
|
|
|
|
|
|
|
Weighted average discount rate
|
3.65%
|
|
3.70%
|
|||
Rate of compensation increase
|
2.25
|
%
|
-
|
8.50%
|
|
N/A
|
December 31, 2016
|
|
|
|
|
|
|
Weighted average discount rate
|
4.30%
|
|
4.45%
|
|||
Rate of compensation increase
|
2.25
|
%
|
-
|
8.50%
|
|
N/A
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
|||
Year Ended December 31, 2017
|
|
|
|
|
|
|
Weighted average discount rate
|
4.30%
|
|
4.45%
|
|||
Weighted average expected rate of return on plan assets
|
6.00%
|
|
5.36%
|
|||
Rate of compensation increase
|
2.25
|
%
|
-
|
8.50%
|
|
N/A
|
Year Ended December 31, 2016
|
|
|
|
|
|
|
Weighted average discount rate
|
4.13%
|
|
4.37%
|
|||
Weighted average expected rate of return on plan assets
|
6.00%
|
|
5.53%
|
|||
Rate of compensation increase
|
2.25
|
%
|
-
|
8.50%
|
|
N/A
|
Year Ended December 31, 2015
|
|
|
|
|
|
|
Weighted average discount rate
|
4.10%
|
|
4.10%
|
|||
Weighted average expected rate of return on plan assets
|
6.25%
|
|
5.70%
|
|||
Rate of compensation increase
|
2.25
|
%
|
-
|
8.50%
|
|
N/A
|
|
December 31,
|
||||||||||
|
2017
|
|
2016
|
||||||||
|
Before
Age 65
|
|
Age 65 and
older
|
|
Before
Age 65
|
|
Age 65 and
older
|
||||
Following year
|
5.6
|
%
|
|
6.6
|
%
|
|
6.8
|
%
|
|
13.0
|
%
|
Ultimate rate to which cost increase is assumed to decline
|
4.0
|
%
|
|
4.3
|
%
|
|
4.0
|
%
|
|
4.3
|
%
|
Year in which the ultimate trend rate is reached
|
2086
|
|
2098
|
|
2077
|
|
2092
|
|
|
One Percent
Increase |
|
One Percent
Decrease |
||||
|
|
(In millions)
|
||||||
Effect on total of service and interest costs components
|
|
$
|
9
|
|
|
$
|
(8
|
)
|
Effect of accumulated postretirement benefit obligations
|
|
$
|
186
|
|
|
$
|
(154
|
)
|
|
|
December 31,
|
||||||||||||||||
|
|
2017
|
|
2016
|
||||||||||||||
|
|
U.S. Pension
Benefits |
|
U.S. Other
Postretirement
Benefits (1)
|
|
U.S. Pension
Benefits
|
|
U.S. Other
Postretirement
Benefits (1)
|
||||||||||
|
|
Target
|
|
Actual
Allocation |
|
Target
|
|
Actual
Allocation |
|
Actual
Allocation
|
|
Actual
Allocation
|
||||||
Asset Class
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Fixed maturity securities
|
|
82
|
%
|
|
82
|
%
|
|
85
|
%
|
|
84
|
%
|
|
81
|
%
|
|
76
|
%
|
Equity securities (2)
|
|
10
|
%
|
|
10
|
%
|
|
15
|
%
|
|
15
|
%
|
|
11
|
%
|
|
24
|
%
|
Alternative securities (3)
|
|
8
|
%
|
|
8
|
%
|
|
—
|
%
|
|
1
|
%
|
|
8
|
%
|
|
—
|
%
|
Total assets
|
|
|
|
100
|
%
|
|
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
(1)
|
U.S. other postretirement benefits do not reflect postretirement life’s plan assets invested in fixed maturity securities.
|
(2)
|
Equity securities percentage includes derivative assets.
|
(3)
|
Alternative securities primarily include hedge, private equity and real estate funds.
|
|
|
December 31, 2017
|
||||||||||||||||||||||||||||||
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
||||||||||||||||||||||||||||
|
|
Fair Value Hierarchy
|
|
|
|
Fair Value Hierarchy
|
|
|
||||||||||||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated Fair Value |
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated Fair Value |
||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate
|
|
$
|
—
|
|
|
$
|
3,833
|
|
|
$
|
1
|
|
|
$
|
3,834
|
|
|
$
|
20
|
|
|
$
|
362
|
|
|
$
|
—
|
|
|
$
|
382
|
|
U.S. government bonds
|
|
1,256
|
|
|
528
|
|
|
—
|
|
|
1,784
|
|
|
269
|
|
|
6
|
|
|
—
|
|
|
275
|
|
||||||||
Foreign bonds
|
|
—
|
|
|
1,037
|
|
|
—
|
|
|
1,037
|
|
|
—
|
|
|
102
|
|
|
—
|
|
|
102
|
|
||||||||
Federal agencies
|
|
35
|
|
|
134
|
|
|
—
|
|
|
169
|
|
|
—
|
|
|
17
|
|
|
—
|
|
|
17
|
|
||||||||
Municipals
|
|
—
|
|
|
335
|
|
|
—
|
|
|
335
|
|
|
—
|
|
|
28
|
|
|
—
|
|
|
28
|
|
||||||||
Short-term investments
|
|
135
|
|
|
192
|
|
|
—
|
|
|
327
|
|
|
8
|
|
|
390
|
|
|
—
|
|
|
398
|
|
||||||||
Other (1)
|
|
7
|
|
|
388
|
|
|
10
|
|
|
405
|
|
|
—
|
|
|
68
|
|
|
—
|
|
|
68
|
|
||||||||
Total fixed maturity securities
|
|
1,433
|
|
|
6,447
|
|
|
11
|
|
|
7,891
|
|
|
297
|
|
|
973
|
|
|
—
|
|
|
1,270
|
|
||||||||
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Common stock - domestic
|
|
480
|
|
|
90
|
|
|
—
|
|
|
570
|
|
|
80
|
|
|
—
|
|
|
—
|
|
|
80
|
|
||||||||
Common stock - foreign
|
|
317
|
|
|
87
|
|
|
3
|
|
|
407
|
|
|
74
|
|
|
—
|
|
|
—
|
|
|
74
|
|
||||||||
Total equity securities
|
|
797
|
|
|
177
|
|
|
3
|
|
|
977
|
|
|
154
|
|
|
—
|
|
|
—
|
|
|
154
|
|
||||||||
Other investments
|
|
19
|
|
|
144
|
|
|
622
|
|
|
785
|
|
|
—
|
|
|
9
|
|
|
—
|
|
|
9
|
|
||||||||
Derivative assets
|
|
33
|
|
|
2
|
|
|
—
|
|
|
35
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
1
|
|
||||||||
Total assets
|
|
$
|
2,282
|
|
|
$
|
6,770
|
|
|
$
|
636
|
|
|
$
|
9,688
|
|
|
$
|
452
|
|
|
$
|
982
|
|
|
$
|
—
|
|
|
$
|
1,434
|
|
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
||||||||||||||||||||||||||||
|
|
Fair Value Hierarchy
|
|
|
|
Fair Value Hierarchy
|
|
|
||||||||||||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated Fair Value |
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
Estimated Fair Value |
||||||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate
|
|
$
|
—
|
|
|
$
|
3,499
|
|
|
$
|
—
|
|
|
$
|
3,499
|
|
|
$
|
20
|
|
|
$
|
306
|
|
|
$
|
—
|
|
|
$
|
326
|
|
U.S. government bonds
|
|
1,656
|
|
|
4
|
|
|
—
|
|
|
1,660
|
|
|
210
|
|
|
1
|
|
|
—
|
|
|
211
|
|
||||||||
Foreign bonds
|
|
—
|
|
|
862
|
|
|
—
|
|
|
862
|
|
|
—
|
|
|
79
|
|
|
—
|
|
|
79
|
|
||||||||
Federal agencies
|
|
—
|
|
|
196
|
|
|
—
|
|
|
196
|
|
|
—
|
|
|
27
|
|
|
—
|
|
|
27
|
|
||||||||
Municipals
|
|
—
|
|
|
313
|
|
|
—
|
|
|
313
|
|
|
—
|
|
|
23
|
|
|
—
|
|
|
23
|
|
||||||||
Short-term investments
|
|
118
|
|
|
217
|
|
|
—
|
|
|
335
|
|
|
13
|
|
|
416
|
|
|
—
|
|
|
429
|
|
||||||||
Other (1)
|
|
—
|
|
|
362
|
|
|
9
|
|
|
371
|
|
|
—
|
|
|
55
|
|
|
—
|
|
|
55
|
|
||||||||
Total fixed maturity securities
|
|
1,774
|
|
|
5,453
|
|
|
9
|
|
|
7,236
|
|
|
243
|
|
|
907
|
|
|
—
|
|
|
1,150
|
|
||||||||
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Common stock - domestic
|
|
474
|
|
|
—
|
|
|
—
|
|
|
474
|
|
|
113
|
|
|
—
|
|
|
—
|
|
|
113
|
|
||||||||
Common stock - foreign
|
|
380
|
|
|
69
|
|
|
—
|
|
|
449
|
|
|
122
|
|
|
—
|
|
|
—
|
|
|
122
|
|
||||||||
Total equity securities
|
|
854
|
|
|
69
|
|
|
—
|
|
|
923
|
|
|
235
|
|
|
—
|
|
|
—
|
|
|
235
|
|
||||||||
Other investments
|
|
30
|
|
|
105
|
|
|
637
|
|
|
772
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Derivative assets
|
|
16
|
|
|
(3
|
)
|
|
65
|
|
|
78
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
1
|
|
||||||||
Total assets
|
|
$
|
2,674
|
|
|
$
|
5,624
|
|
|
$
|
711
|
|
|
$
|
9,009
|
|
|
$
|
479
|
|
|
$
|
907
|
|
|
$
|
—
|
|
|
$
|
1,386
|
|
(1)
|
Other primarily includes money market securities, mortgage-backed securities, collateralized mortgage obligations and ABS.
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||||||||||||||||||||
|
|
Pension Benefits
|
||||||||||||||||||||||
|
|
Fixed Maturity Securities:
|
|
Equity Securities:
|
|
|
|
|
||||||||||||||||
|
|
Corporate
|
|
Foreign
Bonds
|
|
Other (1)
|
|
Common Stock - Foreign
|
|
Other
Investments
|
|
Derivative
Assets
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Balance, January 1, 2016
|
|
$
|
77
|
|
|
$
|
17
|
|
|
$
|
7
|
|
|
$
|
—
|
|
|
$
|
723
|
|
|
$
|
76
|
|
Realized gains (losses)
|
|
2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3
|
|
||||||
Unrealized gains (losses)
|
|
3
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
33
|
|
|
(18
|
)
|
||||||
Purchases, sales, issuances and settlements, net
|
|
(20
|
)
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
(119
|
)
|
|
6
|
|
||||||
Transfers into and/or out of Level 3
|
|
(62
|
)
|
|
(11
|
)
|
|
2
|
|
|
—
|
|
|
—
|
|
|
(2
|
)
|
||||||
Balance, December 31, 2016
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
9
|
|
|
$
|
—
|
|
|
$
|
637
|
|
|
$
|
65
|
|
Realized gains (losses)
|
|
(10
|
)
|
|
—
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
(22
|
)
|
||||||
Unrealized gains (losses)
|
|
10
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(12
|
)
|
|
6
|
|
||||||
Purchases, sales, issuances and settlements, net
|
|
—
|
|
|
—
|
|
|
8
|
|
|
(4
|
)
|
|
—
|
|
|
(48
|
)
|
||||||
Transfers into and/or out of Level 3
|
|
1
|
|
|
—
|
|
|
(7
|
)
|
|
5
|
|
|
(3
|
)
|
|
(1
|
)
|
||||||
Balance, December 31, 2017
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
10
|
|
|
$
|
3
|
|
|
$
|
622
|
|
|
$
|
—
|
|
(1)
|
Other includes ABS and collateralized mortgage obligations.
|
|
|
Pension Benefits
|
|
Other Postretirement Benefits
|
||||
|
|
(In millions)
|
||||||
2018
|
|
$
|
604
|
|
|
$
|
87
|
|
2019
|
|
$
|
618
|
|
|
$
|
90
|
|
2020
|
|
$
|
634
|
|
|
$
|
90
|
|
2021
|
|
$
|
645
|
|
|
$
|
89
|
|
2022
|
|
$
|
664
|
|
|
$
|
90
|
|
2023-2027
|
|
$
|
3,523
|
|
|
$
|
450
|
|
|
|
U.S. Tax Reform
|
||
|
|
(In millions)
|
||
Income (loss) from continuing operations before provision for income tax
|
|
$
|
(289
|
)
|
Provision for income tax expense (benefit):
|
|
|
||
Deemed repatriation
|
|
170
|
|
|
Deferred tax revaluation
|
|
(1,790
|
)
|
|
Total provision for income tax expense (benefit)
|
|
(1,620
|
)
|
|
Income (loss) from continuing operations, net of income tax
|
|
1,331
|
|
|
Income tax (expense) benefit related to items of other comprehensive income (loss)
|
|
144
|
|
|
Increase to net equity from U.S. Tax Reform
|
|
$
|
1,475
|
|
•
|
Deemed Repatriation Transition Tax - The Company has recorded a
$170 million
charge for this item. This charge is in addition to the
$180 million
charge recorded in the third quarter of 2017 resulting from the post-Separation review of the Company’s capital needs. The total transition tax liability recorded for the year ended
December 31, 2017
is
$350 million
.
|
•
|
Global Intangible Low-Tax Income -
U.S. Tax Reform
imposes a minimum tax on global intangible low-tax income, which is generally the excess income of foreign subsidiaries over a 10% rate of routine return on tangible business assets. The Company has not yet formally adopted an accounting policy for this item. For the year ended December 31, 2017, the Company did not record a tax charge and tax incurred in future periods related to global intangible low-tax income will be recorded in the period incurred.
|
•
|
Compensation and Fringe Benefits -
U.S. Tax Reform
limits certain employer deductions for fringe benefit and related expenses and also repeals the exception allowing the deduction of certain performance-based compensation paid to certain senior executives. The Company has recorded an
$8 million
tax charge, included within the deferred tax revaluation.
|
•
|
Alternative Minimum Tax Credits -
U.S. Tax Reform
eliminates the corporate alternative minimum tax and allows for minimum tax credit carryforwards to be used to offset future regular tax or to be refunded over the next few years. However, pursuant to the requirements of the Balanced Budget and Emergency Deficit Control Act of 1985, as amended, refund payments issued for corporations claiming refundable prior year alternative minimum tax credits are subject to a sequestration rate of
6.6%
. The application of this fee to refunds in future years is subject to further guidance. Additionally, the sequestration reduction rate in effect at the time is subject to uncertainty. The Company has recorded a
$9 million
tax charge included within the deferred tax revaluation.
|
•
|
Tax Credit Partnerships - Certain tax credit partnership investments derive returns in part from income tax credits. The Company recognizes changes in tax attributes at the partnership level when reported by the investee in its financial information. U.S. Tax Reform may impact the tax attributes of tax credit partnerships. However, investee financial information is not yet available to enable the Company to determine the impacts of U.S. Tax Reform. Accordingly, the Company has applied prior law to these equity method investments in accordance with SAB 118. During the one year measurement period under SAB 118, the impacts of U.S. Tax Reform will be recognized as the investee financial information is made available.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Current:
|
|
|
|
|
|
||||||
Federal
|
$
|
(246
|
)
|
|
$
|
520
|
|
|
$
|
632
|
|
State and local
|
5
|
|
|
3
|
|
|
10
|
|
|||
Foreign
|
891
|
|
|
628
|
|
|
556
|
|
|||
Subtotal
|
650
|
|
|
1,151
|
|
|
1,198
|
|
|||
Deferred:
|
|
|
|
|
|
||||||
Federal
|
(2,373
|
)
|
|
(827
|
)
|
|
194
|
|
|||
Foreign
|
253
|
|
|
369
|
|
|
198
|
|
|||
Subtotal
|
(2,120
|
)
|
|
(458
|
)
|
|
392
|
|
|||
Provision for income tax expense (benefit)
|
$
|
(1,470
|
)
|
|
$
|
693
|
|
|
$
|
1,590
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Income (loss) from continuing operations:
|
|
|
|
|
|
||||||
Domestic
|
$
|
684
|
|
|
$
|
185
|
|
|
$
|
1,874
|
|
Foreign
|
2,852
|
|
|
4,096
|
|
|
3,777
|
|
|||
Total
|
$
|
3,536
|
|
|
$
|
4,281
|
|
|
$
|
5,651
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Tax provision at U.S. statutory rate
|
$
|
1,238
|
|
|
$
|
1,498
|
|
|
$
|
1,977
|
|
Tax effect of:
|
|
|
|
|
|
||||||
Dividend received deduction
|
(67
|
)
|
|
(69
|
)
|
|
(71
|
)
|
|||
Tax-exempt income
|
(97
|
)
|
|
(86
|
)
|
|
(70
|
)
|
|||
Prior year tax (1)
|
(27
|
)
|
|
(13
|
)
|
|
559
|
|
|||
Low income housing tax credits
|
(278
|
)
|
|
(270
|
)
|
|
(221
|
)
|
|||
Other tax credits
|
(102
|
)
|
|
(98
|
)
|
|
(67
|
)
|
|||
Foreign tax rate differential (2), (3), (4)
|
(95
|
)
|
|
(332
|
)
|
|
(555
|
)
|
|||
Change in valuation allowance
|
(8
|
)
|
|
(9
|
)
|
|
5
|
|
|||
Separation tax benefits
|
(540
|
)
|
|
—
|
|
|
—
|
|
|||
U.S. Tax Reform impact (5)
|
(1,519
|
)
|
|
—
|
|
|
—
|
|
|||
Other, net
|
25
|
|
|
72
|
|
|
33
|
|
|||
Provision for income tax expense (benefit)
|
$
|
(1,470
|
)
|
|
$
|
693
|
|
|
$
|
1,590
|
|
(1)
|
As discussed further below, for the year ended December 31, 2015, prior year tax includes a
$557 million
non-cash charge related to an uncertain tax position.
|
(2)
|
For the year ended December 31, 2017, foreign tax rate differential includes a net tax charge of
$180 million
as a result of repatriation. Included in the net tax charge of
$180 million
is a
$444 million
tax charge related to the repatriation of approximately
$3.0 billion
of pre-2017 earnings following the post-Separation review of the Company’s capital needs. This charge was partially offset by a
$264 million
tax benefit associated with dividends from other non-U.S. operations. This charge was recorded prior to U.S. Tax Reform and is incremental to the
$170 million
repatriation transition tax recorded for the year ended December 31, 2017.
|
(3)
|
For the year ended December 31, 2016, foreign tax rate differential includes a tax benefit of
$110 million
in Japan related to a change in tax rate, offset by a tax charge of
$19 million
in Chile related to a change in tax rate.
|
(4)
|
For the year ended December 31, 2015, foreign tax rate differential includes tax benefits of
$174 million
related to a Japan tax rate change,
$61 million
related to restructuring in Chile,
$57 million
related to the repatriation of earnings from Japan,
$41 million
related to certain non-portfolio net investment gains that were non-taxable and
$31 million
related to the devaluation of the peso in Argentina. These benefits were partially offset by charges of
$23 million
related to the impact of foreign exchange on investment gains in Argentina.
|
(5)
|
U.S. Tax Reform impact of
($1.5) billion
excludes
($101) million
of tax provision at the U.S. statutory rate for a total tax reform benefit of
($1.6) billion
.
|
|
December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Deferred income tax assets:
|
|
|
|
||||
Policyholder liabilities and receivables
|
$
|
2,654
|
|
|
$
|
2,029
|
|
Net operating loss carryforwards
|
512
|
|
|
1,420
|
|
||
Employee benefits
|
802
|
|
|
1,045
|
|
||
Capital loss carryforwards
|
6
|
|
|
9
|
|
||
Tax credit carryforwards
|
1,322
|
|
|
1,375
|
|
||
Litigation-related and government mandated
|
160
|
|
|
268
|
|
||
Other
|
657
|
|
|
743
|
|
||
Total gross deferred income tax assets
|
6,113
|
|
|
6,889
|
|
||
Less: Valuation allowance
|
189
|
|
|
161
|
|
||
Total net deferred income tax assets
|
5,924
|
|
|
6,728
|
|
||
Deferred income tax liabilities:
|
|
|
|
||||
Investments, including derivatives
|
2,772
|
|
|
2,940
|
|
||
Intangibles
|
1,321
|
|
|
1,213
|
|
||
Net unrealized investment gains
|
4,783
|
|
|
5,423
|
|
||
DAC
|
3,206
|
|
|
3,619
|
|
||
Other
|
609
|
|
|
425
|
|
||
Total deferred income tax liabilities
|
12,691
|
|
|
13,620
|
|
||
Net deferred income tax asset (liability)
|
$
|
(6,767
|
)
|
|
$
|
(6,892
|
)
|
|
Net Operating Loss Carryforwards
|
|
Capital Loss Carryforwards
|
||||||||||||
|
Domestic
|
|
State
|
|
Foreign
|
|
Domestic
|
||||||||
|
(In millions)
|
||||||||||||||
Expiration:
|
|
|
|
|
|
|
|
||||||||
2018-2022
|
$
|
1
|
|
|
$
|
49
|
|
|
$
|
46
|
|
|
$
|
27
|
|
2023-2027
|
—
|
|
|
64
|
|
|
28
|
|
|
—
|
|
||||
2028-2032
|
8
|
|
|
13
|
|
|
—
|
|
|
—
|
|
||||
2033-2037
|
2,095
|
|
|
2
|
|
|
—
|
|
|
—
|
|
||||
Indefinite
|
—
|
|
|
—
|
|
|
397
|
|
|
—
|
|
||||
|
$
|
2,104
|
|
|
$
|
128
|
|
|
$
|
471
|
|
|
$
|
27
|
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Balance at January 1,
|
$
|
1,146
|
|
|
$
|
1,259
|
|
|
$
|
719
|
|
Additions for tax positions of prior years (1)
|
70
|
|
|
24
|
|
|
574
|
|
|||
Reductions for tax positions of prior years
|
(101
|
)
|
|
(112
|
)
|
|
(24
|
)
|
|||
Additions for tax positions of current year
|
33
|
|
|
23
|
|
|
24
|
|
|||
Reductions for tax positions of current year
|
(3
|
)
|
|
—
|
|
|
—
|
|
|||
Settlements with tax authorities
|
(43
|
)
|
|
(48
|
)
|
|
(34
|
)
|
|||
Balance at December 31, (1)
|
$
|
1,102
|
|
|
$
|
1,146
|
|
|
$
|
1,259
|
|
Unrecognized tax benefits that, if recognized, would impact the effective rate
|
$
|
1,073
|
|
|
$
|
1,112
|
|
|
$
|
1,215
|
|
(1)
|
The significant increase in 2015 is related to a non-cash charge the Company recorded to net income of
$792 million
, net of tax. The charge was related to an uncertain tax position and was comprised of a
$557 million
charge included in provision for income tax expense (benefit) and a
$362 million
(
$235 million
, net of tax) charge included in other expenses. This charge is the result of the Company’s consideration of certain decisions of the U.S. Court of Appeals for the Second Circuit upholding the disallowance of foreign tax credits claimed by other corporate entities not affiliated with the Company. The Company’s action relates to tax years from 2000 to 2009, during which MLIC held non-U.S. investments in support of its life insurance business through a United Kingdom investment subsidiary that was structured as a joint venture at the time.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Interest recognized on the consolidated statements of operations (1)
|
$
|
37
|
|
|
$
|
(41
|
)
|
|
$
|
388
|
|
|
|
|
|
|
|
||||||
|
|
|
December 31,
|
||||||||
|
|
|
2017
|
|
2016
|
||||||
|
|
|
(In millions)
|
||||||||
Interest included in other liabilities on the consolidated balance sheets
|
|
|
$
|
659
|
|
|
$
|
623
|
|
(1)
|
The significant increase in 2015 is related to the non-cash charge discussed above.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions, except per share data)
|
||||||||||
Weighted Average Shares:
|
|
|
|
|
|
||||||
Weighted average common stock outstanding for basic earnings per common share
|
1,069.7
|
|
|
1,100.5
|
|
|
1,117.8
|
|
|||
Incremental common shares from assumed exercise or issuance of stock-based awards
|
8.8
|
|
|
8.0
|
|
|
10.5
|
|
|||
Weighted average common stock outstanding for diluted earnings per common share
|
1,078.5
|
|
|
1,108.5
|
|
|
1,128.3
|
|
|||
Income (Loss) from Continuing Operations:
|
|
|
|
|
|
||||||
Income (loss) from continuing operations, net of income tax
|
$
|
5,006
|
|
|
$
|
3,588
|
|
|
$
|
4,061
|
|
Less: Income (loss) from continuing operations, net of income tax, attributable to noncontrolling interests
|
10
|
|
|
4
|
|
|
12
|
|
|||
Less: Preferred stock dividends
|
103
|
|
|
103
|
|
|
116
|
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
42
|
|
|||
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders
|
$
|
4,893
|
|
|
$
|
3,481
|
|
|
$
|
3,891
|
|
Basic
|
$
|
4.57
|
|
|
$
|
3.16
|
|
|
$
|
3.48
|
|
Diluted
|
$
|
4.53
|
|
|
$
|
3.13
|
|
|
$
|
3.44
|
|
Income (Loss) from Discontinued Operations:
|
|
|
|
|
|
||||||
Income (loss) from discontinued operations, net of income tax
|
$
|
(986
|
)
|
|
$
|
(2,734
|
)
|
|
$
|
1,324
|
|
Less: Income (loss) from discontinued operations, net of income tax, attributable to noncontrolling interests
|
—
|
|
|
—
|
|
|
—
|
|
|||
Income (loss) from discontinued operations, net of income tax, available to MetLife, Inc.’s common shareholders
|
$
|
(986
|
)
|
|
$
|
(2,734
|
)
|
|
$
|
1,324
|
|
Basic
|
$
|
(0.92
|
)
|
|
$
|
(2.48
|
)
|
|
$
|
1.19
|
|
Diluted
|
$
|
(0.91
|
)
|
|
$
|
(2.46
|
)
|
|
$
|
1.18
|
|
Net Income (Loss):
|
|
|
|
|
|
||||||
Net income (loss)
|
$
|
4,020
|
|
|
$
|
854
|
|
|
$
|
5,385
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
10
|
|
|
4
|
|
|
12
|
|
|||
Less: Preferred stock dividends
|
103
|
|
|
103
|
|
|
116
|
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
42
|
|
|||
Net income (loss) available to MetLife, Inc.’s common shareholders
|
$
|
3,907
|
|
|
$
|
747
|
|
|
$
|
5,215
|
|
Basic
|
$
|
3.65
|
|
|
$
|
0.68
|
|
|
$
|
4.67
|
|
Diluted
|
$
|
3.62
|
|
|
$
|
0.67
|
|
|
$
|
4.62
|
|
|
December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions, except number of claims)
|
||||||||||
Asbestos personal injury claims at year end
|
62,930
|
|
|
67,223
|
|
|
67,787
|
|
|||
Number of new claims during the year
|
3,514
|
|
|
4,146
|
|
|
3,856
|
|
|||
Settlement payments during the year (1)
|
$
|
48.6
|
|
|
$
|
50.2
|
|
|
$
|
56.1
|
|
(1)
|
Settlement payments represent payments made by MLIC during the year in connection with settlements made in that year and in prior years. Amounts do not include MLIC’s attorneys’ fees and expenses.
|
|
December 31,
|
||||||
|
2017
|
|
2016
|
||||
|
(In millions)
|
||||||
Other Assets:
|
|
|
|
||||
Premium tax offset for future discounted and undiscounted assessments
|
$
|
56
|
|
|
$
|
30
|
|
Premium tax offsets currently available for paid assessments
|
50
|
|
|
33
|
|
||
Total
|
$
|
106
|
|
|
$
|
63
|
|
Other Liabilities:
|
|
|
|
||||
Insolvency assessments
|
$
|
75
|
|
|
$
|
47
|
|
|
|
Amount
|
||
|
|
(In millions)
|
||
2018
|
|
$
|
302
|
|
2019
|
|
265
|
|
|
2020
|
|
256
|
|
|
2021
|
|
237
|
|
|
2022
|
|
209
|
|
|
Thereafter
|
|
993
|
|
|
Total
|
|
$
|
2,262
|
|
|
|
Three Months Ended
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
March 31, 2017
|
|
June 30, 2017
|
|
September 30, 2017
|
|
December 31, 2017
|
||||||||||||||||||||||||||||||||||||||||
|
|
Prior to
Revision (1)
|
|
Revisions (2)
|
|
As
Revised |
|
Prior to
Revision (1)
|
|
Revisions (2)
|
|
As
Revised
|
|
As
Previously
Reported
|
|
Revisions (2)
|
|
As
Revised
|
|
As
Previously
Reported
|
|
Revisions (2)
|
|
As
Revised
|
||||||||||||||||||||||||
|
|
(in millions, except per share data)
|
||||||||||||||||||||||||||||||||||||||||||||||
Total revenues
|
|
$
|
14,925
|
|
|
$
|
39
|
|
|
$
|
14,964
|
|
|
$
|
15,286
|
|
|
$
|
47
|
|
|
$
|
15,333
|
|
|
$
|
16,104
|
|
|
$
|
67
|
|
|
$
|
16,171
|
|
|
$
|
15,754
|
|
|
$
|
86
|
|
|
$
|
15,840
|
|
Total expenses
|
|
$
|
13,921
|
|
|
$
|
(29
|
)
|
|
$
|
13,892
|
|
|
$
|
14,309
|
|
|
$
|
6
|
|
|
$
|
14,315
|
|
|
$
|
15,603
|
|
|
$
|
83
|
|
|
$
|
15,686
|
|
|
$
|
14,879
|
|
|
$
|
—
|
|
|
$
|
14,879
|
|
Income (loss) from continuing operations, net of income tax
|
|
$
|
908
|
|
|
$
|
44
|
|
|
$
|
952
|
|
|
$
|
829
|
|
|
$
|
27
|
|
|
$
|
856
|
|
|
$
|
893
|
|
|
$
|
(10
|
)
|
|
$
|
883
|
|
|
$
|
2,134
|
|
|
$
|
181
|
|
|
$
|
2,315
|
|
Income (loss) from discontinued operations, net of income tax
|
|
$
|
(79
|
)
|
|
$
|
3
|
|
|
$
|
(76
|
)
|
|
$
|
58
|
|
|
$
|
—
|
|
|
$
|
58
|
|
|
$
|
(968
|
)
|
|
$
|
—
|
|
|
$
|
(968
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Net income (loss)
|
|
$
|
829
|
|
|
$
|
47
|
|
|
$
|
876
|
|
|
$
|
887
|
|
|
$
|
27
|
|
|
$
|
914
|
|
|
$
|
(75
|
)
|
|
$
|
(10
|
)
|
|
$
|
(85
|
)
|
|
$
|
2,134
|
|
|
$
|
181
|
|
|
$
|
2,315
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
6
|
|
|
$
|
(2
|
)
|
|
$
|
—
|
|
|
$
|
(2
|
)
|
Net income (loss) attributable to MetLife, Inc.
|
|
$
|
826
|
|
|
$
|
47
|
|
|
$
|
873
|
|
|
$
|
884
|
|
|
$
|
27
|
|
|
$
|
911
|
|
|
$
|
(81
|
)
|
|
$
|
(10
|
)
|
|
$
|
(91
|
)
|
|
$
|
2,136
|
|
|
$
|
181
|
|
|
$
|
2,317
|
|
Less: Preferred stock dividends
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
6
|
|
|
$
|
46
|
|
|
$
|
—
|
|
|
$
|
46
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
6
|
|
|
$
|
45
|
|
|
$
|
—
|
|
|
$
|
45
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
820
|
|
|
$
|
47
|
|
|
$
|
867
|
|
|
$
|
838
|
|
|
$
|
27
|
|
|
$
|
865
|
|
|
$
|
(87
|
)
|
|
$
|
(10
|
)
|
|
$
|
(97
|
)
|
|
$
|
2,091
|
|
|
$
|
181
|
|
|
$
|
2,272
|
|
Basic earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders
|
|
$
|
0.82
|
|
|
$
|
0.05
|
|
|
$
|
0.87
|
|
|
$
|
0.73
|
|
|
$
|
0.03
|
|
|
$
|
0.76
|
|
|
$
|
0.83
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.82
|
|
|
$
|
1.99
|
|
|
$
|
0.17
|
|
|
$
|
2.16
|
|
Income (loss) from discontinued operations, net of income tax, attributable to MetLife, Inc.
|
|
$
|
(0.07
|
)
|
|
$
|
—
|
|
|
$
|
(0.07
|
)
|
|
$
|
0.05
|
|
|
$
|
—
|
|
|
$
|
0.05
|
|
|
$
|
(0.91
|
)
|
|
$
|
—
|
|
|
$
|
(0.91
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Net income (loss) attributable to MetLife, Inc.
|
|
$
|
0.76
|
|
|
$
|
0.04
|
|
|
$
|
0.80
|
|
|
$
|
0.82
|
|
|
$
|
0.04
|
|
|
$
|
0.86
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.09
|
)
|
|
$
|
2.03
|
|
|
$
|
0.17
|
|
|
$
|
2.20
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
0.75
|
|
|
$
|
0.05
|
|
|
$
|
0.80
|
|
|
$
|
0.78
|
|
|
$
|
0.03
|
|
|
$
|
0.81
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.09
|
)
|
|
$
|
1.99
|
|
|
$
|
0.17
|
|
|
$
|
2.16
|
|
Diluted earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders
|
|
$
|
0.82
|
|
|
$
|
0.04
|
|
|
$
|
0.86
|
|
|
$
|
0.72
|
|
|
$
|
0.03
|
|
|
$
|
0.75
|
|
|
$
|
0.82
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.81
|
|
|
$
|
1.97
|
|
|
$
|
0.17
|
|
|
$
|
2.14
|
|
Income (loss) from discontinued operations, net of income tax, attributable to MetLife, Inc.
|
|
$
|
(0.07
|
)
|
|
$
|
—
|
|
|
$
|
(0.07
|
)
|
|
$
|
0.05
|
|
|
$
|
—
|
|
|
$
|
0.05
|
|
|
$
|
(0.90
|
)
|
|
$
|
—
|
|
|
$
|
(0.90
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Net income (loss) attributable to MetLife, Inc.
|
|
$
|
0.75
|
|
|
$
|
0.04
|
|
|
$
|
0.79
|
|
|
$
|
0.82
|
|
|
$
|
0.03
|
|
|
$
|
0.85
|
|
|
$
|
(0.08
|
)
|
|
$
|
—
|
|
|
$
|
(0.08
|
)
|
|
$
|
2.01
|
|
|
$
|
0.17
|
|
|
$
|
2.18
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
0.75
|
|
|
$
|
0.04
|
|
|
$
|
0.79
|
|
|
$
|
0.77
|
|
|
$
|
0.03
|
|
|
$
|
0.80
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.09
|
)
|
|
$
|
1.97
|
|
|
$
|
0.17
|
|
|
$
|
2.14
|
|
|
|
Three Months Ended
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
March 31, 2016
|
|
June 30, 2016
|
|
September 30, 2016
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||||||||||||
|
|
As
Previously Reported |
|
Revisions (2)
|
|
As
Revised
|
|
As
Previously Reported |
|
Revisions (2)
|
|
As
Revised
|
|
As
Previously
Reported
|
|
Revisions (2)
|
|
As
Revised
|
|
As
Previously
Reported
|
|
Revisions (2)
|
|
As
Revised
|
||||||||||||||||||||||||
|
|
(in millions, except per share data)
|
||||||||||||||||||||||||||||||||||||||||||||||
Total revenues
|
|
$
|
16,097
|
|
|
$
|
148
|
|
|
$
|
16,245
|
|
|
$
|
16,025
|
|
|
$
|
324
|
|
|
$
|
16,349
|
|
|
$
|
15,833
|
|
|
$
|
(27
|
)
|
|
$
|
15,806
|
|
|
$
|
12,635
|
|
|
$
|
(248
|
)
|
|
$
|
12,387
|
|
Total expenses
|
|
$
|
13,780
|
|
|
$
|
(28
|
)
|
|
$
|
13,752
|
|
|
$
|
13,979
|
|
|
$
|
—
|
|
|
$
|
13,979
|
|
|
$
|
14,674
|
|
|
$
|
43
|
|
|
$
|
14,717
|
|
|
$
|
14,017
|
|
|
$
|
41
|
|
|
$
|
14,058
|
|
Income (loss) from continuing operations, net of income tax
|
|
$
|
1,770
|
|
|
$
|
130
|
|
|
$
|
1,900
|
|
|
$
|
1,475
|
|
|
$
|
211
|
|
|
$
|
1,686
|
|
|
$
|
1,024
|
|
|
$
|
(51
|
)
|
|
$
|
973
|
|
|
$
|
(795
|
)
|
|
$
|
(176
|
)
|
|
$
|
(971
|
)
|
Income (loss) from discontinued operations, net of income tax
|
|
$
|
433
|
|
|
$
|
(1
|
)
|
|
$
|
432
|
|
|
$
|
(1,361
|
)
|
|
$
|
—
|
|
|
$
|
(1,361
|
)
|
|
$
|
(451
|
)
|
|
$
|
16
|
|
|
$
|
(435
|
)
|
|
$
|
(1,291
|
)
|
|
$
|
(79
|
)
|
|
$
|
(1,370
|
)
|
Net income (loss)
|
|
$
|
2,203
|
|
|
$
|
129
|
|
|
$
|
2,332
|
|
|
$
|
114
|
|
|
$
|
211
|
|
|
$
|
325
|
|
|
$
|
573
|
|
|
$
|
(35
|
)
|
|
$
|
538
|
|
|
$
|
(2,086
|
)
|
|
$
|
(255
|
)
|
|
$
|
(2,341
|
)
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
$
|
2
|
|
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
4
|
|
|
$
|
—
|
|
|
$
|
4
|
|
|
$
|
(4
|
)
|
|
$
|
—
|
|
|
$
|
(4
|
)
|
|
$
|
2
|
|
|
$
|
—
|
|
|
$
|
2
|
|
Net income (loss) attributable to MetLife, Inc.
|
|
$
|
2,201
|
|
|
$
|
129
|
|
|
$
|
2,330
|
|
|
$
|
110
|
|
|
$
|
211
|
|
|
$
|
321
|
|
|
$
|
577
|
|
|
$
|
(35
|
)
|
|
$
|
542
|
|
|
$
|
(2,088
|
)
|
|
$
|
(255
|
)
|
|
$
|
(2,343
|
)
|
Less: Preferred stock dividends
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
6
|
|
|
$
|
46
|
|
|
$
|
—
|
|
|
$
|
46
|
|
|
$
|
6
|
|
|
$
|
—
|
|
|
$
|
6
|
|
|
$
|
45
|
|
|
$
|
—
|
|
|
$
|
45
|
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
2,195
|
|
|
$
|
129
|
|
|
$
|
2,324
|
|
|
$
|
64
|
|
|
$
|
211
|
|
|
$
|
275
|
|
|
$
|
571
|
|
|
$
|
(35
|
)
|
|
$
|
536
|
|
|
$
|
(2,133
|
)
|
|
$
|
(255
|
)
|
|
$
|
(2,388
|
)
|
Basic earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders
|
|
$
|
1.60
|
|
|
$
|
0.12
|
|
|
$
|
1.72
|
|
|
$
|
1.30
|
|
|
$
|
0.19
|
|
|
$
|
1.49
|
|
|
$
|
0.93
|
|
|
$
|
(0.05
|
)
|
|
$
|
0.88
|
|
|
$
|
(0.77
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
(0.92
|
)
|
Income (loss) from discontinued operations, net of income tax, attributable to MetLife, Inc.
|
|
$
|
0.39
|
|
|
$
|
—
|
|
|
$
|
0.39
|
|
|
$
|
(1.24
|
)
|
|
$
|
—
|
|
|
$
|
(1.24
|
)
|
|
$
|
(0.41
|
)
|
|
$
|
0.02
|
|
|
$
|
(0.39
|
)
|
|
$
|
(1.17
|
)
|
|
$
|
(0.08
|
)
|
|
$
|
(1.25
|
)
|
Net income (loss) attributable to MetLife, Inc.
|
|
$
|
2.00
|
|
|
$
|
0.12
|
|
|
$
|
2.12
|
|
|
$
|
0.10
|
|
|
$
|
0.19
|
|
|
$
|
0.29
|
|
|
$
|
0.52
|
|
|
$
|
(0.03
|
)
|
|
$
|
0.49
|
|
|
$
|
(1.90
|
)
|
|
$
|
(0.23
|
)
|
|
$
|
(2.13
|
)
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
1.99
|
|
|
$
|
0.12
|
|
|
$
|
2.11
|
|
|
$
|
0.06
|
|
|
$
|
0.19
|
|
|
$
|
0.25
|
|
|
$
|
0.52
|
|
|
$
|
(0.03
|
)
|
|
$
|
0.49
|
|
|
$
|
(1.94
|
)
|
|
$
|
(0.23
|
)
|
|
$
|
(2.17
|
)
|
Diluted earnings per common share (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Income (loss) from continuing operations, net of income tax, available to MetLife, Inc.’s common shareholders
|
|
$
|
1.59
|
|
|
$
|
0.12
|
|
|
$
|
1.71
|
|
|
$
|
1.29
|
|
|
$
|
0.19
|
|
|
$
|
1.48
|
|
|
$
|
0.92
|
|
|
$
|
(0.05
|
)
|
|
$
|
0.87
|
|
|
$
|
(0.77
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
(0.92
|
)
|
Income (loss) from discontinued operations, net of income tax, attributable to MetLife, Inc.
|
|
$
|
0.39
|
|
|
$
|
—
|
|
|
$
|
0.39
|
|
|
$
|
(1.23
|
)
|
|
$
|
—
|
|
|
$
|
(1.23
|
)
|
|
$
|
(0.41
|
)
|
|
$
|
0.02
|
|
|
$
|
(0.39
|
)
|
|
$
|
(1.17
|
)
|
|
$
|
(0.08
|
)
|
|
$
|
(1.25
|
)
|
Net income (loss) attributable to MetLife, Inc.
|
|
$
|
1.99
|
|
|
$
|
0.11
|
|
|
$
|
2.10
|
|
|
$
|
0.10
|
|
|
$
|
0.19
|
|
|
$
|
0.29
|
|
|
$
|
0.52
|
|
|
$
|
(0.03
|
)
|
|
$
|
0.49
|
|
|
$
|
(1.90
|
)
|
|
$
|
(0.23
|
)
|
|
$
|
(2.13
|
)
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
|
$
|
1.98
|
|
|
$
|
0.12
|
|
|
$
|
2.10
|
|
|
$
|
0.06
|
|
|
$
|
0.19
|
|
|
$
|
0.25
|
|
|
$
|
0.51
|
|
|
$
|
(0.03
|
)
|
|
$
|
0.48
|
|
|
$
|
(1.94
|
)
|
|
$
|
(0.23
|
)
|
|
$
|
(2.17
|
)
|
(1)
|
Results of operations were revised to reflect Brighthouse as discontinued operations. See Note 3.
|
(2)
|
See Note 1 information on prior period revisions.
|
(3)
|
For the three months ended
December 31, 2016
,
9.2 million
shares related to the assumed exercise or issuance of stock-based awards have been excluded from the weighted average common shares outstanding - diluted, as to include these assumed shares would be anti-dilutive to net income (loss) available to common shareholders per common share - diluted.
|
Types of Investments
|
Cost or
Amortized Cost (1) |
|
Estimated Fair Value
|
|
Amount at
Which Shown on Balance Sheet |
||||||
Fixed maturity securities:
|
|
|
|
|
|
||||||
Bonds:
|
|
|
|
|
|
||||||
Foreign government securities
|
$
|
55,351
|
|
|
$
|
61,534
|
|
|
$
|
61,534
|
|
U.S. government and agency securities
|
43,446
|
|
|
47,394
|
|
|
47,394
|
|
|||
Public utilities
|
12,087
|
|
|
13,581
|
|
|
13,581
|
|
|||
State and political subdivision securities
|
10,752
|
|
|
12,455
|
|
|
12,455
|
|
|||
All other corporate bonds
|
115,238
|
|
|
123,445
|
|
|
123,445
|
|
|||
Total bonds
|
236,874
|
|
|
258,409
|
|
|
258,409
|
|
|||
Mortgage-backed and asset-backed securities
|
48,106
|
|
|
49,318
|
|
|
49,318
|
|
|||
Redeemable preferred stock
|
1,089
|
|
|
1,204
|
|
|
1,204
|
|
|||
Total fixed maturity securities
|
286,069
|
|
|
308,931
|
|
|
308,931
|
|
|||
FVO securities
|
14,656
|
|
|
16,745
|
|
|
16,745
|
|
|||
Equity securities:
|
|
|
|
|
|
||||||
Common stock:
|
|
|
|
|
|
||||||
Industrial, miscellaneous and all other
|
1,538
|
|
|
1,807
|
|
|
1,807
|
|
|||
Banks, trust and insurance companies
|
83
|
|
|
154
|
|
|
154
|
|
|||
Public utilities
|
66
|
|
|
74
|
|
|
74
|
|
|||
Non-redeemable preferred stock
|
453
|
|
|
478
|
|
|
478
|
|
|||
Total equity securities
|
2,140
|
|
|
2,513
|
|
|
2,513
|
|
|||
Mortgage loans
|
68,731
|
|
|
|
|
68,731
|
|
||||
Policy loans
|
9,669
|
|
|
|
|
9,669
|
|
||||
Real estate and real estate joint ventures
|
9,589
|
|
|
|
|
9,589
|
|
||||
Real estate acquired in satisfaction of debt
|
48
|
|
|
|
|
48
|
|
||||
Other limited partnership interests
|
5,708
|
|
|
|
|
5,708
|
|
||||
Short-term investments
|
4,870
|
|
|
|
|
4,870
|
|
||||
Other invested assets
|
17,263
|
|
|
|
|
17,263
|
|
||||
Total investments
|
$
|
418,743
|
|
|
|
|
$
|
444,067
|
|
(1)
|
The FVO securities portfolio is mainly comprised of fixed maturity and equity securities, including mutual funds and, to a lesser extent, short-term investments and cash and cash equivalents. Cost or amortized cost for fixed maturity securities and mortgage loans represents original cost reduced by repayments, valuation allowances and impairments from other-than-temporary declines in estimated fair value that are charged to earnings and adjusted for amortization of premiums or accretion of discounts; for equity securities, cost represents original cost reduced by impairments from other-than-temporary declines in estimated fair value; for real estate, cost represents original cost reduced by impairments and depreciation; for real estate joint ventures and other limited partnership interests, cost represents original cost reduced for impairments or original cost adjusted for equity in earnings and distributions.
|
|
2017
|
|
2016
|
||||
Condensed Balance Sheets
|
|
|
|
||||
Assets
|
|
|
|
||||
Investments:
|
|
|
|
||||
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $4,520 and $3,900, respectively)
|
$
|
4,510
|
|
|
$
|
3,894
|
|
Fair value option securities, at estimated fair value
|
1,357
|
|
|
—
|
|
||
Short-term investments, principally at estimated fair value
|
30
|
|
|
148
|
|
||
Other invested assets, at estimated fair value
|
127
|
|
|
499
|
|
||
Total investments
|
6,024
|
|
|
4,541
|
|
||
Cash and cash equivalents
|
516
|
|
|
334
|
|
||
Accrued investment income
|
24
|
|
|
74
|
|
||
Investment in subsidiaries
|
73,274
|
|
|
85,429
|
|
||
Loans to subsidiaries
|
100
|
|
|
1,200
|
|
||
Other assets
|
1,153
|
|
|
1,529
|
|
||
Total assets
|
$
|
81,091
|
|
|
$
|
93,107
|
|
Liabilities and Stockholders’ Equity
|
|
|
|
||||
Liabilities
|
|
|
|
||||
Payables for collateral under derivatives transactions
|
$
|
36
|
|
|
$
|
147
|
|
Long-term debt — unaffiliated
|
14,599
|
|
|
15,505
|
|
||
Long-term debt — affiliated
|
2,000
|
|
|
3,100
|
|
||
Collateral financing arrangement
|
—
|
|
|
2,797
|
|
||
Junior subordinated debt securities
|
2,454
|
|
|
1,734
|
|
||
Other liabilities
|
3,326
|
|
|
2,294
|
|
||
Total liabilities
|
22,415
|
|
|
25,577
|
|
||
Stockholders’ Equity
|
|
|
|
||||
Preferred stock, par value $0.01 per share; $2,100 aggregate liquidation preference
|
—
|
|
|
—
|
|
||
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,168,710,101 and 1,164,029,985 shares issued, respectively; 1,043,588,396 and 1,095,519,005 shares outstanding, respectively
|
12
|
|
|
12
|
|
||
Additional paid-in capital
|
31,111
|
|
|
30,944
|
|
||
Retained earnings
|
26,527
|
|
|
34,683
|
|
||
Treasury stock, at cost; 125,121,705 and 68,510,980 shares, respectively
|
(6,401
|
)
|
|
(3,474
|
)
|
||
Accumulated other comprehensive income (loss)
|
7,427
|
|
|
5,366
|
|
||
Total stockholders’ equity
|
58,676
|
|
|
67,531
|
|
||
Total liabilities and stockholders’ equity
|
$
|
81,091
|
|
|
$
|
93,108
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Condensed Statements of Operations
|
|
|
|
|
|
||||||
Revenues
|
|
|
|
|
|
||||||
Equity in earnings of subsidiaries
|
$
|
7,162
|
|
|
$
|
1,833
|
|
|
$
|
6,048
|
|
Net investment income
|
101
|
|
|
129
|
|
|
170
|
|
|||
Other revenues
|
59
|
|
|
151
|
|
|
124
|
|
|||
Net investment gains (losses)
|
(1,142
|
)
|
|
86
|
|
|
12
|
|
|||
Net derivative gains (losses)
|
(186
|
)
|
|
(68
|
)
|
|
(7
|
)
|
|||
Total revenues
|
5,994
|
|
|
2,131
|
|
|
6,347
|
|
|||
Expenses
|
|
|
|
|
|
||||||
Interest expense
|
1,108
|
|
|
1,152
|
|
|
1,171
|
|
|||
Goodwill impairment
|
—
|
|
|
147
|
|
|
—
|
|
|||
Termination of financing arrangements
|
294
|
|
|
2
|
|
|
—
|
|
|||
Other expenses
|
657
|
|
|
388
|
|
|
180
|
|
|||
Total expenses
|
2,059
|
|
|
1,689
|
|
|
1,351
|
|
|||
Income (loss) before provision for income tax
|
3,935
|
|
|
442
|
|
|
4,996
|
|
|||
Provision for income tax expense (benefit)
|
(75
|
)
|
|
(408
|
)
|
|
(377
|
)
|
|||
Net income (loss)
|
4,010
|
|
|
850
|
|
|
5,373
|
|
|||
Less: Preferred stock dividends
|
103
|
|
|
103
|
|
|
116
|
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
42
|
|
|||
Net income (loss) available to common shareholders
|
$
|
3,907
|
|
|
$
|
747
|
|
|
$
|
5,215
|
|
Comprehensive income (loss)
|
$
|
7,391
|
|
|
$
|
1,449
|
|
|
$
|
(574
|
)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Condensed Statements of Cash Flows
|
|
|
|
|
|
||||||
Cash flows from operating activities
|
|
|
|
|
|
||||||
Net income (loss)
|
$
|
4,010
|
|
|
$
|
850
|
|
|
$
|
5,373
|
|
Earnings of subsidiaries
|
(7,162
|
)
|
|
(1,833
|
)
|
|
(6,048
|
)
|
|||
Dividends from subsidiaries
|
6,745
|
|
|
4,470
|
|
|
2,335
|
|
|||
(Gains) losses on investments and from sales of businesses, net
|
1,142
|
|
|
(86
|
)
|
|
(12
|
)
|
|||
Goodwill impairment
|
—
|
|
|
147
|
|
|
—
|
|
|||
Tax separation agreement charge
|
1,093
|
|
|
—
|
|
|
—
|
|
|||
Other, net
|
634
|
|
|
199
|
|
|
(42
|
)
|
|||
Net cash provided by (used in) operating activities
|
6,462
|
|
|
3,747
|
|
|
1,606
|
|
|||
Cash flows from investing activities
|
|
|
|
|
|
||||||
Sales of fixed maturity securities
|
7,217
|
|
|
8,603
|
|
|
7,952
|
|
|||
Purchases of fixed maturity securities
|
(7,733
|
)
|
|
(7,409
|
)
|
|
(7,957
|
)
|
|||
Cash received in connection with freestanding derivatives
|
452
|
|
|
311
|
|
|
930
|
|
|||
Cash paid in connection with freestanding derivatives
|
(629
|
)
|
|
(561
|
)
|
|
(510
|
)
|
|||
Sales of businesses
|
—
|
|
|
291
|
|
|
—
|
|
|||
Expense paid on behalf of subsidiaries
|
(42
|
)
|
|
(68
|
)
|
|
(40
|
)
|
|||
Receipts on loans to subsidiaries
|
—
|
|
|
140
|
|
|
761
|
|
|||
Issuances of loans to subsidiaries
|
—
|
|
|
(140
|
)
|
|
(300
|
)
|
|||
Returns of capital from subsidiaries
|
610
|
|
|
80
|
|
|
5
|
|
|||
Capital contributions to subsidiaries
|
(339
|
)
|
|
(1,733
|
)
|
|
(667
|
)
|
|||
Net change in short-term investments
|
118
|
|
|
120
|
|
|
110
|
|
|||
Other, net
|
(14
|
)
|
|
(18
|
)
|
|
2
|
|
|||
Net cash provided by (used in) investing activities
|
(360
|
)
|
|
(384
|
)
|
|
286
|
|
|||
Cash flows from financing activities
|
|
|
|
|
|
||||||
Net change in payables for collateral under derivative transactions
|
(111
|
)
|
|
(80
|
)
|
|
(122
|
)
|
|||
Long-term debt issued
|
—
|
|
|
—
|
|
|
2,739
|
|
|||
Long-term debt repaid
|
(1,000
|
)
|
|
(1,250
|
)
|
|
(1,000
|
)
|
|||
Fees paid for the termination of a committed facility related to Separation
|
(244
|
)
|
|
(2
|
)
|
|
—
|
|
|||
Treasury stock acquired in connection with share repurchases
|
(2,927
|
)
|
|
(372
|
)
|
|
(1,930
|
)
|
|||
Preferred stock issued, net of issuance costs
|
—
|
|
|
—
|
|
|
1,483
|
|
|||
Repurchase of preferred stock
|
—
|
|
|
—
|
|
|
(1,460
|
)
|
|||
Preferred stock repurchase premium
|
—
|
|
|
—
|
|
|
(42
|
)
|
|||
Dividends on preferred stock
|
(103
|
)
|
|
(103
|
)
|
|
(116
|
)
|
|||
Dividends on common stock
|
(1,717
|
)
|
|
(1,736
|
)
|
|
(1,653
|
)
|
|||
Other, net
|
182
|
|
|
93
|
|
|
187
|
|
|||
Net cash provided by (used in) financing activities
|
(5,920
|
)
|
|
(3,450
|
)
|
|
(1,914
|
)
|
|||
Change in cash and cash equivalents
|
182
|
|
|
(87
|
)
|
|
(22
|
)
|
|||
Cash and cash equivalents, beginning of year
|
334
|
|
|
421
|
|
|
443
|
|
|||
Cash and cash equivalents, end of year
|
$
|
516
|
|
|
$
|
334
|
|
|
$
|
421
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Supplemental disclosures of cash flow information
|
|
|
|
|
|
||||||
Net cash paid (received) for:
|
|
|
|
|
|
||||||
Interest
|
$
|
1,096
|
|
|
$
|
1,146
|
|
|
$
|
1,133
|
|
Income tax:
|
|
|
|
|
|
||||||
Amounts paid to (received from) subsidiaries, net
|
$
|
(1,552
|
)
|
|
$
|
(569
|
)
|
|
$
|
(226
|
)
|
Amounts paid to Brighthouse in accordance with the tax separation agreement
|
729
|
|
|
—
|
|
|
—
|
|
|||
Income tax paid (received) by MetLife, Inc., net
|
(37
|
)
|
|
136
|
|
|
55
|
|
|||
Total income tax, net
|
$
|
(860
|
)
|
|
$
|
(433
|
)
|
|
$
|
(171
|
)
|
Non-cash transactions:
|
|
|
|
|
|
||||||
Dividends from subsidiary
|
$
|
—
|
|
|
$
|
2,652
|
|
|
$
|
—
|
|
Returns of capital from subsidiaries
|
$
|
17,518
|
|
|
$
|
372
|
|
|
$
|
4,284
|
|
Capital contributions to subsidiaries
|
$
|
15,655
|
|
|
$
|
157
|
|
|
$
|
4,120
|
|
Distribution of Brighthouse
|
$
|
10,346
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Payables to subsidiaries for future capital contributions
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
120
|
|
Allocation of interest expense to subsidiary
|
$
|
15
|
|
|
$
|
39
|
|
|
$
|
28
|
|
Allocation of interest income to subsidiary
|
$
|
4
|
|
|
$
|
54
|
|
|
$
|
57
|
|
|
|
December 31, 2016
|
||||||||||
Condensed Balance Sheets
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised |
||||||
|
|
(In millions)
|
||||||||||
Assets
|
|
|
|
|
|
|
||||||
Investment in subsidiaries
|
|
$
|
85,207
|
|
|
$
|
222
|
|
|
$
|
85,429
|
|
Total assets
|
|
$
|
92,885
|
|
|
$
|
222
|
|
|
$
|
93,107
|
|
Stockholders’ Equity
|
|
|
|
|
|
|
||||||
Retained earnings
|
|
$
|
34,480
|
|
|
$
|
203
|
|
|
$
|
34,683
|
|
Accumulated other comprehensive income (loss)
|
|
$
|
5,347
|
|
|
$
|
19
|
|
|
$
|
5,366
|
|
Total stockholders’ equity
|
|
$
|
67,309
|
|
|
$
|
222
|
|
|
$
|
67,531
|
|
Total liabilities and stockholders’ equity
|
|
$
|
92,886
|
|
|
$
|
222
|
|
|
$
|
93,108
|
|
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||
|
|
2016
|
|
2015
|
||||||||||||||||||||
Condensed Statements of Operations
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised |
|
As
Previously Reported |
|
Revisions
|
|
As
Revised |
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Equity in earnings of subsidiaries
|
|
$
|
1,783
|
|
|
$
|
50
|
|
|
$
|
1,833
|
|
|
$
|
5,985
|
|
|
$
|
63
|
|
|
$
|
6,048
|
|
Total revenues
|
|
$
|
2,081
|
|
|
$
|
50
|
|
|
$
|
2,131
|
|
|
$
|
6,284
|
|
|
$
|
63
|
|
|
$
|
6,347
|
|
Income (loss) before provision for income tax
|
|
$
|
392
|
|
|
$
|
50
|
|
|
$
|
442
|
|
|
$
|
4,933
|
|
|
$
|
63
|
|
|
$
|
4,996
|
|
Net income (loss)
|
|
$
|
800
|
|
|
$
|
50
|
|
|
$
|
850
|
|
|
$
|
5,310
|
|
|
$
|
63
|
|
|
$
|
5,373
|
|
Net income (loss) available to common shareholders
|
|
$
|
697
|
|
|
$
|
50
|
|
|
$
|
747
|
|
|
$
|
5,152
|
|
|
$
|
63
|
|
|
$
|
5,215
|
|
Comprehensive income (loss)
|
|
$
|
1,376
|
|
|
$
|
73
|
|
|
$
|
1,449
|
|
|
$
|
(568
|
)
|
|
$
|
(6
|
)
|
|
$
|
(574
|
)
|
|
|
For the Years Ended December 31,
|
||||||||||||||||||||||
|
|
2016
|
|
2015
|
||||||||||||||||||||
Condensed Statements of Cash Flows
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
|
As
Previously Reported |
|
Revisions
|
|
As
Revised
|
||||||||||||
|
|
(In millions)
|
||||||||||||||||||||||
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net income (loss)
|
|
$
|
800
|
|
|
$
|
50
|
|
|
$
|
850
|
|
|
$
|
5,310
|
|
|
$
|
63
|
|
|
$
|
5,373
|
|
Earnings of subsidiaries
|
|
$
|
(1,783
|
)
|
|
$
|
(50
|
)
|
|
$
|
(1,833
|
)
|
|
$
|
(5,985
|
)
|
|
$
|
(63
|
)
|
|
$
|
(6,048
|
)
|
|
Interest Rates (1)
|
|
|
|
|
|
December 31,
|
||||||||||
|
Range
|
|
Weighted
Average |
|
Maturity
|
|
2017
|
|
2016
|
||||||||
|
(Dollars in millions)
|
||||||||||||||||
Senior notes — unaffiliated (2)
|
3.00%
|
-
|
7.72%
|
|
4.84%
|
|
2018
|
-
|
2046
|
|
$
|
14,599
|
|
|
$
|
15,505
|
|
Senior notes — affiliated
|
3.03%
|
-
|
5.86%
|
|
4.58%
|
|
2019
|
-
|
2021
|
|
2,000
|
|
|
3,100
|
|
||
Total
|
|
|
|
|
|
|
|
|
|
|
$
|
16,599
|
|
|
$
|
18,605
|
|
(1)
|
Range of interest rates and weighted average interest rates are for the year ended December 31,
2017
.
|
(2)
|
Net of
$86 million
and
$92 million
of unamortized issuance costs and net premiums and discounts at December 31,
2017
and
2016
, respectively.
|
|
Years Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
|
(In millions)
|
||||||||||
Long-term debt — unaffiliated
|
$
|
774
|
|
|
$
|
811
|
|
|
$
|
833
|
|
Long-term debt — affiliated
|
112
|
|
|
160
|
|
|
168
|
|
|||
Collateral financing arrangements
|
27
|
|
|
47
|
|
|
36
|
|
|||
Junior subordinated debt securities
|
195
|
|
|
134
|
|
|
134
|
|
|||
Total
|
$
|
1,108
|
|
|
$
|
1,152
|
|
|
$
|
1,171
|
|
Segment
|
|
DAC
and
VOBA
|
|
Future Policy Benefits,
Other Policy-Related
Balances and
Policyholder Dividend
Obligation
|
|
Policyholder
Account
Balances
|
|
Policyholder
Dividends
Payable
|
|
Unearned
Premiums (1), (2)
|
|
Unearned
Revenue (1) |
||||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
U.S.
|
|
$
|
614
|
|
|
$
|
65,610
|
|
|
$
|
70,455
|
|
|
$
|
—
|
|
|
$
|
1,907
|
|
|
$
|
24
|
|
Asia
|
|
9,261
|
|
|
39,702
|
|
|
59,702
|
|
|
80
|
|
|
2,378
|
|
|
916
|
|
||||||
Latin America
|
|
2,050
|
|
|
10,397
|
|
|
6,361
|
|
|
—
|
|
|
115
|
|
|
675
|
|
||||||
EMEA
|
|
1,673
|
|
|
5,768
|
|
|
13,811
|
|
|
7
|
|
|
24
|
|
|
454
|
|
||||||
MetLife Holdings
|
|
4,797
|
|
|
73,317
|
|
|
32,176
|
|
|
595
|
|
|
167
|
|
|
205
|
|
||||||
Corporate & Other
|
|
24
|
|
|
816
|
|
|
13
|
|
|
—
|
|
|
1
|
|
|
—
|
|
||||||
Total
|
|
$
|
18,419
|
|
|
$
|
195,610
|
|
|
$
|
182,518
|
|
|
$
|
682
|
|
|
$
|
4,592
|
|
|
$
|
2,274
|
|
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
U.S.
|
|
$
|
616
|
|
|
$
|
61,578
|
|
|
$
|
67,539
|
|
|
$
|
—
|
|
|
$
|
1,843
|
|
|
$
|
30
|
|
Asia
|
|
8,707
|
|
|
36,308
|
|
|
53,114
|
|
|
95
|
|
|
2,167
|
|
|
912
|
|
||||||
Latin America
|
|
1,808
|
|
|
9,163
|
|
|
5,597
|
|
|
—
|
|
|
448
|
|
|
563
|
|
||||||
EMEA
|
|
1,472
|
|
|
5,439
|
|
|
12,636
|
|
|
6
|
|
|
64
|
|
|
372
|
|
||||||
MetLife Holdings
|
|
5,246
|
|
|
72,220
|
|
|
33,982
|
|
|
604
|
|
|
204
|
|
|
209
|
|
||||||
Corporate & Other
|
|
(259
|
)
|
|
(2,739
|
)
|
|
(382
|
)
|
|
(9
|
)
|
|
(2
|
)
|
|
(27
|
)
|
||||||
Total
|
|
$
|
17,590
|
|
|
$
|
181,969
|
|
|
$
|
172,486
|
|
|
$
|
696
|
|
|
$
|
4,724
|
|
|
$
|
2,059
|
|
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
U.S.
|
|
$
|
615
|
|
|
$
|
59,413
|
|
|
$
|
63,986
|
|
|
$
|
—
|
|
|
$
|
1,820
|
|
|
$
|
33
|
|
Asia
|
|
8,386
|
|
|
34,397
|
|
|
49,094
|
|
|
88
|
|
|
1,859
|
|
|
974
|
|
||||||
Latin America
|
|
1,753
|
|
|
8,142
|
|
|
5,880
|
|
|
—
|
|
|
491
|
|
|
597
|
|
||||||
EMEA
|
|
1,532
|
|
|
5,837
|
|
|
13,172
|
|
|
7
|
|
|
60
|
|
|
336
|
|
||||||
MetLife Holdings
|
|
5,436
|
|
|
70,764
|
|
|
33,320
|
|
|
621
|
|
|
171
|
|
|
218
|
|
||||||
Corporate & Other
|
|
(292
|
)
|
|
(2,345
|
)
|
|
(322
|
)
|
|
(7
|
)
|
|
—
|
|
|
(23
|
)
|
||||||
Total
|
|
$
|
17,430
|
|
|
$
|
176,208
|
|
|
$
|
165,130
|
|
|
$
|
709
|
|
|
$
|
4,401
|
|
|
$
|
2,135
|
|
(1)
|
Amounts are included within the future policy benefits, other policy-related balances and policyholder dividend obligation column.
|
(2)
|
Includes premiums received in advance.
|
Segment
|
|
Premiums and
Universal Life and Investment-Type Product Policy Fees |
|
Net
Investment Income |
|
Policyholder
Benefits and Claims and Interest Credited to Policyholder Account Balances |
|
Amortization of
DAC and VOBA Charged to Other Expenses |
|
Other
Expenses (1) |
||||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
||||||||||
U.S.
|
|
$
|
24,644
|
|
|
$
|
6,201
|
|
|
$
|
25,103
|
|
|
$
|
459
|
|
|
$
|
3,235
|
|
Asia
|
|
8,352
|
|
|
3,299
|
|
|
6,799
|
|
|
1,310
|
|
|
1,802
|
|
|||||
Latin America
|
|
3,737
|
|
|
1,288
|
|
|
2,973
|
|
|
224
|
|
|
1,111
|
|
|||||
EMEA
|
|
2,492
|
|
|
1,157
|
|
|
2,012
|
|
|
356
|
|
|
966
|
|
|||||
MetLife Holdings
|
|
5,603
|
|
|
5,426
|
|
|
7,097
|
|
|
234
|
|
|
2,550
|
|
|||||
Corporate & Other
|
|
(326
|
)
|
|
(8
|
)
|
|
(64
|
)
|
|
98
|
|
|
2,507
|
|
|||||
Total
|
|
$
|
44,502
|
|
|
$
|
17,363
|
|
|
$
|
43,920
|
|
|
$
|
2,681
|
|
|
$
|
12,171
|
|
2016
|
|
|
|
|
|
|
|
|
|
|
||||||||||
U.S.
|
|
$
|
22,490
|
|
|
$
|
5,942
|
|
|
$
|
22,892
|
|
|
$
|
471
|
|
|
$
|
3,244
|
|
Asia
|
|
8,914
|
|
|
2,807
|
|
|
6,916
|
|
|
1,350
|
|
|
1,795
|
|
|||||
Latin America
|
|
3,554
|
|
|
1,133
|
|
|
2,770
|
|
|
184
|
|
|
1,007
|
|
|||||
EMEA
|
|
2,442
|
|
|
1,229
|
|
|
2,064
|
|
|
408
|
|
|
924
|
|
|||||
MetLife Holdings
|
|
6,034
|
|
|
5,670
|
|
|
7,521
|
|
|
424
|
|
|
3,392
|
|
|||||
Corporate & Other
|
|
(749
|
)
|
|
9
|
|
|
(629
|
)
|
|
(119
|
)
|
|
1,892
|
|
|||||
Total
|
|
$
|
42,685
|
|
|
$
|
16,790
|
|
|
$
|
41,534
|
|
|
$
|
2,718
|
|
|
$
|
12,254
|
|
2015
|
|
|
|
|
|
|
|
|
|
|
||||||||||
U.S.
|
|
$
|
21,804
|
|
|
$
|
6,020
|
|
|
$
|
22,100
|
|
|
$
|
471
|
|
|
$
|
3,197
|
|
Asia
|
|
8,491
|
|
|
2,859
|
|
|
6,808
|
|
|
1,262
|
|
|
1,619
|
|
|||||
Latin America
|
|
3,702
|
|
|
1,046
|
|
|
2,853
|
|
|
271
|
|
|
1,075
|
|
|||||
EMEA
|
|
2,455
|
|
|
347
|
|
|
1,109
|
|
|
492
|
|
|
998
|
|
|||||
MetLife Holdings
|
|
6,116
|
|
|
5,855
|
|
|
7,215
|
|
|
722
|
|
|
3,597
|
|
|||||
Corporate & Other
|
|
(595
|
)
|
|
78
|
|
|
(526
|
)
|
|
(34
|
)
|
|
2,463
|
|
|||||
Total
|
|
$
|
41,973
|
|
|
$
|
16,205
|
|
|
$
|
39,559
|
|
|
$
|
3,184
|
|
|
$
|
12,949
|
|
(1)
|
Includes other expenses and policyholder dividends, excluding amortization of DAC and VOBA charged to other expenses.
|
|
|
Gross Amount
|
|
Ceded
|
|
Assumed
|
|
Net Amount
|
|
% Amount Assumed to Net
|
|||||||||
2017
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Life insurance in-force
|
|
$
|
4,594,523
|
|
|
$
|
513,091
|
|
|
$
|
581,246
|
|
|
$
|
4,662,678
|
|
|
12.5
|
%
|
Insurance premium
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Life insurance (1)
|
|
$
|
22,379
|
|
|
$
|
1,863
|
|
|
$
|
1,531
|
|
|
$
|
22,047
|
|
|
6.9
|
%
|
Accident & health insurance
|
|
13,593
|
|
|
442
|
|
|
223
|
|
|
13,374
|
|
|
1.7
|
%
|
||||
Property & casualty insurance
|
|
3,623
|
|
|
71
|
|
|
19
|
|
|
3,571
|
|
|
0.5
|
%
|
||||
Total insurance premium
|
|
$
|
39,595
|
|
|
$
|
2,376
|
|
|
$
|
1,773
|
|
|
$
|
38,992
|
|
|
4.5
|
%
|
2016
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Life insurance in-force
|
|
$
|
4,098,780
|
|
|
$
|
481,028
|
|
|
$
|
613,693
|
|
|
$
|
4,231,445
|
|
|
14.5
|
%
|
Insurance premium
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Life insurance (1)
|
|
$
|
20,857
|
|
|
$
|
1,614
|
|
|
$
|
1,089
|
|
|
$
|
20,332
|
|
|
5.4
|
%
|
Accident & health insurance
|
|
13,551
|
|
|
447
|
|
|
257
|
|
|
13,361
|
|
|
1.9
|
%
|
||||
Property & casualty insurance
|
|
3,567
|
|
|
75
|
|
|
17
|
|
|
3,509
|
|
|
0.5
|
%
|
||||
Total insurance premium
|
|
$
|
37,975
|
|
|
$
|
2,136
|
|
|
$
|
1,363
|
|
|
$
|
37,202
|
|
|
3.7
|
%
|
2015
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Life insurance in-force
|
|
$
|
4,080,869
|
|
|
$
|
546,122
|
|
|
$
|
593,722
|
|
|
$
|
4,128,469
|
|
|
14.4
|
%
|
Insurance premium
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Life insurance (1)
|
|
$
|
20,854
|
|
|
$
|
1,570
|
|
|
$
|
1,150
|
|
|
$
|
20,434
|
|
|
5.6
|
%
|
Accident & health insurance
|
|
12,677
|
|
|
377
|
|
|
219
|
|
|
12,519
|
|
|
1.7
|
%
|
||||
Property & casualty insurance
|
|
3,513
|
|
|
76
|
|
|
13
|
|
|
3,450
|
|
|
0.4
|
%
|
||||
Total insurance premium
|
|
$
|
37,044
|
|
|
$
|
2,023
|
|
|
$
|
1,382
|
|
|
$
|
36,403
|
|
|
3.8
|
%
|
(1)
|
Includes annuities with life contingencies.
|
•
|
Ineffective design and operating effectiveness of the controls related to processes and procedures for identifying unresponsive and missing group annuity annuitants and pension beneficiaries (Control Activities); and
|
•
|
Ineffective design and operating effectiveness of the controls intended to ensure timely communication and escalation of the issue throughout the Company (Information & Communication).
|
•
|
Ineffective design and operating effectiveness of the controls related to data validation and monitoring of reserves for variable annuity guarantees issued by a former operating joint venture in Japan and reinsured by the Company and included within MetLife Holdings (Control Activities).
|
•
|
The Company is implementing immediate changes to its administrative and accounting procedures and search practices to identify, contact, and record responses from “unresponsive and missing” plan annuitants and to otherwise locate missing annuitants.
|
•
|
The Company is reviewing its practices regarding timely communication and escalation of issues throughout the Company.
|
•
|
The Company will engage third party advisors to undertake a comprehensive examination and analysis of the facts and circumstances giving rise to the material weakness, under the supervision of MetLife, Inc.’s Chief Risk Officer.
|
•
|
The Company is implementing immediate changes to how data for MetLife Holdings assumed variable annuity guarantee reserves is controlled and reviewed.
|
•
|
The Company will engage third party advisors to undertake a
comprehensive examination and analysis of the facts and circumstances giving rise to the material weakness.
|
•
|
Ineffective design and operating effectiveness of the controls related to processes and procedures for identifying unresponsive and missing group annuity annuitants and pension beneficiaries; and
|
•
|
Ineffective design and operating effectiveness of the controls intended to ensure timely communication and escalation of the issue throughout the Company
|
•
|
Ineffective design and operating effectiveness of the controls related to data validation and monitoring of reserves for variable annuity guarantees issued by a former operating joint venture in Japan and reinsured by the Company and included within MetLife Holdings
|
|
|
Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights (1)
|
|
Weighted-average Exercise Price of Outstanding Options, Warrants and Rights (2)
|
|
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))(3)
|
||||
Plan Category
|
|
(a)
|
|
(b)
|
|
(c)
|
||||
Equity compensation plans approved by security holders
|
|
27,948,185
|
|
|
$
|
38.77
|
|
|
37,869,420
|
|
Equity compensation plans not approved by security holders
|
|
None
|
|
|
—
|
|
|
None
|
|
|
Total
|
|
27,948,185
|
|
|
$
|
38.77
|
|
|
37,869,420
|
|
(1)
|
Column (a) reflects the following items outstanding as of
December 31, 2017
:
|
Stock Options
|
16,009,754
|
|
Restricted Stock Units
|
3,304,377
|
|
Performance Shares (assuming future payout at maximum performance factor)
|
7,059,080
|
|
Deferred Shares
|
1,574,974
|
|
Shares that will or may be issued
|
27,948,185
|
|
•
|
Stock Options under the MetLife, Inc. 2015 Stock and Incentive Compensation Plan (the “2015 Stock Plan”) and its predecessor plan, the MetLife, Inc. 2005 Stock and Incentive Compensation Plan (the “2005 Stock Plan) were outstanding;
|
•
|
Restricted Stock Units and Performance Shares under the 2015 Stock Plan were outstanding; and
|
•
|
Deferred Shares related to awards under the 2015 Stock Plan, MetLife, Inc. 2015 Non-Management Directors Stock Compensation Plan (the “2015 Director Stock Plan”), 2005 Stock Plan, MetLife, Inc. 2005 Non-Management Directors Stock Compensation Plan (the “2005 Director Stock Plan”), and earlier plans, were outstanding. Deferred Shares are Shares that are covered by awards that have become payable under any plan, but the issuance of which has been deferred.
|
(2)
|
Column (b) reflects the weighted average exercise price of all Stock Options under any plan that, as of
December 31, 2017
, had been granted but not forfeited, expired, or exercised. Performance Shares, Restricted Stock Units, and Deferred Shares are not included in determining the weighted average in column (b) because they have no exercise price.
|
(3)
|
Column (c) reflects the following items outstanding as of
December 31, 2017
:
|
|
Number of Shares
|
|
At January 15, 2015, the effective date of the 2015 Stock Plan and 2015 Director Stock Plan:
|
|
|
Shares newly authorized for issuance under the 2015 Stock Plan
|
11,750,000
|
|
Shares remaining authorized for issuance under the 2005 Stock Plan or other plans that were not covered by awards (i)
|
18,023,959
|
|
Shares authorized for issuance under the 2015 Director Stock Plan (ii)
|
1,642,208
|
|
Total Shares authorized for issuance at January 1, 2015
|
31,416,167
|
|
Additional Shares recovered for issuance (iii) in:
|
|
|
2015
|
4,475,737
|
|
2016
|
6,344,455
|
|
2017
|
6,636,193
|
|
Total Shares recovered for issuance since January 1, 2015
|
17,456,385
|
|
Less: Shares covered by new awards and new imputed reinvested dividends on Deferred Shares (iv) in:
|
|
|
2015
|
4,413,785
|
|
2016
|
6,036,177
|
|
2017
|
4,532,897
|
|
Total Shares covered by new awards and new imputed reinvested dividends on Deferred Shares since January 1, 2015
|
14,982,859
|
|
Net shares added to the 2015 Stock Plan and 2015 Director Plan authorizations in light of the Separation (v)
|
3,979,727
|
|
Shares remaining available for future issuance under the 2015 Stock Plan and 2015 Director Stock Plan
|
37,869,420
|
|
(i)
|
Consisting of Shares that were not covered by awards, including Shares previously covered by awards but recovered due to forfeiture of awards or other reasons and once again available for issuance.
|
(ii)
|
Consists of Shares remaining authorized for issuance under the predecessor plan, the 2005 Director Stock Plan, that were not covered by awards, including Shares previously covered by awards but recovered due to forfeiture of awards or other reasons and once again available.
|
(iii)
|
Consists of Shares utilized under the 2005 Stock Plan or 2015 Stock Plan that were recovered during each of the indicated calendar years, and therefore once again available for issuance, due to: (i) termination of the award by expiration, forfeiture, cancellation, lapse, or otherwise without issuing Shares; (ii) settlement of the award in cash either in lieu of Shares or otherwise; (iii) exchange of the award for awards not involving Shares; (iv) payment of the exercise price of a Stock Option, or the tax withholding requirements with respect to an award, satisfied by tendering Shares to MetLife, Inc. (by either actual delivery or by attestation); (v) satisfaction of tax withholding requirements with respect to an award satisfied by MetLife, Inc. withholding Shares otherwise issuable; and (vi) the payout of Performance Shares at any performance factor less than the maximum performance factor.
|
(iv)
|
Consists of Shares covered by awards granted under the 2015 Stock Plan (including Performance Shares assuming future payout at maximum performance factor). Shares covered by awards granted under the 2015 Directors Stock Plan and Shares covered by imputed reinvested dividends credited on Deferred Shares owed to directors, employees or agents, in each case during each of the indicated calendar years.
|
(v)
|
In light of the Separation, and in order to maintain the Share authorizations under each plan at the levels that shareholders had approved, MetLife, Inc. increased the number of Shares authorized for issuance under the 2015 Stock Plan and 2015 Director Plan as of August 4, 2017, excluding those Shares from the authorizations that had already been issued, by the Adjustment Ratio. MetLife, Inc. also increased the number of Shares covered by outstanding Stock Options, Performance Shares, Restricted Stock Units, and Deferred Shares on that date by the Adjustment Ratio, in order to maintain the intrinsic value of those awards and Deferred Shares, which decreased the number of Shares available for issuance under both plans. The amount in this row is the net increase in the Share authorization under both the 2015 Stock Plan and 2015 Director Plan as a result of these adjustments. For a description of the adjustment to Stock Options, Performance Shares, Restricted Stock Units, and Deferred Shares, see Note
15
of the Notes to the Consolidated Financial Statements.
|
|
|
|
|
Incorporated by Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.1
|
|
|
|
S-1
|
|
333-91517
|
|
2.1
|
|
November 23, 1999
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.2
|
|
|
|
S-1/A
|
|
333-91517
|
|
2.2
|
|
March 29, 2000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.3
|
|
|
8-K
|
|
001-15787
|
|
2.1
|
|
August 7, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
|
10-K
|
|
001-15787
|
|
3.1
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
|
10-K
|
|
001-15787
|
|
3.2
|
|
March 1, 2017
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.3
|
|
|
10-K
|
|
001-15787
|
|
3.3
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.4
|
|
|
10-K
|
|
001-15787
|
|
3.4
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.5
|
|
|
10-Q
|
|
001-15787
|
|
3.6
|
|
November 7, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.6
|
|
|
8-K
|
|
001-15787
|
|
3.1
|
|
April 30, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.7
|
|
|
8-K
|
|
001-15787
|
|
3.1
|
|
May 28, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.8
|
|
|
10-Q
|
|
001-15787
|
|
3.7
|
|
November 5, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.9
|
|
|
8-K
|
|
001-15787
|
|
3.1
|
|
October 24, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.10
|
|
|
8-K
|
|
001-15787
|
|
3.2
|
|
September 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
|
S-1/A
|
|
333-91517
|
|
4.1
|
|
March 9, 2000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.4
|
|
|
8-A
|
|
001-15787
|
|
99.6
|
|
June 10, 2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.6
|
|
|
8-K
|
|
001-15787
|
|
4.2
|
|
May 28, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.7
|
|
Certificate of Amendment of Amended and Restated Certificate of Incorporation of MetLife, Inc., dated October 23, 2017
(See Exhibit 3.9 above).
Certain instruments defining the rights of holders of long-term debt of MetLife, Inc. and its consolidated subsidiaries are omitted pursuant to Item 601(b)(4)(iii) of Regulation S-K. MetLife, Inc. hereby agrees to furnish to the Securities and Exchange Commission, upon request, copies of such instruments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1
|
|
|
10-K
|
|
001-15787
|
|
10.1
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2
|
|
|
10-K
|
|
001-15787
|
|
10.2
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.3
|
|
|
10-Q
|
|
001-15787
|
|
10.2
|
|
November 7, 2012
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.4
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
May 16, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.5
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
June 15, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.6
|
|
|
10-Q
|
|
001-15787
|
|
10.1
|
|
August 6, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.7
|
|
|
10-Q
|
|
001-15787
|
|
10.1
|
|
November 5, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.8
|
|
|
10-Q
|
|
001-15787
|
|
10.2
|
|
November 5, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.9
|
|
|
10-K
|
|
001-15787
|
|
10.13
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.10
|
|
|
10-K
|
|
001-15787
|
|
10.14
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11
|
|
|
10-Q
|
|
001-15787
|
|
10.1
|
|
August 5, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12
|
|
|
10-K
|
|
001-15787
|
|
10.24
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.13
|
|
|
10-K
|
|
001-15787
|
|
10.24
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.14
|
|
|
10-K
|
|
001-15787
|
|
10.25
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.15
|
|
|
10-K
|
|
001-15787
|
|
10.28
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.16
|
|
|
10-K
|
|
001-15787
|
|
10.29
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.17
|
|
|
8-K
|
|
001-15787
|
|
10.9
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.18
|
|
|
8-K
|
|
001-15787
|
|
10.10
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.19
|
|
|
8-K
|
|
001-15787
|
|
10.4
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.20
|
|
|
8-K
|
|
001-15787
|
|
10.5
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.21
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.22
|
|
|
8-K
|
|
001-15787
|
|
10.2
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.23
|
|
|
8-K
|
|
001-15787
|
|
10.3
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.24
|
|
|
10-K
|
|
001-15787
|
|
10.24
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.25
|
|
|
10-K
|
|
001-15787
|
|
10.25
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.26
|
|
|
8-K
|
|
001-15787
|
|
10.11
|
|
February 15, 2013
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.27
|
|
|
8-K
|
|
001-15787
|
|
10.12
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.28
|
|
|
8-K
|
|
001-15787
|
|
10.13
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.29
|
|
|
8-K
|
|
001-15787
|
|
10.6
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.30
|
|
|
8-K
|
|
001-15787
|
|
10.7
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.31
|
|
|
8-K
|
|
001-15787
|
|
10.8
|
|
February 15, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.32
|
|
|
S-1
|
|
333-91517
|
|
10.12
|
|
November 23, 1999
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.33
|
|
|
10-K
|
|
001-15787
|
|
10.62
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.34
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
June 4, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.35
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
November 24, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.36
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
December 21, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.37
|
|
|
10-K
|
|
001-15787
|
|
10.72
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.38
|
|
|
10-K
|
|
001-15787
|
|
10.74
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.39
|
|
|
10-K
|
|
001-15787
|
|
10.48
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.40
|
|
|
10-K
|
|
001-15787
|
|
10.75
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.41
|
|
|
10-K
|
|
001-15787
|
|
10.77
|
|
February 27, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.42
|
|
|
10-K
|
|
001-15787
|
|
10.78
|
|
February 27, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.43
|
|
|
10-K
|
|
001-15787
|
|
10.52
|
|
February 25, 2016
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.44
|
|
|
10-K
|
|
001-15787
|
|
10.53
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.45
|
|
|
10-K
|
|
001-15787
|
|
10.45
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.46
|
|
|
10-K
|
|
001-15787
|
|
10.46
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.47
|
|
|
10-K
|
|
001-15787
|
|
10.81
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.48
|
|
|
10-K
|
|
001-15787
|
|
10.84
|
|
February 27, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.49
|
|
|
10-K
|
|
001-15787
|
|
10.85
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.50
|
|
|
10-K
|
|
001-15787
|
|
10.86
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.51
|
|
|
10-K
|
|
001-15787
|
|
10.60
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.52
|
|
|
10-K
|
|
001-15787
|
|
10.52
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.53
|
|
|
10-K
|
|
001-15787
|
|
10.53
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.54
|
|
|
10-K
|
|
001-15787
|
|
10.54
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.55
|
|
|
10-K
|
|
001-15787
|
|
10.88
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.56
|
|
|
10-K
|
|
001-15787
|
|
10.56
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.57
|
|
|
10-K
|
|
001-15787
|
|
10.57
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.58
|
|
|
S-8
|
|
333-214710
|
|
4.1
|
|
November 18, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.59
|
|
|
10-K
|
|
001-15787
|
|
10.94
|
|
February 27, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.60
|
|
|
10-K
|
|
001-15787
|
|
10.60
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.61
|
|
|
10-K
|
|
001-15787
|
|
10.61
|
|
March 1, 2017
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.62
|
|
|
10-K
|
|
001-15787
|
|
10.95
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.63
|
|
|
10-K
|
|
001-15787
|
|
10.98
|
|
February 27, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.64
|
|
|
10-K
|
|
001-15787
|
|
10.99
|
|
February 27, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.65
|
|
|
10-K
|
|
001-15787
|
|
10.71
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.66
|
|
|
10-K
|
|
001-15787
|
|
10.102
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.67
|
|
|
10-K
|
|
001-15787
|
|
10.73
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.68
|
|
|
10-K
|
|
001-15787
|
|
10.101
|
|
February 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.69
|
|
|
10-K
|
|
001-15787
|
|
10.69
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.70
|
|
|
|
10-K
|
|
001-15787
|
|
10.70
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.71
|
|
|
10-K
|
|
001-15787
|
|
10.71
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.72
|
|
|
10-K
|
|
001-15787
|
|
10.72
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.73
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
May 4, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.74
|
|
|
10-K
|
|
001-15787
|
|
10.79
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.75
|
|
|
10-Q
|
|
001-15787
|
|
10.2
|
|
August 8, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.76
|
|
|
10-K
|
|
001-15787
|
|
10.111
|
|
February 27, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.77
|
|
|
10-K
|
|
001-15787
|
|
10.77
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.78
|
|
|
10-K
|
|
001-15787
|
|
10.78
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.79
|
|
|
10-K
|
|
001-15787
|
|
10.79
|
|
March 1, 2017
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.80
|
|
|
10-K
|
|
001-15787
|
|
10.80
|
|
March 1, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.81
|
|
|
S-8
|
|
333-198141
|
|
4.1
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.82
|
|
|
S-8
|
|
333-198145
|
|
4.1
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.83
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.84
|
|
|
8-K
|
|
001-15787
|
|
10.2
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.85
|
|
|
8-K
|
|
001-15787
|
|
10.3
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.86
|
|
|
8-K
|
|
001-15787
|
|
10.4
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.87
|
|
|
8-K
|
|
001-15787
|
|
10.5
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.88
|
|
|
8-K
|
|
001-15787
|
|
10.6
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.89
|
|
|
8-K
|
|
001-15787
|
|
10.7
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.90
|
|
|
8-K
|
|
001-15787
|
|
10.8
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.91
|
|
|
8-K
|
|
001-15787
|
|
10.9
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.92
|
|
|
8-K
|
|
001-15787
|
|
10.10
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.93
|
|
|
8-K
|
|
001-15787
|
|
10.11
|
|
December 11, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.94
|
|
|
10-K
|
|
001-15787
|
|
10.95
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.95
|
|
|
10-K
|
|
001-15787
|
|
10.96
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.96
|
|
|
10-K
|
|
001-15787
|
|
10.97
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.97
|
|
|
10-K
|
|
001-15787
|
|
10.98
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.98
|
|
|
10-K
|
|
001-15787
|
|
10.99
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.99
|
|
|
10-K
|
|
001-15787
|
|
10.100
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.100
|
|
|
10-K
|
|
001-15787
|
|
10.101
|
|
February 25, 2016
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.101
|
|
|
10-K
|
|
001-15787
|
|
10.102
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.102
|
|
|
10-K
|
|
001-15787
|
|
10.103
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.103
|
|
|
10-K
|
|
001-15787
|
|
10.104
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.104
|
|
|
10-K
|
|
001-15787
|
|
10.105
|
|
February 25, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.105
|
|
|
S-8
|
|
333-198143
|
|
4.1
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.106
|
|
|
S-8
|
|
333-198143
|
|
4.2
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.107
|
|
|
S-8
|
|
333-198143
|
|
4.3
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.108
|
|
|
S-8
|
|
333-198143
|
|
4.4
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.109
|
|
|
S-8
|
|
333-198143
|
|
4.5
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.110
|
|
|
S-8
|
|
333-198143
|
|
4.6
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.111
|
|
|
10-Q
|
|
001-15787
|
|
10.1
|
|
May 6, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.112
|
|
|
10-Q
|
|
001-15787
|
|
10.1
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.113
|
|
|
10-Q
|
|
001-15787
|
|
10.2
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.114
|
|
|
10-Q
|
|
001-15787
|
|
10.3
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.115
|
|
|
10-Q
|
|
001-15787
|
|
10.4
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.116
|
|
|
10-Q
|
|
001-15787
|
|
10.5
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.117
|
|
|
10-Q
|
|
001-15787
|
|
10.6
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.118
|
|
|
10-Q
|
|
001-15787
|
|
10.1
|
|
August 5, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.119
|
|
|
10-Q
|
|
001-15787
|
|
10.15
|
|
February 25, 2016
|
|
|
|
|
|
|
Incorporated By Reference
|
|
|
||||||
Exhibit No.
|
|
Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
Filed or Furnished
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.120
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
August 7, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.121
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
November 6, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.122
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
November 21, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.123
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.124
|
|
|
8-K
|
|
001-15787
|
|
10.1
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.125
|
|
|
8-K
|
|
001-15787
|
|
10.2
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.126
|
|
|
8-K
|
|
001-15787
|
|
10.3
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.127
|
|
|
8-K
|
|
001-15787
|
|
10.4
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.128
|
|
|
8-K
|
|
001-15787
|
|
10.5
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.129
|
|
|
8-K
|
|
001-15787
|
|
10.6
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.130
|
|
|
8-K
|
|
001-15787
|
|
10.7
|
|
February 20, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.2
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
METLIFE, INC.
|
||
|
|
|
By
|
|
/s/ Steven A. Kandarian
|
|
|
Name: Steven A. Kandarian
|
|
|
Title: Chairman of the Board, President
and Chief Executive Officer |
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
|
|
|
/s/ Cheryl W. Grisé
|
|
Director
|
|
March 1, 2018
|
Cheryl W. Grisé
|
|
|
|
|
|
|
|
|
|
/s/ Carlos M. Gutierrez
|
|
Director
|
|
March 1, 2018
|
Carlos M. Gutierrez
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Gerald L. Hassell
|
|
|
|
|
|
|
|
|
|
/s/ David L. Herzog
|
|
Director
|
|
March 1, 2018
|
David L. Herzog
|
|
|
|
|
|
|
|
|
|
/s/ R. Glenn Hubbard
|
|
Director
|
|
March 1, 2018
|
R. Glenn Hubbard
|
|
|
|
|
|
|
|
|
|
/s/ Alfred F. Kelly, Jr.
|
|
Director
|
|
March 1, 2018
|
Alfred F. Kelly, Jr.
|
|
|
|
|
|
|
|
|
|
/s/ Edward J. Kelly, III
|
|
Director
|
|
March 1, 2018
|
Edward J. Kelly, III
|
|
|
|
|
|
|
|
|
|
/s/ William E. Kennard
|
|
Director
|
|
March 1, 2018
|
William E. Kennard
|
|
|
|
|
|
|
|
|
|
/s/ James M. Kilts
|
|
Director
|
|
March 1, 2018
|
James M. Kilts
|
|
|
|
|
|
|
|
|
|
/s/ Catherine R. Kinney
|
|
Director
|
|
March 1, 2018
|
Catherine R. Kinney
|
|
|
|
|
|
|
|
|
|
/s/ Denise M. Morrison
|
|
Director
|
|
March 1, 2018
|
Denise M. Morrison
|
|
|
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Steven A. Kandarian
|
|
Chairman of the Board, President and
|
|
March 1, 2018
|
Steven A. Kandarian
|
|
Chief Executive Officer
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ John C. R. Hele
|
|
Executive Vice President and
|
|
March 1, 2018
|
John C. R. Hele
|
|
Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ William O’Donnell
|
|
Executive Vice President and
|
|
March 1, 2018
|
William O’Donnell
|
|
Chief Accounting Officer
(Principal Accounting Officer)
|
|
|
(a)
|
Neither this Section 5 nor any other provision of this Agreement prohibit or restrict you or your attorney from providing information or testimony to, otherwise assisting or participating in an investigation or proceeding with or brought by, or filing a charge or complaint with any government agency, law enforcement or organization, legislative body, regulatory organization, or self-regulatory organization (“SRO”), including, but not limited to, the SEC, Financial Industry Regulatory Authority (“FINRA”), Commodity Futures Trading Commission (“CFTC”), Department
|
(b)
|
You are not prohibited from disclosing this Agreement to your spouse, civil union or domestic partner, attorney, account, or tax or financial advisor, provided that such individuals are advised that they may not disclose this Agreement and have agreed to be bound by the same restrictions against disclosure that apply to you.
|
(c)
|
You are not prohibited from providing a prospective employer or broker dealer with information concerning your former job title, salary, job responsibilities, and qualifications.
|
/s/ Maria R. Morris
|
|
9/26/17
|
Associate’s Signature
|
|
Date
|
Maria R. Morris
|
|
|
Associate’s Printed Name
|
|
|
STATE OF
|
New Jersey
|
)
|
COUNTY OF
|
Morris
|
)
|
/s/ Carol C. Cucelli
|
By:
|
/s/ Alana Simmons
|
|
OCT 04 2017
|
|
ALANA SIMMONS / CSR
|
|
Name & Title
|
|
Years Ended December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
|
(In millions, except ratios)
|
||||||||||||||||||
Income (loss) from continuing operations before provision for income tax
|
$
|
3,536
|
|
|
$
|
4,281
|
|
|
$
|
5,651
|
|
|
$
|
6,883
|
|
|
$
|
3,686
|
|
Less: Undistributed income (loss) from equity investees
|
444
|
|
|
164
|
|
|
299
|
|
|
418
|
|
|
337
|
|
|||||
Adjusted earnings before fixed charges
|
$
|
3,092
|
|
|
$
|
4,117
|
|
|
$
|
5,352
|
|
|
$
|
6,465
|
|
|
$
|
3,349
|
|
Add: Fixed charges
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest and debt issue costs
|
1,185
|
|
|
1,188
|
|
|
1,544
|
|
|
1,189
|
|
|
1,194
|
|
|||||
Estimated interest component of rent expense
|
15
|
|
|
24
|
|
|
25
|
|
|
28
|
|
|
33
|
|
|||||
Interest credited to bank deposits
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2
|
|
|||||
Interest credited to policyholder account balances
|
5,607
|
|
|
5,176
|
|
|
4,415
|
|
|
5,726
|
|
|
6,881
|
|
|||||
Total fixed charges
|
$
|
6,807
|
|
|
$
|
6,388
|
|
|
$
|
5,984
|
|
|
$
|
6,943
|
|
|
$
|
8,110
|
|
Preferred stock dividends (1)
|
107
|
|
|
123
|
|
|
219
|
|
|
170
|
|
|
150
|
|
|||||
Total fixed charges and preferred stock dividends
|
$
|
6,914
|
|
|
$
|
6,511
|
|
|
$
|
6,203
|
|
|
$
|
7,113
|
|
|
$
|
8,260
|
|
Total earnings and fixed charges
|
$
|
9,899
|
|
|
$
|
10,505
|
|
|
$
|
11,336
|
|
|
$
|
13,408
|
|
|
$
|
11,459
|
|
Ratio of earnings to fixed charges
|
1.45
|
|
|
1.64
|
|
|
1.89
|
|
|
1.93
|
|
|
1.41
|
|
|||||
Total earnings, including fixed charges and preferred stock dividends
|
$
|
10,006
|
|
|
$
|
10,628
|
|
|
$
|
11,555
|
|
|
$
|
13,578
|
|
|
$
|
11,609
|
|
Ratio of earnings to fixed charges and preferred stock dividends
|
1.45
|
|
|
1.63
|
|
|
1.86
|
|
|
1.91
|
|
|
1.41
|
|
(1)
|
For the year ended December 31, 2015, preferred stock dividends includes the repurchase premium of $59 million associated with the repurchased and canceled 6.50% non-cumulative Series B preferred stock.
|
1.
150 NORTH RIVERSIDE PE MEMBER, LLC (DE)
|
2.
23
RD
STREET INVESTMENTS, INC. (DE)
|
3.
85 BROAD STREET MEZZANINE LLC (DE)
|
4.
334 MADISON EURO INVESTMENTS, INC. (DE)
|
5.
500 GRANT STREET ASSOCIATES LIMITED PARTNERSHIP (CT)
|
6.
500 GRANT STREET GP LLC (DE)
|
7.
1001 PROPERTIES, LLC (DE)
|
8.
1201 TAB MANAGER, LLC (DE)
|
9.
1320 GP LLC (DE)
|
10.
1320 OWNER LP (DE)
|
11.
1320 VENTURE LLC (DE)
|
12.
1925 WJC OWNER, LLC (DE)
|
13.
6104 HOLLYWOOD, LLC (DE)
|
14.
10700 WILSHIRE, LLC (DE)
|
15.
AFP GENESIS ADMINISTRADORA DE FONDOS Y FIDECOMISOS S.A. (ECUADOR)
|
16.
AGENVITA S.R.L. (ITALY)
|
17.
ALICO EUROPEAN HOLDINGS LIMITED (IRELAND)
|
18.
ALICO HELLAS SINGLE MEMBER LIMITED LIABILITY COMPANY (GREECE)
|
19.
ALICO OPERATIONS, LLC (DE)
|
20.
ALTERNATIVE FUELS I, LLC (DE)
|
21.
AMERICAN LIFE INSURANCE COMPANY (DE)
|
22.
BEST MARKET S.A. (ARGENTINA)
|
23.
BORDERLAND INVESTMENTS LIMITED (DE)
|
24.
BOULEVARD RESIDENTIAL, LLC (DE)
|
25.
BUFORD LOGISTICS CENTER, LLC (DE)
|
26.
CC HOLDCO MANAGER, LLC (DE)
|
27.
CHESTNUT FLATS WIND, LLC (DE)
|
28.
COMMUNICATION ONE KABUSHIKI KAISHA (JAPAN)
|
29.
COMPANIA INVERSORA METLIFE S.A. (ARGENTINA)
|
30.
CONVENT STATION EURO INVESTMENTS FOUR COMPANY (UK)
|
31.
CORPORATE REAL ESTATE HOLDINGS, LLC (DE)
|
32.
COVA LIFE MANAGEMENT COMPANY (DE)
|
33.
DELAWARE AMERICAN LIFE INSURANCE COMPANY (DE)
|
34.
ECONOMY FIRE & CASUALTY COMPANY (IL)
|
35.
ECONOMY PREFERRED INSURANCE COMPANY (IL)
|
36.
ECONOMY PREMIER ASSURANCE COMPANY (IL)
|
37.
EL CONQUISTADOR MAH II LLC (DE)
|
38.
ENTERPRISE GENERAL INSURANCE AGENCY, INC. (DE)
|
39.
ENTRECAP REAL ESTATE II LLC (DE)
|
40.
EURO CL INVESTMENTS, LLC (DE)
|
41.
EXCELENCIA OPERATIVA Y TECNOLOGICA, S.A de C.V. (MEXICO)
|
42.
FEDERAL FLOOD CERTIFICATION LLC (TX)
|
43.
FIRST AMERICAN – HUNGARIAN INSURANCE AGENCY LIMITED (HUNGARY)
|
44.
FUNDACION METLIFE MEXICO, A.C. (MEXICO)
|
45.
GALIC HOLDINGS LLC (DE)
|
46.
GENERAL AMERICAN LIFE INSURANCE COMPANY (MO)
|
47.
GLOBAL PROPERTIES, INC. (DE)
|
48.
HASKELL EAST VILLAGE, LLC (DE)
|
49.
HOUSING FUND MANAGER, LLC (DE)
|
50.
HPZ ASSETS LLC (DE)
|
51.
HYATT LEGAL PLANS OF FLORIDA, INC. (FL)
|
52.
HYATT LEGAL PLANS, INC. (DE)
|
53.
INTERNATIONAL INVESTMENT HOLDING COMPANY LIMITED (RUSSIA)
|
54.
INTERNATIONAL TECHNICAL AND ADVISORY SERVICES LIMITED (DE)
|
55.
INVERSIONES METLIFE HOLDCO DOS LIMITADA (CHILE)
|
56.
INVERSIONES METLIFE HOLDCO TRES LIMITADA (CHILE)
|
57.
JOINT STOCK COMPANY METLIFE INSURANCE COMPANY (RUSSIA)
|
58.
LHC HOLDINGS (US) LLC (DE)
|
59.
LHCW HOLDINGS (US) LLC (DE)
|
60.
LHCW HOTEL HOLDING LLC (DE)
|
61.
LHCW HOTEL HOLDING (2002) LLC (DE)
|
62.
LHCW HOTEL OPERATING COMPANY (2002) LLC (DE)
|
63.
LOGAN CIRCLE PARTNERS I LLC (PA)
|
64.
LOGAN CIRCLE PARTNERS, L.P. (PA)
|
65.
LOGAN CIRCLE PARTNERS GP, LLC (PA)
|
66.
LOGAN CIRCLE PARTNERS INVESTMENT MANAGEMENT, LLC (DE)
|
67.
LONG ISLAND SOLAR FARM LLC (DE)
|
68.
MARKETPLACE RESIDENCES, LLC (DE)
|
69.
MCP VOA HOLDINGS, LLC (DE)
|
70.
MCP VOA I & III, LLC (DE)
|
71.
MCP VOA II, LLC (DE)
|
72.
MCPP OWNERS, LLC (DE)
|
73.
MET0 SIEFORE, S.A. de C.V. (MEXICO)
|
74.
MET1 SIEFORE, S.A. de C.V. (MEXICO)
|
75.
MET2 SIEFORE, S.A. de C.V. (MEXICO)
|
76.
MET3 SIEFORE BASICA, S.A. de C.V. (MEXICO)
|
77.
MET4 SIEFORE, S.A. de C.V. (MEXICO)
|
78.
META SIEFORE ADICIONAL, S.A. de C.V. (MEXICO)
|
79.
MET CANADA SOLAR ULC (CANADA)
|
80.
METLIFE 425 MKT MEMBER, LLC (DE)
|
81.
METLIFE 555 12TH MEMBER, LLC (DE)
|
82.
METLIFE 1007 STEWART, LLC (DE)
|
83.
METLIFE 1201 TAB MEMBER, LLC (DE)
|
84.
METLIFE ADMINISTRADORA DE FUNDOS MULTIPATROCINADOS LTDA. (BRAZIL)
|
85.
METLIFE AFORE, S.A. DE C.V. (MEXICO)
|
86.
METLIFE ALTERNATIVES GP, LLC (DE)
|
87.
METLIFE ASIA HOLDING COMPANY PTE. LTD. (SINGAPORE)
|
88.
METLIFE ASIA LIMITED (HONG KONG)
|
89.
METLIFE ASSET MANAGEMENT CORP. (JAPAN)
|
90.
METLIFE ASSIGNMENT COMPANY, INC. (DE)
|
91.
METLIFE AUTO & HOME INSURANCE AGENCY, INC. (RI)
|
92.
METLIFE BL FEEDER, LP (CAYMAN)
|
93.
METLIFE BL FEEDER, LP (DE)
|
94.
METLIFE CABO HILTON MEMBER, LLC (DE)
|
95.
METLIFE CAMINO RAMON MEMBER, LLC (DE)
|
96.
METLIFE CANADIAN PROPERTY VENTURES, LLC (NY)
|
97.
METLIFE CAPITAL CREDIT L.P. (DE)
|
98.
METLIFE CAPITAL TRUST IV (DE)
|
99.
METLIFE CAPITAL, LIMITED PARTNERSHIP (DE)
|
100.
METLIFE CB W/A, LLC (DE)
|
101.
METLIFE CC MEMBER, LLC (DE)
|
102.
METLIFE CHILE ADMINISTRADORA DE MUTUOS HIPOTECARIOS S.A. (CHILE)
|
103.
METLIFE CHILE INVERSIONES LIMITADA (CHILE)
|
104.
METLIFE CHILE SEGUROS DE VIDA S.A. (CHILE)
|
105.
METLIFE CHILE SEGUROS GENERALES S.A. (CHILE)
|
106.
METLIFE CHINO MEMBER, LLC (DE)
|
107.
METLIFE COLOMBIA SEGUROS de VIDA S.A. (COLOMBIA)
|
108.
METLIFE CONSUMER SERVICES, INC. (DE)
|
109.
METLIFE COMMERCIAL MORTGAGE INCOME FUND GP, LLC (DE)
|
110.
METLIFE CONSQUARE MEMBER, LLC (DE)
|
111.
METLIFE CORE PROPERTY FUND GP, LLC (DE)
|
112.
METLIFE CREDIT CORP.(DE)
|
113.
METLIFE EMEKLILIK VE HAYAT A.S. (TURKEY)
|
114.
METLIFE EU HOLDING COMPANY LIMITED (IRELAND)
|
115.
METLIFE EUROPE INSURANCE d.a.c.(IRELAND)
|
116.
METLIFE EUROPE d.a.c. (IRELAND)
|
117.
METLIFE EUROPE SERVICES LIMITED (IRELAND)
|
118.
METLIFE EUROPEAN HOLDINGS, LLC. (DE)
|
119.
METLIFE FINANCIAL SERVICES, CO., LTD (SOUTH KOREA)
|
120.
METLIFE FM HOTEL MEMBER, LLC (DE)
|
121.
METLIFE FUNDING, INC. (DE)
|
122.
METLIFE GENERAL INSURANCE LIMITED (AUSTRALIA)
|
123.
METLIFE GLOBAL BENEFITS, LTD. (CAYMAN ISLANDS)
|
124.
METLIFE GLOBAL HOLDING COMPANY I GmbH (SWISS I) (SWITZERLAND)
|
125.
METLIFE GLOBAL HOLDING COMPANY II GmbH (SWISS II) (SWITZERLAND)
|
126.
METLIFE GLOBAL HOLDINGS CORPORATION S.A. De C.V.(MEXICO)
|
127.
METLIFE GLOBAL OPERATIONS SUPPORT CENTER PRIVATE LIMITED(INDIA)
|
128.
METLIFE GLOBAL, INC. (DE)
|
129.
METLIFE GROUP, INC. (NY)
|
130.
METLIFE HCMJV 1 GP, LLC (DE)
|
131.
METLIFE HEALTH PLANS, INC. (DE)
|
132.
METLIFE HOLDINGS, INC. (DE)
|
133.
METLIFE HOME LOANS, LLC (DE)
|
134.
METLIFE INNOVATION CENTRE LIMITED (IRELAND)
|
135.
METLIFE INNOVATION CENTRE PTE. LTD. (SINGAPORE)
|
136.
METLIFE INSURANCE AND INVESTMENT TRUST (AUSTRALIA)
|
137.
METLIFE INSURANCE BROKERAGE, INC. (NY)
|
138.
METLIFE INSURANCE K.K. (JAPAN)
|
139.
METLIFE INSURANCE LIMITED (AUSTRALIA)
|
140.
METLIFE INTERNATIONAL HF PARTNERS, LP (CAYMAN ISLANDS)
|
141.
METLIFE INTERNATIONAL HOLDINGS, LLC (DE)
|
142.
METLIFE INTERNATIONAL LIMITED, LLC (DE)
|
143.
METLIFE INTERNATIONAL PE FUND I, LP (CAYMAN ISLANDS)
|
144.
METLIFE INTERNATIONAL PE FUND II, LP (CAYMAN ISLANDS)
|
145.
METLIFE INTERNATIONAL PE FUND III, LP (CAYMAN ISLANDS)
|
146.
METLIFE INTERNATIONAL PE FUND IV, LP (CAYMAN ISLANDS)
|
147.
METLIFE INTERNATIONAL PE FUND V, LP (CAYMAN ISLANDS)
|
148.
METLIFE INTERNATIONAL PE FUND VI, LP (CAYMAN ISLANDS)
|
149.
METLIFE INVESTMENT ADVISORS, LLC (DE)
|
150.
METLIFE INVESTMENT MANAGEMENT HOLDINGS (IRELAND) LIMITED (IRELAND)
|
151.
METLIFE INVESTMENTS ASIA LIMITED (HONG KONG)
|
152.
METLIFE INVESTMENTS LIMITED (UNITED KINGDOM)
|
153.
METLIFE INVESTMENT MANAGEMENT HOLDINGS, LLC (DE)
|
154.
METLIFE INVESTMENT MANAGEMENT LIMITED (UNITED KINGDOM)
|
155.
METLIFE INVESTMENTS PTY LIMITED (AUSTRALIA)
|
156.
METLIFE INVESTMENTS SECURITIES, LLC (DE)
|
157.
METLIFE INVESTORS DISTRIBUTION COMPANY (MO)
|
158.
METLIFE INVESTORS GROUP, LLC (DE)
|
159.
METLIFE IRELAND HOLDINGS ONE LIMITED (IRELAND)
|
160.
METLIFE IRELAND TREASURY D.A.C. (IRELAND)
|
161.
METLIFE LATIN AMERICA ASESORIAS E INVERSIONES LIMITADA (CHILE)
|
162.
METLIFE LHH MEMBER, LLC (DE)
|
163.
METLIFE LIFE INSURANCE S.A. (GREECE)
|
164.
METLIFE LIMITED (HONG KONG)
|
165.
METLIFE LOAN ASSET MANAGEMENT LLC (DE)
|
166.
METLIFE MALL VENTURES LIMITED PARTNERSHIP (DE)
|
167.
METLIFE MAS, S.A. DE C.V. (MEXICO)
|
168.
METLIFE MEMBER SOLAIRE, LLC (DE)
|
169.
METLIFE MEXICO HOLDINGS, S. DE R.L. DE C.V. (MEXICO)
|
170.
METLIFE MEXICO S.A. (MEXICO)
|
171.
METLIFE MEXICO SERVICIOS, S.A. DE C.V. (MEXICO)
|
172.
METLIFE OBSMEMBER, LLC (DE)
|
173.
METLIFE OFC MEMBER, LLC (DE)
|
174.
METLIFE ONTARIO STREET MEMBR, LLC (DE)
|
175.
METLIFE PARK TOWER MEMBER, LLC (DE)
|
176.
METLIFE PENSIONES MEXICO S.A. (MEXICO)
|
177.
METLIFE PENSION TRUSTEES LIMITED (UK)
|
178.
METLIFE PLANOS ODONTOLOGICOS LTDA. (BRAZIL)
|
179.
METLIFE POWSZECHNE TOWARTZYSTWO EMERYTALNE S.A. (POLAND)
|
180.
METLIFE PRIVATE EQUITY HOLDINGS, LLC (DE)
|
181.
METLIFE PROPERTIES VENTURES, LLC (DE)
|
182.
METLIFE PROPERTY VENTURES CANADA ULC (CANADA)
|
183.
METLIFE RC SF MEMBER, LLC (DE)
|
184.
METLIFE REAL ESTATE LENDING LLC (DE)
|
185.
METLIFE REAL ESTATE LENDING MANAGER LLC (DE)
|
186.
METLIFE REINSURANCE COMPANY OF BERMUDA LTD. (BERMUDA)
|
187.
METLIFE REINSURANCE COMPANY OF CHARLESTON (SC)
|
188.
METLIFE REINSURANCE COMPANY OF VERMONT (VT)
|
189.
METLIFE RETIREMENT SERVICES LLC (NJ)
|
190.
METLIFE SAENGMYOUNG INSURANCE COMPANY LTD. (SOUTH KOREA)- (also known as MetLife Insurance Company of Korea Limited)
|
191.
METLIFE SECURITIZATION DEPOSITOR, LLC (DE)
|
192.
METLIFE SEGUROS DE RETIRO S.A. (ARGENTINA)
|
193.
METLIFE SEGUROS S.A. (URUGUAY)
|
194.
METLIFE SEGUROS S.A. (ARGENTINA)
|
195.
METLIFE SERVICES AND SOLUTIONS, LLC (DE)
|
196.
METLIFE SERVICES CYPRUS LIMITED (CYPRUS)
|
197.
METLIFE SERVICES EAST PRIVATE LIMITED (INDIA)
|
198.
METLIFE SERVICES EEIG (IRELAND)
|
199.
METLIFE SERVICES EOOD (BULGARIA)
|
200.
METLIFE SERVICES, SOCIEDAD LIMITADA (SPAIN)
|
201.
METLIFE SERVICES SP Z.O.O (POLAND)
|
202.
METLIFE SERVICIOS S.A. (ARGENTINA)
|
203.
METLIFE SLOVAKIA S.R.O.(SLOVAKIA)
|
204.
METLIFE SOLUTIONS PTE. LTD. (SINGAPORE)
|
205.
METLIFE SOLUTIONS S.A.S. (FRANCE)
|
206.
METLIFE SP HOLDINGS, LLC (DE)
207.
METLIFE SYNDICATED BANK LOAN FUND, SCSP (LUXEMBOURG)
|
208.
MetLife Syndicated Bank Loan Lux GP, S.à.r.l. (Luxembourg))
|
209.
METLIFE THR INVESTOR, LLC (DE)
|
210.
METLIFE TOWARZYSTWO FUNDUSZY INWESTYCYJNYCH S.A. (POLAND)
|
211.
METLIFE TOWARZYSTWO UBEZPIECZEN NA ZYCIE I REASEKURACJI S.A. (POLAND)
|
212.
METLIFE TOWER RESOURCES GROUP, INC. (DE)
|
213.
METLIFE TREAT TOWERS MEMBER, LLC (DE)
|
214.
METLIFE WORLDWIDE HOLDINGS, LLC (DE)
|
215.
METROPOLITAN CASUALTY INSURANCE COMPANY (RI)
|
216.
METROPOLITAN DIRECT PROPERTY AND CASUALTY INSURANCE COMPANY (RI)
|
217.
METROPOLITAN GENERAL INSURANCE COMPANY (RI)
|
218.
METROPOLITAN GLOBAL MANAGEMENT, LLC. (DE/ IRELAND)
|
219.
METROPOLITAN GROUP PROPERTY AND CASUALTY INSURANCE COMPANY (RI)
|
220.
METROPOLITAN LIFE INSURANCE COMPANY (NY)
|
221.
METROPOLITAN LIFE INSURANCE COMPANY OF HONG KONG LIMITED (HONG KONG)
|
222.
METROPOLITAN LIFE SEGUROS E PREVIDÊNCIA PRIVADA S.A. (BRAZIL)
|
223.
METROPOLITAN LIFE SOCIETATE de ADMINISTRARE a UNUI FOND de PENSII ADMINISTRAT PRIVAT S.A. (ROMANIA)
|
224.
METROPOLITAN LLOYDS, INC. (TX)
|
225.
METROPOLITAN PROPERTY AND CASUALTY INSURANCE COMPANY (RI)
|
226.
METROPOLITAN TOWER LIFE INSURANCE COMPANY (DE)
|
227.
METROPOLITAN TOWER REALTY COMPANY, INC. (DE)
|
228.
MEX DF PROPERTIES, LLC (DE)
|
229.
MIDTOWN HEIGHTS, LLC (DE)
|
230.
MIM PROPERTY MANAGEMENT, LLC (DE)
|
231.
MISSOURI REINSURANCE, INC. (CAYMAN ISLANDS)
|
232.
ML-AI METLIFE MEMBER 1, LLC (DE)
|
233.
ML-AI METLIFE MEMBER 2, LLC (DE)
|
234.
ML-AI METLIFE MEMBER 3, LLC (DE)
|
235.
MLA COMERCIAL, S.A. DE C.V. (MEXICO)
|
236.
MLA SERVICIOS, S.A. DE C.V. (MEXICO)
|
237.
MLIA SBAF MANAGER, LLC (DE)
|
238.
ML BRIDGESIDE APARTMENTS LLC (DE)
|
239.
ML CAPACITACION COMERCIAL S.A. DE C.V. (MEXICO)
|
240.
ML DOLPHIN GP, LLC (DE)
|
241.
ML DOLPHIN MEZZ, LLC (DE)
|
242.
ML MILILANI MEMBER, LLC (DE)
|
243.
ML NEW RIVER VILLAGE III, LLC (DE)
|
244.
ML SENTINEL SQUARE MEMBER, LLC (DE)
|
245.
ML SOUTHMORE, LLC (DE)
|
246.
MLIC ASSET HOLDINGS II LLC (DE)
|
247.
MLIC ASSET HOLDINGS LLC (DE)
|
248.
MLIC CB HOLDINGS LLC (DE)
|
249.
ML SWAN GP, LLC (DE)
|
250.
ML SWAN MEZZ, LLC (DE)
|
251.
ML TERRACES, LLC (DE)
|
252.
MPLIFE, S. DE R.L. DE C.V
|
253.
MM GLOBAL OPERATIONS SUPPORT CENTER, S.A. DE C.V. (MEXICO)
|
254.
MSV IRVINE PROPERTY, LLC (DE)
|
255.
MTC FUND I, LLC (DE)
|
256.
MTC FUND II, LLC (DE)
|
257.
MTC FUND III, LLC (DE)
|
258.
MTL LEASING, LLC (DE)
|
259.
NATILOPORTEM HOLDINGS, LLC (DE)
|
260.
NEWBURY INSURANCE COMPANY, LIMITED (DE)
|
261.
OCONEE GOLF COMPANY, LLC (DE)
|
262.
OCONEE HOTEL COMPANY, LLC (DE)
|
263.
OCONEE LAND COMPANY, LLC (DE)
|
264.
OCONEE LAND DEVELOPMENT COMPANY, LLC (DE)
|
265.
OCONEE MARINA COMPANY, LLC (DE)
|
266.
OMI MLIC INVESTMENTS LIMITED (CAYMAN ISLANDS)
|
267.
PARK TOWER JV MEMBER, LLC (DE)
|
268.
PARK TOWER REIT, INC. (DE)
|
269.
PARK TWENTY THREE INVESTMENTS COMPANY (UNITED KINGDOM)
|
270.
PJSC METLIFE (UKRAINE)
|
271.
PLAZA DRIVE PROPERTIES LLC (DE)
|
272.
PREFCO DIX-HUIT LLC (CT)
|
273.
PREFCO FOURTEEN LIMITED PARTNERSHIP (CT)
|
274.
PREFCO IX REALTY LLC (CT)
|
275.
PREFCO TEN LIMITED PARTNERSHIP (CT)
|
276.
PREFCO TWENTY LIMITED PARTNERSHIP (CT)
|
277.
PREFCO VINGT LLC (CT)
|
278.
PREFCO X HOLDINGS LLC (CT)
|
279.
PREFCO XIV HOLDINGS LLC (CT)
|
280.
PROVIDA INTERNACIONAL S.A. (CHILE)
|
281.
SAFEGUARD HEALTH PLANS, INC. (CA)
|
282.
SAFEGUARD HEALTH PLANS, INC. (FL)
|
283.
SAFEGUARD HEALTH PLANS, INC. (NV)
|
284.
SAFEGUARD HEALTH PLANS, INC. (TX)
|
285.
SAFEGUARD HEALTH ENTERPRISES, INC. (DE)
|
286.
SAFEHEALTH LIFE INSURANCE COMPANY (CA)
|
287.
SANDPIPER COVE ASSOCIATES, LLC (DE)
|
288.
SANDPIPER COVE ASSOCIATES II, LLC (DE)
|
289.
ST. JAMES FLEET INVESTMENTS TWO LIMITED (CAYMAN ISLANDS)
|
290.
THE BUILDING AT 575 FIFTH AVENUE MEZZANINE LLC (DE)
|
291.
THE BUILDING AT 575 FIFTH RETAIL HOLDING LLC (DE)
|
292.
THE BUILDING AT 575 FIFTH RETAIL OWNER (DE)
|
293.
THE DIRECT CALL CENTRE PTY LIMITED (AUSTRALIA)
|
294.
TRANSMOUNTAIN LAND & LIVESTOCK COMPANY (MT)
|
295.
VIRIDIAN MIRACLE MILE, LLC (DE)
|
296.
WFP 1000 HOLDING COMPANY GP, LLC (DE)
|
297.
WHITE OAK ROYALTY COMPANY (OK)
|
298.
ZAO MASTER D (RUSSIA)
|
299.
60 11
th
STREET, LLC (DE)
|
300.
AFP PROVIDA S.A. (CHILE) 94.7%
|
301.
ALICO PROPERTIES, INC. (DE) 51%
|
302.
AMMETLIFE INSURANCE BERHAD (MALAYSIA) 50.000001%
|
303.
AMMETLIFE TAKAFUL BERHAD (MALAYSIA) 49.999999%
|
304.
BIDV METLIFE LIFE INSURANCE LIMITED LIABILITY COMPANY (VIETNAM) 60%
|
305.
HELLENIC ALICO LIFE INSURANCE COMPANY, LTD. (CYPRUS) 27.5%
|
306.
MAGNOLIA PARK GREENVILLE, LLC (DE) 20%
|
307.
MAGNOLIA PARK GREENVILLE VENTURE, LLC (DE) 20%
|
308.
MAXIS GBN S.A.S. (FRANCE) 50%
|
309.
MCMIF HOLDCO I, LLC (DE) 29.2%
|
310.
MCP 7 RIVERWAY, LLC (DE) 20%
|
311.
MCP 60 11
TH
STREET MEMBER, LLC (DE) 20%
|
312.
MCP 100 CONGRESS MEMBER, LLC (DE) 20%
|
313.
MCP 550 WEST WASHINGTON, LLC (DE) 20%
|
314.
MCP 22745 &22755 RELOCATION DRIVE, LLC (DE)
|
315.
MCP 3040 POST OAK, LLC (DE) 20%
|
316.
MCP 1900 MCKINNEY, LLC (DE) 20%
|
317.
MCP 4600 SOUTH SYRACUSE, LLC (DE) 20%
|
318.
MCP 9020 MURPHY ROAD, LLC (DE) 20%
|
319.
MCP ALLEY 24 EAST, LLC (DE) 20%
|
320.
MCP ASHTON SOUTH END, LLC (DE) 20%
|
321.
MCP BLOCK 23 MEMBERS, LLC
|
322.
MCP BUFORD LOGISTICS CENTER 2 MEMBER, LLC (DE) 20%
|
323.
MCP BUFORD LOGISTICS CENTER BUILDING B, LLC (DE)
|
324.
MCP BURNSIDE MEMBER, LLC (DE)
|
325.
MCP DMCBP PHASE II MEMBER, LLC (DE) 20%
|
326.
MCP DENVER PAVILIONS MEMBER, LLC (DE)20%
|
327.
MCP ENV CHICAGO, LLC (DE) 20%
|
328.
MCP FIFE ENTERPRISE MEMBER, LLC (DE) 20%
|
329.
MCP HIGHLAND PARK LENDER, LLC (DE) 20%
|
330.
MCPF ACQUISITION, LLC (DE) 20%
|
331.
MCP LODGE AT LAKECREST, LLC (DE) 20%
|
332.
MCP MAGNOLIA PARK MEMBER, LLC (DE) 20%
|
333.
MCP MAIN STREET VILLAGE, LLC (DE) 20%
|
334.
MCP MOUNTAIN TECHNOLOGY CENTER MEMBER TRS, LLC (DE)
|
335.
MCP NORTHYARDS HOLDCO, LLC (DE) 20%
|
336.
MCP NORTHYARDS OWNER, LLC (DE) 20%
|
337.
MCP NORTHYARDS MASTER LESSEE, LLC (DE) 20%
|
338.
MCP ONE WESTSIDE, LLC (DE) 20%
|
339.
MCP PARAGON POINT, LLC (DE) 20%
|
340.
MCP PLAZA AT LEGACY, LLC (DE) 20%
|
341.
MCP PROPERTY MANAGEMENT, LLC (DE) 20%
|
342.
MCP SEVENTH AND OSBORNE MF MEMBER, LLC
|
343.
MCP SEVENTH AND OSBORNE RETAIL MEMBER, LLC
|
344.
MCP SOCAL INDUSTRIAL – ANAHEIM, LLC (DE) 20%
|
345.
MCP SOCAL INDUSTRIAL – BERNARDO, LLC (DE) 20%
|
346.
MCP SOCAL INDUSTRIAL – CANYON, LLC (DE) 20%
|
347.
MCP SOCAL INDUSTRIAL – CONCOURSE, LLC (DE) 20%
|
348.
MCP SOCAL INDUSTRIAL – FULLERTON, LLC (DE) 20%
|
349.
MCP SOCAL INDUSTRIAL – KELLWOOD, LLC (DE) 20%
|
350.
MCP SOCAL INDUSTRIAL – LAX, LLC (DE) 20%
|
351.
MCP SOCAL INDUSTRIAL – LOKER, LLC (DE) 20%
|
352.
MCP SOCAL INDUSTRIAL – ONTARIO, LLC (DE) 20%
|
353.
MCP SOCAL INDUSTRIAL – REDONDO, LLC (DE) 20%
|
354.
MCP SOCAL INDUSTRIAL – SPRINGDALE, LLC (DE) 20%
|
355.
MCP THE PALMS AT DORAL, LLC (DE) 20%
|
356.
MCP TRIMBLE CAMPUS, LLC (DE) 20%
|
357.
MCP WATERFORD ATRIUM, LLC (DE) 20%
|
358.
METLIFE AMERICAN INTERNATIONAL GROUP AND ARAB NATIONAL BANK COOPERATIVE INSURANCE COMPANY (SAUDI ARABIA) 30%
|
359.
METLIFE COMMERCIAL MORTGAGE INCOME FUND, LP (DE) 29.2%
|
360.
METLIFE COMMERCIAL MORTGAGE ORIGINATOR, LLC (DE) 29.2%
|
361.
METLIFE COMMERCIAL MORTGAGE REIT, LLC (DE) 29.2%
|
362.
METLIFE CORE PROPERTY FUND, LP (DE) 23.7%
|
363.
METLIFE CORE PROPERTY HOLDINGS, LLC (DE) 23.7%
|
364.
METLIFE CORE PROPERTY REIT, LLC (DE) 23.7%
|
365.
METLIFE CORE PROPERTY TRS, LLC (DE) 20%
|
366.
METLIFE MUTUAL FUND COMPANY (GREECE) 90%
|
367.
METROPOLITAN LLOYDS INSURANCE COMPANY OF TEXAS (TX)
|
368.
METLIFE, LIFE INSURANCE COMPANY (EGYPT) 84.125%
|
369.
PNB METLIFE INDIA INSURANCE COMPANY LIMITED (INDIA) (26%)
|
370.
SINO-US UNITED METLIFE INSURANCE CO., LTD. (CHINA) 50%
|
371.
SEATTLE GATEWAY I MEMBER, LLC (DE) 95%
|
372.
SEATTLE GATEWAY II MEMBER, LLC (DE) 95%
|
373.
UBB-METLIFE ZHIVOTOZASTRAHOVATELNO DRUJESTVO AD (BULGARIA) 40%
|
377.
1075 PEACHTREE, LLC (DE)
|
378.
BRIGHTHOUSE ASSIGNMENT COMPANY (CT)
|
379.
BRIGHTHOUSE CONNECTICUT PROPERTIES VENTURES, LLC (CTDA)
|
380.
BRIGHTHOUSE FINANCIAL, INC. (DE)
|
381.
BRIGHTHOUSE HOLDINGS, LLC (DE)
|
382.
BRIGHTHOUSE INVESTMENT ADVISERS, LLC (DE)
|
383.
BRIGHTHOUSE LIFE INSURANCE COMPANY (DE)
|
384.
BRIGHTHOUSE LIFE INSURANCE COMPANY OF NY (NY)
|
385.
BRIGHTHOUSE REINSURANCE COMPANY OF DELAWARE (DE)
|
386.
BRIGHTHOUSE RENEWABLES HOLDINGS, LLC(DE)
|
387.
BRIGHTHOUSE SECURITIES, LLC (DE)
|
388.
BRIGHTHOUSE SERVICES, LLC (DE)
|
389.
DANIEL/BRIGHTHOUSE MIDTOWN ATLANTA MASTER LIMITED LIABILITY COMPANY (DE)
|
390.
EURO TI INVESTMENTS LLC (DE)
|
391.
EURO TL INVESTMENTS LLC (DE)
|
392.
GREATER SANDHILL I, LLC (DE)
|
393.
ML 1065 HOTEL, LLC (DE)
|
394.
NEW ENGLAND LIFE INSURANCE COMPANY (MA)
|
395.
THE PROSPECT COMPANY (DE)
|
396.
TIC EUROPEAN REAL ESTATE LP, LLC (DE)
|
397.
TLA HOLDINGS II LLC (DE)
|
398.
TLA HOLDINGS LLC (DE)
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ Steven A. Kandarian
|
|
Steven A. Kandarian
|
|
Chairman of the Board, President and
Chief Executive Officer |
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
|
/s/ John C. R. Hele
|
|
John C. R. Hele
|
|
Executive Vice President and
|
|
Chief Financial Officer
|
|
/s/ Steven A. Kandarian
|
|
Steven A. Kandarian
|
|
Chairman of the Board, President and
Chief Executive Officer
|
|
/s/ John C. R. Hele
|
|
John C. R. Hele
|
|
Executive Vice President and
Chief Financial Officer |